DDrare: Database of Drug Development for Rare Diseases

13. 多発性硬化症／視神経脊髄炎　［臨床試験数：1,398，薬物数：1,426（DrugBank：306），標的遺伝子数：216，標的パスウェイ数：210］

Searched query = "Multiple sclerosis", "Neuromyelitis optica", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Drug = (-)-trans-delta-9-tetrahydrocannabinol; (im) avonex®; (r) 3-(5-dimethylcarbamoyl-pent-1-enyl)-n-(2-hydroxy-1- methylethyl) benzamide; 0,5 mg fingolimod; 0.25mg rpc1063; 1 - andrographis paniculata p/st extract; 1% steroid cream; 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1h-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone; 1.0mg rpc1063; 10 milligram (mg) fampridine-sr (4-aminopyridine, 4-ap); 10000iu vitamin d; 11c-acetate; 11c-pib; 13-pcv booster; 13-valent pneumococcal conjugate vaccine (13-pcv); 15 mg fampridine-sr (4-aminopyridine, 4-ap); 18f-dpa-714 and 18f-fdg; 18f-fdg; 19 nor vitamin d; 2 - excipients; 2-cda; 2-cda, 2-chloro-2’-deoxy-beta-d-adenosine; 2-cda, 2-chloro-2’-deoxy-ß-d-adenosine; 2-chloro-2'-deoxyadenosine, 2cda; 2-chloro-2’-deoxyadenosine (2-cda); 20 mg fampridine-sr (4-aminopyridine, 4-ap); 20 mg ga; 200106 or emd 28162; 20mg/0.5ml ga; 20mg/0.5ml glatiramer acetate; 23-ppv; 23-valent pneumococcal polysaccharide vaccine; 23-valent pneumococcal polysaccharide vaccine (23-ppv); 25oh-vitamin d; 2b3-201; 2cda; 3 mg melatonin; 3,4-diaminopyridine; 4-aminopyridine; 4-ap; 4.5 mg naltrexone; 40 mg ga; 40 mg glatiramer acetate; 5 mg melatonin; 5000iu vitamin d; 52069.00.01; 9060x; 95% pure ecgc capsules 200mg; A4i antagonist; Ab1010; Abatacept; Abobotulinumtoxin a; Abr-215062 sodium salt; Abt-555; Abt-874/human monoclonal antibody against il-12; Abx-1431 hcl; Acetaminophen; Acetaminophen tab 650mg; Acetate; Acetazolamide; Acetylcysteine; Acetylsalicylic acid; Acetylsalicylic acid at 1st visit,; Aclasta; Aclasta 5 mg infusionslösung; Aclasta 5mg solution for infusion; Act-128800; Act-128800 dose 1; Act-128800 dose 2; Act-128800 dose 3; Acth; Acthar; Acthar gel; Acthar gel (acth); Active comparator receiving extavia®; Active control; Actos (pioglitazone); Acyclovir; Adderall xr; Adderall xr 10 mg; Adderall xr 5mg; Adenosine; Adrenocorticotropic hormone; Adrenocorticotropic hormone (acth) gel (h.p. acthar®); Ads-5102; Ads-5102, 137 mg; Ads-5102, 274 mg; Aert, (r)-baclofen; Agee cream; Aimspro; Ain457; Alanine; Albumin (human) 25%, united states pharmacopeia (usp); Albuterol; Alcohol; Alemtuzumab; Alemtuzumab (gz402673); Alemtuzumab 12 mg; Alemtuzumab 24 mg; Alemtuzumab gz402673; Alemtuzumab immunotherapy; Alemtuzumab injection [lemtrada]; Alfuzosin; Alks 8700; Alks 8700 delayed release (dr); Alks 8700 delayed release (dr) capsule; Allogeneic human umbilical cord tissue-derived mesenchymal stem cells; Alpha lipoic acid; Alpha-lipoic acid; Alpha1-antitrypsin; Altri farmaci del sistema nervoso; Amantadine; American ginseng; American ginseng extract ht-1001; Amiloride; Amiloride hydrochloride; Amiloride hydrochloride, 2 h2o; Amilostad hct; Amilostad hct tablets; Ampyra; An100226; An100226, bg00002; Anakinra; Androgel 1 % topical gel; Androgel 100mg gel; Andrographolides; Anesthetic topical adhesive synera; Anti lp40 antibody, subclass igg4 la294; Anti-cd25 humanized monoclonal antibody; Anti-cd52 monoclonal antibody; Anti-il-12; Anti-thymocyte globulin; Anticholinergic medication; Antihistamine; Antimycotic; Antithymocyte; Antithymocyte immunoglobulin (rabbit); Arbaclofen; Arbaclofen er tablets; Arbaclofen extended release tablets; Arbaclofen placarbil; Arbaclofen placarbil 15 mg bid; Arbaclofen placarbil 30 mg bid; Arbaclofen placarbil 45 mg bid; Aricept; Aricept 10 mg; Aricept 10 mg filmdragerade tabletter; Aricept 5 mg; Aricept 5 mg filmdragerade tabletter; Arm 1 - geh120714 (18f) injection; Armodafinil; Arn-6039; Arzerra; Asb-683699; Aspartate; Aspirin; Aspirin 650mg oral capsule; Ata188; Atacicept; Atacicept 150 mg; Atacicept 25 mg; Atacicept 75 mg; Atl1102; Atomoxetine; Atorvastatin; Atx-ms-1467; Aubagio; Aubagio - 14 mg - compressa rivestita con film - uso orale - blister (alu/alu) - 28 compresse; Aubagio®; Autologous adipose derived mesenchymal cells; Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved; Autologous bone marrow-derived mononuclear stem cells; Autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope; Autologous hematopoietic stem cell; Autologous mesenchymal cell product; Autologous mesenchymal stem cell transplantation; Autologous mesenchymal stem cells; Autologous stem cells; Autologous t-lymphocytes; Autologous vitd3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (toldc-vitd3); Av605; Avonex; Avonex (interferon beta 1a); Avonex (interferon beta-1a), biogen idec ltd; Avonex 30 µg/0,5 ml solution for injection; Avonex and topamax; Avonex im 4sir 30mcg/0,5ml 4ag; Avonex/betaseron/copaxone/rebif; Avonex/zocor; Avonex®; Avonex® monotherapy (6.0 miu administered i.m. each week); Avp-923; Azathioprine; Azatioprina; Azatioprina hex. 50cpr 50mg bl; Azithromycin; Bacille calmette-guerin vaccine; Bacille of calmette-guerin; Baclofen; Baclofen 20 mg; Baclofen ir; Baf312; Baf312 0,25 mg tablet; Baf312 1 mg tablet; Baf312 4 mg tablet; Baf312 hemifumarate; Baf312a; Bafiertam; Balance; Baminercept; Baseline treatment; Bat4406f; Bay 79-4998; Bay86-5046; Bay86-5046_interferon-beta-1b; Bazedoxifene; Bazedoxifene acetate; Bbr 2778; Bcd-033 (interferon beta 1a); Bcd-054 180 mcg; Bcd-054 240 mcg; Bcd-063; Bcd-132; Bcg20-0134; Beam; Beam regimen; Beetainterferoni -1a; Best available therapy (bat); Beta interferon; Beta-1b interferoni; Beta-alanine; Beta-alanine supplementation; Beta-carotene; Beta-interferon; Betacarotene; Betaferon; Betaferon 250 microgram/ml; Betaferon 250 microgram/ml, powder and solvent for solution for injection; Betaferon 250µg; Betaferon 500mcg; Betaferon 500µg; Betaferon sc 15f 0,25mg 15sir; Betaferon*15confez 0,25mg/ml+; Betaferon, bay 86-5046; Betaferon/betaseron; Betaferon®; Betaferon® (interferon beta-1b); Betaseron; Betaseron (interferon beta-1b, bay86-5046); Betaseron (interferon beta-1b, bay86-5046), bayer healthcare ag; Betmiga; Bevacizumab; Bexarotene; Bg00002; Bg00002 (natalizumab); Bg00002-e (natalizumab high titer); Bg00012; Bg00012 (dmf); Bg00012 (dmf) (tecfidera®.); Bg0002 (natalizumab); Bg9418 (interferon beta 1-a); Bg9418 (interferon beta-1a); Bgg492; Bht-3009; Bht-3009 0.5 mg; Bht-3009 1.5 mg; Bht-3009-01; Biib017; Biib017 (peginterferon beta-1a); Biib019; Biib019 (daclizumab); Biib033; Biib033 (anti-lingo); Biib033 (opicinumab); Biib041; Biib041 (fampridine); Biib041 (fampridine-sr); Biib041 (pr fampridine); Biib061; Biotin; Birt 2584 xx; Bisacodyl; Blood sample; Blood samples; Blood sampling; Bmmnc; Bms 188667 (abatacept); Bone marrow autologous mesenchymal stem cells transplantation; Borage oil; Borage oil 20% gla; Bosentan; Boswelan; Boswellia serrata; Boswellia serrata extract; Boswellia serrata extract ps0201bo capsules; Boswellic acids (boswelan); Botox; Botox®; Botulinum toxin a; Botulinum toxin a - haemagglutinin complex; Botulinum toxin type a; Bx-1; C1-esterase inhibitor (cinryze); C105; Calcio; Calcio folinato dc.it; Calcium; Calcium carbonate; Calcium levofolinate; Cannabidiol; Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabis; Cannabis based medicine extract (sativex); Cannabis, medical; Cannador; Caprylic triglyceride; Capsules with 160 mg teavigo (at least 94% egcg); Carbidopa; Carbonate; Carmustine; Carmustine, etoposide, cytarabine, and melphalan (beam); Carnitine; Carnosine; Carnosine, capsulle, 2 g/day, 8 weeks; Cci-779; Cdp323; Cellular therapy with ebv specific autologous ctl infusion; Ceralifimod; Ceralifmod; Cesamet™ (nabilone); Ceterizine; Cetirizina; Cetirizina mylan generics; Cetirizine; Cetirizine hydrochloride; Cgp 77116; Charcoal; Chloride; Cholecalciferol; Cholecalciferol, vitamin d3; Cholestyramine; Chr-1103 / gbr500; Cianocobalamina; Cianocobalamina fu dc.it; Ciclofosfamide; Circadin; Circadin ( inn= melatonin); Cisapride; Cladribine; Cladribine 3.5 mg/kg; Cladribine 5.25 mg/kg; Cladribine tablets; Clemastine; Clostridium botulinum; Clostridium botulinum toxin type a; Cnm-au8; Cnp-ms-0601; Cnto 1275; Co-14; Coconut; Coconut oil; Coconut oil and epigallocatechin gallate; Coenzyme q; Colecalciferol; Colecalciferol concentrate (oily form); Control; Cop-1; Cop-1/copolymer-1; Copaxone; Copaxone 20 mg/ml; Copaxone 20 mg/ml solution for injection, pre-filled syringe; Copaxone 40 mg/ml solution for injection, pre-filled syringe; Copaxone subcutaneous injection syringe; Copaxone-teva; Copaxone®; Copolymer 1; Copolymer-1; Corticosteroid; Corticosteroids & tancart19/20; Corticotropin; Cranberry; Creatine; Cs-0777 tablets; Curcumin; Cyclophosfamide; Cyclophosphamide; Cyclophosphamide (drug); Cyclophosphamide and atg; Cyclophosphamide monohydrate; Cyclophosphamide/glatiramer acetate; Cymbalta; Cysteine; Cytarabine; Cytolytic cd4+ t cells; Células madre mesenquimales; D mannose; D-aspartate; D-biotin; Dac-hyp; Daclizumab; Daclizumab (anti-cd25 humanized monoclonal antibody); Daclizumab high yield process; Daclizumab hyp; Daclizumab hyp (dac hyp); Daclizumab with greek suufix; Dalfampridine; Dalfampridine er; Dalfampridine-er 10mg; Dalfampridine-er 5mg; Darifenacin; Dc-tab; Dekristol; Dekristol 20000 ie; Dekristol® 400-tabletten; Dekristol®-tablette 1 (400 ie); Delta-9-tetrahydrocannabinol; Demestril septem; Dexamethason; Dexamethasone; Dexamethasone soduim phosphate; Dexchlorpheniramine; Dexrazoxane; Dexrazoxane (drz) plus mitoxantrone (mx); Dextromethorphan; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dibase; Diclofenac; Diclofenac sodium topical gel; Dimethyl fumarate; Dimethyl fumarate (dmf); Dimethyl fumarate [dmf]; Dimetilfumarato; Diphenydramine; Diroximel fumarate; Diroximel fumarate (drf); Dirucotide; Dirucotide acetate; Discontinuation of disease modifying therapy; Disease modifying therapy; Dmt continuation; Domperidone; Donepezil; Donepezil hci (drug); Dotarem 0,5mmol/ml,; Doxycycline; Dpa-714 pet/mri; Dronabinol; Dronabinol capsule 2,5 mg; Dtpa; Duloxetine; Duloxetine hydrochloride (hci); Dydrogesterone; Dysport; Dysport®; Early highly effective therapies group; Ebixa; Ecp002a; Eculizumab; Efalizumab; Egb 761® (tanakan®); Egcg; Ek-12; Elezanumab; Elnd002; Emselex 15 mg retardtabletten; Emselex 7,5 mg retardtabletten; Ena713; Encapsulated simvastatin tablets; Endoxan; Endoxan - ciclofosfamide; Endoxan baxter; Enriched hematopoetic stem cell infusion; Eparmefolin 30 cpr 0,1/0,5mg; Epigallocatechin; Epigallocatechin gallate; Epoetin alfa; Epoetin beta; Erypo/erypo fs; Erythropoietin; Escalation therapies group; Escitalopram; Escitalopram oxalate antidepressant; Essential - hydroxytyrosol; Essential fatty acids; Estradiol; Estradiol hemihydrate; Estriol; Estroprogestins; Eszopiclone; Ethinylestradiol; Etifoxine; Etims; Etims (edc-fixed autologous pbmcs coupled with 7 immunodominant myelin peptides in ms patients); Etoposide; Eu/1/08/454/001-002, eu/1/08/454/005-007; Eu/1/95/003/005-010; Eu/1/97/033/002; Eu/1/98/063/001-003; Eu/1/98/063/004-006; Evobrutinib; Exelon; Exelon transdermales pflaster; Experimental glatiramer acetate; Extavia; Extavia (interferon beta-1b), novartis pharma ag; Extavia 250 microgram/ml; Extavia 250 micrograms/ml; Extavia*sc 15fl 250mcg/ml+15si; Extavia®; Extended release fampridine; Extended-release oxycodone; Extended-release quetiapine fumarate; F-18 fedaa1106 (bay85-8101); Fampridine; Fampridine sr; Fampridine-sr; Fampridine-sr b.i.d. (twice daily); Fampyra; Fampyra 10 mg prolonged-release tablets; Fampyra 10mg prolonged release tablets; Febuxostat; Fecal microbial transplant (fmt); Fecal microbial transplants; Fecal microbiota; Femoston 1/10; Femoston 2/10; Feraheme; Ferumoxytol; Filgrastim; Fingolimob (fty); Fingolimod; Fingolimod (fty720); Fingolimod 0.5 mg; Fingolimod 1.25 mg; Fingolimod hydrochloride; Fingolimodi; Fingolmod; Firategrast; Firategrast (usan approved name); Firategrast 150 mg; Firategrast 300 mg; Firategrast gastro-retentive solution; Firategrast immediate release tablet; Firategrast modified release tablet; Fish oil; Fish oil concentrate; Fish oil, rich in omega-3-acids; Fish oil,rich in omega 3 acids; Fludara; Fludarabine; Flumazenil; Fluoxetin; Fluoxetin hexal; Fluoxetine; Fluoxetine hydrochloride; Flupirtin; Flupirtine; Flupirtinmaleat; Flurbiprofen; Fmp30 donor stool; Folate; Folatescan (technetium tc 99mec20); Formulation a; Formulation b; Formulation c; Formulation d; Freshly-pressed extra virgin olive oil; Fty720; Fty720d; Full spectrum vitamin; Fully humanized anti-human il-6 receptor (il-6r) neutralizing monoclonal antibody; Fumaric acid; G-csf; G2-sfm (ifn-beta-1a from clone 484-39,fbs-free process); Ga 20 mg/ml; Ga 40 mg/ml; Ga depot; Ga depot 40 mg; Ga depot 40mg once monthly; Ga depot 80 mg; Gabapentin; Gabapentine; Gabapentine 300mg; Gadobenate; Gadobenate dimeglumine; Gadobutrol; Gadolinium; Gadolinium-based contrast; Gadoteric acid; Gadoteridol; Gadovist 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado; Gadovist 1.0 mmol/ml injektionslösung; Gamma-tocopherol; Gd-dtpa-st; Genotropin; Gilenya; Gilenya / imusera; Gilenya®; Gileyna; Ginkgo; Ginkgo biloba; Ginseng; Glatiramer; Glatiramer acetate; Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Glucose; Glutamate; Glutamate and aspartate; Glycerol; Glycerol-1,3-didecanoate-2-octadeca-(6z,9z,12z)-trienoate; Gnbac1; Gnbac1 monoclonal antibody; Gold; Gold nanocrystals; Granulocyte-colony stimulating factor (g-csf) and prednisone; Growth hormone; Gsk1223249; Gsk1841157; Gsk2018682; Gsk2018682 cd2 capsule; Gsk239512; Gsk2395612; Gtr.ace; Guanabenz; Gw-1000-02; Gz402668; Gz402673; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Helminth ova; Hematopoetic stem cell infusion; Hematopoietic stem cell transplantation; High dose aspirin (1300 mg/day); High/low sodium diet; Histidine; Hmr 1726d; Hmr1726; Hmr1726d; Hookworm larvae; Hp184; Human anti-il-12 igg1 mab; Human anti-il-12 mab; Human anti-lingo-1 monoclonal antibody; Human autologous mesenchymal stem cells; Human fetal-derived neural stem cells (hnscs); Human interferon beta; Human interferon beta 1a (rebif); Human interferon beta-1a and glatiramer acetate; Human leucocyte interferon-alpha; Human monoclonal antibody (cnto 1275) to interleukin-12p40; Human neural stem cells; Human normal immunoglobulin; Human recombinant growth hormone; Human umbilical cord mesenchymal stem cells; Humax-cd20; Hydrochlorothiazide; Hydroxychloroquine; Hydroxytyrosol; Hydroxyurea; Ibudilast; Ibuprofen; Idebenone; Ifa incomplete freund's adjuvant; Ifn beta 1 a + curcumin (bcm 95); Ifn beta-1a; Ifn-beta-1a (rebif®); Ifn-beta-1a, (avonex®); Ifn-ß-1a (rebif®); Ifn-ß-1a, (avonex®); Il2; Imatinib; Imatinib mesilate; Imatinib mesylate; Immune globulin; Immune globulin iv [human], 10% caprylate/chromatography purified; Immunoglobulin; Immunoglobulin g; Impact; Imu-838 (30 mg/day); Imu-838 (45 mg/day); Incabotulinumtoxina; Inf beta-1a; Influenza vaccine; Inhaled cannabis; Injectable ms dmt; Injection of autologous stem cells; Injection of cell free media; Inn colecalciferol; Inosine; Insulin; Int131; Interferon beta; Interferon beta - 1a (ifn); Interferon beta -1b; Interferon beta 1; Interferon beta 1-a; Interferon beta 1-b (betaferon/betaseron, bay86-5046); Interferon beta 1a; Interferon beta 1a 30 ug im once weekly; Interferon beta 1a, oral doxycycline; Interferon beta 1b; Interferon beta 1b (betaseron, bay86-5046); Interferon beta treatment to add-on atorvastatin treatment; Interferon beta type 1a; Interferon beta-1 a; Interferon beta-1a; Interferon beta-1a (avonex); Interferon beta-1a (avonex®); Interferon beta-1a (current approved manufacturing process invloving fbs); Interferon beta-1a (new process, manufactured without fbs); Interferon beta-1a (rebif); Interferon beta-1a 30 µg; Interferon beta-1a fbs-free/hsa-free, rnf; Interferon beta-1a hsa+ biosimilar; Interferon beta-1a hsa-free biosimilar; Interferon beta-1a original; Interferon beta-1b; Interferon beta-1b (betaferon, bay 86-5046); Interferon beta-1b (betaferon, bay86-5046); Interferon beta-1b (betaferon/betaseron, bay86-5046); Interferon beta-1b (betaferon®, bay 86-5046); Interferon beta-1b (betaseron, bay86-5046); Interferon beta-1b (betaseron, betaferon, bay86-5046); Interferon beta-1b (pf530, betaferon); Interferon beta-1b and tacrolimus; Interferon beta-1b group; Interferon beta-1b, (betaseron bay86-5046); Interferon beta-1b/atorvastatin group; Interferon beta1a; Interferon ß-1a; Interferon ß-1a (avonex®); Interferon ß-1a 30 µg; Interferon ß-1b; Interferon-1beta (betaseron, bay86-5046); Interferon-beta; Interferon-beta (ifn-beta); Interferon-beta 1a; Interferon-beta 1a fbs-free/hsa free, rnf; Interferon-beta 1a fbs-free/hsa-free, rnf; Interferon-beta 1b; Interferon-beta 1b (betaseron); Interferon-beta-1a; Interferon-beta-1a fbs-free/hsa free, rnf; Interferon-beta-1a fbs-free/hsa-free; Interferon-beta-1b; Interferon-beta1; Interferon-ß-1a; Interferon-ß-1b; Intradetrusor injection of botulinum toxin-a; Intratect; Intrathecal administration of autologous msc-np; Intrathecal methotrexate; Intrathecal msc-np injection; Intravenous (iv) infusions; Intravenous injection of mesenchymal stem cells; Intravenous steroid; Ipx056; Ipx056-10 mg; Ipx056-20 mg; Ipx056-30 mg; Ipx056-35 mg; Ipx056-40 mg; Ir902; Iron; Iron oxide; Isentress; Isoxsuprine; Isoxsuprine hydrochloride; Iv methylprednisolone; Iv methylprednisolone (steroids); Ivig; Ixazomib; Ixazomib (ninlaro®) capsules; Jm-4; Kemstro; Kepivance; Keppra; Keppra 250mg; Keppra 500mg; Keppra ®; Ketamine; Ketoconazole; Keyhole limpet hemocyanin; Keyhole limpet hemocyanin (klh); Keyhole limpet hemocyanin (klh) neo-antigen; L acetyl carnitine; L-000124467; L-carnitine; L-histidine; L04aa04 - immunoglobulina antitimocitaria (di coniglio) immunoglobulina di coniglio antitimociti umani thymoglobuline; L04aa31; L04ax01; Lactose; Lactose monohydrate; Lamotrigine; Lamotrigine extended release tablets; Laquinimod; Laquinimod 0.6; Laquinimod 1.2; Laquinimod capsules 0.3 mg; Laquinimod capsules 0.6 mg; Laquinimod sodium (usan); Laquinimod tablets 0.3 mg; Lemtrada; Lemtrada 12 mg konzentrat zur herstellung einer infusionslösung; Levetiracetam; Levitra; Levocarnil; Levofolene; Levofolene 4 mg 30 cpr; Levonorgestrel; Lfb-r603; Lidocaine; Lidocaine patch 5%; Linoleic acid; Linoleic acid/oleic acid; Liothyronine; Liothyronine sodium; Lipoic acid; Lipoic acid (la) with fish oil and la without fish oil; Lipoic acid and omega-3 fatty acids; Lisdexamfetamine; Lisdexamfetamine sulfate; Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; Lithium carbonate; Live hookworm larvae; Live necator americanus larvae; Loperamide; Loratadine; Losartan; Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Low dose aspirin (162 mg/day); Low immunogenic interferon-beta-1a; Lubiprostone; Lumbar puncture; Lutenyl; Ly2127399; Ly248686; Lysine; M2951; Mabcampath; Mabcampath ®; Mabthera; Mabthera (rituximab); Mabthera or biosimilar rituximab product; Mabthera®; Magnesium; Maltodextrin; Maltodextrin fiber supplement; Mangafodipir; Mangafodipir (teslascan); Mannose; Mantadan*20cpr 100mg; Marijuana; Masitinb mesylate; Masitinib; Masitinib mesylate; Mastinib; Mavenclad®; Mbp peptide; Mbp8298; Mbp8298 synthetic peptide; Md1003; Md1003 100mg capsule; Medi-551; Medi-551 iv; Medi-551 sc; Medical marijuana; Medrol; Megadose oral methylprednisolone; Melatonin; Melphalan; Memantine; Meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent); Menitorix; Mesenchymal stem cells; Mesenchymal stem cells (mscs); Mesenchymal stem/stromal cells; Mesna; Metex; Metformin; Methelphenidate; Methotrexat; Methotrexate; Methyl b12; Methyl folate; Methyloprednisolone; Methylphenidate; Methylphenidate hydrochloride; Methylphenidate modified release; Methylphenidate modified release 20 mg; Methylphenidate modified release 30 mg; Methylphenidate modified release 40 mg; Methylprednisolon; Methylprednisolon-21-hydrogensuccinat, natriumsalz; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Microgynon; Microgynon®; Micropirin; Midazolam; Mineral boost (magnesium); Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Mirabegron; Mis416; Mitoquinone; Mitoxantrone; Mk0812; Mln1202; Modafinil; Mog peptide; Monitor; Monoclonal antibody m-t412; Montelukast; Mor103; Msc2015; Msc2304479a; Msc2304480a; Msc2304481a; Msc2304482a; Msc2358825a; Msc2430913a or ono-4641 (to be used as synonyms); Msc2491529a; Msdmds other than betaseron (interferon beta-1b, bay86-5046); Mstc-001 (ms-stat); Mt-1303; Mt-1303-forma; Mt-1303-formb; Mt-1303-high; Mt-1303-low; Mt-1303-middle; Multiferon; Multiple (4 autologous subcutaneous t cell vaccinations with t cell lines reactive to nine myelin peptides); Mutagrip; Mycophenolate; Mycophenolate mofetil; Mycophenolate mofetil (cellcept); N acetylcysteine; N-acetyl cysteine; N-acetylcysteine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N.a.; N02bg10; N03ax12; N06dx01; Nabilone; Naltrexone; Namisol; Nanocort; Nanocurcumin; Naproxen; Natalizumab; Natalizumab (bg00002); Natalizumab (ntz); Natalizumab (tysabri); Natalizumab for iv infusion; Natalizumab for subcutaneous injection; Natalizumab treatment; Nbi-5788; Nebido® testosterone undecanoate 1000 mg/4 ml solution for injection; Necator americanus; Neorecormon; Nerispirdine; Nerispirdine (hp184); Nerispirdine hydrochloride; Neupogen; Neuroaspis plp10®; Neurontin; Neurontin 300 mg hard capsule; Neurovax; Neurovax 300ug/ml dose for im injection; New formulation of rebif - human interferon beta-1a; Niacinamide; Nitrofurantoin; Nivolumab; Nomegestrol; Nomegestrol acetate; Non-pegylated interferon; Norethindrone; Normal saline for injection; Novantrone*inf 2mg/ml 5ml; Npb-01; Nt-ko-003; Nu100; Null; Nurown (msc-ntf cells); Ocrelizumab; Ocrelizumab 300 mg; Ocrelizumab 300mg; Ocrelizumab 300mg /10ml; Ocrelizumab 300mg/10ml; Ocrelizumab 600 mg; Ocrelizumab dose 1; Ocrelizumab dose 2 and dose 3; Ocrevus; Octagam 5%; Octagam 50 mg/ml; Ofatumumab; Ofatumumab 100; Ofatumumab 300; Ofatumumab 30mg; Ofatumumab 3mg; Ofatumumab 60mg; Ofatumumab 700; Ofatumumab subcutaneous injection; Oleic acid; Oleovit d3 14.400 iu/ml oral drops, solution; Olesoxime (tro19622); Olive; Olive oil; Omb157; Omega 3; Omega 3 fatty acids; Omega-3; Omega-3 fatty acids; Omeprazole; Onabotulinumtoxina; Ono-4641; Ono-4641/msc2430913a; Opicinumab; Oral lipoic acid (la); Oral thc; Ory2001; Os440; Other disease-modifying therapy; Other h1 antagonist; Other nervous system drugs; Ovastat; Ovastat 1000; Ovastat 5000; Oxcarbazepine; Oxine; Oxycodone; Ozanimod; Ozanimod 0.5 mg; Ozanimod 1 mg; Ozanimod hydrochloride; Palifermin; Pantoprazole; Paracetamol; Paroxetine; Part a: 100 mg/ml gsk2618960; Part b: dose of gsk2618960 decided from part a; Part c: dose of gsk2618960 decided from part a and b; Peg-liposomal prednisolone sodium phosphate; Peginterferon beta-1a; Pegylated intereron beta-1a; Pegylated interferon beta-1a; Pending; Pent; Pet with 11c-flumazenil; Pf-06342674 0.25 mg/kg; Pf-06342674 1.5 mg/kg; Pf-06342674 6.0 mg/kg; Phenylcyclopropylamine derivatives and dual lsd1/mao-b (lysine-specific demethylase 1 and monoamine oxidase-b) inhibitor; Phenytoin; Phosphate; Pi-2301; Pioglitazone; Pixantrone; Pl 04515/0127; Pl 12762/0049; Placebo; Platelet transfusion; Plegridy; Plegridy (peginterferon beta-1a), biogen idec ltd; Plegridy 125 micrograms; Pleneva tm bgc20-0134; Plovamer acetate; Plp peptide; Pneumovax ii; Pnu-215062 sodium salt; Polyphenon e; Ponesimod; Ponesimod 10 mg; Ponesimod 20 mg; Ponesimod 40 mg; Pravastatin; Prebiotics (prebiotin prebiotic fiber stick pac); Prednisolone; Prednisolone sodium phosphate; Prednisone; Pregabalin; Prepulsid; Prn2246; Probiotics (visbiome®); Prohance (gadoteridol); Prolonged-release fampridine; Prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis a, hepatitis b, tick-borne encephalitis, meningococcal, pneumococcal); Provigil; Provigil (modafinil); Prucalopride; Ptl201; Quetiapine; Quinidine; R lipoic acid; Rabbit; Rabbit human t lymphocyte immunoglobulin; Ralenova; Raltegravir; Ramatroban; Ranitidine; Raptiva 100 mg/ml powder and solvent for solution for injection; Ratg; Rc18 160 mg; Rebif; Rebif (ifn beta-1a subcutaneous three times per week); Rebif (ifn ß-1a subcutaneous three times per week); Rebif (ifnbeta-1b); Rebif (ifnß-1b); Rebif (interferon beta 1a); Rebif (interferon beta-1a); Rebif (interferon beta-1a), merck serono europe ltd; Rebif 22; Rebif 22 micrograms; Rebif 22 y 44 mcg; Rebif 22®; Rebif 44; Rebif 44 microgramos solución inyectable; Rebif 44 micrograms; Rebif 44 µg; Rebif 44®; Rebif 8,8 µg, rebif 22µg; Rebif new formulation + ibuprofen prn; Rebif new formulation + prophylactic ibuprofen; Rebif new formulation 44mcg multidose cartridge; Rebif new formulation non titrated; Rebif new formulation titrated; Rebif sc 12sir 12000000ui44mcg; Rebif sc 12sir 6000000ui 22mcg; Rebif*sc 12sir 12000000ui44mcg; Rebif®; Rebif® (clone 484-39); Rebif® new formulation; Rebif® new formulation (rnf); Rebif® new formulation (rnf) using rebismarttm; Recombinant human alpha b-crystallin; Recombinant human erythropoietin; Recombinant human interferon beta; Recombinant humanized anti-alpha 4 integrin antibody; Recombinant interferon beta-1b; Repository corticotropin injection; Revaxis; Rg2077 (ctla4-igg4m); Rhb-104; Rhepo; Rhifn beta-1b; Rhigf-1 (cep-151); Rhigm22; Rhumab 2h7; Rhumab to il-17a (igg1-k-class); Rhuph20; Riboflavin; Rifampin; Riluzole; Ritalin; Ritalin la 20mg capsules; Ritalin la 30mg capsules; Ritalin la 40mg capsules; Rituximab; Rituximab infusion; Rituximab it; Rituximab iv; Rivastigmin; Rivastigmine; Rivastigmine transdermal patch; Rns60; Rns60 125 ml; Rns60 250 ml; Ro 496-4913/f07; Ro0506997; Ro4964913; Ro4964913 f07; Ro4964913/f03; Ro4964913/f07; Ro4964913/f07-01; Ro4964913/f07-01 (commercial); Ro4964913/f07-01 (development); Rolipram; Rpc-1063; Rpc1063; Rtl1000 (recombinant t cell receptor ligand); S-warfarin; Sa237; Sa237-120 pfs with nsd; Sa237-120/vial; Saline; Sar339658; Sar442168; Sativex; Sativex oromucosal spray; Sativex®; Satralizumab; Satralizumab (r-inn); Sb-683699; Sb683699; Sc interferon beta-1a; Sc interferon beta-1b; Sc peginterferon beta-1a; Sclerolym; Seasonal quadrivalent influenza vaccine; Second-generation fumaric acid; Secukinumab; Selenium; Sendoxan; Serum containing avonex; Serum free avonex; Sh u 555 c; Silodyx; Simethicone; Simvahexal® 40 mg filmtabletten; Simvastatin; Simvastatin 40 mg film-coated tablets; Simvastatin alternova; Simvastatina; Simvastatina sandoz 40 mg comprimidos recubiertos con película efg; Simvastatine; Simvastatine sandoz 40 mg filmomhulde tabletten; Simvastatine sandoz 40mg deelbare filmomhulde tabletten; Sinvastatina sandoz 40 mg comprimidos revestidos por película; Siponimod; Siponimod 0.25 mg tablet; Siponimod 0.5 mg tablet; Siponimod 1 mg tablet; Siponimod 2 mg tablet; Sirolimus; Sivatin 40 mg film-coated tablets; Sivelestat; Smderpept; Smoked cannabis; Sodium chlorid; Sodium chloride; Sodium chloride solution; Soliris; Solu-medrol; Solu-moderin 1 g; Solumedrol; Somatorelin; Spiropent; Sr-fampridine; Ss-interferon; Standard gadolinium contrast; Standard ms dmts; Standard of care; Standard treatment with a conventional drug; Statin; Stem cell transplantation; Study drug; Sub0750mig; Sub22282; Sublingual tizanidine 12 mg; Sulfate; Sunphenon; Sunphenon egcg; Sunphenon egcg tm; Suspension media; Sustained-release oral dalfampridine; Suvorexant; T cell vaccination; T-cell vaccination; Taci-fc5; Tacrolimus; Tanakan; Tarenflurbil; Targretin; Taurine; Tauroursodeoxycholic acid; Tcelna; Tecfidera; Tecfidera (bg12); Tecfidera®; Tecfidera® 120 mg; Tecfidera® 120mg magensaftresistente hartkapseln; Tecfidera® 240 mg; Tecfidera® 240mg magensaftresistente hartkapseln; Tecifdera (dimethyl fumarate); Temsirolimus; Temsirolimus tablets; Teriflunomide; Teriflunomide (hmr1726); Teriflunomide 14 mg; Teriflunomide 14 mg oral tablet [aubagio]; Teriflunomide hmr1726; Teriflunomide orally; Testosterone; Testosterone undecanoate; Tetanus diphtheria toxoid vaccine (td); Tetanus diphtheria toxoids vaccine; Tetanus toxoid (tt) containing vaccine (td, tdap); Tetracycline; Tetracycline - statin - antimycotic; Tetrahydrocannabinol; Tg-1101; Thiamine; Thioplex; Thiotepa; Thymoglobuline; Tissue selective estrogen complex; Tizanidine; Tizanidine (sublingual or oral); Tizanidine hydrochloride capsule; Tmp001; Tocilizumab; Tocilizumab injection; Tocopherol; Tolerogenic dendritic cells (toldc); Tolerogenic dendritic cells loaded with myelin peptides; Tolperisone; Tolperisone hc1; Tolperisone hcl; Tolpersan; Tolposan; Topical preparation h arm; Torvast*10cpr 10mg; Tovaxin; Tovaxin autologous t cell vaccine; Tracleer; Trancopal dolo; Treosulfan; Trichuris suis eggs; Trichuris suis ova; Trichuris suis ova (eggs), embryonated, viable; Trileptal; Triomar™ (omega-3 fatty acids); Tro19622; Tt vaccine; Tv-5010; Tv-5600; Tylenol pill; Tysabri; Tysabri 300 mg concentrate for solution for infusion; Tysabri 300 mg solution à diluer pour perfusion; Tysabri and avonex; Tysabri ® (natalizumab); Tysabri®; Tysabri® (natalizumab); Ublituximab; Ucb l059; Ultra small particles of iron oxide (uspio); Ultrasmall particles of iron oxide; Umbilical cord derived mesenchymal stem cells; Umbilical cord mesenchymal stem cells; Undifferentiated autologous mesenchymal stem cells; Untreated to atorvastatin treatment; Urbason 40 mg; Urbason 40 mg comprimidos; Urbason forte; Urbason solubile forte 1000mg; Urbason® solubile forte 1000 mg; Urine samples; Uvedose 100 000 ui; Uvedose 100 000 ui, solution buvable en ampoule; V08ca02; V08ca09; Vaginal estriol; Vardenafil; Vardenafil (hidrocloride); Vardenafilo; Vardenafilo hidrocloruro; Vatelizumab; Vay736; Vb13s1; Vb5s2; Vb6s5; Venlafaxin hexal; Venlafaxine; Venlafaxine hydrochloride; Verum arm receiving gilenya®; Verum arm receiving vitamin d oil; Vigantol; Vigantol oel; Vigantol oil; Vigantol® öl 20.000 i.e./ml; Vitamin a; Vitamin d; Vitamin d3; Vitamin e; Vitamin e/selenium; Vitamin k; Vitamina d3 kern pharma solución oleosa; Vsn16r; Vsn16r 100mg; Vx15/2503; Warfarin; Water; Way-130799; Xbd173; Xcel-mc-alpha; Xeomin; Zenapax; Zk 157046; Zol446h; Zoledronic acid; Zoledronic acid monohydrate; [11c]flumazenil; [123i]clinde; [14c]-rpc1063 solution (0.1 mg/ml) for oral administration; [18f] pbr06; [18f]-feppa; [18f]dpa-714; [18f]florbetapir and pet imaging; [c-11]methylreboxetine; [f-18]pbr06; [zr-89]oxine-labeled leukocytes pet/mr

No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02912897	September 2020	22 October 2019	Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis	An Open Single-center, Phase I Proof of Concept Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis	Multiple Sclerosis	Biological: Cellular therapy with EBV specific autologous CTL infusion	Nantes University Hospital		Not recruiting	18 Years	45 Years	All	7	Phase 1	France
2	NCT03404388	April 1, 2020	29 July 2019	Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis	Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis	Multiple Sclerosis	Behavioral: Balance Training	Wayne State University		Recruiting	18 Years	65 Years	All	150	N/A	United States
3	NCT04150549	February 2020	11 November 2019	FMT for MS Patients	Fecal Microbial Transplantation for Relapsing Multiple Sclerosis Patients - a Placebo-controlled, Double-blinded, Randomized Trial	Multiple Sclerosis	Biological: Fecal Microbial Transplants	Lawson Health Research Institute		Not recruiting	18 Years	55 Years	All	34	Phase 2
4	NCT04140305	January 5, 2020	4 November 2019	Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)	A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)	Multiple Sclerosis	Drug: RPC-1063	Celgene		Not recruiting	18 Years	65 Years	All	250	Phase 3
5	NCT04079088	December 23, 2019	7 October 2019	Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-ß1) in Relapsing Multiple Sclerosis (RMS)	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Oral BIIB061 as Add-On Therapy to Interferon-Beta 1 Therapies in Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: Placebo;Drug: BIIB061;Biological: Interferon-beta1	Biogen		Not recruiting	18 Years	55 Years	All	300	Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT04075266	December 11, 2019	4 November 2019	A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis	An Open-Label, Parallel-Group Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab	Hoffmann-La Roche		Not recruiting	10 Years	18 Years	All	12	Phase 2	United States;Italy
7	NCT04130997	December 2019	11 November 2019	An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis	TG1101-RMS303 is an Open-label, Single-arm Extension Study Designed to Evaluate Long-term Safety and Efficacy of Ublituximab in Subjects With Relapsing Multiple Sclerosis. Subjects Who Complete the 96-week, Double-blind Treatment Period o TG1101-RMS301 or TG1101-RMS302 Are Eligible for Participation in This Open Label Extension (OLE) Study.	Relapsing Multiple Sclerosis (RMS)	Biological: Ublituximab	TG Therapeutics, Inc.		Not recruiting	18 Years	N/A	All	1000	Phase 3
8	NCT04025554	November 13, 2019	11 November 2019	Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis	Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis	Multiple Sclerosis	Drug: Anakinra	National Institute of Neurological Disorders and Stroke (NINDS)		Recruiting	18 Years	100 Years	All	10	Phase 1/Phase 2	United States
9	NCT04146285	November 5, 2019	4 November 2019	A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders	A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders	Neuromyelitis Optica Spectrum Disorders	Drug: BAT4406F	Bio-Thera Solutions		Not recruiting	18 Years	65 Years	All	48	Phase 1	China
10	NCT03829566	November 2019	11 November 2019	Autologous Transplant To End NMO Spectrum Disorder	Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica;Devic's Disease;NMO Spectrum Disorder	Drug: Rituximab;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University		Not recruiting	18 Years	65 Years	All	0	Phase 2/Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	NCT03983720	November 2019	28 October 2019	Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?	Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?	Sclerosis, Multiple	Other: Evaluation of degree chronic fatigue.;Other: Questionnaires;Biological: Blood sample;Other: Cardiopulmonary evaluation;Device: Capacity of muscular oxygen extraction;Device: Sleep assessment;Device: Metabolic fatigue;Other: Neuromuscular evaluation	Centre Hospitalier Universitaire de Saint Etienne		Not recruiting	18 Years	70 Years	All	60	Phase 2	France
12	NCT04038541	November 2019	28 October 2019	Prebiotic vs Probiotic in Multiple Sclerosis	Prebiotic and Probiotic Treatment Trial in Multiple Sclerosis	Multiple Sclerosis;Clinically Isolated Syndrome (CIS)	Dietary Supplement: Prebiotics (Prebiotin Prebiotic Fiber Stick Pac);Dietary Supplement: Probiotics (Visbiome®)	Columbia University		Recruiting	18 Years	N/A	All	20	N/A	United States
13	NCT04047628	November 2019	4 November 2019	Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)	Relapsing Multiple Sclerosis;Relapsing Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Procedure: Autologous Hematopoietic Stem Cell Transplantation;Biological: Best Available Therapy (BAT)	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN)	Not recruiting	18 Years	55 Years	All	156	Phase 3	United States;United Kingdom
14	NCT04155424	November 2019	11 November 2019	A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder	A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder	Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder	Drug: Eculizumab	Alexion Pharmaceuticals		Not recruiting	2 Years	17 Years	All	15	Phase 2/Phase 3	United States;Canada;Germany;Italy;Japan;Korea, Republic of;Spain
15	NCT03958877	October 31, 2019	22 October 2019	A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis	An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension	Multiple Sclerosis, Relapsing-Remitting	Drug: BIIB017 (peginterferon beta-1a);Drug: Interferon beta type 1a	Biogen		Recruiting	10 Years	18 Years	All	142	Phase 3	United States;Bulgaria;Czechia;France;Italy;Spain;Greece
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	NCT04096443	October 14, 2019	30 September 2019	Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis	A Pilot Study of Oral FMT (Fecal Microbial Transplant) in Subjects With Multiple Sclerosis	Multiple Sclerosis	Biological: Fecal microbial transplant (FMT)	Griffin Hospital	Yale-Griffin Prevention Research Center;Multiple Sclerosis Treatment Center, Derby, Connecticut	Recruiting	18 Years	40 Years	All	15	Early Phase 1	United States
17	NCT04129736	October 10, 2019	28 October 2019	Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis	Determination of Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis Treated With Teriflunomide 14 mg Daily.	Multiple Sclerosis, Pharmacokinetics	Drug: Teriflunomide 14 MG	Jan Lycke		Recruiting	18 Years	65 Years	All	20	Phase 4	Sweden
18	NCT04115488	October 1, 2019	11 November 2019	Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®	Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)	Relapsing-Remitting Multiple Sclerosis (RRMS)	Biological: Intravenous (IV) infusions	Polpharma Biologics S.A.		Recruiting	18 Years	60 Years	All	260	Phase 3	Poland
19	NCT03963375	October 2019	14 October 2019	Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis	Cladribine Tablets: Collaborative Study to Evaluate the Impact On Central Nervous System Biomarkers in Multiple Sclerosis	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Cladribine	Washington University School of Medicine	EMD Serono	Recruiting	18 Years	65 Years	All	50	Phase 4	United States
20	NCT04121403	October 2019	22 October 2019	Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)	Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) A Prospective Randomized Open-label Blinded Endpoint (PROBE) Multicenter Non-inferiority Study	Relapsing Multiple Sclerosis;Multiple Sclerosis	Biological: Rituximab;Drug: Cladribine	Oslo University Hospital	University of Oslo;Göteborg University;Sykehuset Ostfold;Sykehuset Telemark;Vestre Viken Hospital Trust;Sorlandet Hospital HF;Helse Stavanger HF;Sykehuset Innlandet HF;Sykehuset i Vestfold HF;Helse Forde;University Hospital of North Norway	Recruiting	18 Years	65 Years	All	264	Phase 3	Norway
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
21	NCT04121468	October 2019	22 October 2019	A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis	A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: Metformin;Other: Placebo	The Hospital for Sick Children	Queen's University;Ontario Institute for Regenerative Medicine	Not recruiting	10 Years	18 Years	All	30	Phase 1/Phase 2
22	NCT04144257	October 2019	4 November 2019	Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue	Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue	Multiple Sclerosis	Drug: [F-18]PBR06;Drug: [C-11]Methylreboxetine	Brigham and Women's Hospital	United States Department of Defense	Not recruiting	18 Years	60 Years	All	12	Phase 1/Phase 2	United States
23	NCT03807973	September 30, 2019	30 September 2019	Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.	Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.	Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy	Drug: [Zr-89]Oxine-labeled leukocytes PET/MR	University of Alabama at Birmingham		Not recruiting	18 Years	65 Years	All	120	Phase 1
24	NCT03996291	September 23, 2019	14 October 2019	Long Term Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis	Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: SAR442168	Sanofi		Recruiting	18 Years	55 Years	All	105	Phase 2	United States
25	NCT04035889	September 23, 2019	7 October 2019	Melatonin for Sleep in MS	A Randomized, Crossover Pilot Trial of Melatonin for Sleep Disturbance in Adults With Multiple Sclerosis (MS)	Multiple Sclerosis	Dietary Supplement: Placebo;Dietary Supplement: Melatonin	University of California, San Francisco		Recruiting	20 Years	70 Years	All	30	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
26	NCT04121221	September 19, 2019	22 October 2019	A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS	A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Safety and Tolerability of GA Depot, a Long Acting IM Injection of Glatiramer Acetate, Once Monthly Compared to Placebo	Multiple Sclerosis, Relapsing-Remitting	Drug: GA Depot;Other: Placebo	Mapi Pharma Ltd.		Recruiting	18 Years	55 Years	All	960	Phase 3	United States
27	NCT04002934	September 10, 2019	11 November 2019	Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis	A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Delayed-Start Trial to Assess the Efficacy, Safety, and Tolerability of Bazedoxifene Acetate (BZA) as a Remyelinating Agent in Patients With Multiple Sclerosis	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Bazedoxifene Acetate	Riley Bove, MD		Recruiting	40 Years	65 Years	Female	50	Phase 2	United States
28	ChiCTR1900025744	2019-09-01	30 September 2019	Clinical effectiveness and safety of Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial	Clinical effectiveness and safety Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial	neuromyelitis optica spectrum disorder (NMOSD)	1:Intravenous 200mg Rituximab, 1/week2, if the proportion of CD19+ B lymphocytes in peripheral blood is above 1% then repeat administration (200mg);2:Oral azathioprine* (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (750~3000mg/day);	The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital		Recruiting	18	70	Both	1:30;2:30;	Phase 4	China
29	NCT03993171	September 2019	16 September 2019	31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis (REPAIR-MS)	A Phase 2, Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: gold nanocrystals	Clene Nanomedicine	University of Texas Southwestern Medical Center	Not recruiting	18 Years	55 Years	All	24	Phase 2	United States
30	NCT04032158	August 26, 2019	11 November 2019	Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety	Relapsing-remitting Multiple Sclerosis	Drug: Evobrutinib;Drug: Avonex®;Drug: Placebo	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Recruiting	18 Years	55 Years	All	950	Phase 3	United States;Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Montenegro;Poland;Russian Federation;Serbia;Spain;Taiwan;Ukraine;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
31	NCT04032171	August 19, 2019	29 July 2019	Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety	Relapsing-remitting Multiple Sclerosis	Drug: Evobrutinib;Drug: Avonex®;Drug: Placebo	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Not recruiting	18 Years	55 Years	All	950	Phase 3	United States;Germany
32	NCT03961204	August 15, 2019	22 October 2019	Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis (MS)	Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials	Multiple Sclerosis	Drug: Cladribine	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Recruiting	18 Years	65 Years	All	971	Phase 4	United States;Georgia;Korea, Republic of;Germany
33	NCT03972306	August 12, 2019	28 October 2019	A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis	A Phase Ib, Open-Label, Multicenter Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: Ocrelizumab;Drug: rHuPH20	Hoffmann-La Roche		Recruiting	18 Years	65 Years	All	135	Phase 1	United States
34	NCT04035005	August 12, 2019	22 October 2019	A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive	Drug: Ocrelizumab;Drug: Placebo	Hoffmann-La Roche		Recruiting	18 Years	65 Years	All	1000	Phase 3	United States;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Colombia;Croatia;Egypt;France;Georgia;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom
35	JPRN-JapicCTI-194838	31/7/2019	10 September 2019	Investigation for immune response against JC virus in Multiple Sclerosis patients on treatment with fingolimod	A 18-month, multicenter, two-cohort, prospective, observational study to investigate immune response against JC virus in Multiple Sclerosis patients on treatment with 0.5 mg fingolimod (FTY720)	Multiple Sclerosis	Intervention name : Gilenya / Imusera INN of the intervention : Fingolimod Dosage And administration of the intervention : 0.5mg/day Fingolimod orally Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	Novartis Pharma K.K.	Mitsubishi Tanabe Pharma Corporation	Recruiting	18		BOTH	280	NA	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
36	NCT03933202	July 22, 2019	22 October 2019	A Study of Suboptimally Controlled Participants Previously Taking Oral Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)	Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Oral Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (MASTER-2)	Multiple Sclerosis	Drug: Cladribine Tablets	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Recruiting	18 Years	N/A	All	200	N/A	United States
37	NCT04022473	July 7, 2019	29 July 2019	Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers	A Randomized, Double-Blind Study to Compare Gastrointestinal Tolerability Following Oral Administration of Bafiertam™ (Monomethyl Fumarate) or Tecfidera® (Dimethyl Fumarate) to Healthy Male and Female Volunteers	Multiple Sclerosis	Drug: Bafiertam;Drug: Tecfidera	Banner Life Sciences LLC		Recruiting	18 Years	65 Years	All	200	Phase 1	United States
38	NCT03983252	July 2019	24 June 2019	Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis	Effect of Alemtuzumab on Microglial Activation Assessed Using Novel [F-18]-Based Positron Emission Tomography (PET) Ligand in Multiple Sclerosis	Multiple Sclerosis	Drug: [F-18]PBR06	Brigham and Women's Hospital	Genzyme, a Sanofi Company	Not recruiting	18 Years	60 Years	All	10	Phase 1/Phase 2	United States
39	NCT03656627	June 27, 2019	22 October 2019	Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease	Autoimmune Diseases;Non-small Cell Lung Cancer;Rheumatoid Arthritis;Psoriasis;Giant Cell Arteritis;Polymyalgia Rheumatica;Systemic Lupus Erythematosus;Crohn Disease;Multiple Sclerosis;Ulcerative Colitis	Drug: Nivolumab	Alliance Foundation Trials, LLC.	Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	72	Phase 1	United States
40	NCT03774407	June 20, 2019	2 September 2019	Vaginal Estriol in Multiple Sclerosis	Dual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis;Neurogenic Bladder	Drug: vaginal estriol	Texas Tech University Health Sciences Center		Recruiting	40 Years	65 Years	Female	20	Phase 2/Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
41	NCT03887065	June 15, 2019	20 May 2019	Magnetic Resonance Imaging Study of JM-4 in Multiple Sclerosis/Clinically Patients	Magnetic Resonance Imaging 12 Day Study for Multiple Sclerosis/Clinically Isolated Syndrome Trial of JM-4 Novel Human Peptide	Multiple Sclerosis	Drug: JM-4	Cook, Stuart, MD		Not recruiting	18 Years	55 Years	All	15	Early Phase 1
42	NCT03995810	June 15, 2019	15 July 2019	Oral Carnosine for Neuromuscular Performance in Multiple Sclerosis	Oral Carnosine for Neuromuscular Performance, Brain Biomarkers of Carnosine Metabolism and Health-related Quality of Life in Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Carnosine, capsulle, 2 g/day, 8 weeks	University of Novi Sad, Faculty of Sport and Physical Education	CarnoMed	Recruiting	18 Years	65 Years	All	3	N/A	Serbia
43	NCT03873389	June 12, 2019	15 July 2019	Ocrelizumab Effects on the Metabolome in MS	Evaluating the Effects of Ocrelizumab on the Circulating Metabolome in Multiple Sclerosis (MS)	Multiple Sclerosis	Drug: Ocrelizumab	Johns Hopkins University	Genentech, Inc.	Recruiting	18 Years	75 Years	All	50	Phase 1	United States
44	NCT03783416	June 1, 2019	21 January 2019	SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis	Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis: A Phase 1b Randomised, Double-blind, Placebo-controlled Trial.	Relapsing Remitting Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: Ixazomib (NINLARO®) capsules / Matching placebo capsules	Queen Mary University of London	Takeda Pharmaceuticals International, Inc.	Not recruiting	18 Years	65 Years	All	72	Phase 1	United Kingdom
45	NCT03910738	June 2019	23 April 2019	TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis	TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection;Drug: Placebo 4 mL Solution for Injection;Procedure: MRI;Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities;Behavioral: Assessment of disability	University Hospital, Strasbourg, France	Bayer;Fédération Hospitalo-Universitaire NEUROGENYCS	Not recruiting	18 Years	55 Years	Male	40	Phase 2	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
46	NCT03933215	May 21, 2019	22 October 2019	A Study of Suboptimally Controlled Participants Previously Taking Injectable Disease-modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS)	Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Injectable Disease-Modifying Drugs (DMDs) for Relapsing Forms of Multiple Sclerosis (RMS) (CLICK-MS)	Multiple Sclerosis	Drug: Cladribine Tablets	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Recruiting	18 Years	N/A	All	200	N/A	United States
47	NCT03824938	April 30, 2019	15 July 2019	Aspirin for Exercise in Multiple Sclerosis (ASPIRE)	Aspirin for Exercise in Multiple Sclerosis (ASPIRE): A Double-Blind RCT of Aspirin or Acetaminophen Pretreatment to Improve Exercise Performance in Multiple Sclerosis (MS)	Multiple Sclerosis	Drug: Aspirin 650mg Oral Capsule;Drug: Acetaminophen Tab 650mg;Other: Placebo	Columbia University	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Recruiting	18 Years	65 Years	All	60	Phase 1/Phase 2	United States
48	NCT03816345	April 4, 2019	11 November 2019	Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer	A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)	Advanced Malignant Neoplasm;Autoimmune Disease;Crohn Disease;Dermatomyositis;Inflammatory Bowel Disease;Metastatic Malignant Neoplasm;Multiple Sclerosis;Rheumatoid Arthritis;Sjogren Syndrome;Systemic Lupus Erythematosus;Systemic Scleroderma;Ulcerative Colitis;Unresectable Malignant Neoplasm	Biological: Nivolumab	National Cancer Institute (NCI)		Recruiting	18 Years	N/A	All	264	Phase 1	United States
49	NCT03025269	April 2, 2019	29 April 2019	Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis	Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab	University at Buffalo		Recruiting	18 Years	60 Years	All	30	N/A	United States
50	NCT03853746	April 1, 2019	27 May 2019	Short-term B-cell Depletion in Relapsing Multiple Sclerosis	Evaluating the Effects of Short-term B-cell Depletion on Long-term Disease Activity and Immune Tolerance in Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab	Johns Hopkins University	National Multiple Sclerosis Society	Recruiting	18 Years	99 Years	All	10	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
51	NCT03888924	April 1, 2019	1 April 2019	Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)	Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)	Multiple Sclerosis	Drug: Placebo;Drug: Bacille Calmette-Guerin vaccine	S. Andrea Hospital		Not recruiting	18 Years	N/A	All	100	Phase 2	Italy
52	NCT02466074	April 2019	19 November 2018	Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis	Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis	Multiple Sclerosis	Drug: Acetazolamide;Drug: Placebo	The University of Texas Health Science Center, Houston		Not recruiting	18 Years	55 Years	All	60	Phase 2	United States
53	NCT03856619	March 27, 2019	15 April 2019	To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis	A Single Arm Phase IV Clinical Trial to Describe the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: TERIFLUNOMIDE HMR1726	Sanofi		Recruiting	18 Years	N/A	All	193	Phase 4	India
54	NCT03945006	March 25, 2019	20 May 2019	Balance, Trunk Impairment and Fear of Falling in Multiple Sclerosis Patients With Incontinence	An Investigation of Balance, Trunk Impairment, and Fear of Falling in Multiple Sclerosis Patients With Incontinence	Multiple Sclerosis;Physical Therapy;Incontinence	Other: Incontinence Severity;Other: Balance;Other: Trunk impairment;Other: Fear of falling	Ankara Yildirim Beyazit University		Not recruiting	24 Years	58 Years	All	36	N/A	Turkey
55	NCT03870763	March 19, 2019	28 October 2019	Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Dimethyl Fumarate;Drug: Peginterferon Beta-1a;Drug: Placebo	Biogen		Recruiting	10 Years	17 Years	All	340	Phase 3	United States;Colombia;Estonia;Hungary;Korea, Republic of;Taiwan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
56	EUCTR2018-003927-12-SK	18/03/2019	30 April 2019	Dose-finding study for SAR442168 in relapsing multiple sclerosis	A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10067063 Term: Progressive relapsing multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: SAR442168 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Not available CAS Number: 1971920-73-6 Current Sponsor code: SAR442168 Other descriptive name: PRN2246 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- INN or Proposed INN: Not available CAS Number: 1971920-73-6 Current Sponsor code: SAR442168 Other descriptive name: PRN2246 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Genzyme Corporation		Authorised			Female: yes Male: yes	160	Phase 2	France;United States;Estonia;Czech Republic;Slovakia;Canada;Spain;Ukraine;Russian Federation;Norway;Netherlands;Sweden
57	NCT03799718	March 13, 2019	26 August 2019	Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS	A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS	Multiple Sclerosis, Chronic Progressive	Biological: NurOwn (MSC-NTF cells)	Brainstorm-Cell Therapeutics		Recruiting	18 Years	65 Years	All	20	Phase 2	United States
58	EUCTR2018-000516-22-HU	04/03/2019	30 April 2019	Study to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TECFIDERA Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Plegridy Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: PEGINTERFERON BETA-1A CAS Number: 1211327-92-2 Current Sponsor code: BIIB017 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Biogen Idec Research Limited		Authorised			Female: yes Male: yes	340	Phase 3	Serbia;Portugal;United States;Saudi Arabia;Taiwan;Estonia;Greece;Thailand;Turkey;Russian Federation;Israel;Colombia;Italy;Hungary;Mexico;Jordan;Malaysia;Croatia;Bulgaria;Tunisia;Korea, Republic of
59	NCT03896217	March 2019	8 April 2019	Simvastatin in Secondary Progressive Multiple Sclerosis	A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage	Secondary Progressive Multiple Sclerosis	Drug: Simvastatin	University College, London	MS Society	Not recruiting	18 Years	65 Years	All	40	Phase 2	United Kingdom
60	NCT03737812	February 27, 2019	4 November 2019	A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: elezanumab;Drug: placebo	AbbVie		Recruiting	18 Years	65 Years	All	90	Phase 2	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
61	NCT03808142	February 20, 2019	4 November 2019	PROmyBETAappGame: a Study to Learn More About the Medication Usage & Patient Reported Outcomes Via the myBETAapp and to Find Out More About the Usage of Game Principles and Game Design Elements (Gamification) in Medical Care of Patients With Multiple Sclerosis Treated With Betaferon	PROmyBETAappGame: Ascertaining Medication Usage & Patient Reported Outcomes Via the myBETAapp and Exploring Gamification in Patients With Multiple Sclerosis Treated With Betaferon	Multiple Sclerosis	Other: myBETAapp;Other: PEAK;Drug: Betaferon, BAY 86-5046;Device: BETACONNECT	Bayer		Recruiting	18 Years	N/A	All	200	Phase 2	Germany
62	NCT03756974	February 18, 2019	11 November 2019	BX-1 in Spasticity Due to Multiple Sclerosis	A Phase III, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Investigate the Efficacy and Safety of BX-1 for the Symptomatic Relief of Spasticity in Patients With Multiple Sclerosis (MS)	Spasticity Due to Multiple Sclerosis	Drug: BX-1;Drug: Placebo	Bionorica SE		Recruiting	18 Years	65 Years	All	384	Phase 3	Czechia;Germany;Hungary;Poland;Spain
63	NCT03752307	February 15, 2019	13 May 2019	Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses	Double-blind, Placebo-controlled, Randomized Study of the Safety and Tolerability of Isoxsuprine HCL Combined With High Dose Steroid Treatment of Multiple Sclerosis (MS) Relapse	Multiple Sclerosis	Drug: Isoxsuprine Hydrochloride;Drug: Placebo;Drug: Corticosteroid	University of New Mexico		Recruiting	18 Years	50 Years	All	20	Phase 1/Phase 2	United States
64	NCT03623243	February 14, 2019	8 April 2019	Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Advancing RMS Patients.	Exploring the Safety and Tolerability of Conversion From Oral or Injectable Disease Modifying Therapies to Dose-titrated Oral Siponimod in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb Study	Multiple Sclerosis, Relapsing MS, Advancing Multiple Sclerosis	Drug: Siponimod	Novartis Pharmaceuticals		Recruiting	18 Years	65 Years	All	300	Phase 3	United States
65	NCT03822858	February 12, 2019	30 September 2019	Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis	Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally	Multiple Sclerosis	Drug: Intrathecal MSC-NP injection	Tisch Multiple Sclerosis Research Center of New York		Not recruiting	18 Years	70 Years	All		Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
66	NCT03759522	February 3, 2019	8 April 2019	Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.	Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.	Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy	Drug: DPA-714 PET/MRI	University of Alabama at Birmingham		Recruiting	18 Years	65 Years	All	120	Phase 1	United States
67	NCT03784547	February 1, 2019	26 August 2019	Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM	Real-world Patient Profile and Treatment Persistence of Ocrelizumab in Multiple Sclerosis: A Retrospective Analysis in Latin America	Multiple Sclerosis	Drug: Ocrelizumab	Hospital Italiano de Buenos Aires		Recruiting	N/A	N/A	All	100	N/A	Argentina
68	NCT03825601	February 1, 2019	11 February 2019	PET With [18F]Flumazenil as an Index of Neurodegeneration in MS	PET With [18F]Flumazenil as an Index of Neurodegeneration in MS: Sensitivity at an Early Disease Stage and Pathophysiological Meaning	Multiple Sclerosis;Relapsing-Remitting Multiple Sclerosis	Diagnostic Test: PET with [11C]Flumazenil	Institut National de la Santé Et de la Recherche Médicale, France		Not recruiting	18 Years	55 Years	All	45	N/A
69	NCT03846219	January 28, 2019	4 March 2019	MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)	Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial Assessing the Effect of IMU-838 on Disease Activity, as Measured by Magnetic Resonance Imaging (MRI), as Well as Safety and Tolerability in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: IMU-838 (30 mg/day);Drug: IMU-838 (45 mg/day);Drug: Placebo	Immunic AG		Recruiting	18 Years	55 Years	All	195	Phase 2	Bulgaria
70	NCT03653273	January 24, 2019	18 March 2019	Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)	Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years	Multiple Sclerosis	Drug: DMT continuation;Other: DMT withdrawal	Rennes University Hospital		Recruiting	50 Years	N/A	All	250	Phase 3	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
71	NCT03745144	January 17, 2019	28 October 2019	Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck KGaA, Darmstadt, Germany		Recruiting	18 Years	45 Years	Female	34	Phase 1	Germany;Poland
72	NCT04086225	January 17, 2019	16 September 2019	Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany		Recruiting	18 Years	45 Years	Female	34	Phase 1	Germany;Poland
73	EUCTR2018-000516-22-EE	14/01/2019	28 February 2019	Study to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TECFIDERA Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Plegridy Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: PEGINTERFERON BETA-1A CAS Number: 1211327-92-2 Current Sponsor code: BIIB017 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Biogen Idec Research Limited		Authorised			Female: yes Male: yes	340	Phase 3	Serbia;Portugal;United States;Saudi Arabia;Estonia;Taiwan;Greece;Thailand;Turkey;Russian Federation;Israel;Colombia;Italy;Hungary;Mexico;Jordan;Malaysia;Croatia;Bulgaria;Tunisia;Korea, Republic of
74	EUCTR2017-004886-29-IE	11/01/2019	28 February 2019	A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la Roche Sponsored Ocrelizumab Clinical Trial	A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL	Multiple sclerosis (MS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	750	Phase 3	Estonia;Finland;Spain;Ireland;Turkey;United Kingdom;Italy;France;Czech Republic;Denmark;Netherlands;Norway;Sweden
75	NCT03803800	January 9, 2019	28 January 2019	Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis	Periodized Rehabilitation and Beta-alanine Supplementation in Multiple Sclerosis	Multiple Sclerosis	Other: Classic, progressive endurance training;Other: Periodized exercise training;Dietary Supplement: beta-alanine	Hasselt University		Recruiting	18 Years	75 Years	All	80	N/A	Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
76	NCT03535298	January 3, 2019	26 August 2019	Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS	Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Early Highly Effective Therapies Group;Drug: Escalation Therapies Group	The Cleveland Clinic	University of Nottingham	Recruiting	18 Years	60 Years	All	800	Phase 4	United States;United Kingdom
77	NCT04106830	January 1, 2019	22 October 2019	Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE)	Prospective Cohort Study of Clinical and Imaging Patterns of Neuroinflammation Diseases (CLUE)	NMO Spectrum Disorder;MRI;Multiple Sclerosis	Drug: Intravenous steroid	Beijing Tiantan Hospital		Recruiting	16 Years	80 Years	All	1000	N/A	China
78	NCT03650114	December 28, 2018	14 October 2019	Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS	An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Biological: Ofatumumab;Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);Biological: Seasonal Quadrivalent influenza vaccine;Biological: Keyhole limpet hemocyanin (KLH) neo-antigen	Novartis Pharmaceuticals		Recruiting	18 Years	N/A	All	2010	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Israel;Japan;Latvia;Lithuania;Netherlands;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;United Kingdom
79	NCT03847545	December 12, 2018	11 March 2019	Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking Technique	Muscle Strain in Multiple Sclerosis Patients Measured by Ultrasound Speckle Tracking	Multiple Sclerosis	Drug: Fampridine	University of Southern Denmark	Odense University Hospital;Sygehus Lillebaelt;University of Miami;Region of Southern Denmark;The Augustinus Foundation, Denmark.;The Lounkaer Foundation;Fonden for scleroseramte paa Fyn;The Danish Multiple Sclerosis Society;The Lily Benthine Lunds Foundation	Recruiting	18 Years	100 Years	All	60	N/A	Denmark
80	NCT03737851	December 11, 2018	4 November 2019	A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis (MS)	Drug: elezanumab;Drug: placebo	AbbVie		Recruiting	18 Years	65 Years	All	165	Phase 2	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
81	EUCTR2018-002315-98-DK	06/12/2018	30 April 2019	The effect of cannabis products on nerve pain and muscle stiffness in patients with multiple sclerosis and in patients with spinal cord injury.	The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial - The effect of medical cannabis on neuropathic pain and spasticity in patients with MS and SCI	Central neuropathic pain and spasticity MedDRA version: 20.0 Level: PT Classification code 10028335 Term: Muscle spasticity System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10077975 Term: Central neuropathic pain System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cannabidiol capsule 5 mg Product Code: N/A Pharmaceutical Form: Capsule INN or Proposed INN: Cannabidiol CAS Number: 13956-29-1 Other descriptive name: CBD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Dronabinol capsule 2,5 mg Product Code: N/A Pharmaceutical Form: Capsule INN or Proposed INN: DRONABINOL CAS Number: 1972-08-3 Other descriptive name: THC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Cannabidiol / Dronabinol capsule 5 mg+2,5 mg Product Code: N/A Pharmaceutical Form: Capsule INN or Proposed INN: DRONABINOL CAS Number: 1972-08-3 Other descriptive name: THC Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.5- INN or Proposed INN: Cannabidiol CAS Number: 13956-29-1 Other descriptive name: CBD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Aarhus Universitetshospital		Authorised			Female: yes Male: yes	448	Phase 2	Denmark
82	NCT03944447	December 1, 2018	7 October 2019	Outcomes Mandate National Integration With Cannabis as Medicine	Outcomes Mandate National Integration With Cannabis as Medicine	Chronic Pain;Chronic Pain Syndrome;Chronic Pain Due to Injury;Chronic Pain Due to Trauma;Fibromyalgia;Seizures;Hepatitis C;Cancer;Crohn Disease;HIV/AIDS;Multiple Sclerosis;Traumatic Brain Injury;Sickle Cell Disease;Post Traumatic Stress Disorder;Tourette Syndrome;Ulcerative Colitis;Glaucoma;Epilepsy;Inflammatory Bowel Diseases;Parkinson Disease;Amyotrophic Lateral Sclerosis;Chronic Traumatic Encephalopathy;Anxiety;Depression;Insomnia;Autism;Opioid-use Disorder;Bipolar Disorder	Drug: Cannabis, Medical	OMNI Medical Services, LLC		Recruiting	7 Years	N/A	All	100000	Phase 2	United States
83	NCT03689972	November 28, 2018	7 October 2019	A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment	A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab	Biogen		Not recruiting	18 Years	60 Years	All	480	Phase 3	United States;Australia;Belgium;Canada;France;Germany;Israel;Italy;Netherlands;Spain;United Kingdom
84	NCT03536559	November 23, 2018	28 January 2019	Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis	A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis;Optic Neuropathy;Optic; Neuritis, With Demyelination	Drug: CNM-Au8;Drug: Placebo	Clene Nanomedicine	Clene Australia Pty Ltd	Recruiting	18 Years	50 Years	All	150	Phase 2	Australia
85	EUCTR2017-004703-51-SK	21/11/2018	14 January 2019	Long-term safety, tolerability and effectiveness study of ofatumumab in subjects with relapsing multiple sclerosis	An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis	Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Novartis Pharma AG		Authorised			Female: yes Male: yes	2233	Phase 3	Portugal;United States;Taiwan;Estonia;Slovakia;Greece;Thailand;Spain;Russian Federation;Israel;Italy;Switzerland;India;France;Peru;Australia;Denmark;South Africa;Netherlands;Latvia;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Belgium;Croatia;Bulgaria;Norway;Germany;Japan;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
86	NCT03594487	November 16, 2018	18 December 2018	Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis	Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis: A Phase 1b Clinical Trial to Evaluate Feasibility, Safety, Tolerability and Effects on Immune Function	Relapsing Remitting Multiple Sclerosis	Drug: FMP30 Donor Stool;Procedure: Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool;Other: Observational Control	University of California, San Francisco		Recruiting	18 Years	60 Years	All	30	Phase 1	United States
87	NCT03621761	November 15, 2018	4 November 2019	Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue	A Randomized Controlled Trial of Telephone-delivered Cognitive Behavioral-therapy, Modafinil, and Combination Therapy of Both Interventions for Fatigue in Multiple Sclerosis	Multiple Sclerosis	Behavioral: Telephone-based Cognitive Behavioral Therapy;Drug: Modafinil	University of Michigan	University of Washington;Patient-Centered Outcomes Research Institute;National Multiple Sclerosis Society	Recruiting	18 Years	N/A	All	330	Phase 4	United States
88	NCT03691077	November 11, 2018	18 December 2018	Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714	A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714	Multiple Sclerosis;Relapse;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab	Assistance Publique - Hôpitaux de Paris	Roche Pharma AG;Institut du Cerveau et de la Moelle épinière	Recruiting	18 Years	60 Years	All	51	Phase 3	France
89	NCT04120675	November 9, 2018	22 October 2019	Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis	Randomized, Double Blind, Controlled Prospective Study, to Evaluate the Therapeutic Effects of Early Harvest Olive Oil in Cognitive Functions of Patients With Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis.	Progressive Multiple Sclerosis	Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil	Aristotle University Of Thessaloniki	Greek Alzheimer's Association and Related Disorders;YANNI'S OLIVE GROVE	Recruiting	18 Years	65 Years	All	150	N/A	Greece
90	EUCTR2018-000001-23-ES	06/11/2018	7 January 2019	Clinical study to investigate the efficacy and safety of the test substance BX-1 (dronabinol) for the symptomatic relief of spasticity in patients with multiple sclerosis	A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in patients with multiple sclerosis - BX-1 in spasticity due to MS	Symptomatic relief of spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Dronabinol Product Code: BX-1 Pharmaceutical Form: Oral solution INN or Proposed INN: Dronabinol CAS Number: 1972-08-3 Current Sponsor code: BX-1 Other descriptive name: Dronabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	Bionorica SE		Authorised			Female: yes Male: yes	548	Phase 3	Hungary;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
91	NCT03283397	November 4, 2018	16 December 2017	A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS	A Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Neuropeptide Combination of Metenkefalin and Tridecactide (EK-12) in Comparison to Interferon Beta-1a (REBIF®) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis, Relapsing-Remitting	Drug: EK-12;Drug: INF beta-1a	Bosnalijek D.D	MonitorCRO	Not recruiting	18 Years	55 Years	All	400	Phase 3
92	NCT03593590	November 2, 2018	11 November 2019	Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis	A Multicentre Non-interventional Study to Assess the Real-world Effectiveness of Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis - The MuSicalE STUDY	Multiple Sclerosis	Drug: Ocrelizumab	Hoffmann-La Roche		Recruiting	18 Years	N/A	All	1250	Phase 3	Austria;Belgium;Bulgaria;Colombia;Dominican Republic;Egypt;Italy;Kuwait;Montenegro;Netherlands;Panama;Paraguay;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Slovakia;Spain;Turkey;United Arab Emirates;United Kingdom;Israel
93	EUCTR2018-000001-23-HU	25/10/2018	6 November 2018	Clinical study to investigate the efficacy and safety of the test substance BX-1 (dronabinol) for the symptomatic relief of spasticity in patients with multiple sclerosis	A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in patients with multiple sclerosis - BX-1 in spasticity due to MS	Symptomatic relief of spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Dronabinol Product Code: BX-1 Pharmaceutical Form: Oral solution INN or Proposed INN: Dronabinol CAS Number: 1972-08-3 Current Sponsor code: BX-1 Other descriptive name: Dronabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	Bionorica SE		Authorised			Female: yes Male: yes	548	Phase 3	Hungary
94	EUCTR2017-004702-17-CZ	23/10/2018	28 February 2019	A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients.	A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients	Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Novartis Pharma AG		Authorised			Female: yes Male: yes	284	Phase 2	United States;Estonia;Czech Republic;Poland;Spain;Lithuania;Austria;Russian Federation;Bulgaria;Latvia;Germany;Italy
95	EUCTR2018-003231-30-ES	19/10/2018	7 January 2019	EFFECTIVENESS OF REPEATED INJECTIONS OF BOTULINUM TOXIN IN THE GAIT AND QUALITY OF LIFE OF ADULT PATIENTS WITH WEAKNESS AND MUSCLE RIGIDITY DUE TO MULTIPLE ESCLEROSIS	EFFECTIVENESS OF THE REPEATED INFILTRATIONS OF BOTULINUM TOXIN A IN THE GAIT AND QUALITY OF LIFE IN ADULTS WITH SPASTIC PARAPARESIA SECONDARY TO MULTIPLE SCLEROSIS - BOTULINUM TOXIN IN PATIENTS WITH SPASTIC PARAPARESIA ASSOCIATED WITH ESCLEROSIS MULTIPLE	Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Dysport Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Current Sponsor code: Dysport Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: range Concentration number: 250-1000	Aránzazu Vázquez Doce		Authorised			Female: yes Male: yes	84	Phase 3	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
96	NCT03740295	October 5, 2018	11 November 2019	Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis	Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Coconut oil and epigallocatechin gallate;Other: Placebo	Fundación Universidad Católica de Valencia San Vicente Mártir	Valencian Institute of Neurorehabilitation Foundation	Not recruiting	19 Years	65 Years	All	60	Phase 2	Spain
97	NCT03674099	October 1, 2018	26 August 2019	Imatinib for Multiple Sclerosis (MS) Relapses	Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study	Multiple Sclerosis	Drug: Imatinib Mesylate;Drug: Methylprednisolone	Tomas Olsson	The Swedish Research Council	Recruiting	18 Years	55 Years	All	200	Phase 2	Denmark;Norway;Sweden
98	NCT03396822	September 24, 2018	7 October 2019	Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis	Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis	Multiple Sclerosis	Drug: Gadoteridol	University of Maryland, Baltimore	Genentech, Inc.	Recruiting	18 Years	65 Years	All	22	Phase 1	United States
99	NCT03355365	September 21, 2018	11 June 2019	Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis	Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally	Multiple Sclerosis	Biological: Intrathecal MSC-NP injection;Other: Intrathecal saline injection	Tisch Multiple Sclerosis Research Center of New York		Recruiting	18 Years	65 Years	All	50	Phase 2	United States
100	EUCTR2017-004702-17-EE	17/09/2018	1 October 2018	A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients.	A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients	Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Novartis Pharma AG		Authorised			Female: yes Male: yes	284	Phase 2	United States;Czech Republic;Estonia;Poland;Spain;Lithuania;Austria;Russian Federation;Bulgaria;Latvia;Germany;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
101	NCT03166800	September 15, 2018	15 July 2019	MitoQ for Fatigue in Multiple Sclerosis	MitoQ for Fatigue in Multiple Sclerosis: a Placebo Controlled Trial	Multiple Sclerosis;Fatigue	Drug: Mitoquinone	Oregon Health and Science University	MitoQ Ltd	Recruiting	18 Years	70 Years	All	60	Phase 1/Phase 2	United States
102	NCT03606460	September 14, 2018	30 September 2019	A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)	A Phase IIIb, Open-Label Study To Evaluate The Safety And Tolerability Of Shorter Infusions Of Ocrelizumab In Patients With Primary Progressive And Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab Dose 1;Drug: Ocrelizumab Dose 2 and Dose 3	Genentech, Inc.		Not recruiting	18 Years	55 Years	All	140	Phase 3	United States
103	EUCTR2017-004158-40-FR	11/09/2018	30 April 2019	NA	A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714 - INN-MS	Patients with Relapsing MS or primary progressive MS MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrevus Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab Other descriptive name: ocrelizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)		Authorised			Female: yes Male: yes	71	Phase 3	France
104	EUCTR2017-004702-17-AT	01/09/2018	19 November 2018	A 12 week study to evaluate bioequivalence of ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients.	A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients	Multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-	Novartis Pharma AG		Authorised			Female: yes Male: yes	284	Phase 2	United States;Estonia;Czech Republic;Poland;Spain;Lithuania;Austria;Russian Federation;Bulgaria;Latvia;Germany;Italy
105	NCT03605238	August 15, 2018	30 September 2019	Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20	Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Refractory AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders (NMOSD)	Neuromyelitis Optica Spectrum Disorder	Biological: Corticosteroids & tanCART19/20	Chinese PLA General Hospital		Not recruiting	12 Years	75 Years	All	0	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
106	NCT03500289	August 10, 2018	16 September 2019	Ketamine for Treatment of MS Fatigue	Ketamine for Treatment of Multiple Sclerosis-related Fatigue	Multiple Sclerosis;Fatigue	Drug: Ketamine;Drug: Midazolam	Johns Hopkins University	National Multiple Sclerosis Society	Not recruiting	18 Years	65 Years	All	18	Phase 1/Phase 2	United States
107	EUCTR2017-004886-29-CZ	08/08/2018	7 January 2019	A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la Roche Sponsored Ocrelizumab Clinical Trial	A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL	Multiple sclerosis (MS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	750	Phase 3	Estonia;Finland;Spain;Ireland;Turkey;United Kingdom;Italy;France;Czech Republic;Denmark;Netherlands;Norway;Sweden
108	NCT03589105	August 6, 2018	30 September 2019	A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting	An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab 300 mg;Drug: Ocrelizumab 600 mg	Hoffmann-La Roche		Not recruiting	18 Years	N/A	All	423	Phase 4	France
109	NCT03584672	August 5, 2018	23 July 2018	The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis.	The Reliability, Validity, and Responsiveness of the Static Balance Test in Patients With Multiple Sclerosis.	Multiple Sclerosis	Other: One-leg Stance Test;Other: Functional Reach Test;Other: Four Square Step Test;Other: Timed Up an Go Test;Other: Berg Balance Scale;Other: Static Balance Test	Gazi University		Not recruiting	18 Years	N/A	All	30	N/A
110	NCT03562975	July 23, 2018	4 November 2019	Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus	A Single-center Prospective Measurement of Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus™	Multiple Sclerosis;Pathologic Processes;Demyelinating Diseases;Nervous System Diseases;Autoimmune Diseases;Immune System Diseases;Primary Progressive Multiple Sclerosis;Relapsing Remitting Multiple Sclerosis	Drug: Ocrelizumab	University of South Florida	Genentech, Inc.	Recruiting	18 Years	70 Years	All	35	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
111	NCT03567057	July 18, 2018	10 September 2018	A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment	A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment	Multiple Sclerosis;Walking Impairment	Drug: ADS-5102	Adamas Pharmaceuticals, Inc.		Recruiting	18 Years	70 Years	All	540	Phase 3	United States
112	NCT03979456	July 4, 2018	24 June 2019	RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS	RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS. A Randomized Trial of Long-term Dosage of Rituximab in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Rituximab	Karolinska Institutet		Recruiting	20 Years	52 Years	All	200	Phase 3	Sweden
113	NCT03000127	July 1, 2018	11 November 2019	Testosterone for Fatigue in Men With MS	A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis	Multiple Sclerosis	Drug: AndroGel 1 % Topical Gel;Drug: Placebos	University of California, Los Angeles	Washington University School of Medicine	Not recruiting	18 Years	60 Years	Male	0	Phase 2	United States
114	NCT03161028	July 1, 2018	11 November 2019	Lipoic Acid for Progressive Multiple Sclerosis (MS)	Lipoic Acid for the Treatment of Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Lipoic acid;Drug: Placebo	VA Office of Research and Development		Recruiting	18 Years	70 Years	All	118	Phase 2	United States;Canada
115	EUCTR2017-004886-29-DK	21/06/2018	19 November 2018	A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la Roche Sponsored Ocrelizumab Clinical Trial	A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED OCRELIZUMAB PHASE IIIb/IV CLINICAL TRIAL	Multiple sclerosis (MS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	750	Phase 3	Estonia;Finland;Spain;Ireland;Turkey;United Kingdom;Italy;France;Czech Republic;Denmark;Netherlands;Norway;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
116	NCT03369665	June 20, 2018	22 October 2019	Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS)	A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad®	Multiple Sclerosis	Drug: Mavenclad®	Merck KGaA, Darmstadt, Germany		Not recruiting	18 Years	N/A	All	486	Phase 4	Austria;Belgium;Czechia;Denmark;Finland;France;Greece;Hungary;Italy;Lithuania;Netherlands;Norway;Poland;Portugal;Slovakia;Spain;Sweden;United Kingdom;Germany
117	NCT03423121	June 19, 2018	26 August 2019	A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis	A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients	Progressive Multiple Sclerosis	Drug: Tauroursodeoxycholic Acid;Drug: Placebo oral capsule	Johns Hopkins University		Recruiting	18 Years	N/A	All	60	Phase 1/Phase 2	United States
118	EUCTR2017-000635-13-DE	08/06/2018	30 April 2019	Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption	Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption	Multiple Sclerosis (MS), acute episode MedDRA version: 20.0 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Pharmaceutical Form: Powder and solution for solution for injection INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2000-	Universität Leipzig		Authorised			Female: yes Male: yes	140	Phase 3	Germany
119	NCT03493841	June 8, 2018	1 April 2019	Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis	Comparing Gastrointestinal Tolerability and Absorption of Racemic Lipoic Acid and R-lipoic Acid in Progressive Multiple Sclerosis: a Randomized Crossover Trial	Multiple Sclerosis;Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Alpha Lipoic Acid	Rebecca Spain		Not recruiting	18 Years	N/A	All	20	Phase 1	United States
120	NCT03526224	June 4, 2018	22 October 2018	Teriflunomide Tecfidera LMCE	Effect of Teriflunomide on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective Observational Case-control Pilot Study	Tecfidera;Teriflunomide	Drug: Dimethyl Fumarate;Drug: Teriflunomide	University at Buffalo		Not recruiting	18 Years	65 Years	All	120	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
121	NCT03364036	May 28, 2018	2 September 2019	Evaluation of the Onset of Action in Highly Active Multiple Sclerosis (MS)	A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Mavenclad®	Merck KGaA, Darmstadt, Germany		Not recruiting	18 Years	N/A	All	270	Phase 4	Australia;Austria;Canada;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Poland;Spain;Sweden;United Kingdom;Belgium
122	NCT03523858	May 28, 2018	22 October 2019	A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis	An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis (PMS)	Drug: Ocrelizumab	Hoffmann-La Roche		Recruiting	18 Years	65 Years	All	600	Phase 3	United States;Algeria;Bosnia and Herzegovina;Brazil;Canada;Colombia;Costa Rica;Czechia;Denmark;Egypt;France;Guatemala;Hungary;Ireland;Italy;Lebanon;Mexico;Morocco;Netherlands;Panama;Poland;Russian Federation;Saudi Arabia;Spain;United Arab Emirates
123	NCT03610139	May 21, 2018	24 September 2018	Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients	Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients: A Single-Blind Randomized Clinical Trial	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting;Clinically Isolated Syndrome;Clinically Isolated Syndrome, CNS Demyelinating;Vitamin D3 Deficiency	Dietary Supplement: Vitamin D3	American University of Beirut Medical Center		Recruiting	18 Years	N/A	All	162	N/A	Lebanon
124	EUCTR2017-001313-93-ES	11/05/2018	18 June 2018	A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis	AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS	Progressive multiple sclerosis (PMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30-	Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD		Authorised			Female: yes Male: yes	600	Phase 3	United Arab Emirates;Saudi Arabia;Morocco;Costa Rica;Spain;Ireland;Lebanon;Russian Federation;Colombia;Italy;France;Denmark;Kuwait;Netherlands;Bosnia and Herzegovina;Panama;Guatemala;Egypt;Czech Republic;Hungary;Mexico;Canada;Brazil;Poland;Algeria
125	NCT03498131	May 9, 2018	7 October 2019	Melatonin in Patients With Multiple Sclerosis (MS).	Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS)	Relapsing Remitting Multiple Sclerosis	Drug: 3 mg Melatonin;Drug: 5 mg Melatonin	Providence Health & Services		Recruiting	18 Years	65 Years	All	30	Early Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
126	NCT03574428	May 8, 2018	3 June 2019	Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers	A Randomised, Double-Blind, Placebo Controlled, Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers	Multiple Sclerosis	Drug: GNbAC1;Other: GNbAC1 Placebo	GeNeuro Australia PTY Ltd		Not recruiting	18 Years	55 Years	Male	24	Phase 1	Australia
127	EUCTR2017-001313-93-IE	03/05/2018	7 January 2019	A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis	AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS	Progressive multiple sclerosis (PMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913/F07-01 (development) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913/F07-01 (commercial) Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	600	Phase 3	United Arab Emirates;Saudi Arabia;Morocco;Costa Rica;Spain;Ireland;Lebanon;Russian Federation;Colombia;Italy;France;Denmark;Kuwait;Netherlands;Bosnia and Herzegovina;Panama;Guatemala;Egypt;Czech Republic;Hungary;Mexico;Canada;Brazil;Poland;Algeria
128	NCT03585569	May 1, 2018	23 July 2018	Treating MS Patients With Lower Extremity Spasticity Using Dysport	A Prospective, Open Label, Single Center Study of Patients With Multiple Sclerosis With Lower Extremity Spasticity Who Are Treated With Dysport	Multiple Sclerosis;Spasticity, Muscle	Biological: Abobotulinumtoxin A	Neurology Center of New England P.C.	Ipsen	Recruiting	N/A	N/A	All	30	Phase 3	United States
129	EUCTR2018-000620-34-SE	24/04/2018	3 September 2018	Imatinib treatment for Multiple Sclerosis (MS) Relapses	Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study - Imatinib MS	Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where there are radiological and/or cerebrospinal fluid signs consistent with MS), which display an acute relapse MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: LLT Classification code 10028247 Term: Multiple sclerosis like syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Pharmaceutical Form: Film-coated tablet INN or Proposed INN: IMATINIB MESILATE CAS Number: 220127-57-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- Trade Name: Solu-Medrol Product Name: Solu-Medrol Pharmaceutical Form: Injection INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Concentration unit: g gram(s) Concentration type: equal Concentration number: 1-	Department of Clinical Neuroscience, Karolinska Institutet		Authorised			Female: yes Male: yes	200	Phase 2	Sweden
130	EUCTR2017-000426-35-AT	17/04/2018	10 September 2018	The efficacy of treatment of patients with multiple sclerosis, a chronic, inflammatory, autoimmune, disease that leads to neurologic deficits and aggravates with flairs, with low doses of rituximab, an antibody directed against the CD20 epitope on B Lymphocytes, specific cells of the immune system contributing to the progression of the disease - a pilot trial	Efficacy of Rituximab at low doses in Multiple Sclerosis – A prospective, randomized, double-blind, active controlled, pilo trial - Low-dose Rituximab in MS	Relapse Remitting Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera or biosimilar rituximab product Product Name: Rituximab Product Code: Rituximab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: Rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Mabthera or biosimilar rituximab product Product Name: Rituximab Product Code: Rituximab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Current Sponsor code: Rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Medical University of Vienna - Department of Neurology		Authorised			Female: yes Male: yes	70	Phase 2	Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
131	NCT03464448	April 17, 2018	16 September 2019	Mechanistic Studies of Teriflunomide in RRMS	Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS	Relapsing Remitting Multiple Sclerosis	Drug: Teriflunomide	University of Michigan		Recruiting	18 Years	65 Years	All	30	Phase 3	United States
132	NCT03501342	April 9, 2018	22 October 2018	Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis	Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis	Multiple Sclerosis	Other: Dynamic Balance Training;Other: Virtual reality group	Gazi University		Not recruiting	18 Years	65 Years	All	39	N/A	Turkey
133	EUCTR2017-001313-93-DK	04/04/2018	30 April 2019	A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis	AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS	Progressive multiple sclerosis (PMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	600	Phase 3	United Arab Emirates;Saudi Arabia;Morocco;Costa Rica;Spain;Ireland;Lebanon;Russian Federation;Colombia;Italy;France;Denmark;Kuwait;Netherlands;Bosnia and Herzegovina;Panama;Guatemala;Egypt;Czech Republic;Hungary;Mexico;Canada;Brazil;Poland;Algeria
134	NCT03319732	April 3, 2018	28 January 2019	A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS	An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)	Multiple Sclerosis;Spasticity, Muscle	Drug: Arbaclofen	Osmotica Pharmaceutical US LLC		Not recruiting	18 Years	65 Years	All	323	Phase 3	United States
135	JPRN-UMIN000031135	2018/04/01	2 April 2019	Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients		Neuromyelitis Optica	Mycophenolate mofetil treatment for 1 year	Kobe University Hospital		Recruiting	20years-old	80years-old	Male and Female	10	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
136	NCT03850301	April 1, 2018	18 March 2019	Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target	An Experimental Medicine Study to Validate the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target in Multiple Sclerosis	Multiple Sclerosis	Drug: XBD173;Drug: Etifoxine	Imperial College London		Recruiting	35 Years	65 Years	All	44	N/A	United Kingdom
137	NCT03436199	March 29, 2018	20 August 2018	Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment	A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment	Walking Impairment;Multiple Sclerosis	Other: Placebo;Drug: ADS-5102, 274 mg;Drug: ADS-5102, 137 mg	Adamas Pharmaceuticals, Inc.		Recruiting	18 Years	70 Years	All	540	Phase 3	United States
138	NCT03387046	March 26, 2018	26 August 2019	A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)	Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)	Multiple Sclerosis, Relapsing-Remitting	Dietary Supplement: D-aspartate;Drug: Placebo;Biological: IFN beta-1a;Drug: Methylprednisolone	Merck KGaA, Darmstadt, Germany		Not recruiting	18 Years	55 Years	All	7	Phase 2	Italy;Germany
139	NCT03266965	March 23, 2018	2 September 2019	Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach	Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach	Multiple Sclerosis	Drug: Carbidopa;Dietary Supplement: L-Histidine	University of Miami	United States Department of Defense	Recruiting	18 Years	60 Years	All	15	Phase 1	United States
140	EUCTR2017-004100-22-PL	21/03/2018	28 February 2019	Arbaclofen Extended-Release Tablets for Treatment of Spasticity in Patients with Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis (Study OS440-3004)	Spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Arbaclofen CAS Number: 69308-37-8 Current Sponsor code: OS440 Other descriptive name: AERT, (R)-Baclofen Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use	Osmotica Pharmaceutical US LLC		Not Recruiting			Female: yes Male: yes	510	Phase 3	Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
141	EUCTR2017-004101-40-PL	21/03/2018	28 February 2019	Long-Term Study of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity	An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity (Study OS440-3005).	Spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Arbaclofen CAS Number: 69308-37-8 Current Sponsor code: OS440 Other descriptive name: AERT, (R)-Baclofen Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-	Osmotica Pharmaceutical US LLC		Authorised			Female: yes Male: yes	300	Phase 3	Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina
142	NCT03477500	March 21, 2018	17 June 2019	RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS	Randomized Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab for Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Cyclophosphamide and ATG;Drug: Alemtuzumab	Haukeland University Hospital		Recruiting	18 Years	50 Years	All	100	Phase 3	Denmark;Netherlands;Norway;Sweden
143	EUCTR2017-004100-22-BG	16/03/2018	7 January 2019	Arbaclofen Extended-Release Tablets for Treatment of Spasticity in Patients with Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multiple Sclerosis (Study OS440-3004)	Spasticity in patients with multiple sclerosis MedDRA version: 20.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Arbaclofen Extended Release Tablets Product Code: OS440 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Arbaclofen CAS Number: 69308-37-8 Current Sponsor code: OS440 Other descriptive name: AERT, (R)-Baclofen Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use	Osmotica Pharmaceutical US LLC		Not Recruiting			Female: yes Male: yes	510	Phase 3	Serbia;Belarus;United States;Poland;Ukraine;Croatia;Russian Federation;Bulgaria;Moldova, Republic of;Bosnia and Herzegovina
144	JPRN-JapicCTI-173711	15/3/2018	10 September 2019	Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab	A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab	Relapsing Multiple Sclerosis	Intervention name : Ofatumumab INN of the intervention : - Dosage And administration of the intervention : Ofatumumab 20 mg subcutaneous injections every 4 weeks Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : Placebo subcutaneous injection matching to ofatumumab every 4 weeks	Novartis Pharma K.K.		Not Recruiting	18	55	BOTH	30	Phase 2	Japan, Russia
145	NCT03249714	March 15, 2018	4 November 2019	Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab	A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab	Relapsing Multiple Sclerosis	Drug: Ofatumumab subcutaneous injection;Drug: Placebo subcutaneous injection matching ofatumumab	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	64	Phase 2	Japan;Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
146	NCT03005119	March 1, 2018	16 December 2017	Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms	A Phase II, Double-blind, Randomized, Placebocontrolled, Parallel-group, Single-center Study to Evaluate the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in Multiple Sclerosis (MS) Patients With Spasticity-related Symptoms	Multiple Sclerosis	Drug: PTL201;Drug: Placebo Oral Capsule	PhytoTech Therapeutics, Ltd.		Not recruiting	18 Years	65 Years	All	70	Phase 2	Israel
147	EUCTR2016-004414-10-SE	23/02/2018	12 March 2018	Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.	Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.	Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Aubagio Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14-	MS Centrum, Department of Neurology, Sshlgrenska University Hospital		Authorised			Female: yes Male: yes	20	Phase 4	Sweden
148	NCT03551275	February 22, 2018	20 August 2018	Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis	A Multicenter Open-Label Non-Comparative Dose Escalation Study (Phase 1) of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 (JSC BIOCAD, Russia) in Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Biological: BCD-132	Biocad		Not recruiting	18 Years	60 Years	All	48	Phase 1	Russian Federation
149	EUCTR2017-001224-22-BE	02/02/2018	28 February 2019	Efficacy and Safety of BIIB033 as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies - Efficacy and Safety of BIIB033 as an Add-on Therapy to DMTs in RMS	Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10067063 Term: Progressive relapsing multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Opicinumab Product Code: BIIB033 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Opicinumab Other descriptive name: BIIB033 (ANTI-LINGO) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Biogen Idec Research Limited		Authorised			Female: yes Male: yes	240	Phase 2	United States;Spain;Israel;Italy;Switzerland;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Netherlands;Germany;Sweden
150	EUCTR2017-003008-30-GB	31/01/2018	21 May 2018	Simvastatin in Secondary Progressive Multiple Sclerosis	A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage - MS-OPT Version 1.0 dated 12/10/17	Multiple Sclerosis (Secondary Progressive) MedDRA version: 20.0 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Simvastatin 40 mg film-coated tablets Product Name: Simvastatin 40 mg film-coated tablets Product Code: Not applicable Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	University College London		Authorised			Female: yes Male: yes	40	Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
151	NCT03290131	January 28, 2018	9 September 2019	A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS	A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis	Multiple Sclerosis;Spasticity, Muscle	Drug: Arbaclofen;Drug: Placebo	Osmotica Pharmaceutical US LLC		Not recruiting	18 Years	65 Years	All	536	Phase 3	Belarus;Bosnia and Herzegovina;Bulgaria;Croatia;Moldova, Republic of;Poland;Serbia;United States
152	NCT03399981	January 24, 2018	24 June 2019	Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries	An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri	Progressive Multifocal Leukoencephalopathy	Biological: Tysabri	Biogen		Not recruiting	N/A	N/A	All	72600	N/A	United States
153	NCT03560739	January 18, 2018	11 November 2019	A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients	A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients	Multiple Sclerosis	Drug: OMB157	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	284	Phase 2	United States;Austria;Bulgaria;Czechia;Estonia;Latvia;Lithuania;Russian Federation;Spain
154	NCT03135249	January 1, 2018	22 October 2019	Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis	Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS)	Multiple Sclerosis (MS)	Drug: Alemtuzumab	University of Texas Southwestern Medical Center	Genzyme, a Sanofi Company	Not recruiting	18 Years	60 Years	All	40	Phase 4	United States
155	EUCTR2018-000516-22-PT		30 April 2019	Study to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TECFIDERA Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Plegridy Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: PEGINTERFERON BETA-1A CAS Number: 1211327-92-2 Current Sponsor code: BIIB017 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: up to Concentration number: 125- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use	Biogen Idec Research Limited		Not Available			Female: yes Male: yes	340	Phase 3	Serbia;Portugal;United States;Saudi Arabia;Taiwan;Estonia;Greece;Thailand;Turkey;Russian Federation;Israel;Colombia;Italy;Hungary;Mexico;Jordan;Malaysia;Croatia;Bulgaria;Tunisia;Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
156	NCT03670459	December 31, 2017	24 September 2018	Forty Five Patients With Multiple Sclerosis Recieved Vestibular Rehabilitation and Balance Training	Cawthorne Cooksey Versus Vestibular Habituation Exercises on Trunk Kinetics and Velocity of Gait in Patients With Multiple Sclerosis	Neurologic Disorder	Other: Cawthorne Cooksey exercises;Other: Vestibular habituation exercises;Other: Balance exercises	October 6 University		Not recruiting	35 Years	55 Years	All	45	N/A	Egypt
157	EUCTR2017-003328-56-GB	19/12/2017	26 November 2018	MS-STAT2 - Multiple Sclerosis – Simvastatin Trial 2	A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed simvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progression of disability - MS-STAT2	Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Simvastatin 40 mg film-coated tablets Product Name: Simvastatin 40 mg film-coated tablets Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Simvastatine Sandoz 40 mg filmomhulde tabletten Product Name: Simvastatine Sandoz 40 mg filmomhulde tabletten Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: SimvaHEXAL® 40 mg Filmtabletten Product Name: SimvaHEXAL® 40 mg Filmtabletten Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG Product Name: Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Sinvastatina Sandoz 40 mg comprimidos revestidos por película Product Name: Sinvastatina Sandoz 40 mg comprimidos revestidos por película Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Sivatin 40 mg film-coated tablets Product Name: Sivatin 40 mg film-coated tablets Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Simvastatine Sandoz 40mg deelbare filmomhulde tabletten Product Name: Simvastatine Sandoz 40mg deelbare filmomhulde tabletten Pharmaceutical Form: Tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: equal	University College London Comprehensive Clinical Trials Unit		Authorised			Female: yes Male: yes	1180	Phase 3	United Kingdom
158	NCT03385356	December 19, 2017	1 April 2019	Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis	Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Vitamin D Deficiency	Drug: Vitamin D	University Medical Centre Maribor	Medical Faculty Maribor	Not recruiting	18 Years	60 Years	All	89	Phase 4	Slovenia
159	EUCTR2017-004846-31-SI	14/12/2017	8 January 2018	Vitamin D supplementation in patients with multiple sclerosis	Impact of vitamin D supplementation in patients with multiple sclerosis	Relapsing remitting multiple sclerosis MedDRA version: 20.1 Level: LLT Classification code 10064137 Term: Progression of multiple sclerosis System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Oleovit D3 14.400 IU/ml oral drops, solution	University medical centre Maribor		Authorised			Female: yes Male: yes	95	Phase 4	Slovenia
160	EUCTR2017-000638-75-PL	13/12/2017	23 July 2018	UbLiTuximab In Multiple Sclerosis Treatment Effects	Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY) - ULTIMATE I STUDY	Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10029202 Term: Nervous system disorder System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ublituximab Product Code: TG-1101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: UBLITUXIMAB Current Sponsor code: TGTX 1101 Other descriptive name: LFB-R603 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Teriflunomide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	TG Therapeutics, Inc.		Authorised			Female: yes Male: yes	440	Phase 3	United Kingdom;Georgia;Russian Federation;Ukraine;Poland;Spain;United States;Belarus;Serbia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
161	NCT03362294	December 11, 2017	16 September 2019	Safety and Efficacy of Monthly Long-acting IM Injection of 40 mg GA Depot in Subjects With PPMS	A Prospective, Multicenter, Single Arm, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)	Primary Progressive Multiple Sclerosis	Drug: GA Depot 40mg once monthly	Mapi Pharma Ltd.		Recruiting	18 Years	65 Years	All	24	Phase 2	Israel
162	EUCTR2017-000638-75-ES	05/12/2017	26 March 2018	UbLiTuximab In Multiple Sclerosis Treatment Effects	Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY) - ULTIMATE I STUDY	Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10029202 Term: Nervous system disorder System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ublituximab Product Code: TG-1101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: UBLITUXIMAB Current Sponsor code: TGTX 1101 Other descriptive name: LFB-R603 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Product Name: Teriflunomide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	TG Therapeutics		Authorised			Female: yes Male: yes	440	Phase 3	Serbia;Belarus;United States;Poland;Spain;Ukraine;Russian Federation;Georgia;United Kingdom
163	EUCTR2017-000639-15-ES	05/12/2017	26 March 2018	UbLiTuximab In Multiple Sclerosis Treatment Effects	Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY) - ULTIMATE II STUDY	Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10029202 Term: Nervous system disorder System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ublituximab Product Code: TG-1101 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: UBLITUXIMAB Current Sponsor code: TGTX 1101 Other descriptive name: LFB-R603 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Product Name: Teriflunomide Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	TG Therapeutics		Authorised			Female: yes Male: yes	440	Phase 3	Belarus;United States;Poland;Spain;Ukraine;Romania;Croatia;Russian Federation;United Kingdom
164	NCT02988401	December 1, 2017	25 February 2019	Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis	Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive	Drug: Insulin;Drug: Placebo (Sterile diluent)	Johns Hopkins University	United States Department of Defense	Recruiting	18 Years	70 Years	All	105	Phase 1/Phase 2	United States
165	NCT03315923	December 1, 2017	3 June 2019	Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients	Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate	Secondary Progressive Multiple Sclerosis	Drug: Glatiramer Acetate;Drug: Rituximab	Isfahan University of Medical Sciences		Not recruiting	18 Years	55 Years	All	84	Phase 2/Phase 3	Iran, Islamic Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
166	NCT03353974	December 1, 2017	22 October 2018	Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients.	The Role of Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients. A Pilot Randomized Controlled Trial.	Multiple Sclerosis	Device: Video game therapy;Device: Balance platform therapy	University Hospital of Ferrara		Recruiting	18 Years	80 Years	All	40	N/A	Italy
167	NCT03347370	November 27, 2017	7 October 2019	A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis	Subcutaneous (SC) Interferon Beta Therapy in Multiple Sclerosis Patients and Characterization of Injection Site Reactions and Flu-Like Symptoms Under Daily Practice Setting	Multiple Sclerosis, Relapsing-Remitting	Drug: SC Peginterferon beta-1a;Drug: SC interferon beta-1a;Drug: SC interferon beta-1b	Biogen	AMS Advanced Medical Services GmbH	Not recruiting	18 Years	N/A	All	626	N/A	Germany
168	NCT03222973	November 14, 2017	13 May 2019	Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies	Multiple Sclerosis	Drug: BIIB033 (opicinumab);Drug: Placebo	Biogen		Not recruiting	18 Years	58 Years	All	263	Phase 2	United States;Australia;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom
169	NCT03342638	November 8, 2017	26 August 2019	Maximizing Outcome of Multiple Sclerosis Transplantation	Maximizing Outcome of Multiple Sclerosis Transplantation: MOST Trial	Multiple Sclerosis, Relapsing-Remitting	Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University		Not recruiting	18 Years	58 Years	All	200	Phase 3	United States
170	EUCTR2017-001176-31-GB	06/11/2017	28 February 2019	A long term follow up study to look at the progress of patients with symptoms suggestive of MS who took part in previous studies with Betaferon®/Betaseron®	BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies	Clinically-isolated syndrome (CIS) and multiple sclerosis (MS) MedDRA version: 20.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10071068 Term: Clinically isolated syndrome System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Betaferon 250 microgram/ml, powder and solvent for solution for injection Product Name: Betaferon Product Code: BAY86-5046 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: RECOMBINANT INTERFERON BETA-1B CAS Number: 145155-23-3 Current Sponsor code: BAY86-5046 Other descriptive name: RECOMBINANT INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250-	Bayer AG,		Not Recruiting			Female: yes Male: yes	300	Phase 4	Portugal;Slovenia;Finland;Spain;Austria;Israel;Italy;United Kingdom;Switzerland;France;Czech Republic;Hungary;Canada;Poland;Belgium;Denmark;Norway;Germany;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
171	NCT03244696	November 2, 2017	11 February 2019	Behavior and Activity Monitoring in MS	Behavior and Activity Monitoring in Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Behavioral: Step Tracking;Behavioral: Water Tracking	Ohio State University	National Multiple Sclerosis Society	Recruiting	30 Years	59 Years	All	200	N/A	United States
172	NCT03350633	November 1, 2017	4 November 2019	Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders	Safety and Efficacy of Tocilizumab Versus Azathioprine in Neuromyelitis Optica Spectrum Disorders: a Randomized, Controlled, Open-label, Phase 2 Trial	Neuromyelitis Optica Spectrum Disorders;Neuromyelitis Optica	Drug: Tocilizumab Injection;Drug: Azathioprine	Tianjin Medical University General Hospital		Not recruiting	18 Years	N/A	All	118	Phase 2/Phase 3	China
173	NCT02200718	November 2017	14 March 2016	A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis	A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis	Multiple Sclerosis	Biological: NeuroVax;Biological: IFA Incomplete Freund's Adjuvant	Immune Response BioPharma, Inc.	Oregon Health and Science University	Not recruiting	5 Years	17 Years	Both	12	Phase 1	United States
174	EUCTR2017-002838-23-ES	27/10/2017	13 November 2017	Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)	Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)	patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS) MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ORY2001 Product Code: ORY2001 Pharmaceutical Form: Capsule INN or Proposed INN: Not yet requested Current Sponsor code: ORY2001 Other descriptive name: PHENYLCYCLOPROPYLAMINE DERIVATIVES AND DUAL LSD1/MAO-B (LYSINE-SPECIFIC DEMETHYLASE 1 AND MONOAMINE OXIDASE-B) INHIBITOR Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0.6-1.2 Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Oryzon Genomics S. A		Authorised			Female: yes Male: yes	24	Phase 2	Spain
175	NCT03368664	October 24, 2017	28 October 2019	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT	A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)	Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: Glatiramer acetate;Drug: Beta-Interferon;Drug: Methylprednisolone;Drug: Ranitidine;Drug: Ceterizine;Drug: Dexchlorpheniramine;Drug: Paracetamol;Drug: Acyclovir;Drug: Prednisolone;Drug: Diphenydramine;Drug: Other H1 antagonist	Genzyme, a Sanofi Company		Recruiting	10 Years	17 Years	All	50	Phase 3	Austria;Belgium;Bulgaria;Czechia;France;Germany;Greece;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;Switzerland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
176	NCT03283826	October 19, 2017	14 October 2019	Phase 1 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis	A Phase 1, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis	Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Biological: ATA188;Drug: Placebo	Atara Biotherapeutics		Recruiting	18 Years	65 Years	All	72	Phase 1	United States;Australia
177	EUCTR2015-005431-41-PL	16/10/2017	10 October 2018	A late stage clinical trial to investigate the efficacy and safety of SA237 monotherapy in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SA237 Product Code: SA237-120/vial Pharmaceutical Form: Solution for injection INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: FULLY HUMANIZED ANTI-HUMAN IL-6 RECEPTOR (IL-6R) NEUTRALIZING MONOCLONAL ANTIBODY Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SA237 Product Code: SA237-120 PFS with NSD Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: FULLY HUMANIZED ANTI-HUMAN IL-6 RECEPTOR (IL-6R) NEUTRALIZING MONOCLONAL ANTIBODY Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120-	Chugai Pharmaceutical Co. Ltd		Authorised			Female: yes Male: yes	90	Phase 3	United States;Taiwan;Ukraine;Turkey;Russian Federation;Italy;Canada;Poland;Malaysia;Croatia;Romania;Bulgaria;Georgia;Korea, Republic of
178	NCT03344094	October 12, 2017	16 December 2017	Mechanism of Action of Ocrelizumab in Multiple Sclerosis	Mechanism of Action of Ocrelizumab in Multiple Sclerosis	Multiple Sclerosis;Immune System Diseases	Drug: ocrelizumab	University of Chicago		Recruiting	18 Years	65 Years	All	30	N/A	United States
179	NCT03207464	October 10, 2017	16 July 2018	Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis	Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis	Multiple Sclerosis	Drug: [C-11]Methylreboxetine	Brigham and Women's Hospital		Recruiting	18 Years	60 Years	All	19	Phase 1/Phase 2	United States
180	EUCTR2017-002636-16-NL	09/10/2017	23 October 2017	Understanding problems with attention, memory and concentration in persons with multiple sclerosis	Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate - GABA and glutamate in cognitive impairment in MS	Multiple Sclerosis (MS). And specifically cognitive problems in MS.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: [11C]flumazenil Pharmaceutical Form: Solution for injection in administration system	VU University medical center Amsterdam		Authorised			Female: yes Male: yes		Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
181	NCT03185065	October 4, 2017	1 April 2019	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis	Fatigue in Multiple Sclerosis	Drug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: Placebos	Johns Hopkins University	Patient-Centered Outcomes Research Institute	Not recruiting	18 Years	N/A	All	140	Phase 3	United States
182	EUCTR2016-004719-10-ES	02/10/2017	16 October 2017	A research study to look at the long term benefits and risks of ponesimod 20 mg treatment for patients with relapsing multiple sclerosis.	Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis - OPTIMUM LT	relapsing multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 6- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 8- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: PONESIMOD Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Product Name: Ponesimod Product Code: ACT-128800	Actelion Pharmaceuticals Ltd.		Authorised			Female: yes Male: yes	800	Phase 3	Bulgaria;Georgia;Germany;Sweden;Croatia;Romania;Poland;Canada;Mexico;Hungary;Czech Republic;United Kingdom;Lithuania;Turkey;Finland;Bosnia and Herzegovina;Latvia;France;Italy;Israel;Russian Federation;Ukraine;Spain;Greece;Portugal;United States;Belarus;Serbia
183	EUCTR2017-002634-24-SE	29/09/2017	6 November 2017	MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis.	MultipleMS – Multiple-omics approach to accelerate personalised medicine in a prospective cohort of newly diagnosed MS and CIS patients. - MultipleMS	Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 500-1000 Trade Name: Tysabri Pharmaceutical Form: Infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Tecfidera Pharmaceutical Form: Capsule INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Gilenya Pharmaceutical Form: Tablet INN or Proposed INN: FINGOLIMOD CAS Number: 162359-55-9 Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Copaxone Pharmaceutical Form: Injection INN or Proposed INN: GLATIRAMER ACETATE CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 20-40 Trade Name: Betaferon Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Trade Name: Extavia Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Trade Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7	Karolinska Institutet		Authorised			Female: yes Male: yes	150	Phase 4	Sweden
184	NCT03122652	September 25, 2017	23 April 2019	Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome	Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study	Multiple Sclerosis	Drug: Teriflunomide 14 MG Oral Tablet [Aubagio];Drug: Placebo Oral Tablet	Centre Hospitalier Universitaire de Nice	Genzyme, a Sanofi Company	Recruiting	18 Years	N/A	All	200	Phase 3	France;Germany;Martinique;Switzerland;Turkey;United Kingdom;Sweden
185	NCT03326505	September 25, 2017	16 December 2017	Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment	The Effect of Stem Cell Therapy and Comprehensive Physical Therapy in Motor and Non-Motor Symptoms in Patients With Multiple Sclerosis: A Comparative Study.	Multiple Sclerosis	Biological: Umbilical cord derived Mesenchymal Stem Cells;Other: Supervised physical therapy	University of Jordan		Recruiting	18 Years	65 Years	All	60	Phase 1/Phase 2	Jordan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
186	NCT03424733	September 25, 2017	26 August 2019	Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects	A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a	Multiple Sclerosis	Drug: Plegridy;Drug: Prednisone;Drug: Tylenol Pill	Holy Name Medical Center, Inc.	Biogen	Recruiting	18 Years	N/A	All	50	Phase 4	United States
187	EUCTR2017-001294-16-PL	22/09/2017	30 April 2019	A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate	A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate	Relapsing-Remitting Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: N/A Product Code: ALKS 8700 Delayed Release (DR) Pharmaceutical Form: Capsule INN or Proposed INN: Not available Current Sponsor code: RDC-5108-00, ALKS8700 Other descriptive name: Diroximel Fumarate (DRF) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 231- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Tecfidera® 120 mg Product Name: Tecfidera® 120 mg Pharmaceutical Form: Capsule INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Trade Name: Tecfidera® 240 mg Product Name: Tecfidera® 240 mg Pharmaceutical Form: Capsule INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Alkermes, Inc.		Authorised			Female: yes Male: yes	420	Phase 3	United States;Poland;Germany
188	NCT03330418	September 21, 2017	28 January 2019	A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders	A Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders.	Neuromyelitis Optica Spectrum Disorders	Biological: Placebo;Biological: RC18 160 mg	RemeGen		Recruiting	18 Years	65 Years	All	118	Phase 3	China
189	EUCTR2016-003622-16-FI	19/09/2017	2 October 2017	The effect of teriflunomide on brain microglial cell activation in multiple sclerosis.	Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study.	Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: AUBAGIO Product Name: Teriflunomide Product Code: L04AA31 Pharmaceutical Form: Film-coated tablet	Turku University Hospital		Authorised			Female: yes Male: yes		Phase 4	Finland
190	NCT03257358	September 19, 2017	2 September 2019	A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod	A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT]	Relapsing Multiple Sclerosis	Drug: Fingolimod	Novartis Pharmaceuticals		Not recruiting	18 Years	N/A	All	370	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
191	NCT03134573	September 15, 2017	8 April 2019	Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study	PROmyBETAapp: Ascertaining Medication Usage & Documentation of Patient Reported Outcomes Utilizing the myBETAapp® in Patients With Multiple Sclerosis Treated With Betaferon®: a Pilot Study	Multiple Sclerosis	Drug: Interferon beta-1b (Betaferon, BAY86-5046);Device: Betaconnect auto-injector;Device: myBETAapp	Bayer		Not recruiting	18 Years	N/A	All	96	Phase 2	Germany
192	NCT03282760	September 9, 2017	28 January 2019	Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients	A Phase I Multicenter Study of Allogenic, Intracerebroventricular Human Neural Stem Cells Transplantation for the Experimental Treatment of Secondary Progressive Multiple Sclerosis Patients	Secondary-progressive Multiple Sclerosis	Biological: Human Neural Stem Cells	Casa Sollievo della Sofferenza IRCCS	Associazione Revert ONLUS;Neurocenter of Southern Switzerland;Fondazione Cellule Staminali	Not recruiting	18 Years	60 Years	All	24	Phase 1	Italy;Switzerland
193	NCT03183869	August 24, 2017	16 December 2017	Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients	Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients	Autoimmune Diseases;Relapsing Multiple Sclerosis	Drug: Fecal microbiota	Lawson Health Research Institute		Recruiting	18 Years	N/A	All	40	Phase 2	Canada
194	EUCTR2017-001253-13-BE	23/08/2017	20 August 2018	Does decresaed perfusion of the brain play a role in the reduced function of axons and the clinical disability and fatigue in patients with multiple sclerosis ?	Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ? - ROCHIMS (Role of Cerebral Hypoperfusion In Multiple Sclerosis)	Patients suffering relapsing- remitting multiple sclerosis will be investigated in this study, with an EDSS score less or equal to 4.0. Patients must be older than 18 years old. There must not be any clinical evidence of an MS relpase within the 3 months prior to inclusion.;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Tracleer Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	UZ Brussel		Authorised			Female: yes Male: yes	30	Phase 2	Belgium
195	NCT03109288	August 11, 2017	4 November 2019	Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)	Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)	Multiple Sclerosis	Drug: Pioglitazone;Drug: Montelukast;Drug: Losartan;Drug: Hydroxychloroquine	National Institute of Allergy and Infectious Diseases (NIAID)		Recruiting	18 Years	99 Years	All	250	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
196	NCT02744222	August 10, 2017	20 August 2018	Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis	An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 µg and 240 µg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Biological: BCD-054 180 mcg;Biological: Avonex®;Biological: BCD-054 240 mcg;Other: Placebo	Biocad		Not recruiting	18 Years	60 Years	All	399	Phase 2/Phase 3	Russian Federation
197	EUCTR2016-000700-29-SE	07/08/2017	28 February 2019	Effect of MD1003 in progressive multiple sclerosis with walking impairment	Effect of MD1003 in progressive multiple sclerosis: a randomized-double blind placebo-controlled study. - SPI2	Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: D-Biotin Product Code: MD1003 Pharmaceutical Form: Capsule, hard INN or Proposed INN: D-BIOTIN CAS Number: 58-85-5 Current Sponsor code: MD1003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	MEDDAY PHARMACEUTICALS SA		Authorised			Female: yes Male: yes	754	Phase 3	United States;Spain;Turkey;United Kingdom;Italy;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Germany;Netherlands;Sweden
198	NCT03138421	August 1, 2017	4 February 2019	Central Pain Study for ABX-1431	A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain	Neuromyelitis Optica Spectrum Disorder;Transverse Myelitis;Multiple Sclerosis;Longitudinally Extensive Transverse Myelitis	Drug: ABX-1431 HCl;Drug: Placebo	Abide Therapeutics		Not recruiting	18 Years	N/A	All	9	Phase 1	United Kingdom
199	NCT03277248	August 1, 2017	11 November 2019	A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)	ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)	Relapsing Multiple Sclerosis (RMS)	Biological: Ublituximab;Drug: Teriflunomide	TG Therapeutics, Inc.		Not recruiting	18 Years	55 Years	All	500	Phase 3	United States
200	NCT03277261	August 1, 2017	11 November 2019	A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)	UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)	Relapsing Multiple Sclerosis (RMS)	Biological: Ublituximab;Drug: Teriflunomide	TG Therapeutics, Inc.		Not recruiting	18 Years	55 Years	All	500	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
201	NCT03232073	July 17, 2017	14 October 2019	Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis	Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Ponesimod	Actelion		Not recruiting	18 Years	65 Years	All	800	Phase 3	United States;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom
202	EUCTR2016-002937-31-BE	10/07/2017	28 February 2019	A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis	An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis	Relapsing remitting multiple sclerosis (RRMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	1078	Phase 3	Portugal;United States;Slovakia;Spain;Lebanon;Switzerland;Italy;France;Australia;Denmark;Kuwait;Netherlands;Slovenia;Turkey;Austria;United Kingdom;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Bulgaria;Norway;Germany;Sweden
203	NCT02903537	July 6, 2017	11 June 2018	Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)	Tolerance-Induction With Dendritic Cells Treated With Vitamin-D3 and Loaded With Myelin Peptides, in Multiple Sclerosis Patients (TOLERVIT-MS)	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Chronic Progressive	Drug: Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3);Drug: Interferon-beta	Fundació Institut Germans Trias i Pujol	Clinica Universidad de Navarra, Universidad de Navarra	Recruiting	18 Years	60 Years	All	16	Phase 1	Spain
204	NCT03250169	July 1, 2017	16 December 2017	Neurofilaments for NEDA Assessing in MS	Neurofilament Heavy and Light Chain Testing for NEDA (No Evidence of Disease Activity) Assessing in Multiple Sclerosis: a Longitudinal Biomarker Study	Multiple Sclerosis	Drug: Alemtuzumab	Queen Mary University of London		Recruiting	18 Years	55 Years	All	60	N/A	United Kingdom
205	EUCTR2016-002937-31-SE	19/06/2017	28 February 2019	A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis	An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis	Relapsing remitting multiple sclerosis (RRMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Ocrevus Product Name: Ocrelizumab Product Code: RO4964913/F07-01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	1078	Phase 3	Portugal;United States;Slovakia;Spain;Lebanon;Switzerland;Italy;France;Australia;Denmark;Kuwait;Netherlands;Slovenia;Turkey;Austria;United Kingdom;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Bulgaria;Norway;Germany;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
206	NCT03239860	June 6, 2017	18 December 2018	Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis	A Long-Term International, Extension of Study GNC-003 With GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: GNbAC1 Monoclonal Antibody	GeNeuro SA	Les Laboratoires Servier;Worldwide Clinical Trials;Institut de Recherches Internationales Servier	Not recruiting	18 Years	55 Years	All	220	Phase 2	Bulgaria;Croatia;Czechia;Estonia;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Spain;Ukraine
207	NCT03381170	June 1, 2017	11 November 2019	An Extension of the TG1101-RMS201 Trial	An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Biological: Ublituximab	TG Therapeutics, Inc.		Not recruiting	18 Years	55 Years	All	48	Phase 2	United States
208	NCT02618902	May 30, 2017	11 June 2018	A NegativeDendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial	A NegativeDendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial	Multiple Sclerosis	Biological: tolerogenic dendritic cells (tolDC)	University Hospital, Antwerp		Recruiting	18 Years	60 Years	All	9	Phase 1	Belgium
209	NCT02901106	May 23, 2017	21 January 2019	Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate	Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate SURV-SEP	Multiple Sclerosis, Relapsing-Remitting	Drug: Dimethyl fumarate	Fondation Ophtalmologique Adolphe de Rothschild		Not recruiting	18 Years	N/A	All	11	Phase 4	France
210	EUCTR2016-003587-39-SE	22/05/2017	4 December 2018	This is a long-term study of the safety, efficacy and patient satisfaction of the drug rituximab in comparison with other immunomodulatory treatments for multiple sclerosis. The study will use a national registry for both retrospective and prospective data retrieval.	COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis) A prospective long-term cohort study of safety, efficacy and patient’s satisfaction of MS disease modulatory treatments in relapsing-remitting multiple sclerosis - COMparison Between All immunoTherapies for Multiple Sclerosis (COMBAT-MS)	Relapsing-remitting multiple sclerosis (RRMS) that has started on their first or second immunomodulatory drug at the earliest 2011-01-01 and at the latest 2018-06-30. The clinical course and response to treatment is thereafter followed until 2021-06-30;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 500-1000 Trade Name: Tysabri Pharmaceutical Form: Infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Tecfidera Pharmaceutical Form: Capsule INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Gilenya Pharmaceutical Form: Tablet INN or Proposed INN: FINGOLIMOD CAS Number: 162359-55-9 Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Copaxone Pharmaceutical Form: Injection INN or Proposed INN: GLATIRAMER ACETATE CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 20-40 Trade Name: Betaferon Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Trade Name: Extavia Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Trade Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7	Karolinska Institutet		Authorised			Female: yes Male: yes	3700	Phase 4	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
211	NCT03126760	May 22, 2017	18 March 2019	Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	Relapsing, Remitting Multiple Sclerosis	Drug: Repository Corticotropin Injection;Drug: Placebo	Mallinckrodt		Recruiting	18 Years	N/A	All	66	Phase 4	United States
212	NCT03269071	May 17, 2017	11 March 2019	Neural Stem Cell Transplantation in Multiple Sclerosis Patients	Neural Stem Cell Transplantation in Multiple Sclerosis Patient: a Phase I Study	Progressive Multiple Sclerosis	Drug: human fetal-derived Neural Stem Cells (hNSCs)	IRCCS San Raffaele	Fondazione Italiana Sclerosi Multipla	Recruiting	18 Years	55 Years	All	4	Phase 1	Italy
213	NCT03028675	May 1, 2017	22 October 2019	pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress	pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress	Multiple Sclerosis	Drug: Gd-DTPA-ST;Drug: Control	NYU Langone Health		Not recruiting	18 Years	65 Years	All	4	Phase 4	United States
214	NCT03345940	April 30, 2017	4 November 2019	Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis	A Multicentric Randomized PRAGmatic Trial to Compare the Effectiveness of Fingolimod Versus Dimethyl-Fumarate on Patient Overall Disease Experience in Relapsing Remitting Multiple Sclerosis: Novel Data to Inform Decision-makers	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod;Drug: Dimethyl Fumarate	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	Patient-Centered Outcomes Research Institute;Universita degli Studi di Genova	Not recruiting	18 Years	N/A	All	55	Phase 4	Italy
215	NCT03073603	April 20, 2017	22 July 2019	Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)	Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)	Multiple Sclerosis	Drug: Discontinuation of disease modifying therapy;Drug: Standard of Care	University of Colorado, Denver	Patient-Centered Outcomes Research Institute;National Multiple Sclerosis Society;University of Alabama at Birmingham	Recruiting	55 Years	N/A	All	250	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
216	NCT02881567	April 18, 2017	7 October 2019	Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: Daclizumab	Biogen	AbbVie	Not recruiting	18 Years	55 Years	All	41	Phase 3	United States;Canada;Germany;Italy;Puerto Rico;France;United Kingdom
217	EUCTR2016-004935-18-HU	12/04/2017	23 October 2017	A clinical study to assess the long-term safety of GNbAC1 in patients with Multiple Sclerosis	A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis - ANGEL-MS	Multiple Sclerosis (MS) MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not Available CAS Number: 1393641-34-3 Current Sponsor code: GNbAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	GeNeuro SA		Authorised			Female: yes Male: yes	240	Phase 2	Serbia;Estonia;Czech Republic;Hungary;Poland;Spain;Ukraine;Croatia;Russian Federation;Bulgaria;Germany;Italy
218	EUCTR2016-003100-30-ES	04/04/2017	10 April 2017	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMT	A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis (RRMS) with Disease Activity on Prior Disease Modifying Therapy (DMT)	Multiple Sclerosis MedDRA version: 19.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Genzyme Corporation		Authorised			Female: yes Male: yes	65	Phase 3	Portugal;Greece;Spain;Turkey;Austria;Russian Federation;Switzerland;United Kingdom;Italy;France;Czech Republic;Poland;Belgium;Bulgaria;Norway;Netherlands;Germany;Sweden
219	NCT03085810	April 4, 2017	11 November 2019	Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)	An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Ocrelizumab	Hoffmann-La Roche		Not recruiting	18 Years	55 Years	All	1233	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Croatia;Denmark;France;Germany;Hungary;Italy;Kuwait;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Romania;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;Finland
220	NCT02907177	March 30, 2017	30 September 2019	Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)	Multicenter, Randomized, Double-blind, Parallel-group, add-on, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)	Multiple Sclerosis	Drug: Ponesimod;Other: Placebo	Actelion		Recruiting	18 Years	55 Years	All	600	Phase 3	United States;Australia;Austria;Belgium;Bulgaria;Canada;Czechia;Denmark;Finland;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;Russian Federation;Spain;Switzerland;United Kingdom;Croatia;Czech Republic;Norway
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
221	NCT03091400	March 28, 2017	25 June 2018	Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)	Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis	Memory Disorders;Multiple Sclerosis	Drug: Atomoxetine;Drug: Placebo	Icahn School of Medicine at Mount Sinai		Not recruiting	21 Years	60 Years	All	11	Phase 2	United States
222	NCT03110315	March 28, 2017	29 April 2019	A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia	A Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia	Multiple Sclerosis;Fatigue;Insomnia	Drug: Suvorexant;Drug: Placebo	Theodore R. Brown, MD MPH	Merck Sharp & Dohme Corp.	Recruiting	18 Years	75 Years	All	30	Phase 4	United States
223	NCT03093324	March 15, 2017	2 September 2019	A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2	A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate	Relapsing Remitting Multiple Sclerosis	Drug: ALKS 8700;Drug: Dimethyl Fumarate	Alkermes, Inc.		Not recruiting	18 Years	65 Years	All	506	Phase 3	United States;Germany;Poland
224	NCT03091569	March 10, 2017	11 June 2018	Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy	Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY)	Relapsing-Remitting Multiple Sclerosis	Other: Vitamin K Cream;Other: Placebo Cream	Biogen		Not recruiting	18 Years	N/A	All	23	Phase 4	Italy
225	EUCTR2016-000700-29-DE	08/03/2017	28 February 2019	Effect of MD1003 in progressive multiple sclerosis with walking impairment	Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study. - SPI2	Multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: D-Biotin Product Code: MD1003 Pharmaceutical Form: Capsule, hard INN or Proposed INN: D-BIOTIN CAS Number: 58-85-5 Current Sponsor code: MD1003 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	MEDDAY PHARMACEUTICALS SA		Authorised			Female: yes Male: yes	754	Phase 3	United States;Spain;Turkey;United Kingdom;Italy;Czech Republic;Hungary;Canada;Poland;Belgium;Australia;Germany;Netherlands;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
226	NCT02975349	March 7, 2017	28 January 2019	A Study of Efficacy and Safety of M2951 in Subjects With Relapsing Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.	Relapsing-remitting Multiple Sclerosis	Drug: M2951;Drug: Placebo;Drug: Tecfidera	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Not recruiting	18 Years	65 Years	All	267	Phase 2	Bulgaria;Czechia;Poland;Russian Federation;Serbia;Slovakia;Spain;Ukraine;Germany;United States
227	NCT03164018	March 7, 2017	25 February 2019	Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis	Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis	Multiple Sclerosis	Drug: Fampridine	Genesis Pharma CNS & Specialty		Not recruiting	18 Years	N/A	All	111	Phase 2	Greece
228	NCT03806387	March 1, 2017	28 January 2019	Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment	Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment - a Prospective Observational Study	Multiple Sclerosis	Drug: Alemtuzumab	University of Aarhus	Genzyme, a Sanofi Company	Recruiting	18 Years	65 Years	All	60	N/A	Denmark
229	NCT02149706	March 2017	14 March 2016	A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis	A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination	Multiple Sclerosis	Biological: NeuroVax;Biological: IFA Incomplete Freund's Adjuvant	Immune Response BioPharma, Inc.	Oregon Health and Science University	Not recruiting	18 Years	70 Years	Both	150	Phase 2	United States
230	EUCTR2016-001448-21-SK	16/02/2017	28 February 2019	A Study of Efficacy and Safety of M2951 in Relapsing Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 with a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients with Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.	Relapsing Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: M2951 Product Code: M2951 Pharmaceutical Form: Tablet INN or Proposed INN: M2951 Current Sponsor code: M2951 Other descriptive name: M2951 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Tecfidera Product Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: Tecfidera Product Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tecfidera CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240-	Merck KGaA		Authorised			Female: yes Male: yes	250	Phase 2	Serbia;United States;Czech Republic;Slovakia;Poland;Spain;Ukraine;Croatia;Turkey;Russian Federation;Bulgaria;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
231	NCT02949908	February 9, 2017	16 December 2017	MEasuring Satisfaction of Treatment With REbif After Initial Treatment of MS (MESTRE-MS)	A Phase IV, Prospective, Multicenter, Open Label, Uncontrolled, Non-interventional, Single Arm Study to Measure Treatment Satisfaction of Multiple Sclerosis (MS) Patients on Rebif® After Discontinuing Initial First-line Treatment	Multiple Sclerosis	Drug: Rebif (IFNß-1b)	Merck KGaA	Merck B.V., Netherlands	Not recruiting	18 Years	65 Years	All	2	N/A	Germany
232	NCT03193866	February 1, 2017	29 April 2019	COMparison Between All immunoTherapies for Multiple Sclerosis.	COMparison Between All immunoTherapies for Multiple Sclerosis. An Observational Long-term Prospective Cohort Study of Safety, Efficacy and Patient's Satisfaction of MS Disease Modulatory Treatments in Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: Rituximab	Karolinska Institutet	Patient-Centered Outcomes Research Institute;Kaiser Foundation Research Institute	Recruiting	18 Years	N/A	All	3700	N/A	Sweden
233	NCT03418376	February 1, 2017	21 January 2019	Carnosine Loading in MS and HC	The Impact of Carnosine Loading and Rehabilitation Therapy on Exercise Capacity in Multiple Sclerosis.	Multiple Sclerosis;Exercise Therapy;Dietary Supplement	Dietary Supplement: Beta-alanine supplementation;Other: Exercise intervention	Hasselt University		Not recruiting	18 Years	75 Years	All	45	N/A	Belgium
234	NCT02057159	February 2017	14 March 2016	A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis	A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis	Secondary Progress Multiple Sclerosis;Multiple Sclerosis	Biological: NeuroVax;Biological: IFA Placebo	Immune Response BioPharma, Inc.	Oregon Health and Science University	Not recruiting	18 Years	50 Years	Both	200	Phase 2/Phase 3	United States
235	NCT03021317	February 2017	16 December 2017	Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses	Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses	Multiple Sclerosis	Drug: ACTHar	University of Chicago		Not recruiting	18 Years	N/A	All	18	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
236	NCT03177083	January 30, 2017	24 September 2018	Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy	Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients With Relapsing Remitting Multiple Sclerosis (MS) Transitioning From Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)	Relapsing Remitting Multiple Sclerosis	Drug: peginterferon beta-1a;Drug: interferon beta-1a;Drug: interferon beta-1b	Biogen		Recruiting	18 Years	65 Years	All	140	Phase 4	Portugal
237	NCT03051646	January 13, 2017	26 November 2018	Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis	A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis	Overheating;Fatigue	Drug: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit;Drug: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit	Columbia University	National Multiple Sclerosis Society	Not recruiting	18 Years	60 Years	All	12	Early Phase 1	United States
238	NCT03032601	January 5, 2017	23 April 2019	Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis	Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: N-acetyl Cysteine	Thomas Jefferson University		Not recruiting	30 Years	80 Years	All	25	N/A	United States
239	NCT03193086	January 1, 2017	16 December 2017	The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients	The Effect of Alemtuzumab on the Blood-brain-barrier and Cerebral Metabolism in Multiple Sclerosis Patients; a New MRI Method for Treatment Response Evaluation in Multiple Sclerosis	Multiple Sclerosis	Drug: Alemtuzumab	Glostrup University Hospital, Copenhagen	Genzyme, a Sanofi Company	Recruiting	18 Years	60 Years	All	35	N/A	Denmark
240	NCT02481882	January 2017	22 October 2018	Baseline Cortical Haemodynamics in MS	Investigating Baseline Cortical Haemodynamics in Multiple Sclerosis	Multiple Sclerosis	Device: Magnetic Resonance Imaging;Drug: Prohance (Gadoteridol)	University of Nottingham		Recruiting	21 Years	80 Years	All	80	N/A	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
241	NCT02980042	January 2017	29 April 2019	Tolerability and Safety of Switching From Rituximab to Ocrelizumab in Patients With Relapsing Forms of Multiple Sclerosis	Evaluating the Tolerability and Safety Profile of Switching From Rituximab to Ocrelizumab: A Real World Evaluation of Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab;Drug: Rituximab	University of Colorado, Denver		Recruiting	18 Years	65 Years	All	200	Phase 3	United States
242	NCT03172741	January 2017	20 August 2018	The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis	The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis	Multiple Sclerosis	Drug: Medical Marijuana;Drug: Placebo	Colorado State University		Not recruiting	21 Years	74 Years	All	0	Phase 2/Phase 3
243	NCT04082260	January 2017	30 September 2019	Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response	Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers for Risk Stratification and Treatment Response	Multiple Sclerosis	Drug: Alemtuzumab Injection [Lemtrada]	University Hospital Muenster		Recruiting	18 Years	N/A	All	150	N/A	Germany
244	EUCTR2017-005129-18-IT		17 September 2018	Clinical trial to evaluate the effectiveness and safety of IFN beta-1a (IFN beta-1a), injected once a week via intramuscolar (i.m.), and glatiramer-acetate (GA) in children/adolescent patients with multiple sclerosis.	Multi-centre, randomised, open label pragmatic trial to compare the effectiveness and safety of interferon beta-1a (IFN-beta-1a) weekly i.m. and glatiramer-acetate (GA) in paediatric patients affected by multiple sclerosis.	Relapsing-remitting multiple sclerosis with paediatric onset MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Copaxone 40 mg/ml solution for injection, pre-filled syringe Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: Glatiramer Acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Trade Name: AVONEX 30 µg/0,5 ml solution for injection Pharmaceutical Form: Suspension for injection in pre-filled syringe INN or Proposed INN: Interferon beta-1a CAS Number: 145258-61-3 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30-	Università degli Studi Aldo Moro		Not Available			Female: yes Male: yes	142	Phase 3	Italy
245	NCT02969304	December 30, 2016	16 December 2017	Study of Utilization Patterns of Dimethyl Fumarate in Germany	Claims Database Study of Utilization Patterns of Dimethyl Fumarate in Germany	Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	N/A	N/A	All	930	N/A	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
246	NCT03186664	December 28, 2016	26 August 2019	The Role of SAtivex® in Robotic-Rehabilitation	The Role of SAtivex® Associated With Robotic-Rehabilitation in Improving the Motor Performances of Multiple Sclerosis Patients (SARR)	Rehabilitation	Device: Lokomat training;Drug: Sativex	IRCCS Centro Neurolesi Bonino-Pulejo		Not recruiting	18 Years	65 Years	All	40	N/A	Italy
247	NCT02977533	December 1, 2016	11 June 2018	A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: GZ402668;Drug: Placebo;Drug: Acyclovir	Sanofi		Not recruiting	18 Years	65 Years	All	20	Phase 1	Germany
248	NCT03561402	December 1, 2016	20 August 2018	Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)	Association of Possible Biomarkers With Disease Activity in Patients Treated With Teriflunomide (Aubagio)	Multiple Sclerosis, Relapsing-Remitting	Drug: Teriflunomide	McGill University		Recruiting	18 Years	55 Years	All	75	Early Phase 1	Canada
249	NCT02936037	December 2016	20 May 2019	Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)	Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study	Multiple Sclerosis	Drug: MD1003 100mg capsule;Drug: PLACEBO	MedDay Pharmaceuticals SA		Not recruiting	18 Years	65 Years	All	642	Phase 3	United States;Australia;Belgium;Canada;Czechia;Germany;Hungary;Italy;Poland;Spain;Sweden;Turkey;United Kingdom;Czech Republic;Netherlands
250	NCT02959658	December 2016	4 March 2019	Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis	Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis	Primary Progressive Multiple Sclerosis	Drug: Dimethyl Fumarate;Drug: Placebo Oral Capsule	Rigshospitalet, Denmark	Biogen	Not recruiting	18 Years	65 Years	All	90	Phase 2	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
251	EUCTR2015-005431-41-HR	30/11/2016	7 January 2019	A late stage clinical trial to investigate the efficacy and safety of SA237 monotherapy in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SA237 Product Code: SA237-120/vial Pharmaceutical Form: Solution for injection INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: SA237-120 PFS with NSD Product Code: L04AX01 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120-	Chugai Pharmaceutical Co. Ltd		Authorised			Female: yes Male: yes	90	Phase 3	United States;Taiwan;Ukraine;Turkey;Italy;Canada;Malaysia;Poland;Croatia;Romania;Bulgaria;Georgia;Korea, Republic of
252	EUCTR2016-002180-33-PL	16/11/2016	29 January 2018	Multiple sclerosis therapy with transdermal myelin peptide stimulation.	Multiple sclerosis therapy with transdermal myelin peptide stimulation.	relapsing-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: SMderpept Pharmaceutical Form: Powder for cutaneous solution INN or Proposed INN: PLP peptide Current Sponsor code: PLP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- INN or Proposed INN: MBP peptide Current Sponsor code: MBP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- INN or Proposed INN: MOG peptide Current Sponsor code: MOG peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Product Name: SMderpept Pharmaceutical Form: Powder for cutaneous solution INN or Proposed INN: PLP peptide Current Sponsor code: PLP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- INN or Proposed INN: MBP peptide Current Sponsor code: MBP peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- INN or Proposed INN: MOG peptide Current Sponsor code: MOG peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Product Name: Avonex Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta 1-A CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30-	Centrum Neurologii Krzysztof Selmaj		Authorised			Female: yes Male: yes	220	Phase 2	Poland
253	EUCTR2012-000541-12-DE	15/11/2016	6 November 2018	Clinical study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®)	Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are treated with dimethyl fumarate (Tecfidera®) - POINT	Relapsing multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s)	Actelion Pharmaceuticals Ltd.		Authorised			Female: yes Male: yes	600	Phase 3	Greece;Finland;United States;Portugal;Spain;Austria;Israel;Italy;France;Czech Republic;Hungary;Canada;Belgium;Poland;Australia;Denmark;Bulgaria;Germany
254	EUCTR2016-000434-21-PT	14/11/2016	30 April 2019	PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)	PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)	Relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Plegridy 125 micrograms Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: Peginterferon beta-1a CAS Number: 1211327-92-2 Other descriptive name: PEGINTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 125- Trade Name: Rebif 22 micrograms Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Trade Name: Rebif 44 micrograms Pharmaceutical Form: Solution for injection in pre-filled pen INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Trade Name: Betaferon 250 microgram/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Recombinant Interferon Beta-1b Other descriptive name: RECOMBINANT INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Extavia 250 micrograms/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Recombinant Interferon Beta-1b Other descriptive name: RECOMBINANT INTERFERON BETA-1B	Biogen Portugal		Authorised			Female: yes Male: yes	140	Phase 4	Portugal
255	NCT03516526	November 3, 2016	22 July 2019	Towards Personalized Dosing of Natalizumab in Multiple Sclerosis	Towards Personalized Dosing of Natalizumab in Multiple Sclerosis	Multiple Sclerosis	Drug: Natalizumab	VU University Medical Center	Sanquin Plasma Products BV;Erasmus Medical Center;St. Antonius Hospital;OLVG;Rijnstate Hospital	Not recruiting	18 Years	N/A	All	61	Phase 4	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
256	NCT02913157	November 2016	29 April 2019	Hydroxychloroquine in Primary Progressive Multiple Sclerosis	Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS)	Multiple Sclerosis, Primary Progressive	Drug: Hydroxychloroquine	University of Calgary		Recruiting	18 Years	65 Years	All	35	Phase 2	Canada
257	EUCTR2016-001515-20-IT	20/10/2016	12 February 2018	nd	EFFECT OF TERIFLUNOMIDE ON T CELL SUBPOPULATIONS IN PERIPHERAL BLOOD FROM RRMS PATIENTS - nd	RELAPSING-REMITTING MULTIPLE SCLEROSIS MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE Product Name: teriflunomide Product Code: nd Pharmaceutical Form: Film-coated tablet	UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI		Authorised			Female: yes Male: yes	30	Phase 4	Italy
258	NCT02587065	October 19, 2016	11 June 2018	Plegridy Satisfaction Study in Participants	Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM)	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: peginterferon beta-1a	Biogen		Not recruiting	18 Years	65 Years	All	199	Phase 4	Italy
259	NCT02601885	October 18, 2016	11 June 2018	A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis	An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: ABT-555;Other: Placebo	AbbVie		Not recruiting	18 Years	60 Years	All	20	Phase 1	United States
260	NCT01649050	October 2016	16 December 2017	Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis	A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Assess the Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis	Muscle Spasticity Due to Multiple Sclerosis	Drug: BGG492;Drug: Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	0	Phase 2	Germany;Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
261	NCT02807285	October 2016	16 December 2017	Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis	An Open Label, MultiCenter, Expanded-Access Program for Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab	Genentech, Inc.		Not recruiting	18 Years	55 Years	All		N/A	United States
262	EUCTR2016-000345-31-NL	30/09/2016	10 October 2016	Reduce the number of natalizumab infusions in patients with multiple sclerosis	Towards personalized dosing of natalizumab in multiple sclerosis - Personalised Dosing of Natalizumab in Multiple Sclerosis (The PDNMS trial)	multiple sclerosis MedDRA version: 18.1 Level: LLT Classification code 10070425 Term: Multiple sclerosis exacerbation System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: tysabri Product Name: natalizumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	VU medical center		Authorised			Female: yes Male: yes	60	Phase 4	Netherlands
263	EUCTR2016-003073-18-GB	29/09/2016	3 April 2017	A study designed to investigate how radiolabelled RPC1063 is taken up, broken down and removed from the body	A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults - ADME study of [14C]-RPC1063 in healthy male subjects (QCL117686)	The drug is a potential treatment for adult patients with relapsing multiple sclerosis (RMS) and for adult patients with moderately to severely active inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). MedDRA version: 19.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856 MedDRA version: 19.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: [14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration Pharmaceutical Form: Oral solution INN or Proposed INN: Ozanimod hydrochloride CAS Number: 1618636-37-5 Current Sponsor code: RPC1063HCL Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.1-	Celgene International II Sàrl		Authorised			Female: no Male: yes	6	Phase 1	United Kingdom
264	NCT03101735	September 23, 2016	20 August 2018	Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece	A Real Life, Non-interventional, Multicentre Study to Assess Resource Utilization and Quality of Life of Patients With Relapsing Forms of Multiple Sclerosis Treated With Dimethyl Fumarate in Greece - the FIDELITY Study	RRMS	Drug: Dimethyl Fumarate (DMF)	Genesis Pharma CNS & Specialty		Not recruiting	18 Years	65 Years	All	455	N/A	Greece
265	JPRN-UMIN000024312	2016/09/20	2 April 2019	Studies of efficacy and safety of the combined use of febuxostat and inosine for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis, and changes of blood and urine purine compounds.		Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic		Not Recruiting	20years-old	80years-old	Male and Female	12	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
266	NCT02792218	September 20, 2016	16 September 2019	Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis	A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: Placebo subcutanous injection matching to ofatumumab;Drug: Teriflunomide orally;Drug: Placebo orally matching to teriflunomide;Drug: Ofatumumab subcutaneous injection	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	929	Phase 3	Sweden;Switzerland;Thailand;Turkey;United Kingdom;United States;Argentina;Australia;Belgium;Bulgaria;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;Slovakia;Spain
267	EUCTR2015-005418-31-EE	12/09/2016	28 February 2019	Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosis	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis	multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Current Sponsor code: OMB157 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Aubagio Product Name: Teriflunomide Pharmaceutical Form: Capsule, hard INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Authorised			Female: yes Male: yes	900	Phase 3	United States;Estonia;Slovakia;Greece;Thailand;Spain;Russian Federation;Israel;Switzerland;India;France;Australia;Denmark;Netherlands;Turkey;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Belgium;Poland;Croatia;Bulgaria;Germany;Sweden
268	EUCTR2016-000283-41-DK	12/09/2016	6 November 2018	Treatment with dimethyl fumarate in patients with primary progressive multiple sclerosis	Dimethyl fumarate treatment of primary progressive multiple sclerosis - FUMAPMS	Primary progressive multiple sclerosis (PPMS) MedDRA version: 20.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera Product Name: dimethyl fumarate Product Code: dimethyl fumarate Pharmaceutical Form: Capsule, hard INN or Proposed INN: dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Finn Sellebjerg		Authorised			Female: yes Male: yes	90	Phase 2	Denmark
269	NCT02861014	September 9, 2016	22 October 2019	A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)	An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment	Multiple Sclerosis, Relapsing-Remitting	Biological: Ocrelizumab	Hoffmann-La Roche		Not recruiting	18 Years	55 Years	All	681	Phase 3	Australia;Belgium;Czechia;Denmark;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;Turkey;United Kingdom;Czech Republic;Hong Kong
270	NCT02898974	September 2016	22 January 2018	Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis	Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis: An Observational Case-control Study	Multiple Sclerosis	Behavioral: Medical Marijuana	Colorado State University	William R. Shaffer, M.D.	Not recruiting	30 Years	60 Years	All	19	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
271	NCT02792231	August 26, 2016	16 September 2019	Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.	A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.	Relapsing Multiple Scelrosis	Drug: Ofatumumab subcutaneous injection;Drug: Placebo orally matching to teriflunomide;Drug: Teriflunomide orally;Drug: Placebo subcutaneous injection matching to ofatumumab	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	900	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Croatia;Czechia;Finland;France;Germany;Hungary;India;Italy;Latvia;Lithuania;Mexico;Norway;Peru;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom
272	EUCTR2015-003147-19-GR	18/07/2016	8 August 2016	To confirm the safety and efficacy of NEUROASPIS PLP10® in the treatment of individuals, who have been diagnosed with relapsing remitting multiple sclerosis (MS).	Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Controlled, Add-on with Interferon Beta, Trial of Efficacy and Safety. - Efficacy and Safety study of NEUROASPIS PLP10® versus placebo	Relapsing-Remitting Multiple Sclerosis (RRMS) MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: NEUROASPIS PLP10® Pharmaceutical Form: Oral liquid INN or Proposed INN: FISH OIL,RICH IN OMEGA 3 ACIDS Other descriptive name: FISH OIL, RICH IN OMEGA-3-ACIDS Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 42.1- INN or Proposed INN: BORAGE OIL 20% GLA CAS Number: 8000051-62-9 Other descriptive name: BORAGE OIL Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 43.7- INN or Proposed INN: beta-Carotene Other descriptive name: BETACAROTENE Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 0.04- INN or Proposed INN: Gamma-tocopherol CAS Number: 54 28 4 Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 4.2- Pharmaceutical form of the placebo: Oral liquid Route of administration of the placebo: Oral use	PALUPA Medical Ltd		Authorised			Female: yes Male: yes	220	Phase 3	Greece
273	NCT03436927	July 15, 2016	26 February 2018	Comparison of Two Different Virtual Reality Methods in Patients With Multiple Sclerosis	Comparison of the Effects of Two Different Virtual Reality Treatment Methods in Patients With Multiple Sclerosis: A Randomized Controlled Trial	Multiple Sclerosis	Other: Nintendo Wii Fit Balance exercises;Other: Balance Trainer Balance Exercises	Biruni University	Istanbul University	Not recruiting	25 Years	60 Years	All	51	N/A
274	NCT02660359	July 8, 2016	11 November 2019	Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2	A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis	Urinary Incontinence;Overactive Bladder	Biological: Botulinum toxin type A;Drug: Placebo	Ipsen		Not recruiting	18 Years	80 Years	All	258	Phase 3	Argentina;Australia;Belgium;Brazil;Chile;Colombia;France;Germany;Israel;Lithuania;Mexico;Peru;Russian Federation;Spain;Ukraine;United Kingdom;New Zealand
275	NCT02760056	July 2016	5 September 2016	Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study	Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study	Multiple Sclerosis	Drug: Liothyronine sodium;Drug: Placebo	Oregon Health and Science University		Recruiting	18 Years	50 Years	Both	24	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
276	NCT02833142	July 2016	9 January 2017	Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes	A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers	Multiple Sclerosis;Acute Optic Neuritis	Drug: BIIB033 (opicinumab)	Biogen		Not recruiting	18 Years	55 Years	Both	28	Phase 1	United States
277	NCT02869425	July 2016	9 September 2019	To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS	A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With Multiple Sclerosis	Multiple Sclerosis;Sperm	Drug: arbaclofen ER Tablets;Drug: Placebo for arbaclofen ER tablets	Osmotica Pharmaceutical US LLC		Not recruiting	18 Years	55 Years	Male	0	Phase 3	United States
278	NCT03069170	July 2016	18 June 2018	Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.	Safety and Efficacy of Immuno-modulation and Autologous Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Multiple Sclerosis.	Multiple Sclerosis	Biological: Stem Cell Transplantation	Stem Cells Arabia		Not recruiting	N/A	N/A	All	50	Phase 1	Jordan
279	NCT02921035	June 30, 2016	30 September 2019	Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis	A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With Relapsing Multiple Sclerosis (RMS) Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a	Relapsing Multiple Sclerosis	Drug: Rebif (Interferon beta-1a)	Merck KGaA, Darmstadt, Germany	Merck Serono Middle East FZ LLC	Not recruiting	18 Years	60 Years	All	594	N/A	Algeria;Argentina;Bahrain;Bulgaria;Egypt;Hungary;Iran, Islamic Republic of;Korea, Republic of;Kuwait;Lebanon;Morocco;Poland;Saudi Arabia;Germany;Tunisia;United Arab Emirates
280	EUCTR2015-000507-44-DE	29/06/2016	21 May 2018	A study to investigate DYSPORT® for the treatment of subjects with loss of bladder control and involuntary urination as a result of spinal cord injury or multiple sclerosis	A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT® FOR THE TREATMENT OF URINARY INCONTINENCE IN SUBJECTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY OR MULTIPLE SCLEROSIS	Urinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis MedDRA version: 20.1 Level: PT Classification code 10046543 Term: Urinary incontinence System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Not possible to specify	Trade Name: Dysport® Product Name: Dysport® Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CLOSTRIDIUM BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Current Sponsor code: 52120 Other descriptive name: BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX Concentration unit: U unit(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intravesical use Trade Name: Dysport® Product Name: Dysport® Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CLOSTRIDIUM BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Current Sponsor code: 52120 Other descriptive name: BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX Concentration unit: U unit(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intravesical use	Ipsen Innovation		Authorised			Female: yes Male: yes	330	Phase 3	Spain;Ukraine;Lithuania;Russian Federation;Chile;Israel;Colombia;United Kingdom;France;Mexico;Argentina;Belgium;Brazil;Peru;Germany;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
281	NCT02797015	June 23, 2016	11 June 2018	Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS	A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: RPC1063	Celgene		Not recruiting	18 Years	55 Years	All	22	Phase 1	United States
282	EUCTR2016-000464-42-DE	13/06/2016	11 June 2018	The Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of Alemtuzumab	A Prospective, Open-label, Interventional Phase IIIb Clinical Trial to Investigate the Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 Courses of Alemtuzumab - LemCourse	Relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Other descriptive name: ALEMTUZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Genzyme GmbH		Authorised			Female: yes Male: yes	100	Phase 3	Germany
283	NCT02424396	June 13, 2016	11 February 2019	Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis	Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study	Relapsing Remitting Multiple Sclerosis	Drug: IL2;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	Fondation ARSEP/AFM	Recruiting	18 Years	65 Years	All	30	Phase 2	France
284	NCT03150966	June 8, 2016	24 September 2018	The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients	The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Multiple Sclerosis Patients	Multiple Sclerosis	Drug: Nanocurcumin;Drug: Placebo	Tabriz University of Medical Sciences		Not recruiting	18 Years	65 Years	All	41	Phase 2	Iran, Islamic Republic of
285	EUCTR2015-005160-41-PL	07/06/2016	28 February 2019	an Open Label Study of ALKS 8700 in Adults with Multiple Sclerosis	A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis - EVOLVE-MS-1	Relapsing Remitting Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: N/A Product Code: ALKS 8700 Delayed Release (DR) Capsule Pharmaceutical Form: Capsule INN or Proposed INN: Not available CAS Number: Not availabl Current Sponsor code: RDC-5108-00, ALKS 8700 Other descriptive name: ALKS 8700 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 231-	Alkermes, Inc.		Authorised			Female: yes Male: yes	800	Phase 3	Serbia;United States;Canada;Belgium;Spain;Poland;Ukraine;Russian Federation;Bulgaria;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
286	NCT02446886	June 2016	14 January 2019	Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS	Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS	Multiple Sclerosis	Drug: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)	Weill Medical College of Cornell University	Mallinckrodt	Recruiting	18 Years	N/A	All	30	Phase 4	United States
287	NCT02609607	June 2016	18 December 2018	Treating Anorectal Dysfunction in MS	Treating Anorectal Dysfunction Associated With Multiple Sclerosis	Constipation;Fecal Incontinence;Multiple Sclerosis	Drug: Bisacodyl;Other: Placebo	David Levinthal	Consortium of Multiple Sclerosis Centers	Not recruiting	18 Years	80 Years	All	11	Phase 2	United States
288	NCT02870023	June 2016	4 March 2019	How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?	How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?	Multiple Sclerosis	Other: Balance training;Other: Strength training	University of Aarhus	VIA University College;TrygFonden, Denmark;Fondazione Don Carlo Gnocchi Onlus	Not recruiting	18 Years	N/A	All	71	N/A	Denmark
289	NCT02784210	May 26, 2016	23 April 2019	Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques	The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study	Multiple Sclerosis	Drug: Methylprednisolone	National Institute of Neurological Disorders and Stroke (NINDS)		Recruiting	25 Years	55 Years	All	10	Phase 2	United States
290	NCT02676739	May 20, 2016	1 April 2019	Adderall XR and Cognitive Impairment in MS	A Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MS	Multiple Sclerosis	Drug: Adderall XR	Sarah Morrow		Recruiting	18 Years	59 Years	All	180	Phase 2/Phase 3	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
291	EUCTR2015-005597-38-GB	19/05/2016	7 January 2019	A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis	An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment - CASTING	Relapsing remitting multiple sclerosis (RRMS) MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ocrelizumab Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30-	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	750	Phase 3	Estonia;Greece;Finland;Spain;Ireland;Turkey;Italy;United Kingdom;Switzerland;France;Czech Republic;Belgium;Denmark;Norway;Netherlands;Germany;Sweden
292	NCT03237832	May 16, 2016	16 December 2017	A Phase 1 Study of ARN-6039	A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Oral Doses of ARN-6039 in Healthy Adult Subjects.	Multiple Sclerosis	Drug: ARN-6039;Other: Placebo	Arrien Pharmaceuticals	Worldwide Clinical Trials	Not recruiting	18 Years	50 Years	All	60	Phase 1
293	EUCTR2015-004059-29-HU	04/05/2016	19 February 2018	Clinical study to assess efficacy, safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis	An international, double-blind, randomised, placebo-controlled phase IIb trial to assess the efficacy, safety, and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis - CHANGE-MS	Multiple Sclerosis (MS) MedDRA version: 19.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not available CAS Number: 1393641-34-3 Current Sponsor code: GNbAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not available CAS Number: 1393641-34-3 Current Sponsor code: GNBAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: GNbAC1 Product Code: GNbAC1 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Not available CAS Number: 1393641-34-3 Current Sponsor code: GNBAC1 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	GeNeuro SA		Not Recruiting			Female: yes Male: yes	260	Phase 2	Serbia;Estonia;Spain;Ukraine;Russian Federation;Italy;France;Hungary;Czech Republic;Poland;Croatia;Bulgaria;Germany
294	NCT02749396	May 2, 2016	26 August 2019	EPID Multiple Sclerosis Pregnancy Study	Pregnancy Outcomes in Multiple Sclerosis Populations Exposed and Unexposed to Interferon ß - a Register-based Study in the Nordic Countries	Multiple Sclerosis	Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG;Drug: Extavia (interferon beta-1b), Novartis Pharma AG;Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd;Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd;Drug: Avonex (interferon beta-1a), Biogen Idec Ltd;Drug: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046);Other: No MSDMDs therapy (control)	Bayer	EPID Research;Biogen;Merck Serono Europe Ltd;Novartis Pharmaceuticals	Not recruiting	N/A	N/A	Female	2089	Early Phase 1	Finland
295	NCT03566251	May 1, 2016	2 July 2018	Core Stability, Trunk Position Sense, Balance and Functional Mobility in Patients With Multiple Sclerosis	The Investigation of the Relationship Between Core Stability and Trunk Position Sense With Balance and Functional Mobility in Patients With Multiple Sclerosis	Physical Therapy	Other: Balance;Other: Functional mobility;Other: Core stability;Other: Trunk position sense	Ankara Yildirim Beyazit University		Not recruiting	18 Years	65 Years	All	74	N/A	Turkey
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
296	NCT02428218	May 2016	25 April 2016	Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)	A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Relapsing Forms of Multiple Sclerosis	Drug: Placebo;Drug: dimethyl fumarate	Biogen		Not recruiting	10 Years	17 Years	Both	0	Phase 3
297	NCT02670161	May 2016	26 August 2019	Quality Improvement and Practice Based Research in Neurology Using the EMR	Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record	Brain Tumors;Epilepsy;Migraine;Mild Cognitive Impairment;Concussion;Multiple Sclerosis;Neuropathy;Parkinson's;Restless Legs Syndrome;Stroke	Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)	NorthShore University HealthSystem		Recruiting	18 Years	100 Years	All	3300	Phase 4
298	NCT02746744	May 2016	17 June 2019	RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.	RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.	Multiple Sclerosis, Relapsing-Remitting	Drug: Rituximab;Drug: Dimethyl fumarate;Drug: Sodium Chloride solution	Anders Svenningsson		Not recruiting	18 Years	50 Years	All	200	Phase 3	Sweden
299	NCT02688985	April 29, 2016	11 November 2019	Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)	An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis	Relapsing Multiple Sclerorsis;Multiple Sclerosis, Primary Progressive	Drug: Ocrelizumab;Procedure: Lumbar Puncture;Drug: Methyloprednisolone;Drug: Antihistamine	Genentech, Inc.		Recruiting	18 Years	55 Years	All	120	Phase 3	United States;Canada;Germany;Sweden
300	NCT02675413	April 2016	8 August 2016	Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS	Mechanisms of Action of Dimethyl Fumarate in Relapsing MS	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Dimethyl Fumarate	Washington University School of Medicine	Biogen	Not recruiting	18 Years	N/A	Both	0	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
301	NCT02769689	April 2016	23 May 2016	Methylprednisolone During the Switch Between Natalizumab and Fingolimod	Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY)	Multiple Sclerosis	Drug: Methylprednisolone;Drug: Placebo;Drug: natalizumab (NTZ);Drug: fingolimob (FTY)	University Hospital, Clermont-Ferrand		Recruiting	18 Years	65 Years	Both	56	Phase 4	France
302	NCT02739542	March 19, 2016	27 May 2019	Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)	Multi-center, Randomized, Double-blinded Assessment of Tecfidera® in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE)	Multiple Sclerosis (MS)	Drug: Tecfidera;Drug: Placebo	University of Texas Southwestern Medical Center	Biogen	Recruiting	18 Years	N/A	All	90	Phase 4	United States
303	NCT02738775	March 18, 2016	11 November 2019	Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis	A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.	Multiple Sclerosis	Biological: Ublituximab;Drug: Placebo	TG Therapeutics, Inc.		Not recruiting	18 Years	55 Years	All	48	Phase 2	United States
304	NCT02636829	March 2016	26 September 2016	Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis	Validation of Self-administered Questionnaire Specifically for Assessing Calcium Intake (QALCIMUM®) in Patients With Multiple Sclerosis (MS) or Chronic Inflammatory Arthritis	Multiple Sclerosis;Rheumatoid Arthritis	Other: QALCIMUM questionnaire;Other: Determination of calcium intake by a dietician interview	Centre Hospitalier Universitaire de Nimes		Not recruiting	18 Years	69 Years	Both	100	N/A	France
305	NCT02660138	March 2016	11 November 2019	Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1	A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis	Urinary Incontinence;Overactive Bladder	Biological: Botulinum toxin type A;Drug: Placebo	Ipsen		Not recruiting	18 Years	80 Years	All	227	Phase 3	United States;Canada;Czechia;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Turkey;Czech Republic;Malaysia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
306	NCT02555215	February 22, 2016	18 December 2018	Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)	A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: dimethyl fumarate	Biogen		Not recruiting	10 Years	17 Years	All	20	Phase 3	United States;Belgium;Bulgaria;Czechia;Germany;Kuwait;Latvia;Lebanon;Poland;Turkey;Czech Republic
307	EUCTR2015-004451-40-CZ	17/02/2016	3 July 2017	SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS	SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL - SAVANT	Moderate to severe spasticity due to MS (multiple sclerosis). MedDRA version: 19.0 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SATIVEX Pharmaceutical Form: Oromucosal spray Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use	Almirall Hermal GmbH		Not Recruiting			Female: yes Male: yes	228	Phase 4	Czech Republic;Austria
308	NCT02575365	February 16, 2016	16 December 2017	Effect of Fingolimod on Neurodegeneration	Effect of Fingolimod on Neurodegeneration, Brain Atrophy and Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients	Cognition;Brain Volume Loss	Drug: 0,5 mg Fingolimod	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	4	Phase 4	Turkey
309	NCT02637856	February 11, 2016	30 September 2019	A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)	An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment	Multiple Sclerosis, Relapsing-Remitting	Drug: Ocrelizumab	Genentech, Inc.		Not recruiting	18 Years	55 Years	All	611	Phase 3	United States;Canada
310	NCT02652091	February 5, 2016	17 September 2018	Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction	Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta-1b (Betaseron, BAY86-5046);Device: BETACONNECT device	Bayer		Not recruiting	18 Years	N/A	All	146	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
311	EUCTR2015-002820-20-NL	03/02/2016	7 January 2019	Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis?	Are alpha blockers effective in the treatment of bladder elimination problems in female patients with Multiple Sclerosis? - Alpha blockers and Multiple Sclerosis (MS)	Bladder dysfunction in Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10069632 Term: Bladder dysfunction System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Silodyx Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Erasmus MC Dept. Urology		Authorised			Female: yes Male: no	30	Phase 3	Netherlands
312	NCT02601131	February 2016	12 December 2016	Post-transfusion Platelet Count	Post-transfusion Platelet Count	Leukemia;Multiple Sclerosis	Biological: Platelet transfusion	Region Skane		Not recruiting	18 Years	N/A	Both	80	N/A	Sweden
313	NCT02641041	February 2016	17 October 2016	Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants	A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects	Central Nervous System (CNS) Demyelinating Disease;Multiple Sclerosis	Biological: BIIB033;Other: Placebo	Biogen		Not recruiting	20 Years	55 Years	Both	24	Phase 1	United Kingdom
314	NCT02644083	February 2016	10 September 2018	Tecfidera and MRI for Brain Energy in MS	Modulation of Cerebral Grey Matter High Energy Phosphate Metabolites in Multiple Sclerosis by Dimethyl Fumarate	Multiple Sclerosis	Drug: Dimethyl fumarate	Oregon Health and Science University	Biogen	Not recruiting	18 Years	55 Years	All	4	N/A	United States
315	NCT02710214	February 2016	15 July 2019	A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis	Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial.	Menopause;Multiple Sclerosis	Drug: Tissue Selective Estrogen Complex;Drug: Placebo	University of California, San Francisco	National Multiple Sclerosis Society	Not recruiting	18 Years	62 Years	Female	24	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
316	NCT02823951	February 2016	12 March 2018	Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®	Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®: A Retrospective Study (PROTRACT)	Relapsing-remitting Multiple Sclerosis	Drug: Rebif;Drug: Tecfidera	IMS HEALTH GmbH & Co. OHG	EMD Serono	Not recruiting	18 Years	55 Years	All	479	N/A	United States;Canada
317	JPRN-UMIN000022201	2016/01/10	2 April 2019	The efficacy and safety of tocilizumab in patients with neuromyelitis optica		neuromyelitis optica	Tocilizumab it to be infused every 4weeks at 8mg/kg of body weight for 2 years.	Department of Neurology, Shimane University Hospital		Recruiting	20years-old	74years-old	Male and Female	3	Not selected	Japan
318	ChiCTR-OPB-16007730	2016-01-01	18 April 2017	Mycophenolate Mofetil Treatment of Neuromyelitis Optica in Chinese Patients (MONICA)	Mycophenolate Mofetil Treatment of Neuromyelitis Optica in Chinese Patients (MONICA)	Neuromyelitis optica	Case series:Mycophenolate Mofetil;	The third affiliated hospital,Sun Yat-sen university		Recruiting	18	65	Both	Case series:100;	Post-market	China
319	NCT02276963	January 2016	17 June 2019	Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses	Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder	Drug: Ublituximab	Johns Hopkins University		Not recruiting	18 Years	100 Years	All	6	Phase 1	United States
320	NCT02644044	January 2016	18 January 2016	Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study	Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study	To Evaluate the Effect of Therapy With IT MTX on the Disease Course of Patients With Progressive MS	Drug: Intrathecal methotrexate	Tel-Aviv Sourasky Medical Center		Not recruiting	18 Years	75 Years	Both	30	Phase 0
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
321	NCT02649985	January 2016	11 June 2018	Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease	Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease	Multiple Sclerosis;Alzheimer's Disease	Drug: [F-18]PBR06	Brigham and Women's Hospital		Recruiting	18 Years	70 Years	All	50	Phase 1/Phase 2	United States
322	NCT02809079	January 2016	27 June 2016	Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients	Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients	Neuromyelitis Optica Spectrum Disorders;Mycophenolate Mofetil;Efficacy and Safety	Drug: Mycophenolate mofetil;Drug: Prednisone	Third Affiliated Hospital, Sun Yat-Sen University	Zhongshan Ophthalmic Centre, Sun Yat-sen University;Nangfang Hospital, Southern Medical University	Recruiting	18 Years	65 Years	Both	100	Phase 4
323	EUCTR2016-003100-30-BG		28 February 2019	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMT	A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis (RRMS) with Disease Activity on Prior Disease Modifying Therapy (DMT)	Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Genzyme Corporation		Not Available			Female: yes Male: yes	65	Phase 3	Norway;Netherlands;Germany;Bulgaria;Poland;Belgium;France;Italy;United Kingdom;Switzerland;Russian Federation;Austria;Turkey;Spain;Greece;Portugal
324	NCT02677077	December 31, 2015	14 January 2019	Clinical Disease Activity With Long Term Natalizumab Treatment	MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab	Relapsing-Remitting Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	18 Years	65 Years	All	277	Phase 2	Belgium;Czechia;Czech Republic
325	EUCTR2015-004116-38-SE	18/12/2015	22 January 2018	A clincial study comparing the effectiveness of two drugs, named Rituximab and Dimethyl Fumarate (Tecfidera®), for the neurological disease Multiple Sclerosis.	RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS A randomized phase 3 study comparing Rituximab with Dimethyl Fumarate in early Relapsing-Remitting Multiple Sclerosis Objective: To compare the efficacy of rituximab on the ability to prevent relapses in early RRMS and CIS compared with dimethyl fumarate (DMF), which is an approved first-line medication for RRMS today, using a phase 3 design. Population: Patients with newly diagnosed RRMS or CIS with no more than 10 years disease duration (since diagnosis), 18 – 50 years of age and previously not treated with immunomodulating drugs OR treated with first-line injectables. Patients should display protocol-defined clinical or radiological disease activity during the preceding year before screening for inclusion. Intervention: Treatment with rituximab (Mabthera®) with an initial dose of 1000 mg intravenously (iv) followed by 500 mg iv every six months. Control: Treatment with DMF (Tecfidera®) 240 mg twice daily. The two treatments are randomised in a 1:1 proportion. Outcome: Primary outcome is the relative risk of experiencing a relapse during the two–year period for either compound. As secondary endpoints worsening on neurological disability, magnetic-resonance imaging-defined disease activity and effect on cerebrospinal fluid biomarkers will be analysed. In addition, health-economic evaluations of using rituximab as first-line treatment for RRMS will be performed.	Patients with multiple sclerosis (MS) or patients presenting with symptoms highly suspicious of MS while not completely fulfilling diagnostic criteria, 18 - 50 years of age and no more than 10 years of disease duration (from diagnosis). Patients treated with immunomodulatory drugs or treated with first-line injectable therapies (eg interferons or glatiramer acetate) may be included.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera Pharmaceutical Form: Infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 500-1000 Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use Trade Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 480-	Department of Clinical Sciences, Danderyd Hospital		Authorised			Female: yes Male: yes	200	Phase 3	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
326	NCT02587195	December 18, 2015	11 June 2018	A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period	A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period	Multiple Sclerosis	Drug: Teriflunomide	Centre Hospitalier Universitaire de Nice		Not recruiting	18 Years	55 Years	All	5	Phase 3	France
327	NCT02583594	December 6, 2015	5 November 2018	A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis	A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: Acyclovir;Drug: Methylprednisolone;Drug: alemtuzumab GZ402673;Drug: Paracetamol;Drug: Loratadine;Drug: Ceterizine;Drug: Dexchlorpheniramine	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	All	24	Phase 1	Spain
328	NCT02011451	December 2015	3 October 2016	Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis	Safety and Neuroprotective Effects of Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis	Multiple Sclerosis	Drug: 95% Pure ECGC capsules 200mg;Drug: Placebo Comparator:	Louisiana State University Health Sciences Center in New Orleans	National Multiple Sclerosis Society	Not recruiting	18 Years	65 Years	Both	0	Phase 2	United States
329	NCT02634307	December 2015	14 October 2019	A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1	A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: ALKS 8700	Alkermes, Inc.		Not recruiting	18 Years	65 Years	All	1057	Phase 3	United States;Belgium;Bulgaria;Germany;Poland;Russian Federation;Serbia;Spain;Ukraine
330	NCT02471560	November 30, 2015	12 February 2018	Tecfidera and the Gut Microbiota	The Effect of Tecfidera® (Dimethyl Fumarate, BG00012) on the Gut Microbiota as a Causal Factor for Gastro Intestinal Associated Adverse Events.	Multiple Sclerosis, Relapsing-Remitting	Drug: dimethyl fumarate;Drug: injectable MS DMT	Biogen		Not recruiting	18 Years	N/A	All	37	Phase 4	Norway
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
331	NCT02545959	November 30, 2015	14 October 2019	Intrathecal Rituximab in Progressive Multiple Sclerosis	Intrathecal Rituximab in Progressive Multiple Sclerosis	Multiple Sclerosis, Chronic Progressive;Nervous System Diseases	Drug: Rituximab IT;Drug: methylprednisolone IV;Drug: Rituximab IV	Centre Hospitalier de PAU	University Hospital, Bordeaux	Not recruiting	45 Years	N/A	All	10	Phase 2	France
332	JPRN-JapicCTI-153058	24/11/2015	16 July 2019	Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) Prevention of Relapse of Multiple Sclerosis	Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) Prevention of Relapse of Multiple Sclerosis	Multiple sclerosis	Intervention name : Copaxone subcutaneous injection syringe Dosage And administration of the intervention : For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily.Participants will receive interventions as part of routine medical care.	TAKEDA PHARMACEUTICAL COMPANY LTD.		Recruiting			BOTH	1000	NA
333	NCT02633033	November 24, 2015	4 February 2019	Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse	A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse	Multiple Sclerosis, Relapsing-Remitting	Drug: H.P. Acthar® Gel (repository corticotropin injection)	Mallinckrodt		Not recruiting	18 Years	N/A	All	160	Phase 3	United States;Puerto Rico
334	EUCTR2012-003735-32-GR	19/11/2015	23 July 2018	Study to compare the efficacy and/or safety of masitinib to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments.	A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with relapsing remitting multiple sclerosis with unsatisfactory response to first line treatment	Relapsing-remitting multiple sclerosis (RR MS) MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinb mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-	AB Science		Not Recruiting			Female: yes Male: yes	450	Phase 3	Slovakia;Greece;Spain;United Kingdom;Italy;Czech Republic;Hungary;Mexico;Argentina;Belgium;Brazil;Bulgaria;Germany
335	EUCTR2015-002500-91-BE	10/11/2015	28 February 2019	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Label Extension (OLE) study	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: 0.25mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: 1.0mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0-	Celgene International II Sàrl (CIS II)		Authorised			Female: yes Male: yes	2496	Phase 3	Serbia;Belarus;United States;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;South Africa;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Lithuania;United Kingdom;Hungary;Belgium;Poland;Croatia;Romania;Bulgaria;Georgia;Germany;New Zealand;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
336	NCT02490982	November 2015	16 December 2017	Teriflunomide Observational Effectiveness Study	Teriflunomide Observational Effectiveness Study	Relapsing Remitting Multiple Sclerosis	Drug: Teriflunomide	Centre hospitalier de l'Université de Montréal (CHUM)	Genzyme, a Sanofi Company;Montreal Neurological Institute and Hospital	Recruiting	18 Years	N/A	All	300	N/A	Canada
337	NCT02686684	November 2015	7 November 2016	Tecfidera Diffusion Tensor Imaging	An Open-label, Observational, Single-blinded, Longitudinal Study to Evaluate the Effect of Dimethyl Fumarate on Gray and White Matter Pathology in Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis, Dimethyl Fumarate, Diffusion Tensor Imaging Magnetic Resonance Imaging	Drug: Dimethyl fumarate	University at Buffalo		Not recruiting	18 Years	N/A	Both	115	N/A
338	NCT02743312	November 2015	24 October 2016	Long-Term Effects of Torso-Weighting	Long-Term Effects of Balance-Based Torso-Weighting: Pilot Study	Multiple Sclerosis	Device: Balance-Based Torso-Weighting (WT);Device: Sham Weights (SW);Device: Fitbit Flex	San Francisco State University	Samuel Merritt University;Samuel Merritt University	Not recruiting	18 Years	N/A	Both	5	N/A	United States
339	NCT02545868	October 27, 2015	11 November 2019	A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis	A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Biological: 23-PPV;Biological: 13-PCV Booster;Biological: Influenza Vaccine;Biological: KLH;Drug: OCR;Biological: TT Vaccine	Hoffmann-La Roche		Not recruiting	18 Years	55 Years	All	102	Phase 3	United States;Canada
340	EUCTR2015-002500-91-HU	12/10/2015	28 February 2019	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Label Extension (OLE) study	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: 0.25mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: 1.0mg RPC1063 Product Code: RPC1063 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Ozanimod Current Sponsor code: RPC1063 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.0-	Celgene International II Sàrl (CIS II)		Authorised			Female: yes Male: yes	2496	Phase 3	Belgium;Serbia;Belarus;United States;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;South Africa;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Lithuania;United Kingdom;Hungary;Poland;Croatia;Romania;Bulgaria;Georgia;Germany;New Zealand;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
341	NCT02529839	October 2015	31 August 2015	Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)	Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation in Patients With Multiple Sclerosis	Multiple Sclerosis	Procedure: Autologous bone marrow transplantation;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Alemtuzumab	Hadassah Medical Organization		Not recruiting	18 Years	65 Years	Both	20	N/A
342	NCT02606630	October 2015	16 December 2017	[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis	A [C-11]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT-555 on Central Nervous System Inflammation in Subjects With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: ABT-555	AbbVie		Not recruiting	18 Years	60 Years	All	4	Phase 1	United Kingdom
343	EUCTR2012-000540-10-DE	23/09/2015	25 June 2018	International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis	Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis - OPTIMUM	relapsing multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Capsule INN or Proposed INN: Ponesimod Current Sponsor code: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: Aubagio® Product Name: Aubagio® Pharmaceutical Form: Tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod Product Code: ACT-128800 Pharmaceutical Form: Tablet INN or Proposed INN: Ponesimod CAS Number: ACT-128800 Other descriptive name: PONESIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Ponesimod	Actelion Pharmaceuticals Ltd		Authorised			Female: yes Male: yes	1100	Phase 3	Serbia;Portugal;Belarus;United States;Greece;Spain;Ukraine;Russian Federation;Israel;Italy;France;Latvia;Bosnia and Herzegovina;Finland;Turkey;Lithuania;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Romania;Croatia;Bulgaria;Georgia;Germany;Sweden
344	EUCTR2014-003498-41-AT	22/09/2015	28 September 2015	Effects of dalfampridine on mobility in the context of daily life	Effects of dalfampridine on mobility in the context of daily life - Fampridine Study in Activities of Daily Living	Motor behaviour and cognition in multiple sclerosis patients;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	Medical University of Vienna		Authorised			Female: yes Male: yes			Austria
345	NCT02486640	September 8, 2015	11 November 2019	Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon	BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence	Multiple Sclerosis	Drug: Interferon beta-1b (Betaferon, BAY86-5046);Device: Betaconnect Autoinjector	Bayer		Not recruiting	18 Years	N/A	All	162	N/A	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
346	NCT03774914	September 1, 2015	26 August 2019	LEMTRADA Pregnancy Registry in Multiple Sclerosis	International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis	Multiple Sclerosis	Drug: Alemtuzumab (GZ402673)	Genzyme, a Sanofi Company		Recruiting	18 Years	55 Years	Female	204	Phase 2	United States;Austria;Belgium;Canada;Denmark;Germany;Italy;Spain;Sweden;United Kingdom
347	NCT02283671	September 2015	25 February 2019	Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B		Multiple Sclerosis;Neuromyelitis Optica	Biological: Tolerogenic Dendritic cells loaded with myelin peptides	Sara Varea		Recruiting	18 Years	65 Years	All	22	Phase 1	Spain
348	NCT03002038	September 2015	9 January 2017	Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients	Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders	Neuromyelitis Optica Spectrum Disorder	Drug: Azathioprine;Drug: Rituximab	Isfahan University of Medical Sciences		Not recruiting	18 Years	50 Years	Both	76	Phase 2/Phase 3	Iran, Islamic Republic of
349	NCT02499900	August 31, 2015	16 December 2017	Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®	A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone® (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily	Multiple Sclerosis	Drug: Copaxone®	Teva Pharmaceutical Industries, Ltd.		Not recruiting	18 Years	N/A	All	861	Phase 4	United States;Argentina;Austria;Belgium;Croatia;Finland;France;Germany;Ireland;Italy;Mexico;Poland;Puerto Rico;Russian Federation;Spain;Turkey
350	NCT02525874	August 31, 2015	3 December 2018	Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).	An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	65 Years	All	218	Phase 3	United States;Belgium;Bulgaria;Kuwait;Lithuania;Poland;Turkey;Croatia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
351	EUCTR2014-000395-26-DE	07/08/2015	30 October 2017	Description ofchanges in that part of the nervous sstem that is processing visual information over an extended perion of time in patients with relapsing remitting multiple sclerosis who take Tecfidera	A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate - VISION	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240-	Biogen GmbH		Not Recruiting			Female: yes Male: yes	600	Phase 4	Germany
352	NCT01532154	August 2015	31 October 2016	Fampridine Pregnancy Exposure Registry	Fampridine Pregnancy Exposure Registry	Multiple Sclerosis;Pregnancy	Drug: Fampridine	Biogen		Not recruiting	N/A	N/A	Female	1	N/A	France;Germany;United Kingdom;United States
353	NCT02493049	August 2015	22 October 2019	Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)	Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Domperidone	University of Calgary	Alberta Innovates Health Solutions	Not recruiting	18 Years	60 Years	All	17	Phase 2	Canada
354	NCT02542787	August 2015	12 March 2018	Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis	A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis	Spasticity in People With Multiple Sclerosis	Drug: VSN16R;Other: Placebo	Canbex Therapeutics Ltd		Not recruiting	18 Years	70 Years	All	160	Phase 2	United Kingdom
355	NCT02632591	August 2015	28 December 2015	Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment	Use on Human Being of a Mix Between Very Well Known Drugs, Tested Upon Registered Trial n° NCT02606929, to Consider Effectiveness of Improvement After 45 Days	Multiple Sclerosis;Autoimmune Disease;Disseminated or Multiple Sclerosis Nos;Multiple Sclerosis, Acute Relapsing;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Chronic Progressive	Drug: Tetracycline;Drug: statin;Drug: antimycotic;Drug: Fingolimod;Drug: copaxone	Università Popolare Homo & Natura		Not recruiting	18 Years	65 Years	Both	90	Phase 1	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
356	NCT02683863	August 2015	16 December 2017	Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers	An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: BG00012 (DMF) (Tecfidera®.)	Multiple Sclerosis Center of Northeastern New York	Biogen	Not recruiting	25 Years	65 Years	All	20	Phase 4	United States
357	NCT02686788	August 2015	3 December 2018	TMP001 in Relapsing-remitting Multiple Sclerosis	TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial	Remitting-Relapsing Multiple Sclerosis	Drug: TMP001	Dr. Frank Behrens	SocraMetrics GmbH	Not recruiting	18 Years	55 Years	All	9	Phase 2	Germany
358	NCT03046251	August 2015	26 August 2019	Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis	Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis	Multiple Sclerosis	Drug: Natalizumab	State University of New York at Buffalo		Recruiting	18 Years	N/A	Female	100	Phase 4	United States
359	NCT02511028	July 28, 2015	1 April 2019	In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging	In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging	Multiple Sclerosis	Other: Ferumoxytol	National Institutes of Health Clinical Center (CC)	National Institute of Neurological Disorders and Stroke (NINDS)	Not recruiting	18 Years	70 Years	All	14	Early Phase 1	United States
360	EUCTR2014-004483-38-DE	16/07/2015	7 May 2018	TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial	TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial	Patients with defined diagnosis of relapsing-remitting multiple sclerosis and at least 1 documented relapse during the previous year OR at least 2 documented relapses during the previous 2 years. MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Tarenflurbil Product Code: TMP001 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Tarenflurbil CAS Number: 5104-49-4 Other descriptive name: FLURBIPROFEN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-	Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)		Not Recruiting			Female: yes Male: yes	55	Phase 2	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
361	JPRN-UMIN000018154	2015/07/01	2 April 2019	11C-acetate PET for Multiple sclerosis	11C-acetate PET for Multiple sclerosis - 11C-acetate PET for Multiple sclerosis	Multiple Sclerosis, NMO	Withdraw blood before and after the injection of 11C-acetate	department of neurology, Osaka university school of medicine		Recruiting	20years-old	75years-old	Male and Female	30	Not applicable	Japan
362	NCT02472938	July 2015	4 January 2016	Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis	Phase IV, Interventional, multicenteR, Double-blind, Randomized, Placebo-controlled Study tO Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With relapsingremitTing Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: dimethyl fumarate;Other: Placebo	Biogen	GB Pharma Services & Consulting S.r.l. Unipersonale	Not recruiting	18 Years	50 Years	Both	0	Phase 4
363	NCT02506751	July 2015	19 February 2018	Open-label Study of Liothyronine in MS	A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals With MS	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive	Drug: liothyronine	Johns Hopkins University		Not recruiting	18 Years	58 Years	All	20	Phase 1	United States
364	NCT02519413	July 2015	5 September 2016	Tecfidera Lymphocyte Chart Review	A Retrospective, Multi-Center, Observational Study to Assess the Effect of Tecfidera® Delayed-Release Capsules on Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis (REALIZE)	Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	Both	483	N/A	United States
365	NCT02521545	July 2015	14 September 2015	Single-Dose Study of a New Formulation of BIIB061	A Single-Dose Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of a New Formulation of BIIB061	Multiple Sclerosis	Drug: BIIB061	Biogen		Not recruiting	20 Years	55 Years	Both	8	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
366	NCT02665221	July 2015	16 December 2017	Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY	Single Center, Randomized, Open Label Study in Relapsing MS Patients on PLEGRIDY to Assess Topical Application of Preparation H (Phenylephrine) on Mitigation of Erythema Severity and Size.	Multiple Sclerosis	Other: No Treatment Arm;Drug: Topical Preparation H arm	New York University School of Medicine		Not recruiting	18 Years	70 Years	All	32	Phase 4	United States
367	NCT02696590	July 2015	11 April 2016	High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients	Isfahan University of Medical Sciences	Relapsing Remitting Multiple Sclerosis	Dietary Supplement: Vitamin D3	Isfahan University of Medical Sciences		Not recruiting	23 Years	59 Years	Both	200	N/A	Iran, Islamic Republic of
368	NCT02410278	June 29, 2015	11 June 2018	Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera	A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera® (Dimethyl Fumarate) Delayed Release Capsules	Multiple Sclerosis	Drug: dimethyl fumarate;Drug: montelukast;Drug: Placebo	Biogen		Not recruiting	18 Years	N/A	All	63	Phase 4	United States
369	EUCTR2015-000303-21-IT	24/06/2015	11 April 2016	Experimental clinical trial regarding relapsing-remitTing Multiple Sclerosis newly diagnosed patients, not yet treated for the evaluation of the onset, the efficacy and speed of action of the treatment with BG00012	A Phase IV, interventional, multicenteR, double-blind, randomized, placebo-controlled study tO explore the onset of efficacy on Magnetic resonance disease activity of BG00012 (dimethyl fumarate) in Patients with relapsing-remitTing Multiple Sclerosis (PROMPT) - PROMPT	Relapsing-remitting Multiple Sclerosis patients MedDRA version: 17.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera® Product Name: Tecfidera® Product Code: BG00012 Pharmaceutical Form: Capsule INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Current Sponsor code: BG00012 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Biogen Idec Italia S.r.l.		Not Recruiting			Female: yes Male: yes		Phase 4	Italy
370	EUCTR2014-004562-22-BE	10/06/2015	30 April 2018	Study to evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with Multiple Sclerosis	A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with Multiple Sclerosis	Multiple Sclerosis MedDRA version: 17.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	300	Phase 3	France;United States;Hungary;Czech Republic;Canada;Spain;Belgium;Australia;Germany;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
371	NCT02425644	June 4, 2015	16 September 2019	Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis	Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: ponesimod;Drug: teriflunomide	Actelion		Not recruiting	18 Years	55 Years	All	1133	Phase 3	United States;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Finland;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Latvia;Lithuania;Mexico;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;Argentina;Czech Republic
372	EUCTR2014-005003-24-LV	01/06/2015	24 October 2016	A study of BG00012 on MRI lesions and Pharmacokinetics in children from 10 to less than 18 years old with a type of Multiple Sclerosis called 'Relapsing, Remitting Multiple Sclerosis'	Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years	Relapsing-Remitting Multiple Sclerosis MedDRA version: 17.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	20	Phase 2	Finland;Lebanon;Lithuania;Turkey;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Australia;Bulgaria;Latvia;Germany;Kuwait
373	NCT02090348	June 2015	14 September 2015	Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate	A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY)	Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	Both	0	Phase 4
374	NCT02239393	June 2015	1 April 2019	Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study	MEsenchymal Stem Cell Therapy for CAnadian MS Patients	Multiple Sclerosis	Biological: Mesenchymal Stem Cells	Ottawa Hospital Research Institute		Not recruiting	18 Years	50 Years	All	40	Phase 2	Canada
375	NCT03113162	May 29, 2015	16 December 2017	Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis	Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis	Multiple Sclerosis	Biological: Autologous Hematopoietic Stem Cell;Drug: BEAM Regimen	Makati Medical Center		Recruiting	18 Years	60 Years	All	15	Phase 1	Philippines
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
376	EUCTR2013-001055-12-IT	28/05/2015	10 July 2015	Study to evaluate the efficacy of cetirizine in the treatment of Flu-like syndrome (FLS) in patients with multiple sclerosis treated with interferoneß.	Flu-like syndrome Inhibition Giving anti-histaminic Therapy. Randomized cross-over, single-center, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine on Flu-like syndrome (FLS) in patients with multiple sclerosis treated with interferoneß. - FLU-LIGHT	Patients with relapsing remitting multiple sclerosis (RRMS) treated with interferoneß, suffering from flu-like syndrome (FLS). MedDRA version: 16.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Cetirizina Mylan Generics Product Name: Cetirizina Mylan Generics Pharmaceutical Form: Tablet INN or Proposed INN: Cetirizina CAS Number: 83881-52-1 Other descriptive name: CETIRIZINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Biogen Idec Italia S.r.l.		Not Recruiting			Female: yes Male: yes			Italy
377	NCT02315872	May 22, 2015	9 September 2019	ACTH for Fatigue in Multiple Sclerosis Patients	The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.	Multiple Sclerosis, Relapsing-Remitting	Drug: ACTH;Drug: Placebo	Providence Health & Services	Mallinckrodt	Not recruiting	18 Years	65 Years	All	8	Phase 3	United States
378	EUCTR2015-001197-18-NO	20/05/2015	25 June 2018	The effect of Tecfidera® (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events.	The effect of Tecfidera® (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events.	multiple sclerosis;Therapeutic area: Diseases [C] - Injuries, poisonings, and occupational diseases [C21]	Trade Name: Tecfidera Product Name: Tecfidera Pharmaceutical Form: Capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: IU/mg international unit(s)/milligram Concentration type: range Concentration number: 240-480	Biogen Idec Norway		Authorised			Female: yes Male: yes	70	Phase 4	Norway
379	EUCTR2014-003481-25-DE	13/05/2015	20 August 2018	Investigation of the effect of Dimethyl fumarate on T cells in patients with relapsing remitting Multiple Sclerosis	A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis - DIMAT-MS	relapsing remitting multiple sclerosis MedDRA version: 19.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera® 120mg magensaftresistente Hartkapseln Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: Tecfidera® 240mg magensaftresistente Hartkapseln Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Dimethyl fumarate CAS Number: 624-49-7 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240-	Universitätsklinikum Münster		Not Recruiting			Female: yes Male: yes	67	Phase 4	Germany
380	NCT02495766	May 11, 2015	22 July 2019	Autologous Mesenchymal Stromal Cells for Multiple Sclerosis	Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: XCEL-MC-ALPHA;Drug: Placebo	Banc de Sang i Teixits	Vall d'Hebron Research Institute (VHIR)	Not recruiting	18 Years	60 Years	All	8	Phase 1/Phase 2	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
381	NCT02461069	May 6, 2015	22 October 2018	Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis	A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)	Multiple Sclerosis, Relapsing-Remitting	Drug: Dimethyl fumarate	University Hospital Muenster	Biogen	Not recruiting	18 Years	60 Years	All	67	Phase 4	Germany
382	NCT02323269	May 2015	18 April 2016	Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)	A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing-Remitting Multiple Sclerosis, Who Are Either Treatment-Naïve or Switching From an Interferon or Glatiramer Acetate After Suboptimal Response (ImPROve)	Multiple Sclerosis, Relapsing-Remitting;Relapsing-Remitting Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	Both	24	N/A	Canada
383	NCT02419378	May 2015	27 June 2016	Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential	Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential	Multiple Sclerosis, Relapsing-Remitting	Drug: Alemtuzumab	University Hospital Muenster	Genzyme, a Sanofi Company	Recruiting	18 Years	55 Years	Both	15	Phase 4	Germany
384	NCT02419638	May 2015	14 March 2016	Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS		Multiple Sclerosis	Drug: Rebif (IFN ß-1a subcutaneous three times per week);Drug: Tecifdera (dimethyl fumarate)	Brigham and Women's Hospital	EMD Serono	Not recruiting	18 Years	65 Years	Both	0	N/A	United States
385	NCT02471222	May 2015	16 December 2017	Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment	Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment	Walking Impairment;Multiple Sclerosis	Drug: ADS-5102;Other: Placebo	Adamas Pharmaceuticals, Inc.		Not recruiting	18 Years	70 Years	All	60	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
386	NCT02736279	May 2015	14 November 2016	Impact of Tecfidera on Gut Microbiota	Measuring the Impact of Tecfidera on the Gut Microbiota: Does a Change in the Gut Flora Correlate With Gastrointestinal Disturbances Following Therapy Initiation?	Multiple Sclerosis	Drug: Dimethyl fumarate	Virginia Simnad	Biogen	Recruiting	18 Years	N/A	Both	25	N/A	United States
387	EUCTR2014-005548-17-FR	28/04/2015	3 April 2017	TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR: A CONTROLED OPEN-LABEL STUDY	TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR: A CONTROLED OPEN-LABEL STUDY	PENDULAR NYSTAGMUS IN PATIENTS WITH MULTIPLE SCLEROSIS OR OCULOPALATAL TREMOR MedDRA version: 18.0 Level: PT Classification code 10029864 Term: Nystagmus System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: NEURONTIN Product Name: Gabapentine Product Code: N03AX12 Pharmaceutical Form: Capsule CAS Number: 60142-96-3 Other descriptive name: GABAPENTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: EBIXA Product Name: MEMANTINE Product Code: N06DX01 Pharmaceutical Form: Coated tablet INN or Proposed INN: MEMANTINE CAS Number: 19982-08-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	HOSPICES CIVILS DE LYON		Not Recruiting			Female: yes Male: yes		Phase 2	France
388	JPRN-UMIN000017217	2015/04/21	23 April 2019	An open-label extension study following the RIN-1 study to investigate the efficacy of rituximab against a relapse of neuromyelitis optica	An open-label extension study following the RIN-1 study to investigate the efficacy of rituximab against a relapse of neuromyelitis optica - RIN-2	Neuromyelitis optica	Rituximab intravenous infusion	Clinical Research Center, Utano National Hospital, National Hospital Organization	Zenyaku Kogyo Co., Ltd.	Not Recruiting	16years-old	80years-old	Male and Female	40	Phase 2,3	Japan
389	NCT02423083	April 21, 2015	11 November 2019	Oral Guanabenz for Multiple Sclerosis	Phase I Study of Oral Guanabenz for Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis	Drug: Guanabenz	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	18 Years	55 Years	All	2	Phase 1	United States
390	EUCTR2014-002592-29-CZ	17/04/2015	17 May 2016	Administration of Mirabegron 50mg in patients with neurogenic bladder	A randomized, double blind, placebo controlled study to evaluate the efficacy and safety of mirabegron 50 mg versus placebo in patients with neurogenic detrusor overactivity - MIRAGE	Spinal cord injury Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Betmiga Product Name: Betmiga Pharmaceutical Form: Coated tablet INN or Proposed INN: mirabegron CAS Number: 223673-61-8 Other descriptive name: MIRABEGRON Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Fakultní nemocnice Ostrava		Authorised			Female: yes Male: yes		Phase 3	Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
391	EUCTR2012-003735-32-SK	01/04/2015	12 November 2018	Study to compare the efficacy and/or safety of masitinib at 3 mg/kg/day with switch to 4.5 then to 6 mg/kg/day to interferon beta-1a, interferon beta-1b, peginterferon beta-1a or glatiramer acetate in patients with relapsing remitting multiple sclerosis with unsatisfactory response to these first line treatments.	A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with relapsing remitting multiple sclerosis with unsatisfactory response to first line treatment	Prospective, multicentre, randomised, open-label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib at 3 mg/kg/day with switch to 4.5 then 6 mg/kg/day as single agent first line treatment.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Product Name: mastinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Other descriptive name: masitinib mesylate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-	AB Science		Not Recruiting			Female: yes Male: yes	450	Phase 3	Slovakia;Greece;Spain;Colombia;Switzerland;United Kingdom;Italy;Mexico;Canada;Argentina;Belgium;Brazil;Bulgaria;Germany
392	NCT02391961	April 1, 2015	29 April 2019	Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis	Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis	Multiple Sclerosis;Internuclear Ophthalmoplegia;Fatigue	Drug: Dalfampridine;Drug: Placebo	VA Office of Research and Development		Not recruiting	18 Years	65 Years	All	20	Phase 2	United States
393	NCT02398461	April 2015	3 September 2018	An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse	A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse	Multiple Sclerosis, Acute Relapsing	Drug: rHIgM22;Drug: Placebo	Acorda Therapeutics	PRA Health Sciences	Not recruiting	18 Years	70 Years	All	27	Phase 1	United States
394	NCT02939079	April 2015	31 October 2016	Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients	Evaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-a , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Fingolimod;Dietary Supplement: Fish Oil;Drug: Placebo (for Fish Oil)	Isfahan University of Medical Sciences	Shiraz University of Medical Sciences	Not recruiting	18 Years	45 Years	Both	50	Phase 2/Phase 3
395	NCT02373098	March 31, 2015	16 December 2017	Fingolimod Effect on Cytokine and Chemokine Levels	Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod 0.5 mg	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	66	Phase 4	Turkey
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
396	EUCTR2014-003021-18-SE	25/03/2015	7 December 2015	A safety and efficacy study of BG00012 in slowing the progression of disability in patients with Secondary Progressive Multiple Sclerosis.	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis MedDRA version: 17.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Dimethyl Fumarate CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: Dimethyl Fumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	1170		Serbia;United States;Slovakia;Finland;Spain;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Denmark;Australia;Bulgaria;Norway;Netherlands;Germany;Sweden
397	NCT02386566	March 20, 2015	24 September 2018	Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab	A Prospective, Multicenter, Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Patients Treated With Natalizumab	Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	18 Years	65 Years	All	48	Phase 1	Switzerland
398	EUCTR2014-003145-99-GB	19/03/2015	17 August 2015	A trial to determine bexarotene's safety and tolerability and it's ability to promote brain repair in patients with multiple sclerosis.	A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial - CCMR One	Relapsing-remitting multiple sclerosis already on interferon-beta therapy MedDRA version: 17.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Targretin Product Name: Bexarotene Pharmaceutical Form: Capsule, hard INN or Proposed INN: Bexarotene CAS Number: 153559-49-0 Concentration unit: mg/m2 milligram(s)/square meter Concentration type: range Concentration number: 100-300 Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge		Authorised			Female: yes Male: yes	50	Phase 2a	United Kingdom
399	NCT02474134	March 2015	23 November 2015	Comparison Study of PF530 and Betaferon in Healthy Subjects	A Phase 1 Double-Blind, Randomised, Two-Treatment Cross-over Study Comparing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF530 and Betaferon Administered by Subcutaneous Injection in Healthy Adult Volunteers	Multiple Sclerosis	Drug: Interferon beta-1b (PF530, Betaferon)	Pfenex, Inc		Not recruiting	18 Years	50 Years	Both	12	Phase 1	Australia
400	NCT02097849	February 28, 2015	16 December 2017	Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.	An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.	Relapsing Forms of Multiple Sclerosis	Drug: dimethyl fumarate;Biological: tetanus diphtheria toxoids vaccine;Biological: 23-valent pneumococcal polysaccharide vaccine;Biological: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent);Drug: non-pegylated interferon	Biogen		Not recruiting	18 Years	55 Years	All	71	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
401	NCT02343159	February 28, 2015	16 December 2017	Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.	A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients.	Multiple Sclerosis	Drug: dimethyl fumarate;Device: Medication Event Monitoring System (MEMS);Behavioral: Adherence counseling	Biogen		Not recruiting	18 Years	65 Years	All	84	Phase 4	United States
402	EUCTR2015-000182-31-NL	11/02/2015	23 February 2015	Study to evaluate the effects of fampridine in patients with multiple sclerosis and eye movement abnormality	A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction in patients with multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO)	Multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra 10 mg prolonged-release tablets Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	CHDR		Authorised			Female: yes Male: yes			Netherlands
403	EUCTR2014-001643-20-DE	10/02/2015	13 February 2017	Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple Sclerosis	A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)	Nervous System Diseases MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: SAR339658 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Vatelizumab CAS Number: 1238217-55-4 Current Sponsor code: SAR339658 Other descriptive name: CHR-1103 / GBR500 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Vatelizumab CAS Number: 1238217-55-4 Current Sponsor code: SAR339658 Other descriptive name: CHR-1103 / GBR500 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Vatelizumab CAS Number: 1238217-55-4 Current Sponsor code: SAR339658 Other descriptive name: CHR-1103 / GBR500 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	168	Phase 2	United States;Czech Republic;Mexico;Canada;Poland;Russian Federation;Germany;Italy;Switzerland;Sweden
404	EUCTR2013-003884-71-BE	05/02/2015	10 July 2015	Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409	A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) - TOPAZ	Relapsing-remitting multiple sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Genzyme Corporation		Authorised			Female: yes Male: yes	799	Phase 3B	Serbia;Spain;Ukraine;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Poland;Belgium;Brazil;Croatia;Australia;Denmark;Netherlands;Germany;Sweden
405	NCT02306811	February 2015	9 January 2017	Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839	A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839	Relapsing-remitting Multiple Sclerosis	Drug: Vatelizumab	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	Both	62	Phase 2	United States;Canada;Poland;Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
406	NCT02308137	February 2015	29 April 2019	Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)	Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)	Multiple Sclerosis, Secondary Progressive	Drug: Domperidone	University of Calgary	Alberta Innovates Health Solutions	Recruiting	18 Years	60 Years	All	62	Phase 2	Canada
407	NCT02403947	February 2015	10 December 2018	MEsenchymal StEm Cells for Multiple Sclerosis	Treatment of Multiple Sclerosis With Mesenchymal Stem Cells: Phase I/II Study	Multiple Sclerosis	Drug: Mesenchymal stem cells;Drug: Suspension media	University Hospital, Toulouse		Not recruiting	18 Years	50 Years	All	1	Phase 1/Phase 2	France
408	NCT02418325	February 2015	17 November 2015	A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis, Relapsing-Remitting	Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapy	Genesis Limited		Not recruiting	18 Years	60 Years	Both	69	Phase 1/Phase 2	Trinidad and Tobago
409	NCT02418351	February 2015	17 November 2015	A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	Multiple Sclerosis, Relapsing-Remitting	Biological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapy	Genesis Limited		Not recruiting	18 Years	60 Years	Both	69	Phase 1/Phase 2	India;Trinidad and Tobago
410	NCT02490046	February 2015	3 August 2015	D-mannose for the Prevention of UTIs in Multiple Sclerosis	Single Centre Open-label Feasibility Study Evaluating the Use of D-mannose in Multiple Sclerosis	Multiple Sclerosis;Recurrent Urinary Tract Infections	Dietary Supplement: D Mannose	University College, London	UCLH	Recruiting	18 Years	65 Years	Both	20	Phase 1	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
411	NCT02587715	February 2015	17 November 2015	A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis, Relapsing-Remitting	Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells;Other: Liberation therapy	Novo Cellular Medicine Institute LLP		Recruiting	18 Years	60 Years	Both	69	Phase 1/Phase 2	Trinidad and Tobago
412	NCT02587806	February 2015	17 November 2015	A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS	Multiple Sclerosis, Relapsing-Remitting	Biological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapy	Novo Cellular Medicine Institute LLP		Recruiting	18 Years	60 Years	Both	69	Phase 1/Phase 2	India;Trinidad and Tobago
413	NCT02638038	February 2015	12 March 2018	This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for = 3 Years	A 6-month, Double-blind, Randomized, Parallel-group, Multicenter Study Comparing Safety and Efficacy of Monotherapy With INT131 1 mg or 3 mg or Placebo Administered Orally Once Daily in Treatment Naïve Patients (Who Never Received Disease Modifying Treatment) With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing Remitting	Drug: INT131	InteKrin Therapeutics, Inc.		Not recruiting	18 Years	50 Years	All	228	Phase 2
414	NCT03092544	February 2015	11 June 2018	Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients	Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients	Multiple Sclerosis	Drug: dimethyl fumarate	Multiple Sclerosis Center of Northeastern New York	Icahn School of Medicine at Mount Sinai;Biogen	Not recruiting	18 Years	65 Years	All	57	Phase 4	United States
415	EUCTR2013-005586-39-DE	29/01/2015	16 November 2015	Natalizumab (BG00002) as an Efficacy Switch in Subjects with Relapsing Multiple Sclerosis (MS) after Failure on Other Therapies	A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS)	Multiple Sclerosis (MS) MedDRA version: 17.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tysabri® Product Name: AN100226, BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	200	Phase 4	United States;Germany;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
416	NCT02166021	January 29, 2015	26 August 2019	Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis	Phase 2 Trial to Investigate the Clinical Efficacy & the Optimal Administration (Based on the Immunological, Clinical & Neuroradiological Effects) of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis	Multiple Sclerosis (MS)	Biological: Mesenchymal stem cells	Dimitrios Karussis		Not recruiting	18 Years	65 Years	All	48	Phase 2	Israel
417	EUCTR2014-005129-10-FI	27/01/2015	2 February 2015	Multiple Sclerosis, menopause and hormone replacement therapy	Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis	Multiple sclerosis MedDRA version: 17.1 Level: LLT Classification code 10064137 Term: Progression of multiple sclerosis System Organ Class: 100000004852 MedDRA version: 17.1 Level: LLT Classification code 10070425 Term: Multiple sclerosis exacerbation System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Femoston 2/10 Product Name: Femoston 2/10 Pharmaceutical Form: Tablet INN or Proposed INN: ESTRADIOL HEMIHYDRATE CAS Number: 35380-71-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- INN or Proposed INN: DYDROGESTERONE CAS Number: 152-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: Femoston 1/10 Product Name: Femoston 1/10 Pharmaceutical Form: Tablet INN or Proposed INN: ESTRADIOL HEMIHYDRATE CAS Number: 35380-71-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- INN or Proposed INN: DYDROGESTERONE CAS Number: 152-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	Irina Elovaara		Authorised			Female: yes Male: no			Finland
418	EUCTR2014-004412-11-GB	16/01/2015	23 May 2016	The purpose of this study is to examine the safety and efficacy of VSN16R and the performance in treating spasticity (tightness, stiffness or pull of muscles) in patients with Multiple Sclerosis (MS).	A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects with Multiple Sclerosis	Multiple Sclerosis MedDRA version: 19.0 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: VSN16R 100mg Product Code: VSN16R Pharmaceutical Form: Capsule INN or Proposed INN: VSN16R Other descriptive name: (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Canbex Therapeutics Ltd		Authorised			Female: yes Male: yes		Phase 2	United Kingdom
419	NCT02284568	January 12, 2015	11 June 2018	A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo	A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)	Primary Progressive Multiple Sclerosis	Drug: Laquinimod;Drug: Placebo	Teva Branded Pharmaceutical Products, R&D Inc.		Not recruiting	25 Years	55 Years	All	374	Phase 2	United States;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom
420	NCT02255656	January 7, 2015	15 April 2019	Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409	A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)	Relapsing Remitting Multiple Sclerosis	Drug: alemtuzumab GZ402673	Genzyme, a Sanofi Company		Not recruiting	18 Years	N/A	All	812	Phase 4	United States;Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Ukraine;United Kingdom;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
421	NCT02200770	January 6, 2015	24 June 2019	A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders	A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders	Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders	Biological: MEDI-551;Other: Placebo	MedImmune LLC		Not recruiting	18 Years	N/A	All	231	Phase 2/Phase 3	United States;Australia;Bulgaria;Canada;Colombia;Czechia;Estonia;Germany;Greece;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;China;Czech Republic;India;Netherlands;Portugal;Ukraine
422	NCT02335450	January 2015	11 April 2016	Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series	Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series	Multiple Sclerosis	Behavioral: Motivational Interviewing;Device: Wristband physical activity monitor	Oakland University		Not recruiting	19 Years	N/A	Both	5	N/A	United States
423	NCT02364986	January 2015	13 June 2016	Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis	Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: Rebif®;Drug: Avonex	PD Dr. Marcus Müller	BfARM, Bonn;DZNE, Bonn	Recruiting	18 Years	65 Years	Both	50	Phase 1	Germany
424	NCT02427776	January 2015	16 December 2017	A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis	A Clinical Trial to Document Safety and Radiological Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis Treated With Autologous CD4+ T Cells, Stimulated and Expanded ex Vivo by a Myelin Oligodendrocyte Glycoprotein Peptide Modified by the Introduction of a Thioreductase Motif Into the Flanking Residues of the Cell Epitope - A First-in-human Trial (SCLEROLYM TRIAL)	Multiple Sclerosis, Relapsing-Remitting	Biological: Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope	Imcyse SA		Not recruiting	18 Years	50 Years	All	2	Phase 1/Phase 2	Belgium
425	NCT02606929	January 2015	23 November 2015	Use of Well Known Drugs for New Destination - MS Improvement (MSNT)	Expanded Access Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Multiple Sclerosis Not Responding With Commonly Used Treatments	Multiple Sclerosis;Autoimmune Diseases;Disseminated or Multiple Sclerosis Nos;Multiple Sclerosis, Acute Relapsing;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Chronic Progressive	Drug: Tetracycline - Statin - Antimycotic	Università Popolare Homo & Natura		Not recruiting	18 Years	65 Years	Both		Phase 0	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
426	EUCTR2015-000137-78-AT		14 March 2016	Mesenchymal stem cells therapy for patients with multiple sclerosis	Randomised, double-blind, cross-over phase II study with intravenous autologous mesenchymal stem cells vs. placebo for multiple sclerosis patients in Austria (MESEMS Austria)	multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Human autologous mesenchymal stem cells Pharmaceutical Form: Infusion INN or Proposed INN: MSC2015 Other descriptive name: UNDIFFERENTIATED AUTOLOGOUS MESENCHYMAL STEM CELLS Concentration unit: Other Concentration type: equal Concentration number: 2 mio cells /kg - Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use	SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMU		Authorised			Female: yes Male: yes		Phase 2	Austria
427	NCT02254304	December 31, 2014	11 June 2018	Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™	Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania Using Electronic Device RebiSmart™	Relapsing Multiple Sclerosis;Clinically Isolated Syndrome	Drug: Rebif	Merck KGaA	Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany	Not recruiting	18 Years	65 Years	All	106	Phase 4	Germany
428	EUCTR2014-000709-10-DE	19/12/2014	18 June 2018	Investigation on how alemtuzumab acts in patients with relapsing remitting multiple sclerosis.	Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential - ALAIN01	relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: LEMTRADA 12 mg Konzentrat zur Herstellung einer Infusionslösung Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Alemtuzumab CAS Number: 216503-57-0 Other descriptive name: ALEMTUZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Universitätsklinikum Münster		Authorised			Female: yes Male: yes	15	Phase 4	Germany
429	EUCTR2014-002547-17-NL	18/12/2014	14 March 2016	Imaging of inflammation in the cortex of the brain in progressive MS patients	Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients - [18F]DPA-714 PET in MS	Progressive multiple sclerosis, both primary and secondary progressive MedDRA version: 17.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: [18F]DPA-714 Pharmaceutical Form: Radiopharmaceutical precursor INN or Proposed INN: [18F]DPA-714 Other descriptive name: [18F]DPA-714 Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 250-	VU University Medical Center		Not Recruiting			Female: yes Male: yes			Netherlands
430	NCT01910259	December 18, 2014	16 December 2017	MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial	A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.	Secondary Progressive Multiple Sclerosis	Drug: Amiloride;Drug: Riluzole;Drug: Fluoxetine;Drug: Placebo	University College, London	Medical Research Council;National Institute for Health Research, United Kingdom;MS Society;University of Edinburgh;Queen Mary University of London;Keele University;University of Sheffield;University of Leeds;University of Warwick	Not recruiting	25 Years	65 Years	All	445	Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
431	EUCTR2014-001012-19-NL	17/12/2014	12 January 2015	Effects of fingolimod on advanced brain measures and clinical measures in multiple sclerosis	Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis - Effect of fingolimod on brain and cognition	Relapsing-remitting (RR) multiple sclerosis (MS);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Pharmaceutical Form: Capsule INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Product Name: Interferon Beta Pharmaceutical Form: INN or Proposed INN: interferon beta-1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0-0.25 INN or Proposed INN: interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: mg milligram(s) Concentration type: range Concentration number: 0-0.044 Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Concentration unit: mg/l milligram(s)/litre Concentration type: equal Concentration number: 20-	VU University Medical Center		Authorised			Female: yes Male: yes			Netherlands
432	EUCTR2014-001081-99-BE	16/12/2014	8 August 2016	A first in human trial for evaluating both safety and preliminary efficacy of a single infusion of stimulated autologous CD4+ cells in patients with Relapsing- Remitting multiple sclerosis	A clinical trial to document safety and radiological disease activity in patients with relapsing-remitting multiple sclerosis treated with autologous CD4+ cells, stimulated and expanded ex vivo by a myelin oligodendrocyte glycoprotein (MOG) peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope (SCLEROLYM trial). First-in-human trial - SCLEROLYM Trial	Multiple sclerosis is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system. MS is characterized initially by episodes of reversible neurologic deficits. In most patients, these episodes are followed by progressive neurologic deterioration over time. Relapsing-remitting multiple sclerosis is characterized by recurrent attacks of neurologic dysfunction (relapses) followed by periods of complete or incomplete recovery (remission) MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: SCLEROLYM Pharmaceutical Form: Suspension for injection INN or Proposed INN: Cytolytic CD4+ T cells Other descriptive name: AUTOLOGOUS T-LYMPHOCYTES Concentration unit: million organisms/ml million organisms/millilitre Concentration type: range Concentration number: 5-50	ImCyse S.A		Not Recruiting			Female: yes Male: yes		Phase 1;Phase 2	Belgium
433	NCT02294058	December 3, 2014	16 December 2017	Phase 3 Study of RPC1063 in Relapsing MS	A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients	Multiple Sclerosis	Drug: RPC1063;Drug: Beta interferon	Celgene		Not recruiting	18 Years	55 Years	All	1346	Phase 3	United States;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;Georgia;Germany;Hungary;Latvia;Lithuania;Moldova, Republic of;Netherlands;New Zealand;Poland;Portugal;Romania;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;Argentina;Austria;Colombia;Czech Republic;Mexico;Peru
434	NCT02087631	December 2014	22 October 2019	Safety and Tolerability of Quetiapine in Multiple Sclerosis	A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Extended-release quetiapine fumarate	University of Calgary	Multiple Sclerosis Society of Canada	Not recruiting	18 Years	65 Years	All	14	Phase 1/Phase 2	Canada
435	NCT02142192	December 2014	10 October 2016	Natalizumab Subcutaneous Immunogenicity and Safety Study	A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	18 Years	65 Years	Both	2	Phase 2	Belgium;Denmark;Germany;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
436	NCT02317263	December 2014	15 August 2016	A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis		Multiple Sclerosis	Drug: testosterone;Drug: placebo gel	University of California, Los Angeles		Not recruiting	18 Years	60 Years	Male	0	Phase 2
437	NCT02389426	December 2014	28 April 2015	Transcranial Doppler in Multiple Sclerosis	Evaluation of Cerebrovascular Hemodynamics With Transcranial Doppler and Near-infrared Spectroscopy in Patients With Multiple Sclerosis	Multiple Sclerosis	Device: TCD baseline;Device: TCD after bosentan administration;Device: NIRS baseline;Device: NIRS after bosentan administration	Universitair Ziekenhuis Brussel		Not recruiting	18 Years	N/A	Both	30	N/A	Belgium
438	EUCTR2014-001579-30-GB	27/11/2014	24 October 2016	A Phase 2 clinical study in subjects with Progressive Multiple Sclerosis to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.5mg/day (experimental drug) as compared to placebo	A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients with Primary Progressive Multiple Sclerosis (PPMS) - ARPEGGIO	Primary Progressive Multiple Sclerosis MedDRA version: 19.0 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Laquinimod Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: LAQUINIMOD CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: Laquinimod Sodium (USAN) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Laquinimod Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: LAQUINIMOD CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: Laquinimod Sodium (USAN) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Teva Pharmaceutical Industries Ltd.		Authorised			Female: yes Male: yes	375	Phase 2	United States;Canada;Poland;Spain;Ukraine;Russian Federation;Netherlands;Germany;Italy;United Kingdom
439	EUCTR2013-002378-26-SE	13/11/2014	25 June 2018	Switch To RItuXimab in MS extension An extension study of an ongoing clinical trial where people with multiple sclerosis switch therapy from interferon or glatiramere injections to rituximab, a monoclonal antibody that eliminate B lymphocytes	Switch To RItuXimab in MS extension An extension study of STRIX-MS - a phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach - STRIX-MSext	The original trial (EudraCT 2010-023021-38) recruited 74 patients with relapsing-remitting multiple sclerosis in stable condition while treated with first line injectible disease-modifying drugs (DMDs), eg beta-interferons or glatiramere acetate. This extension study involves the same patients, those that consent to participate in this extension trial. MedDRA version: 16.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera® Product Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion	Västerbottens Läns Landsting		Not Recruiting			Female: yes Male: yes	74	Phase 2	Sweden
440	NCT02230969	November 12, 2014	6 May 2019	Plegridy Observational Program	Plegridy™ (Peginterferon ß-1a) Real World Effectiveness and Safety Observational Program	Relapsing Forms of Multiple Sclerosis	Drug: peginterferon beta-1a	Biogen		Not recruiting	18 Years	N/A	All	1210	N/A	United States;Australia;Austria;Canada;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Switzerland;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
441	EUCTR2013-004622-29-IT	10/11/2014	11 April 2016	Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Subjects	A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects	Multiple Sclerosis (MS) MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tysabri® Product Name: AN100226, BG00002 Pharmaceutical Form: Concentrate and solvent for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 300- Trade Name: Gilenya Product Name: Fingolimod Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	540		France;United States;Czech Republic;Canada;Spain;Denmark;Australia;Germany;United Kingdom;Italy;Sweden
442	NCT02142764	November 2014	9 January 2017	Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients	Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (MS).	Multiple Sclerosis	Biological: Blood samples	University Hospital, Bordeaux	Merck Serono International SA;ADERA	Not recruiting	18 Years	N/A	Both	30	N/A	France
443	NCT02253264	November 2014	16 December 2017	A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients	A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement	Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: Rituximab	Johns Hopkins University		Not recruiting	18 Years	N/A	All	8	Phase 1	United States
444	NCT02259361	November 2014	19 February 2015	Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS	Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study	Multiple Sclerosis	Drug: Sustained-release oral dalfampridine;Drug: Placebo	Sheba Medical Center		Not recruiting	18 Years	70 Years	Both	30	Phase 4	Israel
445	NCT02310048	November 2014	23 March 2015	Comparative Oral Bioavailability Study of MT-1303	A Randomised, Open-Label, Single-Dose, Parallel Group Study to Assess the Comparative Oral Bioavailability of Two Capsule Formulations of MT-1303 in Healthy Male Subjects	Relapsing-remitting Multiple Sclerosis	Drug: MT-1303-FormA;Drug: MT-1303-FormB	Mitsubishi Tanabe Pharma Corporation		Not recruiting	18 Years	55 Years	Male	34	Phase 1	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
446	NCT02326935	November 2014	11 June 2018	Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis	Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis	Multiple Sclerosis	Biological: Autologous adipose derived mesenchymal cells	American CryoStem Corporation		Not recruiting	18 Years	65 Years	All	2	Phase 1	Cayman Islands
447	EUCTR2014-002335-34-GB	30/10/2014	22 May 2017	Intravenous immunoglobulin vs standard therapy for treatment of transverse myelitis	A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin (IVIg) versus standard therapy for the treatment of transverse myelitis in adults and children - STRiVE	Transverse myelitis (TM) (acute, first onset cases), including first presentation of neuromyelitis optica (NMO) MedDRA version: 17.1 Level: PT Classification code 10028527 Term: Myelitis transverse System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1 Level: PT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Body processes [G] - Immune system processes [G12]	Trade Name: Intratect Product Name: Intratect Pharmaceutical Form: Solution for infusion	Guy's and St Thomas NHS Foundation Trust		Not Recruiting			Female: yes Male: yes	0	Phase 3	United Kingdom
448	EUCTR2014-003669-97-BE	27/10/2014	30 April 2018	A safety study for patients with Relapsing Forms of Multiple Sclerosis who participated STRATA.	A Multicenter, Open-Label Safety Study of Natalizumab administered to Subjects with Relapsing Forms of Multiple Sclerosis who participated in STRATA.	Relapsing Forms of Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tysabri Product Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-	Biogen Idec		Not Recruiting			Female: yes Male: yes	10	Phase 4	Belgium
449	EUCTR2014-000221-20-AT	23/10/2014	23 July 2018	Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial	Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial	Clinically Isolated Syndrome and Relapsing-remitting Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: RNS60 Product Code: RNS60 Pharmaceutical Form: Infusion	University Hospital Zürich		Not Recruiting			Female: yes Male: yes	16	Phase 2	Austria;Switzerland
450	NCT02247310	October 20, 2014	16 December 2017	BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon	BETAEVAL_Global- The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®	Multiple Sclerosis, Relapsing Remitting	Drug: Interferon beta-1b (Betaferon®, BAY 86-5046);Device: BETACONNECT	Bayer		Not recruiting	N/A	N/A	All	498	N/A	Austria;Belgium;Bosnia and Herzegovina;Croatia;Czechia;France;Greece;Hungary;Italy;Spain;Switzerland;Czech Republic;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
451	NCT02096133	October 13, 2014	16 December 2017	Vitamin D3 and the Stress-axis in MS	Regulation of the Stress-axis by Vitamin D3 in Subjects With Multiple Sclerosis; a Double-blinded, Randomized, Placebo-controlled Study	Multiple Sclerosis	Drug: Cholecalciferol;Other: Placebo comparator	Academic MS Center Limburg		Not recruiting	18 Years	N/A	Female	54	Phase 2	Netherlands
452	NCT02104661	October 2014	11 June 2018	Protective Role of Oxcarbazepine in Multiple Sclerosis	OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial	Multiple Sclerosis	Drug: Oxcarbazepine;Drug: Placebo	Queen Mary University of London	National Multiple Sclerosis Society;Novartis Pharmaceuticals;Barts & The London NHS Trust;University College, London;Royal Free Hospital NHS Foundation Trust;Southend University Hospital;Basildon and Thurrock University Hospitals NHS Foundation Trust;St George's Healthcare NHS Trust;Barnet and Chase Farm Hospitals NHS Trust	Not recruiting	18 Years	60 Years	All	30	Phase 2	United Kingdom
453	NCT02212886	October 2014	1 April 2019	Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS	A Prospective 1-year, Open-label, Two Arms, Multicenter, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Once a Month Long-acting Intramuscular Injection of 80 or 40 mg Glatiramer Acetate (GA Depot) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis	Drug: GA Depot 80 mg;Drug: GA Depot 40 mg	Mapi Pharma Ltd.		Not recruiting	18 Years	70 Years	All	25	Phase 1/Phase 2	Israel
454	NCT02228213	October 2014	16 December 2017	Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis	A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Biological: MIS416;Drug: Saline	Innate Immunotherapeutics	INC Research	Not recruiting	18 Years	70 Years	All	93	Phase 2	Australia;New Zealand
455	NCT02234869	October 2014	19 February 2015	Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy	Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Patients With Relapsing Multiple Sclerosis Transitioning From Standard-of-care Subcutaneous Interferon Therapy to Peginterferon Beta-1a (BIIB017)	Relapsing Multiple Sclerosis	Drug: Interferon Beta;Drug: BIIB017 (Peginterferon beta-1a)	Biogen Idec		Not recruiting	18 Years	65 Years	Both	0	Phase 4
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
456	NCT02269930	October 2014	19 February 2015	Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers	An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers	Multiple Sclerosis	Drug: peginterferon beta-1a;Drug: Rebif	Biogen Idec		Not recruiting	18 Years	45 Years	Both	30	Phase 1	United States
457	NCT02280096	October 2014	28 December 2015	Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis	Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.	Multiple Sclerosis	Drug: 4-aminopyridine;Drug: Placebo	Coordinación de Investigación en Salud, Mexico		Not recruiting	18 Years	60 Years	Both	24	Phase 2	Mexico
458	NCT02282826	October 2014	25 April 2016	A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: GZ402668;Drug: placebo;Drug: acyclovir	Genzyme, a Sanofi Company		Not recruiting	18 Years	65 Years	Both	48	Phase 1	Germany
459	NCT02286557	October 2014	19 February 2015	Testing the Effects of Methylphenidate on Multiple Sclerosis	Testing the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical Trial	Fatigue in Multiple Sclerosis	Drug: Methelphenidate;Drug: Placebo	Kessler Foundation		Not recruiting	18 Years	65 Years	Both	36	Phase 2
460	NCT02296346	October 2014	26 August 2019	Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis	A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS)	Secondary Progressive Multiple Sclerosis	Drug: SoluMedrol;Device: Extracorporeal Photopheresis	University of Utah	Mallinckrodt	Not recruiting	18 Years	75 Years	All	13	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
461	EUCTR2011-005249-12-GB	29/09/2014	10 September 2018	Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients with Relapsing Forms of Multiple Sclerosis	A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients with Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension - TERIKIDS	Multiple Sclerosis MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Genzyme Corporation		Authorised			Female: yes Male: yes	165	Phase 3	United States;Serbia;Portugal;Estonia;Morocco;Greece;Spain;Ukraine;Lebanon;Ireland;Russian Federation;Israel;France;Macedonia, the former Yugoslav Republic of;Australia;Tunisia;Netherlands;China;Slovenia;Turkey;Lithuania;United Kingdom;Canada;Belgium;Poland;Bulgaria
462	NCT02232061	September 29, 2014	14 October 2019	Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod	Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod	Multiple Sclerosis	Drug: Fingolimod	Novartis Pharmaceuticals		Recruiting	N/A	N/A	All	40	Phase 4	Belgium;Germany;Italy
463	EUCTR2013-003600-40-GB	15/09/2014	3 April 2017	Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects with Multiple Sclerosis (ENHANCE)	A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects with Multiple Sclerosis (ENHANCE)	Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: Fampridine Product Code: BIIB041 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Current Sponsor code: BIIB041 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	590	Phase 3	United States;Serbia;Finland;Ukraine;Lithuania;Russian Federation;United Kingdom;Switzerland;Italy;Czech Republic;Poland;Bulgaria;Netherlands
464	EUCTR2014-003209-14-FR	01/09/2014	4 August 2015	ASSESSMENT OF EARLY CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS	ASSESSMENT OF EARLY CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS - TYSADIFF	MULTIPLE SCLEROSIS;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TYSABRI 300 mg solution à diluer pour perfusion Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7	Hôpitaux Universitaires de Strasbourg		Authorised			Female: yes Male: yes			France
465	NCT02045732	September 2014	19 October 2017	A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)	A Phase 1b, Double-blinded, Placebo-controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Subjects With Multiple Sclerosis (ms)	Multiple Sclerosis	Biological: PF-06342674 0.25 mg/kg;Biological: Placebo;Biological: PF-06342674 1.5 mg/kg;Biological: PF-06342674 6.0 mg/kg	Pfizer		Not recruiting	18 Years	55 Years	All	4	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
466	NCT02193217	September 2014	2 March 2015	A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303		Relapsing-remitting Multiple Sclerosis	Drug: MT-1303-Low;Drug: MT-1303-High;Drug: Fingolimod;Drug: Placebo	Mitsubishi Tanabe Pharma Corporation		Not recruiting	18 Years	55 Years	Both	81	Phase 1	United Kingdom
467	NCT02273635	September 2014	19 February 2015	Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS	Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis	Primary Progressive Multiple Sclerosis;Multiple Sclerosis, Secondary Progressive	Drug: Andrographolides;Drug: placebo	Innobioscience SpA	Pontificia Universidad Catolica de Chile;University of Chile;Universidad Austral de Chile	Recruiting	18 Years	70 Years	Both	68	Phase 1/Phase 2	Chile
468	NCT02282878	September 2014	16 December 2017	The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis	The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: High/Low Sodium Diet	Yale University		Recruiting	18 Years	60 Years	All	25	N/A	United States
469	NCT02287948	September 2014	15 February 2016	Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects	Validation Study for Using Wii FIT Balance Board to Recording Balance Parameters in Healthy Subjects and Multiple Sclerosis Subjects	Postural Balance;Multiple Sclerosis	Device: Nintendo Wii Fit Balance Board	University Hospital of Ferrara		Not recruiting	18 Years	80 Years	Both	40	N/A	Italy
470	NCT02293967	September 2014	23 March 2015	Mass Balance Study of MT-1303	An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C] MT-1303 After a Single Oral Dose to Healthy Male Subjects.	Relapsing-remitting Multiple Sclerosis	Drug: MT-1303	Mitsubishi Tanabe Pharma Corporation		Not recruiting	30 Years	65 Years	Male	8	Phase 1	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
471	NCT02777060	September 2014	30 May 2016	Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures	Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures	Diabetes;Cancer;Multiple Sclerosis;Arthritis;Parkinson's Disease;Cognitive Disorders;Brain Injury;Stroke	Procedure: Exergame;Procedure: Home based balance training	University of Arizona		Recruiting	18 Years	N/A	Both	200	N/A	United States
472	ChiCTR-ICR-15007177	2014-08-30	18 April 2017	A Prospective Study on the Efficacy andSafety of Rituximab in Treatment for Neuromyelitis Optica associated Optic Neuritis	A Prospective Study on the Efficacy andSafety of Rituximab in Treatment for Neuromyelitis Optica associated Optic Neuritis	Neuromyelitis Optica associated Optic Neuritis	1:Intravenous 100mg Rituximab, 1/week4 ;2:Oral azathioprine* (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (1000-1500mg/day);	The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital		Recruiting	18	70	Both	1:30;2:30;	New Treatment Measure Clinical Study	China
473	NCT02283853	August 28, 2014	16 September 2019	Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)	Open-Label, Randomized, Multicenter, Multiple-Dose,Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension	Relapsing-Remitting Multiple Sclerosis	Drug: dimethyl fumarate;Drug: Interferon ß-1a	Biogen		Not recruiting	10 Years	17 Years	All	142	Phase 3	Belgium;Bulgaria;Canada;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Kuwait;Poland;Serbia;Spain;Sweden;Turkey;United Kingdom;United States;Argentina;Czech Republic;Romania
474	EUCTR2011-005249-12-EE	13/08/2014	28 August 2014	Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients with Relapsing Forms of Multiple Sclerosis	A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients with Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension - TERIKIDS	Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Genzyme Corporation		Authorised			Female: yes Male: yes	165		United States;Estonia;Greece;Canada;Spain;Belgium;Lebanon;Turkey;Australia;Russian Federation;Israel;China
475	NCT02073279	August 5, 2014	17 June 2019	Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica (NMO);NMO Spectrum Disorder (NMOSD)	Drug: Satralizumab;Drug: Placebo	Hoffmann-La Roche	Chugai Pharmaceutical	Not recruiting	18 Years	74 Years	All	95	Phase 3	United States;Bulgaria;Canada;Croatia;Georgia;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Taiwan;Turkey;Ukraine;Bosnia and Herzegovina;Puerto Rico;Singapore
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
476	NCT02209467	August 2014	17 November 2015	Balance and Falls in Multiple Sclerosis	Balance and Falls in Multiple Sclerosis: Intervention and Perceptions From Patients and Next of Kins	Multiple Sclerosis	Other: Group balance training	Örebro County Council		Not recruiting	18 Years	N/A	Both	52	N/A	Sweden
477	NCT02218879	August 2014	12 September 2016	Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS	Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Tecfidera	Yale University		Not recruiting	18 Years	60 Years	Both	7	N/A	United States
478	EUCTR2014-000092-62-BE	30/07/2014	8 August 2016	Management of the infusion-associated reactions in RRMS patients treated with Lemtrada	Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtrada. - EMERALD	Relapsing-remitting multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Lemtrada Product Name: Lemtrada Product Code: GZ402673 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: alemtuzumab CAS Number: 216503-57-0 Current Sponsor code: GZ402673 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	56	Phase 4	France;Spain;Belgium;Netherlands;Switzerland
479	NCT02201108	July 16, 2014	7 October 2019	Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis	A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension	Multiple Sclerosis	Drug: Teriflunomide;Drug: Placebo	Genzyme, a Sanofi Company		Not recruiting	10 Years	18 Years	All	165	Phase 3	United States;Belgium;Bulgaria;Canada;China;Estonia;France;Greece;Israel;Lebanon;Lithuania;Morocco;Netherlands;North Macedonia;Portugal;Russian Federation;Serbia;Slovenia;Spain;Tunisia;Turkey;Ukraine;United Kingdom;Australia;Macedonia, The Former Yugoslav Republic of;Poland
480	NCT02159573	July 2014	13 June 2016	Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)	A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri® (Natalizumab) to Tecfidera® (Dimethyl Fumarate)	Relapsing-Remitting Multiple Sclerosis	Biological: natalizumab;Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	Both	530	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
481	NCT02201849	July 2014	19 February 2015	A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults	A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults	Multiple Sclerosis	Drug: Study Drug;Drug: Active Control;Drug: Placebo	Alkermes, Inc.		Not recruiting	18 Years	55 Years	Both	104	Phase 1	United States
482	NCT02217982	July 2014	16 December 2017	Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation	A Pilot Study to Assess Dimethyl Fumarate (Tecfidera) Related GI Symptom Mitigation Via Food Bolus Alteration and Simethicone/Loperamide Administration	Relapsing Remitting Multiple Sclerosis	Drug: Simethicone;Drug: Loperamide;Other: Peanut Butter	Rocky Mountain MS Research Group, LLC	Biogen	Not recruiting	18 Years	N/A	All	5	Phase 4	United States
483	NCT02727907	July 2014	8 August 2016	Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis	International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: BCD-033 (interferon beta 1a);Drug: Rebif (interferon beta 1a);Drug: Placebo	Biocad		Not recruiting	18 Years	55 Years	Both	147	Phase 2/Phase 3	Russian Federation
484	EUCTR2013-003126-83-DE	23/06/2014	7 October 2014	Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.	A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-ß-1a 30 µg IM Weekly in Subjects with Relapsing Multiple Sclerosis - Efficacy and safety of ONO-4641 versus Interferon-ß-1a in patients with multiple sclerosis	Relapsing multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifimod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.05- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Avonex Product Name: Avonex Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: Avonex CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Intramuscular use Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifimod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck KGaA		Not Recruiting			Female: yes Male: yes	1176	Phase 3	United States;United Arab Emirates;Belarus;Serbia;Slovakia;Greece;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;France;Peru;Denmark;South Africa;Netherlands;Finland;Turkey;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Georgia;Bulgaria;Germany;New Zealand;Sweden
485	NCT02121444	June 23, 2014	16 December 2017	BAY86-5046 (Betaseron), Non Interventional Studies	BETAEVAL - The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®	Multiple Sclerosis	Drug: Interferon beta-1b (Betaferon, BAY 86-5046);Device: BETACONNECT auto-injector.	Bayer		Not recruiting	18 Years	N/A	All	151	N/A	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
486	EUCTR2013-002324-16-CZ	13/06/2014	22 October 2018	Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosis	A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis	relapsing-remitting multiple sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: VAY736 Pharmaceutical Form: Powder for concentrate for solution for infusion Current Sponsor code: VAY736 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	96	Phase 2	United States;Czech Republic;Poland;Ukraine;Russian Federation
487	EUCTR2013-002318-11-SE	05/06/2014	23 October 2017	Phase 3 Efficacy and Safety Study of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMs).	Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension - CONNECT	Relapsing-Remitting Multiple Sclerosis MedDRA version: 20.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: AVONEX Product Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: range Concentration number: 7.5-30	Biogen Idec Research Limited		Authorised			Female: yes Male: yes	132	Phase 3	Serbia;United States;Spain;Turkey;Israel;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Belgium;Denmark;Bulgaria;Kuwait;Germany;Sweden
488	EUCTR2013-002324-16-PL	04/06/2014	12 November 2018	Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosis	A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis	relapsing-remitting multiple sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: VAY736 Pharmaceutical Form: Powder for concentrate for solution for infusion Current Sponsor code: VAY736 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	96	Phase 2	United States;Czech Republic;Poland;Ukraine;Russian Federation
489	EUCTR2011-005249-12-ES	03/06/2014	28 February 2019	A two year, randomized, placebo-controlled study to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide once daily in pediatric patients with relapsing forms of multiple sclerosis	A two year, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate efficacy, safety, tolerability, and pharmacokinetics of teriflunomide administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis - TERIKIDS	Multiple Sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	165	Phase 3	Portugal;United States;Estonia;Slovenia;Greece;Spain;Ireland;Lebanon;Lithuania;Turkey;Israel;Russian Federation;United Kingdom;France;Canada;Belgium;Poland;Australia;Bulgaria;Netherlands;China
490	NCT01883661	June 2014	19 February 2015	Safety and Efficacy of BMMNC in Multiple Sclerosis (MS)	Role of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (MNCs) In Patient With Multiple Sclerosis .It is Self Funded (Patients' Own Funding) Clinical Trial	Multiple Sclerosis	Biological: BMMNC	Chaitanya Hospital, Pune		Recruiting	18 Years	65 Years	Both	15	Phase 1/Phase 2	India
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
491	NCT01941004	June 2014	16 December 2017	Safety and Efficacy of Fingolimod in MS Patients in China	A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis (Relapsing Remitting)	Drug: fingolimod;Drug: Placebo (6mos) + open label fingolimod (6 mos)	Novartis Pharmaceuticals		Not recruiting	18 Years	50 Years	All	0	Phase 3
492	NCT02117050	June 2014	19 October 2017	RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate	RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera™ to Rebif® 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw)	Multiple Sclerosis	Drug: Rebif®	EMD Serono		Not recruiting	18 Years	65 Years	All	1	Phase 4	United States
493	NCT02133664	June 2014	16 December 2017	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Multiple Sclerosis;Cognition	Drug: lipoic acid and omega-3 fatty acids;Drug: Placebo	Oregon Health and Science University	National Multiple Sclerosis Society	Not recruiting	18 Years	65 Years	All	54	Phase 1/Phase 2	United States
494	NCT02258217	June 2014	16 December 2017	Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)	Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)	Relapsing Remitting Multiple Sclerosis	Drug: Acthar	OhioHealth		Not recruiting	18 Years	N/A	All	30	N/A	United States
495	EUCTR2013-003752-21-GB	19/05/2014	7 January 2019	A late stage clinical trial to investigate the efficacy and safety of SA237 in patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder	A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of SA237 in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD)	Neuromyelitis optica (NMO) and NMO spectrum disorder (MNOSD) MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: SA237-120/vial Pharmaceutical Form: Solution for injection INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Code: SA237-120 PFS with NSD Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Satralizumab (r-INN) CAS Number: Not known Current Sponsor code: SA237 Other descriptive name: fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 120-	Chugai Pharmaceutical Co. Ltd		Authorised			Female: yes Male: yes	70	Phase 3	France;United States;Hungary;Taiwan;Poland;Spain;Germany;Japan;Italy;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
496	JPRN-UMIN000013453	2014/05/10	7 October 2019	A multi-center, randomized, double-blind, placebo-controlled trial to determine the efficacy of rituximab against a relapse of neuromyelitis optica spectrum disorders with anti-aquaporin 4 antibody	A multi-center, randomized, double-blind, placebo-controlled trial to determine the efficacy of rituximab against a relapse of neuromyelitis optica spectrum disorders with anti-aquaporin 4 antibody - RIN-1	Neuromyelitis optica	Rituximab intravenous infusion Placebo	Clinical Research Center, NHO Utano National Hospital	Zenyaku Kogyo Co., Ltd.	Not Recruiting	16years-old	80years-old	Male and Female	40	Phase 2,3	Japan
497	EUCTR2013-001486-17-DE	06/05/2014	25 April 2016	TOLERATE - A Study that evaluates the Gastrointestinal Tolerability of DMF in Multiple Sclerosis Patients	A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects with Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE)	Relapsing-Remitting Multiple Sclerosis MedDRA version: 18.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes			Germany
498	EUCTR2013-001895-40-IE	02/05/2014	18 January 2016	A study to evaluate the effect of aspirin on flushing in patients with RRMS treated with Tecfidera	A Phase 4, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis Treated with Tecfidera™ (dimethyl fumarate) delayed-release capsules (ASSURE) - ASSURE	Relapsing-Remitting Multiple Sclerosis MedDRA version: 16.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 16.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Trade Name: Tecfidera Product Name: Tecfidera Product Code: BG00012 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DIMETHYL FUMARATE CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 240- Trade Name: Micropirin Pharmaceutical Form: Capsule INN or Proposed INN: ACETYLSALICYLIC ACID CAS Number: 50-78-2 Other descriptive name: ASA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	240	Phase 4	Ireland;United Kingdom
499	JPRN-JapicCTI-142447	01/5/2014	16 July 2019	Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)	A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Intervention name : BAF312 INN of the intervention : Siponimod Dosage And administration of the intervention : BAF312 will be provided in a dose titration from 0.25 mg to a 2 mg dose. Control intervention name : Placebo Dosage And administration of the control intervention : Matching Placebo administered orally.	Novartis Pharma K.K.		Not Recruiting	18	60	BOTH	1530	Phase 3
500	NCT02046629	May 2014	19 February 2015	A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers	An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tablet in Healthy Chinese Subjects	Multiple Sclerosis	Drug: Teriflunomide HMR1726;Drug: cholestyramine	Sanofi		Not recruiting	18 Years	45 Years	Both	12	Phase 1	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
501	NCT02064816	May 2014	16 December 2017	A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis	Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Rebif®	Merck KGaA		Not recruiting	18 Years	60 Years	All	212	Phase 4	Germany
502	NCT02086188	May 2014	11 November 2019	Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis	Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis (MIRROR)	Multiple Sclerosis	Drug: Mirabegron;Drug: Placebo	Theodore R. Brown, MD MPH	Astellas Pharma Inc	Not recruiting	18 Years	N/A	All	28	Phase 4	United States
503	NCT02143167	May 2014	3 September 2018	Resistance Training and Amino Pyridine in Multiple Sclerosis	RETRAP - A Double Blind, Randomized, Placebo Controlled Study of the Effect of the Combination of Resistance Training and Prolonged Release Fampridine in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: SR-fampridine;Drug: Placebo	University of Southern Denmark	Region of Southern Denmark;Biogen	Not recruiting	18 Years	60 Years	All	40	Phase 4	Denmark
504	NCT02579681	April 30, 2014	16 December 2017	Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012	Single Country Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis Patients Treated With BG00012	Multiple Sclerosis, Relapsing-Remitting	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	All	221	Phase 3	Italy
505	EUCTR2014-000296-12-FI	15/04/2014	28 April 2014	N/A	N/A	Multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Trade Name: Gilenya Product Name: Fingolimodi Pharmaceutical Form: Capsule, hard	Turku University Hospital		Authorised			Female: yes Male: yes			Finland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
506	EUCTR2012-000734-19-ES	10/04/2014	14 April 2014	Bone marrow cell treatment as treatment of multiple sclerosis	Treatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis - EMMES	Multiple Sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: XCEL-MC-ALPHA Product Code: XCEL-MC-ALPHA Pharmaceutical Form: Suspension for injection INN or Proposed INN: Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved Other descriptive name: Mesenchymal Stem Cells Concentration unit: U unit(s) Concentration type: range Concentration number: 800000-1200000 Pharmaceutical form of the placebo: Suspension for injection Route of administration of the placebo: Intravenous use	Banc de Sang i Teixits		Authorised			Female: yes Male: yes			Spain
507	EUCTR2013-002660-17-IT	09/04/2014	11 April 2016	Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis	Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis - ACROSS	multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolmod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720D Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Farma SpA		Not Recruiting			Female: yes Male: yes	281	Phase 2	France;Portugal;Canada;Finland;Spain;Poland;Denmark;Germany;United Kingdom;Switzerland;Italy
508	NCT01933802	April 2014	11 June 2018	Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis	Phase 1 Safety Study of Autologous Bone Marrow-derived Mesenchymal Stem Cell-derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo, Administered Intrathecally in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: intrathecal administration of autologous MSC-NP	Tisch Multiple Sclerosis Research Center of New York		Not recruiting	18 Years	70 Years	All	20	Phase 1	United States
509	NCT01973517	April 2014	17 September 2018	High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases	7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases	Multiple Sclerosis	Drug: Feraheme;Drug: Gadolinium-based contrast	Stanford University		Not recruiting	18 Years	N/A	All	0	Phase 3	United States
510	NCT02865018	April 2014	22 August 2016	Neuromyelitis Optica (NMO) & Cetirizine	An Open Label, add-on Trial of Cetirizine for Patients With Neuromyelitis Optica	Neuromyelitis Optica	Drug: cetirizine	Icahn School of Medicine at Mount Sinai	Guthy Jackson Foundation	Not recruiting	18 Years	85 Years	Both	16	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
511	EUCTR2013-002419-87-GB	18/03/2014	28 February 2019	PROXIMUS (PRotective role of OXcabazepine In MUltiple Sclerosis)	Oxcarbazepine as a neuroprotective agent in MS: phase 2a trial - PROXIMUS - PRotective role of OXcabazepine In MUltiple Sclerosis	Multiple sclerosis MedDRA version: 19.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Trileptal Product Name: Oxcarbazepine Other descriptive name: Trileptal Concentration unit: mg milligram(s) Concentration number: 150- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Queen Mary University London		Not Recruiting			Female: yes Male: yes	30	Phase 2	United Kingdom
512	EUCTR2013-002351-15-EE	13/03/2014	7 October 2014	Study which compares the effectiveness and safety of a not yet approved drug called ONO-4641 versus an approved drug called interferon beta 1a (active comparator) in patients with multiple sclerosis. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving). Patients will be randomly assigned (like the flip of a coin) to receive the study drug (two different doses) or the comparator.	A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-ß-1a 30 µg IM Weekly in Subjects with Relapsing-Remitting Multiple Sclerosis - Efficacy and safety of ONO-4641 versus Interferon-ß-1a in patients with multiple sclerosis	Relapsing remitting multiple sclerosis MedDRA version: 16.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifimod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.05- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Avonex Product Name: Avonex Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: Avonex CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Intramuscular use Product Code: MSC2430913A or ONO-4641 (to be used as synonyms) Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Ceralifmod CAS Number: 891859-12-4 Current Sponsor code: MSC2430913A or ONO-4641 (to be used as synonyms) Other descriptive name: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck KGaA		Not Recruiting			Female: yes Male: yes	1176	Phase 3	United States;United Arab Emirates;Portugal;Belarus;Serbia;Estonia;Morocco;Slovakia;Spain;Ukraine;Lebanon;Chile;Russian Federation;Colombia;Italy;France;Jordan;Denmark;Peru;Latvia;Tunisia;Bosnia and Herzegovina;Finland;Turkey;Lithuania;Austria;United Kingdom;Egypt;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Brazil;Belgium;Romania;Croatia;Georgia;Bulgaria;Germany;Japan;Sweden
513	EUCTR2013-004616-21-DE	13/03/2014	14 March 2016	A study to assess immune function and typical disease characteristics in patients with multiple sclerosis, when switching from the medication Natalizumab to the medication Gilenya.	A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatment with Natalizumab to Gilenya® (Fingolimod) - ToFingo Successor	relapsing remitting multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Current Sponsor code: BG00002 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Universitätsklinikum Münster		Not Recruiting			Female: yes Male: yes			Germany
514	NCT02087813	March 2014	23 April 2019	Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses	A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks	Neuromyelitis Optica	Drug: Alpha1-antitrypsin;Drug: methylprednisolone	Stanford University		Not recruiting	18 Years	75 Years	All	0	Phase 1	United States
515	NCT02137109	March 2014	26 October 2015	Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri	Meta-Analysis of the Safety and Efficacy of Natalizumab in Pediatric Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	N/A	18 Years	Both	400	N/A
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
516	NCT02208050	March 2014	10 September 2018	A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis	A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Fampridine;Drug: Placebo	University College Dublin		Not recruiting	18 Years	70 Years	All	66	Phase 4	Ireland
517	NCT02028884	February 20, 2014	9 September 2019	Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)	A Multicenter, Randomized, Addition to Baseline Treatment, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)	Neuromyelitis Optica (NMO);NMO Spectrum Disorder (NMOSD)	Drug: Satralizumab;Drug: Placebo;Drug: Baseline Treatment	Hoffmann-La Roche	Chugai Pharmaceutical	Not recruiting	12 Years	74 Years	All	83	Phase 3	United States;France;Germany;Hungary;Italy;Japan;Poland;Spain;Taiwan;Ukraine;United Kingdom
518	NCT02084121	February 2014	30 September 2019	Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)	Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)	Metachromatic Leukodystrophy	Biological: Enriched Hematopoetic Stem Cell Infusion	University of Louisville	Duke University	Not recruiting	3 Years	N/A	Male		Phase 4	United States
519	NCT02166346	February 2014	11 June 2018	Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)	Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch)	Transverse Myelitis;Neuromyelitis Optica;Idiopathic Transverse Myelitis;Myelitis NOS	Drug: Dalfampridine;Drug: Placebo	Johns Hopkins University	Acorda Therapeutics	Not recruiting	18 Years	70 Years	All	24	Phase 2	United States
520	NCT02849782	February 2014	20 August 2018	Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.	Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances	Multiple Sclerosis	Drug: Fampridine	Centre Hospitalier Universitaire de Besancon		Recruiting	18 Years	80 Years	All	98	Phase 4	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
521	NCT03033355	February 2014	11 June 2018	Central Nervous System Changes Following BotulinumtoxinA Injection in the Bladder	A Prospective Study of Higher Neural Control Changes Following Intradetrusor Injection of BotulinumtoxinA in Patients With Multiple Sclerosis and Lower Urinary Tract Symptoms.	Multiple Sclerosis;Lower Urinary Tract Symptoms;Neurogenic Bladder;Detrusor, Overactive;Urge Incontinence	Drug: Intradetrusor injection of Botulinum Toxin-A	Rose Khavari, M.D.	The Methodist Hospital System	Recruiting	18 Years	N/A	Female	50	Phase 1	United States
522	EUCTR2012-005450-30-AT	08/01/2014	27 October 2014	Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy	Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment - ABIRISK	Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Avonex Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44- Trade Name: Betaferon Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Extavia Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44- Trade Name: Rebif Pharmaceutical Form: Injection INN or Proposed INN: Interferon-beta 1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44-	Medizinische Universität Innsbruck		Authorised			Female: yes Male: yes	100		Austria
523	JPRN-UMIN000012705	2014/01/07	2 April 2019	The efficacy and safety of an anti-interluekin-6 receptor antibody in relapsing-remitting multiple sclerosis		Relapsing-remitting multiple sclerosis	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 2 years.	Department of Immunology, National Institute of Neuroscience, NCNP		Recruiting	20years-old	65years-old	Male and Female	10	Not applicable	Japan
524	NCT01892345	January 2014	1 April 2019	A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)	Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder	Drug: Eculizumab	Alexion Pharmaceuticals		Not recruiting	18 Years	N/A	All	143	Phase 3	United States;Argentina;Australia;Canada;Colombia;Croatia;Czechia;Denmark;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;Malaysia;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;Austria;Czech Republic;Singapore
525	NCT02034188	January 2014	16 December 2017	Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis	Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: Umbilical cord mesenchymal stem cells	Translational Biosciences		Not recruiting	18 Years	55 Years	All	20	Phase 1/Phase 2	Panama
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
526	NCT02040298	January 2014	25 April 2016	Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis	A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Clemastine;Drug: Placebo	University of California, San Francisco		Not recruiting	18 Years	60 Years	Both	50	Phase 2	United States
527	EUCTR2013-004626-28-FI	20/12/2013	23 December 2013	Does targeting of S1P receptors reduce microglial activation in multiple sclerosis?	Does targeting of S1P receptors reduce microglial activation in multiple sclerosis?	Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Trade Name: REBIF Product Name: beetainterferoni -1a Pharmaceutical Form: Solution for injection CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 6- Trade Name: Gilenya Product Name: Fingolimodi Pharmaceutical Form: Capsule, hard CAS Number: 162359-55-9 Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5- Trade Name: Avonex Pharmaceutical Form: Solution for injection Trade Name: Betaferon Pharmaceutical Form: Concentrate and solvent for solution for injection Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Lemtrada Pharmaceutical Form: Concentrate for solution for infusion CAS Number: 216503-57-0 Other descriptive name: ALEMTUZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 12-	Turku University Hospital		Authorised			Female: yes Male: yes			Finland
528	NCT02038049	December 20, 2013	4 November 2019	A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis	A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis	Relapse Remitting Multiple Sclerosis	Drug: VAY736;Drug: Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	8	Phase 2	United States;Czechia;Ukraine;Czech Republic;Germany;Poland;Russian Federation
529	EUCTR2013-002283-25-CZ	18/12/2013	10 July 2015	A study To Evaluate the Efficacy, Safety and Tolerability of Plovamer Acetate Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis	A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis - Efficacy, safety, and tolerability of plovamer acetate	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Copaxone Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Merck KGaA		Not Recruiting			Female: yes Male: yes	550	Phase 2	Serbia;United States;Greece;Finland;Spain;Turkey;Colombia;United Kingdom;Italy;Czech Republic;Hungary;Mexico;Poland;Croatia;South Africa;Bulgaria
530	EUCTR2013-002558-64-IT	18/12/2013	16 October 2017	improvement of cognitive performance after administration of fampridina in patients with multiple sclerosis	A randomised, placebo-controlled trial investigating the role of fampiridina in improving cognitive function of patients with multiple sclerosis.	MULTIPLE SCLEROSIS MedDRA version: 20.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: fampyra Product Name: FAMPYRA Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Current Sponsor code: CP1/2013 Concentration unit: mg milligram(s) Concentration type: equal Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	dipartimento di neurologia e psichiatria		Not Recruiting			Female: yes Male: yes	123	Phase 4	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
531	EUCTR2013-001151-12-DE	12/12/2013	22 October 2018	EXTENSION STUDY OF ECULIZUMAB IN RELAPSING NEUROMYELITIS OPTICA SUBJECTS	A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)	Neuromyelitis Optica MedDRA version: 20.0 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SOLIRIS Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ECULIZUMAB CAS Number: 219685-50-4 Current Sponsor code: h5G1.1-mAb Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	Alexion Pharmaceuticals, Inc.		Authorised			Female: yes Male: yes	132	Phase 3	United States;United Arab Emirates;Saudi Arabia;Taiwan;Hong Kong;Spain;Russian Federation;Chile;Colombia;Italy;France;Australia;Denmark;Peru;Korea, Republic of;Finland;Turkey;Austria;United Kingdom;Czech Republic;Canada;Argentina;Brazil;Belgium;Singapore;Croatia;Germany;Japan;Sweden
532	EUCTR2013-002916-28-LV	12/12/2013	28 February 2019	An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis	An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10067063 Term: Progressive relapsing multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ATX-MS-1467 Product Code: MSC2358825A Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: MSC2304479A CAS Number: 1147979-29-0 Current Sponsor code: ATX-MS-01 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: MSC2304480A CAS Number: 1147979-31-4 Current Sponsor code: ATX-MS-04 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: MSC2304481A CAS Number: 1147979-32-5 Current Sponsor code: ATX-MS-06 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- INN or Proposed INN: MSC2304482A CAS Number: 1147979-30-3 Current Sponsor code: ATX-MS-07 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200-	Merck KGaA		Authorised			Female: yes Male: yes	20	Phase 2	Russian Federation;Latvia
533	NCT02047734	December 3, 2013	15 July 2019	Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (Radiance Study)	A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients	Relapsing Multiple Sclerosis	Drug: Ozanimod 0.5 mg;Drug: Ozanimod 1 mg;Drug: Ozanimod placebo;Drug: Interferon ß-1a;Drug: IFN ß-1a placebo	Celgene		Not recruiting	18 Years	55 Years	All	1320	Phase 3	United States;Belarus;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Georgia;Greece;Hungary;Italy;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom
534	JPRN-jRCTs031180346	02/12/2013	7 October 2019	Treatment with an anti-interleukin-6 receptor antibody for multiple sclerosis	The efficacy and safety of an anti-interluekin-6 receptor antibody in multiple sclerosis	multiple sclerosis;D009103	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight.	Takashi Yamamura		Not Recruiting	>= 20age old	<= 65age old	Both	6	N/A	none
535	NCT02035514	December 2013	9 January 2017	Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis	Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis (RRMS)	Biological: Bone marrow autologous mesenchymal stem cells transplantation	Germans Trias i Pujol Hospital	Ministerio de Sanidad, Servicios Sociales e Igualdad	Not recruiting	18 Years	50 Years	Both	9	Phase 1/Phase 2	Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
536	NCT02146534	December 2013	18 March 2019	Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients	Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: a Phase IV, Double-blind, Placebo-controlled Study.	Multiple Sclerosis	Drug: extended release fampridine;Drug: Placebo	Clinique Neuro-Outaouais	CogState Ltd.	Not recruiting	18 Years	N/A	All	44	Phase 4	Canada
537	NCT02047097	November 30, 2013	22 July 2019	Dimethyl Fumarate (DMF) Observational Study	A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)	Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Recruiting	18 Years	N/A	All	5600	Phase 4	United States;Argentina;Australia;Austria;Canada;Czechia;Denmark;France;Germany;Hungary;Ireland;Italy;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Slovakia;Spain;Switzerland;United Kingdom;Czech Republic
538	EUCTR2013-000529-30-GB	27/11/2013	23 December 2013	prolonged-release oral fampridine in Neuromyelitis Optica (NMO), Pilot feasibility Study	A pilot study to assess efficacy of prolonged-Release oral fampridine on ambulation and visual function in Neuromyelitis Optica - Assessment of fampridine-PR in NMO	Neuromyelitis optica (NMO);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: fampyra 10mg prolonged release tablets Pharmaceutical Form: Prolonged-release tablet	Walton Centre Foundation Trust		Authorised			Female: yes Male: yes	0		United Kingdom
539	EUCTR2013-002082-19-BE	25/11/2013	8 August 2016	A clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared to Interferon ß-1a (Avonex, authorised drug) administered once weekly.	A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of Laquinimod (0.6 mg/day or 1.2 mg/day) compared to Interferon ß-1a administered Intra Muscular Once Weekly in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) - LIBRETTO	Relapsing remitting multiple sclerosis MedDRA version: 16.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Laquinimod capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: LAQUINIMOD CAS Number: 248281-84-7 Current Sponsor code: TV-5600 Other descriptive name: Laquinimod Sodium (USAN) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Avonex Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Current Sponsor code: INTERFERON BETA-1A Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30-	Teva Pharmaceutical Industries, Ltd.		Not Recruiting			Female: yes Male: yes	600	Phase 3	Finland;Spain;Ireland;Switzerland;United Kingdom;Italy;France;Belgium;Denmark;Norway;Germany;Netherlands;Sweden
540	EUCTR2013-002283-25-HU	25/11/2013	16 March 2015	A study To Evaluate the Efficacy, Safety and Tolerability of Plovamer Acetate Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis	A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients with Relapsing Remitting Multiple Sclerosis - Efficacy, safety, and tolerability of plovamer acetate	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- Product Name: Plovamer acetate Product Code: MSC2491529A Pharmaceutical Form: Solution for injection Current Sponsor code: MSC2491529A Other descriptive name: Plovamer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Copaxone Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Merck KGaA		Not Recruiting			Female: yes Male: yes	550	Phase 2	Serbia;United States;Greece;Finland;Spain;Turkey;Colombia;United Kingdom;Italy;Hungary;Czech Republic;Mexico;Poland;Croatia;South Africa;Bulgaria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
541	EUCTR2013-001439-34-FI	18/11/2013	13 June 2016	Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients	A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients - TERI-PRO	Multiple Sclerosis MedDRA version: 19.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Aubagio Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14-	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	1000	Phase 4	United States;Greece;Canada;Finland;Belgium;Spain;Austria;Chile;Germany;United Kingdom;Switzerland;Sweden
542	NCT01939002	November 2013	19 October 2017	Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-ß) Therapies to Peginterferon Beta-1a (BIIB017)	An Open-Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017	Relapsing Multiple Sclerosis	Drug: BIIB017;Drug: naproxen	Biogen		Not recruiting	18 Years	65 Years	All	251	Phase 3	United States
543	NCT01968902	November 2013	16 December 2017	Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients	A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis	Muscle Spasticity;Multiple Sclerosis	Biological: incabotulinumtoxinA;Biological: Placebo	Multiple Sclerosis Center of Northeastern New York	Merz North America, Inc.	Not recruiting	18 Years	65 Years	All	27	Phase 4	United States
544	NCT01982942	November 2013	11 June 2018	Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis	A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Secondary Progressive	Drug: ibudilast;Drug: Placebo oral capsule	MediciNova	National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS);National Multiple Sclerosis Society	Not recruiting	21 Years	65 Years	All	255	Phase 2	United States
545	NCT02048358	November 2013	19 February 2015	Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients	Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201	Healthy Volunteers;Multiple Sclerosis	Drug: 2B3-201;Drug: Placebo;Drug: Methylprednisolone hemisuccinate	BBB-Therapeutics B.V.		Not recruiting	18 Years	65 Years	Both	47	Phase 1	Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
546	NCT03133403	November 2013	11 June 2018	Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy	Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Tecfidera (BG12);Drug: Gilenya;Drug: Tysabri®;Drug: Avonex/Betaseron/Copaxone/Rebif;Procedure: Hematopoietic stem cell transplantation (HSCT)	Sheffield Teaching Hospitals NHS Foundation Trust		Recruiting	18 Years	55 Years	All	5	Phase 2/Phase 3	United Kingdom
547	NCT01930708	October 31, 2013	15 July 2019	A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes	A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting	Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	All	1114	Phase 4	Austria;Belgium;Canada;Czechia;France;Hungary;Italy;Portugal;Slovakia;Slovenia;Spain;Czech Republic
548	NCT01911767	October 30, 2013	1 April 2019	Biogen Multiple Sclerosis Pregnancy Exposure Registry	Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry	Multiple Sclerosis;Exposure During Pregnancy	Drug: Dimethyl fumarate;Drug: Peginterferon beta-1a	Biogen		Recruiting	N/A	N/A	Female	1125	Phase 2	United States;Australia;Germany;Ireland;Italy;Spain;United Kingdom;Canada
549	NCT01326715	October 17, 2013	14 October 2019	Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis	Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis	Multiple Sclerosis	Drug: Mangafodipir (Teslascan)	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	18 Years	70 Years	All	15	Phase 1	United States
550	NCT01863888	October 2013	23 March 2015	Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis	Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: teriflunomide HMR1726;Drug: cholestyramine;Drug: charcoal	Sanofi		Not recruiting	18 Years	55 Years	Both	70	Phase 3	Belgium;Germany;Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
551	NCT01868048	October 2013	22 August 2016	Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.	A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.	Spasticity;Multiple Sclerosis	Drug: Sativex;Drug: Placebo	GW Research Ltd		Not recruiting	18 Years	N/A	Both	0	Phase 3
552	NCT01911377	October 2013	12 October 2015	Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS	The Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple Sclerosis	Neuropathic Pain;Allodynia	Drug: Botulinum Toxin Type A;Drug: Normal Saline for Injection	University of Manitoba	Allergan	Not recruiting	18 Years	70 Years	Both	12	Phase 2	Canada
553	NCT01950234	October 2013	11 November 2019	ACTH in Progressive Forms of MS	Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel)	Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Progressive Relapsing Multiple Sclerosis	Drug: ACTH;Drug: Placebo	University of Minnesota	Mallinckrodt	Not recruiting	18 Years	N/A	All	100	Phase 2	United States
554	NCT01970410	October 2013	11 June 2018	Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide	Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective?	Multiple Sclerosis	Drug: teriflunomide	Multiple Sclerosis Center of Northeastern New York	Providence Multiple Sclerosis Center	Not recruiting	21 Years	60 Years	All	70	Phase 4	United States
555	NCT02220244	October 2013	16 December 2017	Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis	Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study	Multiple Sclerosis	Drug: MD1003 100mg capsule	MedDay Pharmaceuticals SA		Not recruiting	18 Years	75 Years	All	105	Phase 3	France;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
556	NCT02220933	October 2013	16 December 2017	Effect of MD1003 in Spinal Progressive Multiple Sclerosis	Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study	Multiple Sclerosis	Drug: MD1003 100mg capsule;Drug: Placebo	MedDay Pharmaceuticals SA		Not recruiting	18 Years	75 Years	All	144	Phase 3	France
557	NCT02753088	October 2013	14 November 2016	Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis	International, Multicentre, Double-blind, Placebo-controlled, Comparative, Randomized Study to Compare Efficacy and Safety of the Generic Drug BCD-063 (CJSC BIOCAD, Russia) and Copaxone®-Teva (Teva Pharmaceutical Industries Limited, Israel) in Patients With Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: BCD-063;Drug: Copaxone-Teva;Drug: Placebo	Biocad		Not recruiting	18 Years	55 Years	Both	158	Phase 3
558	EUCTR2012-005324-16-BE	27/08/2013	17 August 2015	Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis	Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis - TERI-DYNAMIC	multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: TERIFLUNOMIDE CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14-	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	68		Belgium;Germany;Netherlands
559	EUCTR2013-001409-10-DK	08/08/2013	17 October 2016	Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS	FATIMS - Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS - FATIMS	Multiple Sclerosis MedDRA version: 14.1 Level: LLT Classification code 10039720 Term: Sclerosis multiple System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: Fampyra Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	Odense University Hospital		Authorised			Female: yes Male: yes		Phase 4	Denmark
560	JPRN-UMIN000010094	2013/08/01	2 April 2019	A pilot study of Elaspol (Sivelestat Sodium) for neuromyelitis optica		neuromyelitis optica	4.8mg/kg Sivelestat Sodium will administered constantly for 5 days in combination with 3 days intravenous methyl-prednisolone administration to sero-positive neuromyelitis optica patients who relapsed within 72 hours before starting treatment.	Tohoku University Hospital		Not Recruiting	20years-old	55years-old	Male and Female	10	Phase 1,2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
561	NCT01890655	August 2013	18 April 2016	Extension Study of MT-1303	A Phase II, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Relapsing-remitting Multiple Sclerosis Who Have Completed the MT-1303-E04 Study	Relapsing-remitting Multiple Sclerosis	Drug: MT-1303-Low;Drug: MT-1303-Middle;Drug: MT-1303-High	Mitsubishi Tanabe Pharma Corporation		Not recruiting	18 Years	60 Years	Both	367	Phase 2	Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Turkey;Ukraine;United Kingdom
562	NCT01903291	August 2013	8 August 2016	Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS	A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate	Relapsing Forms of Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	N/A	Both	333	N/A	United States
563	NCT01906684	August 2013	19 February 2015	Comprehensive Analysis of Relapse in Multiple Sclerosis	Comprehensive Analysis of Relapse in Multiple Sclerosis	Multiple Sclerosis	Drug: Acthar Gel	Tanner Foundation for Multiple Sclerosis	Questcor Pharmaceuticals, Inc.;Auburn University MRI Research Center;iReportoire Inc	Not recruiting	19 Years	65 Years	Both	20	N/A	United States
564	NCT01917019	August 2013	16 December 2017	A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension	Multiple Sclerosis, Remittent Progressive;Multiple Sclerosis, Primary Progressive;Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Multiple Sclerosis	Drug: Placebo;Drug: BIIB041 (fampridine)	Biogen		Not recruiting	18 Years	70 Years	All	101	Phase 3	Japan
565	NCT02141022	August 2013	23 May 2016	Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya	A Pilot Study of Plasticity-Based and Adaptive Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya	Multiple Sclerosis;Cognitive Deficits;Gilenya Modifying Therapy for MS	Other: plasticity-based computerized cognitive remediation program;Drug: Gileyna	Stony Brook University	Novartis	Not recruiting	18 Years	70 Years	Both	20	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
566	NCT02290444	August 2013	10 December 2018	Effects of Acthar on Recovery From Cognitive Relapses in MS	Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis	Multiple Sclerosis	Drug: Adrenocorticotropic Hormone	State University of New York at Buffalo		Not recruiting	18 Years	65 Years	All	60	Phase 3	United States
567	NCT02225977	July 31, 2013	3 September 2018	Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.	Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.	Multiple Sclerosis	Drug: Gilenya	University of Southern California		Not recruiting	18 Years	65 Years	All	125	Phase 3	United States
568	EUCTR2012-004807-10-DE	17/07/2013	23 July 2018	Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuritis	Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuritis	MS patients who suffer from severe Optic Neuritis without satisfying improvement after treatment with steroids (3-5 days with 1 g daily at least 7 days prior to randomization) and with persisting visual acuity < 0.7, duration of symptoms should be = 4 weeks MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: LLT Classification code 10070425 Term: Multiple sclerosis exacerbation System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Urbason® solubile forte 1000 mg Product Name: Methylprednisolone Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Methylprednisolone CAS Number: 83-43-2 Other descriptive name: METHYLPREDNISOLONE Concentration unit: g gram(s) Concentration type: equal Concentration number: 1-	University Medical Center Hamburg Eppendorf		Not Recruiting			Female: yes Male: yes	40	Phase 2	Germany
569	JPRN-UMIN000011111	2013/07/16	2 April 2019	Spinal blood flow and metabolism in neurological diseases		motor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophy	PET scan study with 11C-flumazenil PET scan study with 18F- FDG PET scan study with 15O-H2O	Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences		Recruiting	20years-old	Not applicable	Male and Female	70	Not applicable	Japan
570	NCT01817166	July 16, 2013	15 July 2019	Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome	Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.	Multiple Sclerosis	Drug: Vitamin D;Drug: Placebo;Other: Imaging;Biological: Lumbar puncture;Biological: Blood sampling;Biological: Urine samples	Centre Hospitalier Universitaire de Nimes		Recruiting	18 Years	56 Years	All	316	Phase 3	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
571	EUCTR2012-005086-12-AT	05/07/2013	11 April 2016	Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulin	Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis. - PREDICT trial	relapsing multiple sclerosis MedDRA version: 18.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Octagam 50 mg/ml Pharmaceutical Form: Solution for infusion INN or Proposed INN: Human normal immunoglobulin CAS Number: 308067-58-5 Current Sponsor code: Octagam 5% Other descriptive name: IMMUNOGLOBULIN G Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Trade Name: Copaxone 20 mg/ml Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Rebif 44 micrograms Product Name: Rebif 44 micrograms Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: INTERFERON BETA-1a CAS Number: 145258-61-3 Concentration unit: million IU million international units Concentration type: equal Concentration number: 12- Trade Name: Betaferon 250 microgram/ml Product Name: Betaferon 250 microgram/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INTERFERON BETA-1b CAS Number: 145155-23-3 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Extavia 250 microgram/ml Product Name: Extavia 250 microgram/ml Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INTERFERON BETA-1a CAS Number: 145155-23-3 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250-	Octapharma AG		Not Recruiting			Female: yes Male: yes	216	Phase 3b	Hungary;Poland;Austria;Russian Federation;Bulgaria;Germany
572	NCT01647880	July 2013	10 December 2018	MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)	Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis	Multiple Sclerosis	Drug: Verum arm receiving Gilenya®;Drug: Active Comparator receiving Extavia®	Charite University, Berlin, Germany	NeuroCure Clinical Research Center, Charite, Berlin	Not recruiting	18 Years	55 Years	All	15	Phase 2/Phase 3	Germany
573	NCT01710228	July 2013	9 January 2017	Alternative Treatment Paradigm for Natalizumab Trial	Alternative Treatment Paradigm for Natalizumab Trial	Multiple Sclerosis (MS)	Drug: methylprednisolone	University of Texas Southwestern Medical Center	Teva Pharmaceutical Industries;The University of Texas Health Science Center, Houston;University of Alabama at Birmingham;Charite University, Berlin, Germany	Not recruiting	18 Years	60 Years	Both	0	Phase 2	United States
574	NCT01896700	July 2013	11 June 2018	Methylphenidate to Improve Balance and Walking in MS	Methylphenidate to Improve Balance and Walking in MS	Multiple Sclerosis	Drug: Methylphenidate;Drug: Placebo	Oregon Health and Science University	Portland VA Medical Center	Not recruiting	20 Years	65 Years	All	24	Phase 2/Phase 3	United States
575	NCT01900093	July 2013	16 December 2017	Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses	An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone	Multiple Sclerosis	Drug: Acthar Gel	Aaron Miller	Mallinckrodt	Recruiting	18 Years	65 Years	All	10	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
576	NCT02048072	July 2013	19 October 2017	Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS	Funktionelle Evaluation Des Autonomen Nervensystems im Zusammenhang Mit Der Erstmaligen Einnahme Von 0,5mg Fingolimod (Gilenya) Bei Patienten Mit schubförmig Verlaufender Multipler Sklerose	Multiple Sclerosis;Autonomic Nervous System Dysfunction	Drug: Gilenya	Jochen Vehoff		Not recruiting	18 Years	60 Years	All	33	Phase 4	Switzerland
577	EUCTR2011-006262-40-CZ	18/06/2013	4 July 2016	A study to assess the safety and efficacy of BIIB033 in patients with relapsing forms of multiple sclerosis when used concurrently with Avonex®	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of Multiple Sclerosis When Used Concurrently with Avonex®	Relapsing forms of multiple sclerosis MedDRA version: 19.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BIIB033 Product Code: BIIB033 Pharmaceutical Form: Solution for infusion Current Sponsor code: BIIB033 Other descriptive name: Human anti-LINGO-1 monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Avonex Product Name: AVONEX Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a CAS Number: 145258-61-3 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	396	Phase 2	Serbia;France;United States;Hungary;Czech Republic;Canada;Poland;Spain;Russian Federation;Netherlands;Italy;United Kingdom
578	EUCTR2013-001422-25-IT	11/06/2013	26 February 2018	Study to be conducted only in Italy to evaluate the effect of the treatment with BG00012 on cognitive function in patients with Relapsing Remitting Multiple Sclerosis	Single country study assessing cognition in Relapsing Remitting Multiple Sclerosis patients treated with BG00012	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: dimethyl fumarate [DMF] Product Code: BG00012 Pharmaceutical Form: Capsule, hard INN or Proposed INN: dimetilfumarato CAS Number: 624-49-7 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120-	Biogen Idec Italia S.r.l.		Authorised			Female: yes Male: yes	220	Phase 3	Italy
579	JPRN-JapicCTI-132178	01/6/2013	2 April 2019	A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis	A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis	Multiple Sclerosis	Intervention name : AIN457 INN of the intervention : secukinumab Dosage And administration of the intervention : AIN457 will be administered intravenously. Patients will be randomized to AIN457 Low/Middle/High dose. Control intervention name : Placebo Dosage And administration of the control intervention : Matching placebo will be administered intravenously.	Novartis Pharma K.K.			18	55	BOTH	380	Phase 2
580	NCT03216915	June 1, 2013	21 January 2019	Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis	FINGORHYMS - Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Gilenya®; Novartis Pharmaceuticals Corporation	Universitätsklinikum Hamburg-Eppendorf		Recruiting	18 Years	N/A	All	100	Phase 2	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
581	NCT01621269	June 2013	16 December 2017	ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon	A 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta	Multiple Sclerosis	Drug: Fingolimod	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	0	Phase 4	Germany
582	NCT01651520	June 2013	16 December 2017	Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis	Prognosis Value of the Neuronal Damage Detected by Positrons Emission Tomography (PET) With 11C-Flumazenil in Early Multiple Sclerosis.	Multiple Sclerosis	Drug: PET with 11C-Flumazenil	Assistance Publique - Hôpitaux de Paris		Not recruiting	18 Years	55 Years	All	60	N/A	France
583	NCT01717664	June 2013	8 August 2016	Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)	A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: RHB-104	RedHill Biopharma Limited		Not recruiting	18 Years	N/A	Both	18	Phase 2	Israel
584	NCT01777412	June 2013	19 October 2017	Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations	An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD).	Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorder	Drug: Bevacizumab	Johns Hopkins University	Genentech, Inc.;Guthy Jackson Charitable Foundation	Not recruiting	18 Years	70 Years	All	10	Phase 1	United States
585	NCT01874145	June 2013	19 October 2017	Safety and Tolerability of Glatiramer Acetate	An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: GA 20 mg/mL;Drug: GA 40 mg/mL	Teva Pharmaceutical Industries		Not recruiting	18 Years	N/A	All	209	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
586	NCT01895335	June 2013	19 October 2017	Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients	A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients	Multiple Sclerosis	Drug: Teriflunomide	Sanofi		Not recruiting	18 Years	N/A	All	1001	Phase 4	United States;Austria;Belgium;Canada;Chile;Finland;France;Germany;Greece;Italy;Norway;Spain;Sweden;United Kingdom
587	EUCTR2012-003176-39-DE	31/05/2013	11 December 2017	Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301	A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301 - EXTEND	Relapsing-remitting Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: DACLIZUMAB HYP Product Code: BIIB019 Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab Current Sponsor code: BIIB019 Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	1600	Phase 3	Serbia;United States;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;India;France;Denmark;Australia;Moldova, Republic of;Finland;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Romania;Georgia;Germany;Sweden
588	EUCTR2012-004040-30-AT	24/05/2013	27 October 2014	Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study	Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study	relapse-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: BETAFERON® (interferon beta-1b) Product Name: Betaferon Pharmaceutical Form: Powder and solution for solution for injection INN or Proposed INN: Betaferon CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250-	Ospedale Regionale di Lugano		Authorised			Female: yes Male: yes	72		Austria;Switzerland
589	NCT01854359	May 11, 2013	19 November 2018	Idebenone for Primary Progressive Multiple Sclerosis	Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis	Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Idebenone	National Institute of Allergy and Infectious Diseases (NIAID)		Not recruiting	18 Years	N/A	All	61	Phase 1/Phase 2	United States
590	EUCTR2011-005677-23-LT	10/05/2013	7 January 2019	Safety and efficacy of fingolimod in pediatric patients with multiple sclerosis	A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon ß-1a i.m. once weekly in pediatric patients with multiple sclerosis with five-year fingolimod Extension Phase	Relapsing multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Avonex Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 60- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Intramuscular use Product Name: fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Novartis Pharma Service AG		Authorised			Female: yes Male: yes	190	Phase 3	Serbia;Belarus;United States;Estonia;Slovakia;Spain;Ukraine;Russian Federation;Italy;France;Australia;South Africa;Latvia;Netherlands;Turkey;Lithuania;Austria;United Kingdom;Mexico;Canada;Brazil;Poland;Croatia;Romania;Bulgaria;Germany;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
591	NCT01838174	May 2013	4 November 2019	A Trial of Neuroprotection With ACTH in Acute Optic Neuritis	A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis	Multiple Sclerosis	Drug: ACTHAR Gel (ACTH);Drug: IV methylprednisolone (steroids)	University of Colorado, Denver	Mallinckrodt;University of Pennsylvania	Recruiting	18 Years	55 Years	All	100	Phase 4	United States
592	NCT01845584	May 2013	16 December 2017	Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.	NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.	Neuromyelitis Optica Spectrum Disorder	Drug: NPB-01	Nihon Pharmaceutical Co., Ltd		Not recruiting	20 Years	N/A	All	7	Phase 2	Japan
593	NCT01873417	May 2013	16 December 2017	Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States	A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera™ (Dimethyl Fumarate) Delayed-release Capsules	Relapsing Forms of Multiple Sclerosis	Drug: BG00012 (DMF)	Biogen		Not recruiting	18 Years	N/A	All	237	Phase 4	United States
594	EUCTR2012-004019-29-BE	29/04/2013	21 August 2017	Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis	A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple sclerosis	Relapsing multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Secukinumab Product Code: AIN457 Pharmaceutical Form: Powder for solution for infusion CAS Number: 1229022-83-6 Current Sponsor code: AIN457 Other descriptive name: SECUKINUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Powder for solution for infusion Route of administration of the placebo: Intravenous use	Novartis Pharma AG		Not Recruiting			Female: yes Male: yes	380	Phase 2	Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Czech Republic;Canada;Argentina;Belgium;Poland;Romania;Germany;Japan;Sweden
595	NCT03198351	April 25, 2013	23 July 2018	An Observational Study on Teriflunomide-exposed Pregnancies	Teriflunomide Pregnancy Outcome Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project	Multiple Sclerosis	Drug: Teriflunomide (HMR1726)	Sanofi		Recruiting	16 Years	N/A	Female	325	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
596	EUCTR2012-004436-36-DK	19/04/2013	7 November 2016	Effect of rituximab in secondary progressive multiple sclerosis	A prospective pilotstudy of immunological and radiological effects of intrathecal rituximab in patients with secondary progressive multiple sclerosis	Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: MabThera (Rituximab) Product Name: MabThera Pharmaceutical Form: Injection INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25-	Odense University Hospital		Not Recruiting			Female: yes Male: yes	15	Phase 2	Denmark
597	EUCTR2012-005507-40-IT	15/04/2013	30 June 2014	Study to provide access to fingolimod to Multiple Sclerosis patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable alternative treatment options, but do not have access to the reimbursed drug	An open-label, single arm study to provide access to fingolimod to MS patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable alternative treatment options, but do not have access to the reimbursed drug	Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: FINGOLIMOD CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	NOVARTIS FARMA S.p.A		Not Recruiting			Female: yes Male: yes		Phase 3b	Italy
598	EUCTR2012-005113-39-AT	08/04/2013	22 April 2013	Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve.	A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis - Amiloride Hydrochlorothiazide in acute autoimmune optic neuritis	Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Amilostad HCT Product Name: Amilostad HCT tablets Pharmaceutical Form: Tablet INN or Proposed INN: AMILORIDE HYDROCHLORIDE, 2 H2O Other descriptive name: Amiloride Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5.68- INN or Proposed INN: hydrochlorothiazide Other descriptive name: HYDROCHLOROTHIAZIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Universitätsklinik für Neurologie, Medizinische Universität Wien		Authorised			Female: yes Male: yes		Phase 2a	Austria
599	EUCTR2012-005082-13-IT	02/04/2013	6 January 2015	A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Sclerosis	A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TYSABRI Product Code: AN100226, BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-	Biogen Idec Research Limited		Not Recruiting			Female: yes Male: yes	12	Phase 1	Italy
600	NCT01738347	April 2013	16 December 2017	Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).	Assess Safety, Bio-distribution, and Radiation Dosimetry, and Optimize the Imaging Protocol of GEH120714 (18F) Injection, a Marker of Microglial Activation, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)	Relapsing-remitting Multiple Sclerosis (rrMS)	Drug: Arm 1 - GEH120714 (18F) Injection	GE Healthcare	Centre for Probe Development and Commercialization	Not recruiting	20 Years	50 Years	All	30	Phase 1	Canada;United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
601	NCT01808885	April 2013	5 December 2016	Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.	A 24-Week, Ph1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, to Assess the Safety Profile of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.	Relapsing Remitting Multiple Sclerosis	Drug: olesoxime (TRO19622);Drug: placebo	Hoffmann-La Roche	Hôpital de la Timone;SGS S.A.;STRAGEN Services	Not recruiting	18 Years	N/A	Both	44	Phase 1	France
602	NCT01816100	April 2013	21 December 2015	The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients	The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients: A Multimodal Neuroimaging Investigation	Multiple Sclerosis	Other: specifically design 6 month resistance training program;Behavioral: 6 months weight resistance and balance program	University of Nebraska	Biogen	Not recruiting	19 Years	65 Years	Both	6	N/A	United States
603	NCT01844232	April 2013	25 May 2015	One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity	A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity	Multiple Sclerosis;Spasticity	Drug: arbaclofen	Osmotica Pharmaceutical Corp.		Not recruiting	18 Years	70 Years	Both	150	Phase 3	United States;Russian Federation;Ukraine
604	NCT01888354	April 2013	19 February 2015	Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations	Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations	Multiple Sclerosis (MS)	Drug: H.P. Acthar Gel (repository corticotropin injection)	The University of Texas Health Science Center, Houston		Not recruiting	18 Years	55 Years	Both	25	Phase 4	United States
605	NCT01838668	March 28, 2013	3 December 2018	An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia-Pacific Region and Other Countries With Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis	Drug: Placebo;Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	55 Years	All	225	Phase 3	Czechia;Japan;Korea, Republic of;Poland;Taiwan;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
606	NCT01808482	March 13, 2013	16 December 2017	A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	A First Time in Human Study Exploring Preliminary Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Part A: 100 mg/mL GSK2618960;Drug: Part A: matching placebo;Drug: Part B: Dose of GSK2618960 decided from Part A;Drug: Part B: matching placebo;Drug: Part C: Dose of GSK2618960 decided from Part A and B	GlaxoSmithKline		Not recruiting	18 Years	55 Years	Male	16	Phase 1	United Kingdom
607	EUCTR2011-002959-34-DK	11/03/2013	17 October 2016	RETRAP - A study of the effect of combination of resistance training and prolonged-release fampridine on muscle strength in the legs, walking capacity and quality of life in multiple sclerosis patients.	RETRAP - A double blind, randomized, placebo controlled study of the effect of the combination of resistance training and prolonged release fampridine on muscle strength in the lower extremities, walking capacity and quality of life in relapsing remitting multiple sclerosis - RETRAP	Multiple sclerosis MedDRA version: 15.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: Fampyra Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Sønderjylland Hospital, department of neurology		Not Recruiting			Female: yes Male: yes	125	Phase 4	Denmark
608	EUCTR2012-002639-27-GB	11/03/2013	5 August 2013	A study to assess long-term safety and effectiveness of MT-1303 in subjects who completed the MT-1303-E04 study.	A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study	Relapsing-remitting multiple sclerosis (RRMS) MedDRA version: 16.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.4-	Mitsubishi Tanabe Pharma Corporation (MTPC)		Authorised			Female: yes Male: yes	400	Phase 2	Serbia;Finland;Spain;Ukraine;Lithuania;Turkey;Russian Federation;Italy;United Kingdom;Switzerland;Hungary;Czech Republic;Canada;Poland;Belgium;Croatia;Bulgaria;Latvia;Germany;Sweden;Bosnia and Herzegovina
609	NCT01714089	March 2013	18 April 2016	Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis	A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: RNS60 125 ml;Drug: RNS60 250 ml;Drug: Interferon beta 1a	Revalesio Corporation		Not recruiting	18 Years	50 Years	Both	0	Phase 2	United States
610	NCT01768039	March 2013	19 February 2015	Vitamine D in Multiple Sclerosis	Randomised Double Blind Placebo-controlled Trial of Vitamine D Supplement in Multiple Sclerosis	Multiple Sclerosis	Drug: Vitamin D;Drug: Placebo	Mazandaran University of Medical Sciences		Not recruiting	18 Years	50 Years	Both	240	Phase 3	Iran, Islamic Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
611	NCT01803867	March 2013	9 March 2015	An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis	A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)	Multiple Sclerosis	Drug: rHIgM22	Acorda Therapeutics	PRA Health Sciences	Not recruiting	18 Years	70 Years	Both	72	Phase 1	United States
612	NCT01834586	March 2013	11 June 2018	Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications	Pilot Study of Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (OUCH)	Multiple Sclerosis	Drug: Anesthetic Topical Adhesive Synera	Brown, Theodore R., M.D., MPH		Not recruiting	18 Years	N/A	All	30	Phase 4	United States
613	NCT01791244	February 28, 2013	16 December 2017	A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device	A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device	Multiple Sclerosis;Relapsing-Remitting	Drug: Rebif®	Merck KGaA		Not recruiting	18 Years	N/A	All	93	Phase 4	Germany;Sweden
614	EUCTR2011-000985-36-ES	22/02/2013	2 June 2014	Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex	Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex	Spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex MedDRA version: 14.1 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: SATIVEX Product Name: sativex Product Code: N02BG10 Pharmaceutical Form: Oromucosal solution INN or Proposed INN: pending CAS Number: 13956-29-1 Current Sponsor code: pending Other descriptive name: CANNABIDIOL Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.7-	JOSE MANUEL GARCIA DOMINGUEZ		Not Recruiting			Female: yes Male: yes			Spain
615	NCT01707992	February 20, 2013	11 June 2018	The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)	A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis	Drug: Laquinimod;Drug: Matching Placebo	Teva Branded Pharmaceutical Products, R&D Inc.		Not recruiting	18 Years	55 Years	All	2199	Phase 3	United States;Austria;Belarus;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;France;Georgia;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Macedonia, The Former Yugoslav Republic of;Moldova, Republic of;Montenegro;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;Belgium;Czech Republic;Kazakhstan;Mexico;Portugal
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
616	NCT01797965	February 15, 2013	3 December 2018	Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019	A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301	Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis	Drug: BIIB019 (Daclizumab)	Biogen	AbbVie	Not recruiting	18 Years	N/A	All	1501	Phase 3	United States;Argentina;Australia;Brazil;Canada;Czechia;Denmark;France;Georgia;Germany;Greece;Hungary;India;Ireland;Israel;Italy;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;China;Czech Republic;Finland
617	EUCTR2012-000411-91-DE	13/02/2013	4 December 2018	Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod	Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial - NKZellen-Version1.0	relapsing-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya® Product Name: Gilenya® Product Code: Gilenya® Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-55-9 Current Sponsor code: FINGOLIMOD Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5-	Charité - Universitätsmedizin Berlin		Not Recruiting			Female: yes Male: yes	40	Phase 4	Germany
618	NCT01730547	February 2013	19 February 2015	Mesenchymal Stem Cells for Multiple Sclerosis	Phase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis	Multiple Sclerosis	Biological: Autologous mesenchymal stem cells	Karolinska Institutet		Recruiting	18 Years	50 Years	Both	15	Phase 1/Phase 2	Sweden
619	NCT01772199	February 2013	22 August 2016	Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis	Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: GSK239512;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	50 Years	Both	131	Phase 2	Bulgaria;Canada;Czech Republic;Germany;Spain;Sweden;Ukraine;United Kingdom
620	NCT01802489	February 2013	11 June 2018	Amiloride Clinical Trial In Optic Neuritis	A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis	Optic Neuritis;Multiple Sclerosis	Drug: Amiloride;Drug: Placebo	University of Oxford	Multiple Sclerosis Society of Great Britain and Northern Ireland	Not recruiting	18 Years	55 Years	All	46	Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
621	NCT01848327	February 2013	5 February 2018	Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis	A Randomized Double-Blind Placebo-Controlled Study of Caprylic Triglyceride for Cognitive Impairment in Subjects With Multiple Sclerosis.	Relapsing Remitting MS;Secondary Progressive MS;Primary Progressive MS	Dietary Supplement: Caprylic Triglyceride;Dietary Supplement: Placebo	University of Miami	National Multiple Sclerosis Society;Accera, Inc.	Not recruiting	18 Years	59 Years	All	124	N/A	United States
622	NCT02040116	February 2013	16 December 2017	Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases	Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases	Multiple Sclerosis	Drug: Rituximab Infusion	Wake Forest University Health Sciences		Not recruiting	18 Years	80 Years	All	19	Phase 4	United States
623	EUCTR2012-003627-38-SE	30/01/2013	10 July 2015	Assessing the Potential Ability of GSK239512 to Remyelinate Brain Lesions in Relapsing Remitting Multiple Sclerosis	Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis MedDRA version: 16.0 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: GSK2395612 Pharmaceutical Form: Tablet INN or Proposed INN: 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone CAS Number: 720691-69-0 Current Sponsor code: GSK239512 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: GSK239512 Pharmaceutical Form: Tablet INN or Proposed INN: 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone CAS Number: 720691-69-0 Current Sponsor code: GSK239512 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: GSK239512 Pharmaceutical Form: Tablet INN or Proposed INN: 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone CAS Number: 720691-69-0 Current Sponsor code: GSK239512 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: GSK239512 Pharmaceutical Form: Tablet INN or Proposed INN: 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone CAS Number: 720691-69-0 Current Sponsor code: GSK239512 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 80- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	114		Czech Republic;Canada;Spain;Ukraine;Bulgaria;Germany;United Kingdom;Sweden
624	EUCTR2012-004183-21-GB	25/01/2013	30 April 2019	Melatonin for Nocturia in patients with Multiple Sclerosis	A randomized, double blind, placebo controlled, cross over trial of Melatonin for the treatment of nocturia in adults with progressive multiple sclerosis, with an open label, single-arm extension study - Melatonin for Nocturia in MS	Nocturia; Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Circadin Product Name: Circadin Product Code: N/A Pharmaceutical Form: Modified-release tablet INN or Proposed INN: Circadin ( INN= Melatonin) CAS Number: 73-31-4 Current Sponsor code: N/A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	North Bristol NHS Trust		Not Recruiting			Female: yes Male: yes	80	Phase 2	United Kingdom
625	EUCTR2012-004847-61-GB	16/01/2013	4 August 2015	INSPIRE: Raltegravir (Isentress) Pilot Study in Relapsing MS	A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI - INSPIRE (Isentress Pilot Study in Relapsing MS)	Relapsing Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: ISENTRESS Product Name: raltegravir Pharmaceutical Form: Film-coated tablet INN or Proposed INN: lactose monohydrate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 26.06-	Queen Mary University of London		Not Recruiting			Female: yes Male: yes	24	Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
626	EUCTR2012-004602-97-ES	11/01/2013	11 June 2018	?Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial?	?Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial? - VITADEM	RELAPSING-REMITING MULTIPLE SCLEROSIS MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: VITAMINA D3 KERN PHARMA SOLUCIÓN OLEOSA Pharmaceutical Form: Oral drops, solution INN or Proposed INN: COLECALCIFEROL Other descriptive name: COLECALCIFEROL CONCENTRATE (OILY FORM) Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 4000- Pharmaceutical form of the placebo: Oral drops, solution Route of administration of the placebo: Oral use	Javier Olascoaga Urtaza		Not Recruiting			Female: yes Male: yes	100	Phase 2	Spain
627	NCT01802931	January 7, 2013	16 December 2017	GSK239512 DDI Study	An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512	Multiple Sclerosis	Drug: GSK239512;Drug: ketoconazole	GlaxoSmithKline		Not recruiting	18 Years	45 Years	Male	22	Phase 1	Australia
628	EUCTR2012-005076-34-BE	03/01/2013	7 October 2014	Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study.	Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study.	Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: Fampridine Product Code: BIIB041 Pharmaceutical Form: Prolonged-release tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Cliniques Universitaires Saint-Luc, Neurologie		Authorised			Female: yes Male: yes			Belgium
629	NCT01606215	January 2013	26 August 2019	Stem Cells in Rapidly Evolving Active Multiple Sclerosis	Stem Cells in Rapidly Evolving Active Multiple Sclerosis	Multiple Sclerosis	Drug: Mesenchymal stem cells;Drug: Placebo	Imperial College London		Not recruiting	18 Years	50 Years	All	21	Phase 1/Phase 2	United Kingdom
630	NCT01742052	January 2013	26 September 2016	Dose-finding Study of MT-1303	A Phase II, Multicentre, Randomised, Double-blind,Parallel Group, Placebo-controlled, Dose-finding Study to Evaluate the Safety and Efficacy of Three Different Oral Doses of MT-1303 Administered for a Period of 24 Weeks in Subjects With Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: MT-1303-Low;Drug: MT-1303-Middle;Drug: MT-1303-High;Drug: Placebo	Mitsubishi Tanabe Pharma Corporation		Not recruiting	18 Years	60 Years	Both	415	Phase 2	Belgium;Bulgaria;Canada;Croatia;Czech Republic;Finland;Germany;Hungary;Italy;Lithuania;Poland;Russian Federation;Serbia;Spain;Switzerland;Turkey;Ukraine;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
631	NCT01753375	January 2013	19 February 2015	Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis	Role of Vitamin D on the Relapse Rate of Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Vitamin D3;Dietary Supplement: Placebo	AlJohara M AlQuaiz, M.D.		Not recruiting	18 Years	55 Years	Both	200	Phase 2	Saudi Arabia
632	NCT01755871	January 2013	20 June 2016	Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis	The Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod	Heinrich-Heine University, Duesseldorf	Novartis Pharmaceuticals	Not recruiting	18 Years	65 Years	Both	8	Phase 4	Germany
633	NCT01759602	January 2013	19 October 2017	C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation	Phase 1b Study of C1-esterase Inhibitor (Cinryze) With Standard of Care for Acute Treatment of Neuromyelitis Optica Exacerbations	Neuromyelitis Optica	Drug: C1-esterase inhibitor (Cinryze)	Michael Levy	ViroPharma	Not recruiting	18 Years	65 Years	All	10	Phase 1	United States
634	NCT01779934	January 2013	14 March 2016	OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis	Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis	Primary Progressive Multiple Sclerosis	Drug: FTY720	Novartis Pharmaceuticals		Not recruiting	28 Years	N/A	Both	579	Phase 3	United States;Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom
635	NCT01665144	December 20, 2012	30 September 2019	Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)	A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.	Secondary Progressive Multiple Sclerosis	Drug: BAF312;Drug: Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	60 Years	All	1652	Phase 3	United States;Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Latvia;Lithuania;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;Czech Republic;Egypt
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
636	EUCTR2012-003056-36-SK	10/12/2012	28 February 2019	Study of efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis followed by extended treatment with BAF312	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312 - EXPAND	Secondary progressive multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Siponimod 2 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 1 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 0.5 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 0.25 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	1530	Phase 3	Portugal;United States;Estonia;Slovakia;Greece;Spain;Ireland;Russian Federation;Israel;Switzerland;Italy;France;Australia;Netherlands;Latvia;China;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Hungary;Canada;Argentina;Poland;Belgium;Romania;Bulgaria;Germany;Japan;Sweden
637	EUCTR2012-000721-53-SE	07/12/2012	24 September 2018	An extension trial of intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis	ITT-PMS Extension An extension study of intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis - ITT-PMS Ext	Secondary progressive multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mabthera Product Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Dept of Neurology, Umeå University Hospital, Umeå, Sweden		Not Recruiting			Female: yes Male: yes	30	Phase 2	Sweden
638	NCT01766063	December 6, 2012	26 February 2018	Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon	BETASLEEP - SLEEP Quality and Functional Health Status, Fatigue, Comorbidities and Therapeutic Algorithms Among BETAferon® Treated MS Patients	Multiple Sclerosis	Drug: Interferon beta-1b (Betaferon, BAY 86-5046)	Bayer		Not recruiting	18 Years	N/A	All	138	N/A	Germany
639	NCT01272128	December 2012	26 October 2015	Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study	A Multicenter, Prospective Non-interventional Study to Evaluate the Quality of Life in Belgian Patients With CIS or RRMS in Whom Interferon Beta-1a IM Treatment Has Been Initiated	Multiple Sclerosis	Drug: Interferon beta-1a	Biogen		Not recruiting	18 Years	N/A	Both	100	N/A	Belgium;United States
640	NCT01720849	December 2012	3 August 2015	Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis		Multiple Sclerosis;EDSS 4-7	Drug: Fampyra	Vestre Viken Hospital Trust		Recruiting	18 Years	N/A	Both	50	N/A	Norway
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
641	NCT01764737	December 2012	19 February 2015	Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS	A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: VX15/2503;Drug: Placebo	Vaccinex Inc.	PRA Health Sciences	Not recruiting	18 Years	60 Years	Both	50	Phase 1	United States
642	NCT01879202	December 2012	25 May 2015	Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis	Methylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study.	Multiple Sclerosis;Fatigue	Drug: Methylphenidate modified release;Drug: Maltodextrin	Medical University of Vienna		Recruiting	18 Years	N/A	Both	96	Phase 2	Austria
643	EUCTR2012-000835-18-SE	07/11/2012	21 September 2015	A study to evaluate how safe and effective 0.5 mg FTY720 is in delaying disability progression if taken once daily, in patients with PPMS	Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis - efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis	Primary progressive multiple sclerosis. MedDRA version: 16.0 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359- 56-0 Current Sponsor code: FTY720D Other descriptive name: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	700		United States;Finland;Spain;Turkey;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Sweden
644	EUCTR2012-001965-34-ES	07/11/2012	17 May 2016	Study to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse.	Multicenter, randomized, double-blind clinical trial to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse.	Multiple sclerosis MedDRA version: 15.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Urbason 40 mg Pharmaceutical Form: Capsule CAS Number: 03/03/2375 Other descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE Concentration unit: mg milligram(s) Concentration type: range Concentration number: 625-1250 Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Servicio de Neurología, HU. Germans Trias i Pujol		Not Recruiting			Female: yes Male: yes		Phase 4	Spain
645	NCT01728922	November 6, 2012	16 December 2017	Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome	Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome and Healthy Control Participants. An Exploratory Double Blind Placebo Randomised Controlled Study.	Clinically Isolated Syndrome;Multiple Sclerosis	Dietary Supplement: 5000IU vitamin D;Dietary Supplement: 10000IU vitamin D;Other: Placebo	University College Dublin	University of Dublin, Trinity College;St Vincent's University Hospital, Ireland	Not recruiting	18 Years	55 Years	All	64	Phase 1/Phase 2	Ireland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
646	NCT01679041	November 2012	19 February 2015	High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment	A Phase II Study of High Dose Chemotherapy With Autologous Hematopoietic Progenitor Cell Transplant for Multiple Sclerosis That Failed at Least Two Lines of Therapy	Multiple Sclerosis	Drug: Alemtuzumab;Drug: Fludarabine;Drug: Cyclophosphamide	Seah Lim M.D.		Not recruiting	18 Years	60 Years	Both	1	Phase 2	United States
647	NCT01743651	November 2012	19 February 2015	Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis	A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis	Spasticity;Multiple Sclerosis	Drug: arbaclofen;Drug: baclofen;Drug: Placebo	Osmotica Pharmaceutical Corp.		Not recruiting	18 Years	65 Years	Both	353	Phase 3	United States;Russian Federation;Ukraine
648	NCT01744444	November 2012	19 February 2015	Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis		Pendular Nystagmus Patients With Multiple Sclerosis	Drug: Memantine;Drug: Gabapentin	Hospices Civils de Lyon		Not recruiting	18 Years	N/A	Both	10	Phase 2	France
649	NCT01767493	November 2012	19 February 2015	Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients	An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: [18F]Florbetapir and PET imaging	Institute for Neurodegenerative Disorders	Biogen Idec	Recruiting	18 Years	60 Years	Both	18	N/A	United States
650	NCT02137707	November 2012	19 November 2018	Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya	An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years	Multiple Sclerosis-Relapsing-Remitting	Drug: Gilenya	McGill University	Novartis	Not recruiting	18 Years	65 Years	All	135	Phase 4	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
651	NCT02775110	November 2012	23 May 2016	Natalizumab Temporary Discontinuation Study	Natalizumab Temporary Discontinuation Study	Multiple Sclerosis	Other: Natalizumab discontinuation	University at Buffalo		Not recruiting	18 Years	65 Years	Both	50	Phase 4	United States
652	EUCTR2012-003056-36-HU	31/10/2012	19 November 2018	Study of efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis	A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis	Secondary progressive multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Siponimod 2 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 1 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 0.5 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Siponimod 0.25 mg tablet Product Code: BAF312A Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Siponimod CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Authorised			Female: yes Male: yes	1530	Phase 3	Portugal;United States;Estonia;Slovakia;Greece;Spain;Ireland;Russian Federation;Israel;Switzerland;Italy;France;Australia;Netherlands;Latvia;China;Lithuania;Turkey;Austria;United Kingdom;Hungary;Czech Republic;Canada;Argentina;Poland;Belgium;Romania;Bulgaria;Germany;Japan;Sweden
653	EUCTR2012-002470-31-GB	29/10/2012	4 August 2015	A study to assess safety and effectiveness of the study drug MT-1303 at different dosage strengths	A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for a period of 24 weeks in subjects with relapsing-remitting multiple sclerosis	Relapsing-Remitting Multiple Sclerosis MedDRA version: 15.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.2- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: MT-1303 Product Code: MT-1303 Pharmaceutical Form: Capsule INN or Proposed INN: MT-1303 Current Sponsor code: MT-1303 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.4- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	Mitsubishi Tanabe Pharma Corporation (MTPC)		Not Recruiting			Female: yes Male: yes	400	Phase 2	Serbia;Finland;Spain;Ukraine;Lithuania;Turkey;Russian Federation;Italy;United Kingdom;Switzerland;Hungary;Czech Republic;Canada;Poland;Belgium;Croatia;Bulgaria;Latvia;Germany;Sweden;Bosnia and Herzegovina
654	EUCTR2011-004787-30-DE	26/10/2012	30 May 2016	Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®	Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya® - MOVING	Multiple sclerosis or clinically isolated syndrom;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya® Product Name: Gilenya® Product Code: Gilenya® Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-55-9 Current Sponsor code: Gilenya Other descriptive name: FINGOLIMOD Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5- Trade Name: Extavia® Product Name: Extavia® Product Code: Extavia® Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: Interferon beta 1B CAS Number: 145155-23-3 Current Sponsor code: Extavia Other descriptive name: INTERFERON BETA-1B Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 250-	Charite Universitaetsmedizin Berlin		Not Recruiting			Female: yes Male: yes		Phase 3	Germany
655	EUCTR2012-002357-35-GB	23/10/2012	30 April 2019	Bone marrow stem cells to treat multiple sclerosis	Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS) - Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS)	Multiple Sclerosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Autologous Mesenchymal Cell Product Pharmaceutical Form: Suspension for injection in cartridge Pharmaceutical form of the placebo: Suspension for infusion Route of administration of the placebo: Intravenous use	Imperial College London		Not Recruiting			Female: yes Male: yes	13	Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
656	EUCTR2012-003418-15-AT	23/10/2012	19 November 2012	Methylphenidate modified release as treatment of MS-associated fatigue.	Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial.	Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step pharmacologic therapy. Until now, Amantadine, Modafinil or antidepressants have been used off-label among others, with some success. Until now, methylphenidate has been successfully used to treat fatigue in HIV and parkinson´s disease, data on its efficacy in MS are not available. ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ritalin LA 20mg capsules Product Name: Methylphenidate modified release 20 mg Pharmaceutical Form: Capsule, hard INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE CAS Number: 298-59-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Ritalin LA 30mg capsules Product Name: Methylphenidate modified release 30 mg Pharmaceutical Form: Capsule, hard INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE CAS Number: 298-59-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Trade Name: Ritalin LA 40mg capsules Product Name: Methylphenidate modified release 40 mg Pharmaceutical Form: Capsule, hard INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE CAS Number: 298-59-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-	Medizinische Universität Wien		Authorised			Female: yes Male: yes			Austria
657	EUCTR2012-002637-11-DE	15/10/2012	11 March 2013	A 6 months, multicenter study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patients with relapsing-remitting multiple sclerosis	A 6 months, randomized, multicenter, parallel-group, open-label study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patients with relapsing-remitting multiple sclerosis - STAY	Treatment statisfaction in patients with relapsing remitting Multiple Sclerosis MedDRA version: 15.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: Fingolimod Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Pharma GmbH		Not Recruiting			Female: yes Male: yes			Germany
658	NCT01578330	October 2012	19 October 2017	A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720	A 12 -Month, Open-label, Multi-center Pilot Study to Explore the Health Outcomes of FTY720 in RRMS Patients Who Have Previously Been Treated With Other Disease Modifying Therapies (DMT)- Fine	Multiple Sclerosis;Relapsing-Remitting	Drug: Fingolimod	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	42	Phase 4	Turkey
659	NCT01698086	October 2012	11 February 2019	Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial)	Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most?	Multiple Sclerosis;Balance;Fatigue;Eye Movement	Other: Vestibular rehabilitation: balance and eye movement exercises	University of Colorado, Denver	National Multiple Sclerosis Society	Not recruiting	18 Years	60 Years	All	88	N/A	United States
660	NCT01895439	October 2012	16 December 2017	Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis	Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment	Multiple Sclerosis	Biological: Autologous Mesenchymal Stem Cells	University of Jordan		Not recruiting	18 Years	65 Years	All	13	Phase 1/Phase 2	Jordan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
661	EUCTR2011-001437-16-DE	19/09/2012	25 September 2012	A 3 year study to determine if optical coherence tomography can be used to measure disease progression in patients with multiple sclerosis	A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis -	multiple sclerosis MedDRA version: 15.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Extavia Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1b CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Avonex Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1a CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30-	Novartis Pharma Services AG		Authorised			Female: yes Male: yes	420		Germany;Switzerland;Netherlands;France;Italy;Austria;Australia;Czech Republic;United Kingdom;Canada;Denmark;Spain;United States;Poland
662	EUCTR2012-000635-68-IE	19/09/2012	21 August 2017	An initial, short-duration study of vitamin D versus an inactive therapy on the ability of the human immune system to counteract the effects of Multiple Sclerosis on the brain and the effects of vitamin D on the immune system in healthy individuals.	Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome or early multiple sclerosis and healthy control participants. An exploratory randomised double blind placebo controlled study - N/A	Multiple Sclerosis MedDRA version: 14.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Vigantol Product Name: N/A Product Code: N/A Pharmaceutical Form: Oral drops, solution Pharmaceutical form of the placebo: Oral drops, solution Route of administration of the placebo: Oral use	University College Dublin		Not Recruiting			Female: yes Male: yes		Phase 2	Ireland
663	NCT01628393	September 18, 2012	17 June 2019	Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study)	A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients	Relapsing Multiple Sclerosis	Drug: RPC1063;Drug: placebo	Celgene		Not recruiting	18 Years	55 Years	All	258	Phase 2/Phase 3	United States;Belgium;Bulgaria;Georgia;Greece;Hungary;Italy;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine
664	NCT01413243	September 2012	17 May 2016	Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome	Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome - A Monocentric, Prospective, Randomized, Double-blind and Placebo-controlled Phase 2 Trial	Multiple Sclerosis	Drug: Trichuris suis ova	Charite University, Berlin, Germany		Not recruiting	18 Years	65 Years	Both	50	Phase 2	Germany
665	NCT01624714	September 2012	19 February 2015	Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects	Phase I Trial Monitoring Efficacy and Safety in Treatment of Alemtuzumab Naive Subjects and Data Collecting and Monitoring of Alemtuzumab Experienced Subjects With Refractory Multiple Sclerosis	Multiple Sclerosis	Drug: Alemtuzumab;Drug: Alemtuzumab immunotherapy	Samuel Forrester Hunter, MD, PhD		Not recruiting	18 Years	75 Years	Both	60	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
666	NCT01667484	September 2012	25 May 2015	Adderall XR and Processing Speed in Multiple Sclerosis (MS)	Does Adderall XR Improve Processing Speed in Cognitively Impaired MS Patients?	Impaired Processing Speed;Cognitive Impairment;Multiple Sclerosis	Drug: Adderall XR 5mg;Drug: Adderall XR 10 mg;Drug: Placebo	London Health Sciences Centre		Not recruiting	18 Years	59 Years	Both	70	Phase 2/Phase 3	Canada
667	NCT01667497	September 2012	14 September 2015	Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?	Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? A Cross Over Study	Cognitive Fatigue	Drug: Fampridine SR;Drug: Placebo	London Health Sciences Centre		Not recruiting	18 Years	64 Years	Both	60	Phase 2/Phase 3	Canada
668	NCT01701856	September 2012	19 February 2015	Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis	Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis: A Swiss Multicenter Study Prospective, Controlled, Single-arm, Open-label, Multi-centre, Phase IV Study	Relapsing-remitting Multiple Sclerosis	Drug: Interferon beta-1b	Claudio Gobbi	Bayer	Not recruiting	18 Years	70 Years	Both	5	Phase 4	Switzerland
669	NCT01706055	September 2012	16 December 2017	Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)	Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon®	Multiple Sclerosis	Biological: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	All	629	N/A	Poland
670	NCT02442570	September 2012	7 September 2015	A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis	A Phase IIa, Randomized, Double-blind, Placebo-controlled, Exploratory, Dose-ranging Study to Evaluate the Safety, Effectiveness and Pharmacokinetics of Three Courses of DC-TAB Treatment in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: recombinant human alpha B-crystallin;Other: Placebo comparator	Delta Crystallon BV		Not recruiting	18 Years	55 Years	Both	32	Phase 2	Bulgaria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
671	NCT02463318	September 2012	16 December 2017	The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects		Multiple Sclerosis;Oxidative Stress	Drug: Melatonin;Other: Hydrogen peroxide	Tehran University of Medical Sciences		Not recruiting	20 Years	40 Years	Female	34	N/A	Iran, Islamic Republic of
672	NCT01633112	August 9, 2012	15 October 2018	MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone	A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis (RRMS)	Drug: fingolimod;Drug: copaxone	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	1064	Phase 4	United States;Argentina;Brazil;Canada;Chile;Mexico;Puerto Rico
673	NCT01582126	August 2012	7 April 2015	Group Balance Training for People With Multiple Sclerosis	Group Balance Training for People With Multiple Sclerosis	Multiple Sclerosis	Other: Group balance training	Örebro County Council	Uppsala-Örebro Regional Research Council;Norrbacka-Eugenia Foundation	Not recruiting	18 Years	N/A	Both	87	N/A	Sweden
674	NCT01597297	August 2012	16 December 2017	Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis	Multiple Sclerosis	Drug: BIIB041 (PR Fampridine);Other: Placebo	Biogen		Not recruiting	18 Years	70 Years	All	132	Phase 2	Belgium;Canada;Italy;Netherlands;Sweden;United Kingdom
675	NCT01684761	August 2012	16 December 2017	Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis	A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis	Autoimmune Diseases of the Nervous System;Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Disease Progression;Brain Atrophy	Biological: Tcelna;Biological: Placebo	Opexa Therapeutics, Inc.		Not recruiting	18 Years	60 Years	All	183	Phase 2	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
676	EUCTR2011-005475-16-GB	25/07/2012	31 July 2012	A Phase 1/2 study to test how effective different doses of MEDI-551 is for treating subjects with Relapsing-Remitting Multiple Sclerosis	A Phase 1/2 Randomized, Dose-finding Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: MEDI-551 Product Code: MEDI-551 Pharmaceutical Form: Concentrate for solution for infusion Current Sponsor code: MEDI-551 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Avonex Product Name: Avonex Pharmaceutical Form: Solution for infusion in pre-filled syringe INN or Proposed INN: interferon beta-1a CAS Number: 220581-49-7 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 60-	MedImmune LLC		Authorised			Female: yes Male: yes	512	Phase 1/2	Hungary;Germany;Turkey;Switzerland;Netherlands;France;Ireland;Italy;Austria;Sweden;Israel;Russian Federation;United Kingdom;Czech Republic;Ukraine;Canada;Denmark;Spain;United States;Poland
677	NCT01639300	July 2012	26 February 2018	Safety Study of GNbAC1 in Multiple Sclerosis Patients	Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1	Multiple Sclerosis	Biological: GNbAC1;Biological: GNbAC1 placebo	GeNeuro Innovation SAS		Not recruiting	18 Years	65 Years	All	10	Phase 2	Switzerland
678	NCT01854957	July 2012	19 February 2015	MEsenchymal StEm Cells for Multiple Sclerosis	MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple Sclerosis	Multiple Sclerosis	Biological: Autologous Mesenchymal Stem Cells	Antonio Uccelli	Azienda Ospedaliera Universitaria Integrata Verona;Ospedale San Raffaele	Recruiting	18 Years	50 Years	Both	20	Phase 1/Phase 2	Italy
679	NCT01585298	June 29, 2012	16 December 2017	STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)	A 1-week, Open-label, Multi-center Study to Explore Conduction Abnormalities During First Dose Administration of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: FTY720	Novartis Pharmaceuticals		Not recruiting	18 Years	N/A	All	6996	Phase 4	Germany
680	JPRN-UMIN000009421	2012/06/28	2 April 2019	Efficacy and safety of rituximab for intractable immunogenic neurological disorder in children		neuromyelitis optica (NMO), opsoclonus-myoclonus syndrome (OMS)	administration of rituximab	Department of Pediatrics, Kobe Universtiy Graduate School of Medicine		Recruiting	Not applicable	18years-old	Male and Female	10	Not applicable	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
681	EUCTR2012-000653-32-DE	27/06/2012	2 October 2017	A study to explore heart function during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis	A 1-week, open-label, multi-center study to explore conduction abnormalities during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis (START) - START	Conduction abnormalities in patients with relapsing-remitting multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: Fingolimod Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Pharma GmbH		Not Recruiting			Female: yes Male: yes		Phase 4	Germany
682	EUCTR2012-000518-13-DK	21/06/2012	9 January 2017	Own mesenchymal stem cells for multiple sclerosis patients	Immunomodulating and neuroprotective properties of autologous multipotent mesenchymal stem cells in patients with multiple sclerosis - A randomised placebo-controlled double-blinded phase II study - COMSCIMS	Multiple sclerosis MedDRA version: 18.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Mesenchymal stem/stromal cells Product Name: Mesenchymal stem cells (MSCs) Pharmaceutical Form: Concentrate for solution for infusion Pharmaceutical form of the placebo: Solution for injection/infusion Route of administration of the placebo: Intravenous use	Prof. Per Soelberg Sørensen		Not Recruiting			Female: yes Male: yes		Phase 2	Denmark
683	NCT01623596	June 8, 2012	15 April 2019	Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.	A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod;Drug: Disease Modifying therapy	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	881	Phase 4	United States;Puerto Rico
684	JPRN-jRCTs031180152	04/06/2012	7 October 2019	Tocilizumab in patients with neuromyelitis optica	The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter study - Tocilizumab in patients with neuromyelitis optica	Neuromyelitis optica;D009471	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 months.	Takashi Yamamura		Not Recruiting	>= 20age old	<= 65age old	Both	20	N/A	none
685	NCT01600716	June 2012	19 October 2017	Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)		Urinary Incontinence;Multiple Sclerosis;Neurogenic Bladder	Biological: OnabotulinumtoxinA;Drug: Placebo (Normal Saline)	Allergan		Not recruiting	18 Years	N/A	All	144	Phase 3	United States;Belgium;Canada;Czech Republic;France;Poland;Portugal;Russian Federation
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
686	NCT01656148	June 2012	3 September 2018	FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra	Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra	Multiple Sclerosis	Drug: Fampridine-SR	University of Southern Denmark	Region of Southern Denmark;Biogen	Not recruiting	18 Years	60 Years	All	108	Phase 4	Denmark
687	NCT01712945	June 2012	13 May 2019	Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis	Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: Palifermin;Drug: Alemtuzumab	Cambridge University Hospitals NHS Foundation Trust		Not recruiting	18 Months	50 Years	All	40	Phase 1/Phase 2	United Kingdom
688	EUCTR2012-000287-17-IT	21/05/2012	10 February 2014	functional MRI study to evaluate improvement of hand performance after combined motor exercise and aminopiridine assumption	PROMOTION OF FUNCTIONAL RESTORATION THROUGH PHARMACOLOGICAL MODULATION OF BRAIN PLASTICITY WITH AMINOPYRIDINE IN PATIENTS WITH MULTIPLE SCLEROSIS STUDIED BY FUNCTIONAL MRI	Patients with MS, without relevant medical conditions, with right upper limb impairment assessed by a hand dexterity test will be included.Patients will be in a non-active phase of the disease and under a stable pharmacological treatment.They will not be included if they have received physiotherapy in the previous few months. Healthy volunteers will be recruited if they have no relevant medical condition and no contraindication to perform a MRI scan. MedDRA version: 14.1 Level: LLT Classification code 10028053 Term: MS System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: FAMPYRA Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use	FONDAZIONE SANTA LUCIA		Authorised			Female: yes Male: yes			Italy
689	EUCTR2011-004475-36-BG	19/05/2012	14 March 2016	A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patients with multiple sclerosis	A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patients with multiple sclerosis	Relapsing multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: DC-TAB Product Code: DC-TAB Pharmaceutical Form: Solution for injection Current Sponsor code: recombinant human CRYAB Other descriptive name: recombinant human alpha B-crystallin Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 12.5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	Delta Crystallon B.V.		Not Recruiting			Female: yes Male: yes		Phase 2a	Bulgaria
690	EUCTR2011-005550-57-LV	15/05/2012	25 March 2013	A clinical study in patients with multiple sclerosis to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml (experimental drug).	A multinational, multicenter, randomized, parallel group, double blind, placebo controlled study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml new formulation administered daily by subcutaneous (SC) injection. - GLOW study	Relapsing-remitting Multiple sclerosis (RRMS) MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: 20mg/0.5ml glatiramer acetate Product Code: 20mg/0.5ml GA Pharmaceutical Form: Solution for injection INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Current Sponsor code: 20 mg/0.5 ml GA Other descriptive name: glatiramer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Teva Pharmaceutical Industries Ltd.		Not Recruiting			Female: yes Male: yes	1400		Serbia;United States;Belarus;Estonia;Greece;Ukraine;Lithuania;Russian Federation;Montenegro;Hungary;Czech Republic;Mexico;Macedonia, the former Yugoslav Republic of;Poland;Romania;Croatia;Georgia;Albania;Bulgaria;Germany;Latvia;Moldova, Republic of;Bosnia and Herzegovina
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
691	JPRN-UMIN000007866	2012/05/01	2 April 2019	The safety and efficacy of tocilizumab in patients with neuromyelitis optica: Multicenter Study		neuromyelitis optica	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 years.	Department of Immunology, National Institute of Neuroscience, NCNP	Department of Neurology, Kinki University Faculty of Mediceine	Not Recruiting	20years-old	65years-old	Male and Female	15	Not applicable	Japan
692	NCT01641120	May 2012	19 October 2017	Assessing Tolerability of Avonex Intramuscular Injections	Assessing Tolerability of Avonex Intramuscular Injections With a 25 Gauge Needle Versus 30 Gauge Needle	Multiple Sclerosis	Drug: Avonex	Saint Francis Care	Biogen	Not recruiting	18 Years	65 Years	All	20	N/A	United States
693	NCT01718678	May 2012	19 February 2015	Effect of Melatonin on Multiple Sclerosis Related Fatigue	Study of Melatonin in Treatment of Fatigue in Multiple Sclerosis	Fatigue	Drug: Melatonin;Drug: Placebo	Isfahan University of Medical Sciences		Not recruiting	18 Years	55 Years	Both	44	Phase 2	Iran, Islamic Republic of
694	NCT02142205	May 2012	19 February 2015	Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)	A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®).	Relapsing-Remitting Multiple Sclerosis	Biological: BG00002	Biogen Idec	Biogen Idec International GmbH	Not recruiting	18 Years	60 Years	Both	100	Phase 4	Russian Federation
695	NCT01491100	April 30, 2012	11 June 2018	Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis	Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferon®	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	12 Years	70 Years	All	1085	Phase 4	Albania;Algeria;Argentina;Belgium;Czechia;Egypt;France;Germany;Greece;Hungary;Israel;Kazakhstan;Netherlands;Portugal;Saudi Arabia;Tunisia;Turkey;Bosnia and Herzegovina;Czech Republic;Jordan;Lebanon;Mexico;Poland;Syrian Arab Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
696	EUCTR2011-005606-30-GB	25/04/2012	1 May 2012	Preventing patients with multiple sclerosis from developing side effects following treatment with alemtuzumab (Campath-1H).	Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY - CAM-THY	This trial will test the efficacy of Kepivance in the prevention of new autoimmune diseases in patients who have multiple sclerosis (MS)who are being treated with alemtuzumab. MedDRA version: 14.1 Level: PT Classification code 10058948 Term: Nephritis autoimmune System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1 Level: PT Classification code 10049046 Term: Autoimmune thyroiditis System Organ Class: 10014698 - Endocrine disorders MedDRA version: 14.1 Level: PT Classification code 10061664 Term: Autoimmune disorder System Organ Class: 10021428 - Immune system disorders MedDRA version: 14.1 Level: LLT Classification code 10068004 Term: Autoimmune hyperthyroidism System Organ Class: 10014698 - Endocrine disorders MedDRA version: 14.1 Level: PT Classification code 10050245 Term: Autoimmune thrombocytopenia System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Kepivance Product Name: Kepivance Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Palifermin CAS Number: 162394-19-6 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Trade Name: MabCampath Product Name: Alemtuzumab Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Alemtuzumab CAS Number: 216503-57-0 Other descriptive name: anti-CD52 monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	Cambridge University Hospitals NHS Foundation Trust and University of Cambridge		Authorised			Female: yes Male: yes	86		United Kingdom
697	NCT01480063	April 16, 2012	17 June 2019	An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice	A Multicenter, Multinational, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice (LIBERATE)	Multiple Sclerosis	Drug: Fampridine	Biogen		Not recruiting	N/A	N/A	All	4734	N/A	Argentina;Canada;Czechia;France;Germany;Ireland;Israel;Lebanon;Netherlands;Norway;Portugal;Spain;United Arab Emirates;Australia;Belgium;Czech Republic;Denmark
698	EUCTR2010-020337-99-NL	13/04/2012	28 February 2019	A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis	A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis - OPERA I	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ocrelizumab 300mg /10ml Product Code: RO4964913 F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: range Concentration number: 8.8-22 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s)	F.Hoffmann-La Roche		Authorised			Female: yes Male: yes	800	Phase 3	Portugal;United States;Serbia;Estonia;Morocco;Slovakia;Spain;Ukraine;Israel;Chile;Russian Federation;Italy;Switzerland;Australia;Peru;South Africa;Tunisia;Netherlands;Latvia;Finland;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Argentina;Poland;Brazil;Belgium;Bulgaria;Germany;New Zealand
699	NCT01514370	April 2012	12 September 2016	Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a	ProspeCtive Study to Evaluate Efficacy, Safety and tOlerability of Dietary supplemeNT of Curcumin (BCM95) in Subjects With Active Relapsing MultIple Sclerosis Treated With subcutaNeous Interferon Beta 1a 44 mcg Three Times a Week (TIW)	Multiple Sclerosis	Drug: IFN beta 1 a + curcumin (BCM 95);Drug: IFN beta-1a + placebo	Merck KGaA	Merck Serono S.P.A., Italy	Not recruiting	18 Years	60 Years	Both	80	Phase 2	Italy
700	NCT01538225	April 2012	19 February 2015	Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity	Neurophysiologic Study on Effects of Sativex® on Spasticity in Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Sativex®;Drug: Placebo	Almirall, S.A.		Not recruiting	18 Years	N/A	Both	45	Phase 3	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
701	NCT01585766	April 2012	29 August 2016	Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis	A Phase 1 Randomized Study of MEDI-551 in Subjects With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis, Relapsing Forms	Biological: MEDI-551 IV;Biological: MEDI-551 SC;Drug: Placebo IV;Drug: Placebo SC	MedImmune LLC		Not recruiting	18 Years	65 Years	Both	56	Phase 1	United States;Poland;Spain;Ukraine;Czech Republic;United Kingdom
702	NCT01627938	April 2012	19 February 2015	Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination	A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)	Multiple Sclerosis	Drug: Dexrazoxane (DRZ) plus Mitoxantrone (MX);Drug: Placebo plus Mitoxantrone (MX)	PD Dr. Andrew Chan		Not recruiting	18 Years	55 Years	Both	50	Phase 2	Germany
703	EUCTR2011-002561-38-IE	30/03/2012	18 April 2012	Trial on the effectiveness of Fampridine medication for upper limb function in people with MS.	A double blind, randomized, placebo controlled, crossover study of the effectiveness of oral fampridine in improving upper limb function in progressive multiple sclerosis.	Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: Fampyra Product Code: SUB0750MIG Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use	St. Vincent's University Hospital		Authorised			Female: yes Male: yes			Ireland
704	NCT01404117	March 2012	19 February 2015	A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability		Relapsing Multiple Sclerosis	Drug: Laquinimod 0.6;Drug: Laquinimod 1.2;Other: Glatiramer Acetate or interferon-beta+ Placebo	Teva Pharmaceutical Industries		Not recruiting	18 Years	55 Years	Both	0	Phase 2
705	NCT01436838	March 2012	12 September 2016	China Betaferon Adherence, Coping and Nurse Support Study	Prospective Study of Betaferon in Adherence, Coping and Nurse Support in Patients of Chinese Origin With Multiple Sclerosis	Multiple Sclerosis, Chronic Progressive	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	75 Years	Both	110	N/A	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
706	NCT01490502	March 2012	15 July 2019	Vitamin D Supplementation in Multiple Sclerosis	A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: Vitamin D3	Johns Hopkins University	Oregon Health and Science University;University of California, San Francisco;Washington University School of Medicine;Icahn School of Medicine at Mount Sinai;University of Pennsylvania;Yale University;The Cleveland Clinic;University of Rochester;Stanford University;University of Virginia;Swedish Medical Center;Anne Arundel Health System Research Institute;Columbia University;University of Massachusetts, Worcester;Dignity Health	Not recruiting	18 Years	50 Years	All	172	Phase 3	United States
707	NCT01576354	March 2012	14 December 2015	Characterization of the Effects of Prolonged-release Fampridine on Ambulatory Function in Patients With Multiple Sclerosis	A Phase IIb, Double-blind, Randomized, Mono-center, Placebo-controlled Study With Crossover Design Characterizing the Effects of Prolonged-release Fampridine Treatment on Ambulatory Function in Patients With Multiple Sclerosis Using Detailed Gait Analysis Based on Kinematic and Kinetic Parameters	Multiple Sclerosis	Drug: Prolonged-release Fampridine;Drug: Placebo	University of Zurich		Not recruiting	18 Years	65 Years	Both	70	Phase 2	Switzerland
708	NCT01591551	March 2012	19 February 2015	NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness	NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Relapsing Forms of Multiple Sclerosis Experiencing Fatigue or Sleepiness	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab (Tysabri)	Cornerstone Health Care, PA	Biogen Idec	Not recruiting	18 Years	65 Years	Both	37	Phase 4	United States
709	EUCTR2011-006043-30-NL	27/02/2012	25 September 2012	Study to evaluate the effect of oral BAF312 on a monophasic oral contraceptive in healthy female volunteers	An open-label, multiple-dose, two-treatment period study to evaluate the effect of oral BAF312 on the pharmacokinetices and pharmacodynamics of a monophasic oral contraceptive in healthy female volunteers -	healthy volunteers (Multiple sclerosis is the intended indication for BAF312) ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: BAF312 0,25 mg tablet Product Code: BAF312 Pharmaceutical Form: Film-coated tablet CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Product Name: BAF312 1 mg tablet Product Code: BAF312 Pharmaceutical Form: Film-coated tablet CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Product Name: BAF312 4 mg tablet Product Code: BAF312 Pharmaceutical Form: Film-coated tablet CAS Number: 1234627-85-0 Current Sponsor code: BAF312 Other descriptive name: BAF312 hemifumarate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Trade Name: Microgynon Product Name: Microgynon Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ETHINYLESTRADIOL CAS Number: 57-63-6 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- CAS Number: 797-63-7 Other descriptive name: LEVONORGESTREL Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.15-	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: no	24		Netherlands
710	EUCTR2010-023210-31-DE	24/02/2012	30 June 2014	The aim of the study is to assess the efficacy and safety of intra - detrusor injections of Dysport versus placebo in subjects suffering from neurogenic detrusor overactivity following spinal cord injury or multiple sclerosis.	A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNITS OF DYSPORT IN SUBJECTS SUFFERING FROM NEUROGENIC DETRUSOR OVERACTIVITY FOLLOWING SPINAL CORD INJURY OR MULTIPLE SCLEROSIS	NEUROGENIC DETRUSOR OVERACTIVITY MedDRA version: 15.1 Level: LLT Classification code 10012547 Term: Detrusor hyperreflexia System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Dysport Product Name: Dysport Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: CLOSTRIDIUM BOTULINUM TOXIN TYPE A CAS Number: 93384-43-1 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intramuscular use	Ipsen Innovation		Not Recruiting			Female: yes Male: yes	42	Phase 2A	Czech Republic;Lithuania;Austria;Germany;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
711	EUCTR2011-006151-10-DK	15/02/2012	14 April 2014	FAME - a study of the effect of Fampyra on muscle strength in the lower extremities, walking capacity, coordination in the upper extremitties and cognition in multiple sclerosis patients.	FAME - Fampyra outcome measures study: a study of responsiveness of different outcome measures to Fampyra treatment. - FAME	Multiple Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: Fampyra Pharmaceutical Form: Tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Sønderjylland Hospital, department of neurology		Not Recruiting			Female: yes Male: yes			Denmark
712	NCT01485003	February 7, 2012	25 February 2019	Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants	A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients	Relapsing-Remitting Multiple Sclerosis	Biological: natalizumab	Biogen		Not recruiting	18 Years	65 Years	All	231	Phase 2	United States
713	NCT01433250	February 2012	19 October 2017	A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis	An Open Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: AIN457	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	39	Phase 2	Czech Republic;Russian Federation;Ukraine
714	NCT01480076	February 2012	16 December 2017	Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis	An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects With Multiple Sclerosis	Multiple Sclerosis	Drug: Fampridine	Biogen		Not recruiting	18 Years	75 Years	All	901	Phase 4	Italy;Netherlands;Portugal;United Kingdom;Australia;Belgium;Denmark;France;Germany;United States
715	NCT01497262	February 2012	19 October 2017	Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis	A 4-month, Open-label, Multi-center Study to Explore the Safety and Tolerability of Fingolimod 0.5 mg in Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Fingolimod	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	162	Phase 3	Argentina;Brazil;Colombia;Jordan;Malaysia;Mexico;Panama;Peru;Costa Rica
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
716	NCT01516554	February 2012	19 February 2015	Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients	A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients	Multiple Sclerosis;Fatigue	Drug: Testosterone undecanoate;Drug: placebo	Health Sciences Centre, Winnipeg, Manitoba	University of Manitoba;Consortium of Multiple Sclerosis Centers;Manitoba Medical Service Foundation	Not recruiting	18 Years	65 Years	Male	3	Phase 2	Canada
717	NCT01569451	February 2012	18 June 2018	Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate	A Double Blinded, Randomized Study Comparing Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy in Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: Rituximab;Drug: Glatiramer Acetate;Other: Placebo	University of Colorado, Denver	Rocky Mountain MS Research Group, LLC	Not recruiting	18 Years	55 Years	All	53	Phase 2	United States
718	NCT02305264	February 2012	16 December 2017	Imaging of Intracerebral Inflammation in MS	Imaging of Intracerebral Inflammation in the Progressive Phase of Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive	Drug: 18F-DPA-714 and 18F-FDG	Assistance Publique - Hôpitaux de Paris		Recruiting	18 Years	65 Years	All	65	N/A	France
719	EUCTR2011-002683-24-ES	30/01/2012	26 June 2012	A clinical trial to test if NU100 is safe and can treat patient with relapsing types of multiple sclerosis	A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis	Relapsing forms of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Code: NU100 Pharmaceutical Form: Solution for injection in pre-filled syringe Current Sponsor code: NU100 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Betaferon Product Name: Betaferon Pharmaceutical Form: Powder and solvent for solution for injection CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25-	Nuron Biotech, Inc.		Authorised			Female: yes Male: yes	500	Phase 3	Hungary;Russian Federation;Ukraine;Belarus;Georgia;Bulgaria;Spain;Italy;Croatia;Poland
720	EUCTR2011-003775-11-BE	12/01/2012	7 October 2013	Fluoxetine therapy for multiple sclerosis	Fluoxetine therapy for multiple sclerosis - FLUOX-PMS	progressive multiple sclerosis MedDRA version: 16.0 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 16.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 16.0 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fluoxetine Product Name: Fluoxetine Product Code: fluoxetine Pharmaceutical Form: Capsule INN or Proposed INN: Fluoxetine CAS Number: 59333-67-4 Other descriptive name: N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-40 Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use			Authorised			Female: yes Male: yes	120		Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
721	EUCTR2011-003507-38-GB	06/01/2012	28 January 2013	Long-Term Prolonged-Release Fampridine Treatment and Quality of Life	An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects with Multiple Sclerosis	Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra Product Name: Fampridine Product Code: BIIB041 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: FAMPRIDINE CAS Number: 504-24-5 Current Sponsor code: BIIB041 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	Biogen Idec Research Limited		Authorised			Female: yes Male: yes	800		Sweden;United Kingdom;Italy;Germany;Netherlands;Australia;Denmark;Ireland;Belgium;Portugal;France
722	NCT01500408	January 2012	19 February 2015	Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers	A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of Interferon Beta-1a Manufactured by Two Different Processes	Multiple Sclerosis	Drug: Interferon beta-1a (current approved manufacturing process invloving FBS);Drug: Interferon beta-1a (new process, manufactured without FBS)	Biogen Idec		Not recruiting	18 Years	45 Years	Both	110	Phase 1	United States
723	NCT01517282	January 2012	19 October 2017	Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety and Pharmacokinetics of MOR103, a Human Antibody to GM-CSF, in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: MOR103;Other: Placebo	MorphoSys AG		Not recruiting	18 Years	60 Years	All	32	Phase 1/Phase 2	Germany;Poland;United Kingdom
724	NCT01534182	January 2012	19 October 2017	Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (Fingolimod) 0.5 mg/Day in Patients With Relapsing Remitting Multiple Sclerosis Who Are Candidates for Multiple Sclerosis (MS) Therapy Change From Previous Disease Modifying Therapy (DMT)	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod;Drug: Interferon beta - 1a (IFN);Drug: Glatiramer acetate (GA)	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	298	Phase 4	Russian Federation
725	NCT01535664	January 2012	19 October 2017	An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)	An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10mg in Subjects With MS	Multiple Sclerosis	Other: Withdrawal of dalfampridine-ER 10mg	Acorda Therapeutics	Prometrika, LLC;BCS Consulting, Inc.	Not recruiting	18 Years	70 Years	All	20	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
726	NCT01601119	January 2012	8 June 2015	Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients	The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients	Relapsing Multiple Sclerosis	Drug: Rebif;Other: Other: Disease modifying therapies (DMT)	Merck KGaA	Merck Serono Limited, UK	Not recruiting	18 Years	N/A	Both	545	N/A	United Kingdom
727	NCT01964547	January 2012	19 October 2017	A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients	A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis	Multiple Sclerosis;Spasticity	Drug: Sativex;Drug: Placebo	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	121	Phase 4	Czech Republic
728	NCT02280876	January 2012	4 July 2016	Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS)	Randomized, Comparative, Double Blind Controlled Phase II Clinical Trial, to Evaluate the Efficacy of ApE in Patients With Multiple Sclerosis (MS).	Multiple Sclerosis, Relapsing-Remitting	Drug: 1 - Andrographis paniculata p/st extract;Drug: 2 - Excipients	Universidad Austral de Chile	Comisión Nacional de Investigación Científica y Tecnológica;University of Chile	Not recruiting	18 Years	55 Years	Both	30	Phase 1/Phase 2	Chile
729	NCT01498887	December 21, 2011	16 December 2017	Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy	A Multi-centre, Open-label, Non-randomised, Parallel Group Clinical Trial to Assess the Efficacy of Fingolimod in Naive Patients Versus Fingolimod in Patients Previously Treated With Interferons or Glatiramer Acetate, Based on the Presence of Relapses in Patients With Relapsing-remitting Multiple Sclerosis.	Relapsing Remitting Multiple Sclerosis	Drug: Fingolimod (FTY720)	Novartis Pharmaceuticals		Not recruiting	18 Years	50 Years	All	349	Phase 4	Australia;Spain
730	NCT02967380	December 14, 2011	16 December 2017	Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases	Dynamic Contrast Enhanced Steady State T1-Weighted Perfusion MRI (DCE MRI): Characterization of Intracranial Lesions	Adult Anaplastic (Malignant) Meningioma;Adult Anaplastic Astrocytoma;Adult Anaplastic Ependymoma;Adult Anaplastic Oligodendroglioma;Adult Brain Stem Glioma;Adult Choroid Plexus Neoplasm;Adult Diffuse Astrocytoma;Adult Ependymoblastoma;Adult Ependymoma;Adult Giant Cell Glioblastoma;Adult Glioblastoma;Adult Gliosarcoma;Adult Grade II Meningioma;Adult Medulloblastoma;Adult Mixed Glioma;Adult Oligodendroglioma;Adult Papillary Meningioma;Adult Pineal Gland Astrocytoma;Adult Pineoblastoma;Adult Primary Melanocytic Lesion of Meninges;Adult Supratentorial Primitive Neuroectodermal Tumor;Malignant Adult Intracranial Hemangiopericytoma;Metastatic Malignant Neoplasm in the Brain;Multiple Sclerosis;Recurrent Adult Brain Neoplasm	Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;Drug: Gadobenate Dimeglumine;Drug: Gadobutrol;Radiation: Gadopentetate Dimeglumine	University of Southern California	National Cancer Institute (NCI)	Not recruiting	18 Years	N/A	All	14	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
731	EUCTR2011-003570-89-NL	02/12/2011	19 March 2012	The effect of interferon beta-1a treatment on adaptability of the brain in patients with MS	The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS) - interferon beta-1a and functional adaptation	Multiple sclerosis MedDRA version: 14.0 Level: PT Classification code 10004504 Term: Beta interferon therapy System Organ Class: 10042613 - Surgical and medical procedures ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rebif Pharmaceutical Form: Concentrate and solvent for solution for injection INN or Proposed INN: interferon beta-1a Concentration unit: IU international unit(s) Concentration type: range Concentration number: 2400000-12000000	VU University Medical Center		Authorised			Female: yes Male: yes			Netherlands
732	NCT01377870	December 2011	11 June 2018	Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis	Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis	Multiple Sclerosis	Biological: intravenous injection of mesenchymal stem cells;Biological: injection of cell free media	Royan Institute		Not recruiting	18 Years	55 Years	All	22	Phase 1/Phase 2	Iran, Islamic Republic of
733	NCT01440062	December 2011	10 December 2018	Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)	Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis	Multiple Sclerosis	Drug: Verum arm receiving Vitamin D oil;Drug: low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day	Charite University, Berlin, Germany	NeuroCure Clinical Research Center, Charite, Berlin	Not recruiting	18 Years	65 Years	All	55	Phase 2	Germany
734	NCT01470521	December 2011	8 February 2016	Worms for Immune Regulation of Multiple Sclerosis	Worms for Immune Regulation of Multiple Sclerosis (WIRMS)	Multiple Sclerosis, Relapsing-Remitting	Biological: Hookworm larvae;Biological: Placebo	University of Nottingham	National Multiple Sclerosis Society	Not recruiting	18 Years	65 Years	Both	72	Phase 2	United Kingdom
735	NCT02006160	December 2011	13 May 2019	Effects of Dalfampridine on Cognition in Multiple Sclerosis	Effects of Dalfampridine on Cognition in Multiple Sclerosis	Multiple Sclerosis	Drug: dalfampridine;Drug: placebo	State University of New York at Buffalo		Not recruiting	18 Years	60 Years	All	61	Phase 2/Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
736	NCT01943526	November 30, 2011	11 June 2018	Ireland Natalizumab (TYSABRI) Observational Program	Ireland Natalizumab (TYSABRI®) Observational Program (iTOP)	Relapsing-Remitting Multiple Sclerosis	Biological: natalizumab	Biogen		Not recruiting	N/A	N/A	All	191	Phase 1	Ireland
737	EUCTR2011-002333-19-DE	29/11/2011	21 September 2015	Subcutaneous Ofatumumab in Relapsing Remitting Multiple Sclerosis.	A Randomized, Double-blind, Placebo controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months’ administration of Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) - Ofatumumab sub-cutaneous in RRMS	Relapsing-Remitting Multiple Sclerosis (RRMS) MedDRA version: 15.0 Level: LLT Classification code 10070716 Term: Multiple sclerosis pseudo relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Ofatumumab Product Code: GSK1841157 Pharmaceutical Form: Concentrate for solution for injection INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Current Sponsor code: GSK1841157 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	GlaxoSmithKline Research and Development Limited		Not Recruiting			Female: yes Male: yes	196		United States;Czech Republic;Canada;Spain;Denmark;Bulgaria;Russian Federation;Netherlands;Norway;Germany;Italy
738	EUCTR2011-002969-38-DE	08/11/2011	24 July 2012	A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®), followed by a 6 month optional extension phase	A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®), followed by a 6 month optional extension phase -	Fatigue in Patients with relapsing remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: Fingolimod Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Pharma GmbH		Authorised			Female: yes Male: yes			Germany
739	EUCTR2009-015319-41-DE	03/11/2011	17 May 2016	Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS)	Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS) - TRIOMS	remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]	Product Name: TSO Product Code: TSO Pharmaceutical Form: Oral suspension INN or Proposed INN: Trichuris suis ova (eggs), embryonated, viable Concentration unit: Other Concentration type: equal Concentration number: 2500- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	Charite Universitätsmedizin Berlin		Not Recruiting			Female: yes Male: yes		Phase 2	Germany
740	NCT01457924	November 1, 2011	11 June 2018	Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis	A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis	Drug: Ofatumumab 3mg;Drug: Ofatumumab 30mg;Drug: Ofatumumab 60mg;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	55 Years	All	232	Phase 2	United States;Bulgaria;Canada;Czechia;Denmark;Germany;Italy;Netherlands;Norway;Russian Federation;Spain;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
741	NCT01451593	November 2011	21 September 2015	Neuroprotection With Phenytoin in Optic Neuritis	A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis	Optic Neuritis;Multiple Sclerosis	Drug: Phenytoin;Drug: Placebo	University College, London	National Multiple Sclerosis Society;Multiple Sclerosis Society of Great Britain and Northern Ireland	Not recruiting	18 Years	60 Years	Both	92	Phase 2	United Kingdom
742	NCT01462318	November 2011	16 December 2017	An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis	A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: Midazolam;Other: Caffeine;Drug: S-warfarin;Other: Vitamin K;Drug: Omeprazole;Drug: Dextromethorphan;Biological: BIIB019 (Daclizumab)	Biogen		Not recruiting	18 Years	65 Years	All	133	Phase 3	United States;Czech Republic;Hungary;Poland;Russian Federation
743	EUCTR2010-020337-99-GB	20/10/2011	22 October 2018	A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis	A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis - OPERA I	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: range Concentration number: 8.8-22 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use Trade Name: Ocrevus Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F.Hoffmann-La Roche		Authorised			Female: yes Male: yes	800	Phase 3	Portugal;United States;Serbia;Estonia;Morocco;Slovakia;Spain;Ukraine;Israel;Chile;Russian Federation;Italy;Switzerland;Australia;Peru;South Africa;Netherlands;Tunisia;Latvia;Finland;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Argentina;Poland;Brazil;Belgium;Bulgaria;Germany;New Zealand
744	EUCTR2010-020315-36-SK	18/10/2011	19 November 2018	A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis	A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis - OPERA II	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: range Concentration number: 8.8-22 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: ocrelizumab 300mg Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use Trade Name: Ocrevus Product Name: ocrelizumab 300mg Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F.Hoffmann-La Roche		Authorised			Female: yes Male: yes	800	Phase 3	United States;Belarus;Slovakia;Spain;Ukraine;Ireland;Turkey;Russian Federation;Colombia;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Belgium;Brazil;Croatia;Peru;Bulgaria;Germany;Sweden;Bosnia and Herzegovina
745	NCT01285479	October 15, 2011	21 January 2019	Pregnancy Registry Trial	The Multi-National Pregnancy Fingolimod Exposure Registry in Multiple Sclerosis (Epidemiological Study Protocol FTY720D2404)	Multiple Sclerosis	Drug: Fingolimod	Novartis Pharmaceuticals		Recruiting	N/A	N/A	Female	500	Phase 2	United States;Argentina;Australia;Austria;Belgium;Canada;Cyprus;Czechia;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Lebanon;Mexico;Netherlands;Norway;Poland;Portugal;Russian Federation;Saudi Arabia;Spain;Sweden;Switzerland;United Arab Emirates;United Kingdom;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
746	NCT01453868	October 2011	19 February 2015	The Effects of Aerobics Training on Balance in Patients With Multiple Sclerosis	The Effects of Neuromuscular Training on Balance in Patients With Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Other: Non Impact Aerobics;Other: Passive : lecture series	Nelson Mandela Metropolitan University		Recruiting	20 Years	60 Years	Both	60	Phase 0	United States
747	NCT01464905	October 2011	19 February 2015	Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	A Phase 3, Multicenter, Double-blind,Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of NU100 in Patients With Relapsing Forms of Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Biological: NU100;Biological: Placebo;Biological: rhIFN beta-1b	Nuron Biotech Inc.		Not recruiting	18 Years	60 Years	Both	500	Phase 3	Belarus;Bulgaria;Croatia;Georgia;Hungary;Italy;Lebanon;Poland;Russian Federation;Serbia;Spain;Ukraine;India
748	NCT01466114	October 2011	11 November 2019	Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition	A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.	Relapsing-remitting Multiple Sclerosis;Secondary-progressive Multiple Sclerosis;Primary-progressive Multiple Sclerosis	Drug: estriol;Other: Placebo;Drug: Norethindrone;Other: Progestin Placebo	University of California, Los Angeles		Recruiting	18 Years	55 Years	Female	64	Phase 2	United States
749	EUCTR2011-000888-27-CZ	21/09/2011	24 August 2015	A clinical trial comparing the efficacy, and safety and tolerability of two disease modifying MS drugs (GTR and Copaxone®) in patients with relapsing remitting multiple sclerosis for 9 months followed by a 15 month GTR treatment part to evaluate efficacy and safety of long-term GTR treatment.	Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone® (Teva) in subjects with relapsing remitting multiple sclerosis followed by an open-label 15 month GTR treatment part evaluating the long-term GTR treatment effects - GATE	Relapsing remitting multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: glatiramer acetate Product Code: GTR Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Current Sponsor code: GTR Other descriptive name: GTR.ace Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Copaxone Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Synthon BV		Not Recruiting			Female: yes Male: yes	750		Serbia;United States;Belarus;Estonia;Slovakia;Greece;Spain;Ukraine;Lithuania;Russian Federation;Italy;United Kingdom;Czech Republic;Poland;Romania;Croatia;Bulgaria;Germany
750	NCT01412333	September 20, 2011	7 October 2019	A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis	A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: Interferon beta-1a;Drug: Ocrelizumab-matching placebo;Drug: Ocrelizumab;Drug: Interferon beta-1a-matching placebo	Hoffmann-La Roche		Not recruiting	18 Years	55 Years	All	835	Phase 3	United States;Argentina;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czechia;France;Germany;Ireland;Italy;Mexico;Norway;Poland;Russian Federation;Slovakia;Spain;Sweden;Turkey;Ukraine;United Kingdom;Czech Republic;Morocco
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
751	EUCTR2011-002785-20-DE	19/09/2011	28 August 2017	Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis	Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis - EVIDIMS	Multiple Sclerosis and Clinical isolated Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Vigantol® Öl 20.000 I.E./ml Product Name: Vigantol® Öl 20.000 I.E./ml Product Code: Vigantol® Öl 20.000 I.E./ml Pharmaceutical Form: Oral liquid INN or Proposed INN: COLECALCIFEROL CAS Number: 67-97-0 Current Sponsor code: 25OH-Vitamin D Concentration unit: IU/ml international unit(s)/millilitre Concentration type: equal Concentration number: 20.000 - Pharmaceutical form of the placebo: Oral liquid Route of administration of the placebo: Oral use Trade Name: Dekristol®-Tablette 1 (400 IE) Product Name: Dekristol® 400-Tabletten Product Code: Dekristol® 400-Tabletten Pharmaceutical Form: Tablet INN or Proposed INN: COLECALCIFEROL CAS Number: 67-97-0 Other descriptive name: 25OH-Vitamin D Concentration unit: IU/ml international unit(s)/millilitre Concentration type: equal Concentration number: 400-	Charité - Universitätsmedizin Berlin		Not Recruiting			Female: yes Male: yes		Phase 2	Germany
752	EUCTR2010-021219-17-ES	12/09/2011	28 February 2019	Evaluación de masitinib en esclerosis múltiple	Estudio prospectivo Fase III, multicéntrico, randomizado, doble ciego, de dos grupos paralelos, controlado con placebo y de 96 semanas de duración, para comparar la eficacia y seguridad de masitinib a la dosis de 6 mg/kg/día con placebo en el tratamiento de pacientes con esclerosis múltiple primaria progresiva o esclerosis múltiple secundaria progresiva sin recidiva	Pacientes con esclerosis múltiple primaria progresiva o secundaria progresiva sin recidiva MedDRA version: 14.0 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: masitinib Product Code: AB1010 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	AB Science		Not Recruiting			Female: yes Male: yes	450	Phase 3	France;United States;Czech Republic;Slovakia;Greece;Poland;Spain;Romania;Bulgaria;Germany
753	NCT01435993	September 8, 2011	16 December 2017	Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis	A Randomized, Single Blind, Placebo-controlled, Single Ascending Dose/Repeat Dose Cohort Study to Assess Safety, Tolerability, Pharmacokinetics and Immunogenicity of GSK1223249 in Patients With Relapsing Forms of Multiple Sclerosis.	Multiple Sclerosis, Relapsing-Remitting	Drug: GSK1223249;Other: Saline placebo	GlaxoSmithKline		Not recruiting	18 Years	60 Years	All	3	Phase 1	Germany;Italy;Norway
754	NCT01324232	September 2011	9 July 2018	Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis	A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients With Multiple Sclerosis	Central Neuropathic Pain;Multiple Sclerosis	Drug: AVP-923;Drug: Placebo	Avanir Pharmaceuticals		Not recruiting	18 Years	85 Years	All	200	Phase 2	United States;Argentina;Czechia;Poland;Spain;Czech Republic;Germany;United Kingdom
755	NCT01360489	September 2011	19 February 2015	Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)	An Open Label, 26-Week Study Assessing Arbaclofen Placarbil Safety and Efficacy in Subjects With Spasticity Associated With Multiple Sclerosis With an Addendum Open-Label, 36-Week Study Assessing Arbaclofen Placarbil Safety in Subjects With Spasticity Associated With Multiple Sclerosis	Multiple Sclerosis	Drug: arbaclofen placarbil	XenoPort, Inc.		Not recruiting	18 Years	70 Years	Both	218	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
756	NCT01444300	September 2011	19 October 2017	Dalfampridine for Imbalance in Multiple Sclerosis	Dalfampridine to Improve Imbalance in Multiple Sclerosis: A Pilot Study	Multiple Sclerosis;Fatigue	Drug: Dalfampridine;Drug: Placebo	Oregon Health and Science University	Acorda Therapeutics	Not recruiting	20 Years	59 Years	All	24	Phase 2	United States
757	NCT01450124	September 2011	30 March 2015	Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA)	Safety, Tolerability And Mechanism Of Action Of Boswellic Acids In Multiple Sclerosis and Clinically Isolated Syndrome: A MRI-Controlled, Multicenter, Baseline-To-Treatment, 32-Weeks, Open-Label, Phase IIa Trial	Relapsing Remitting Multiple Sclerosis	Drug: Boswellic acids (BOSWELAN)	Universitätsklinikum Hamburg-Eppendorf		Not recruiting	18 Years	65 Years	Both	29	Phase 2	Germany
758	EUCTR2011-001442-15-DE	26/08/2011	27 January 2014	A study to evaluate disease control and safety in patients with RRMS switching from natalizumab to fingolimod	A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from previous treatment with natalizumab to fingolimod (FTY720)	relapsing remitting multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Gilenya Product Code: FTY720 Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	142		Greece;Finland;Spain;Austria;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Australia;Denmark;Germany;Norway;Sweden
759	NCT01442194	August 1, 2011	26 August 2019	Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies	Long-term, Prospective,Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy	Multiple Sclerosis	Drug: other disease-modifying therapy;Drug: Fingolimod	Novartis Pharmaceuticals		Recruiting	N/A	N/A	All	3620	N/A	United States;Argentina;Australia;Canada;Chile;Mexico;Puerto Rico
760	NCT01411514	August 2011	28 December 2015	Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis	Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort	Multiple Sclerosis	Drug: Prednisone;Drug: Placebo	Claudio Gobbi	Ente Ospedaliero Cantonale, Ticino, Switzerland	Not recruiting	18 Years	80 Years	Both	27	Phase 4	Switzerland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
761	NCT01420055	August 2011	28 November 2016	Fingolimod -Response According to Coping - Evaluation	A 4-month, Prospective, Open-label, Multi-center Phase IV Study to Assess Response to Fingolimod Initiation According to Coping Profile in Adult Patients With Highly Active Relapsing Remitting Multiple Sclerosis in France	Multiple Sclerosis, Relapsing-Remitting	Drug: fingolimod	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	Both	189	Phase 4	France
762	NCT01433497	August 2011	13 May 2019	Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis	A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis	Multiple Sclerosis, Secondary Progressive;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Relapse Free	Drug: Masitinib;Drug: Placebo	AB Science		Not recruiting	18 Years	75 Years	All	656	Phase 3	Bulgaria;France;Germany;Greece;Poland;Romania;Spain;United States
763	EUCTR2011-001160-21-DE	18/07/2011	4 February 2013	Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomide	Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomide treatment and using a population of patients with multiple sclerosis as a reference - TERIVA	Multiple sclerosis MedDRA version: 14.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Trade Name: Mutagrip Product Name: Mutagrip Pharmaceutical Form: Injection	sanofi-aventis recherche & developpement		Not Recruiting			Female: yes Male: yes	120		Canada;Ukraine;Austria;Russian Federation;Germany
764	EUCTR2008-005008-24-GB	07/07/2011	19 March 2012	Worms for immune regulation of multiple sclerosis - MS and hookworm	Worms for immune regulation of multiple sclerosis - MS and hookworm	Relapsing Multiple Sclerosis MedDRA version: 13.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 13.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Product Name: Necator americanus Pharmaceutical Form: Spot-on solution Other descriptive name: Live Necator americanus larvae Concentration unit: U unit(s) Concentration type: equal Concentration number: 25 - Pharmaceutical form of the placebo: Spot-on solution Route of administration of the placebo: Topical use (Noncurrent)	University of Nottingham		Authorised			Female: yes Male: yes	72		United Kingdom
765	JPRN-UMIN000005889	2011/07/01	2 April 2019	The safety and efficacy of tocilizumab in patients with neuromyelitis optica		neuromyelitis optica	Tocilizumab is to be infused every 4 weeks at 8 mg/kg of body weight for 6 months.	Department of Immunology, National Institute of Neuroscience, NCNP		Not Recruiting	20years-old	65years-old	Male and Female	3	Not applicable	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
766	NCT01103583	July 2011	19 February 2015	Hydroxyurea in Primary Progressive Multiple Sclerosis		Multiple Sclerosis	Drug: Hydroxyurea;Other: placebo	S. Andrea Hospital		Not recruiting	18 Years	60 Years	Both	33	Phase 2/Phase 3	Italy
767	NCT01417312	July 2011	10 December 2018	Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients		Multiple Sclerosis, Relapsing-Remitting	Dietary Supplement: Capsules with 160 mg Teavigo (at least 94% EGCG);Dietary Supplement: Placebo	Charite University, Berlin, Germany		Not recruiting	20 Years	60 Years	All	20	N/A	Germany
768	NCT01451723	July 2011	19 October 2017	Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II	Phase 2 Randomized Placebo Controlled Trial of Polyphenon E in MS	Multiple Sclerosis	Drug: Polyphenon E;Other: Placebo	Louisiana State University Health Sciences Center in New Orleans	National Center for Complementary and Integrative Health (NCCIH)	Not recruiting	18 Years	60 Years	All	11	Phase 2	United States
769	NCT01699555	July 2011	19 February 2015	First-in-Human Study With GNbAC1 in Healthy Volunteers	Randomized Placebo-Controlled First-in-Human Study With GNbAC1	Multiple Sclerosis	Biological: GNbAC1;Biological: GNbAC1 placebo	GeNeuro Innovation SAS		Not recruiting	18 Years	55 Years	Male	33	Phase 1
770	EUCTR2011-000926-31-CZ	29/06/2011	17 June 2013	A long term, 50 week, Phase IV multi-centre study to determine if Sativex has an effect on cognition (thinking ability) when prescribed to patients with spasticity due to MS	A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to Multiple Sclerosis	Spasticity in multiple sclerosis (MS). MedDRA version: 14.1 Level: LLT Classification code 10041416 Term: Spasticity System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Sativex Oromucosal Spray Pharmaceutical Form: Oromucosal spray INN or Proposed INN: N/A CAS Number: 1972-08-3 Other descriptive name: delta-9-tetrahydrocannabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 27- INN or Proposed INN: N/A CAS Number: 13956-29-1 Other descriptive name: cannabidiol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use	GW Pharma Ltd.		Not Recruiting			Female: yes Male: yes	120	Phase 4	Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
771	EUCTR2010-024000-10-BE	28/06/2011	17 August 2015	A Study to Evaluate the Effect of Different Doses of TYSABRI on Safety and Efficacy in Relapsing Multiple Sclerosis	A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis - REFINE	Relapsing-Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TYSABRI Product Name: Natalizumab for IV Infusion Product Code: AN100226; BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Current Sponsor code: AN100226; BG00002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Product Name: Natalizumab for Subcutaneous Injection Product Code: AN100226; BG00002 Pharmaceutical Form: Solution for injection INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Current Sponsor code: AN100226; BG00002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Biogen Idec Limited		Not Recruiting			Female: yes Male: yes	300	Phase 2	Spain;Belgium;Germany;Italy
772	EUCTR2011-001280-49-FR	14/06/2011	19 February 2018	« GRACE : Gilenya® - Réponse Au Coping - Evaluation » Etude clinique menée dans plusieurs centres français, d'une durée de 4 mois, visant à comparer la réponse à l'initiation du traitement par fingolimod (Gilenya®) selon le profil d'anxiété chez des patients adultes présentant une sclérose en plaques rémittente-récurrente très active.	« GRACE : Gilenya® - Réponse Au Coping - Evaluation » Etude multicentrique de phase IV, prospective, en ouvert, d'une durée de 4 mois, visant à comparer la réponse à l’initiation du fingolimod (Gilenya®) selon le profil de « coping » chez des patients adultes présentant une sclérose en plaques rémittente-récurrente très active en France. - GRACE	Sclérose en plaques rémittente-récurrente active MedDRA version: 13.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5 -	Novartis Pharma S.A.S		Not Recruiting			Female: yes Male: yes	250	Phase 4	France
773	NCT01395316	June 2011	16 December 2017	Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis	Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Alemtuzumab	University of Chicago	Genzyme, a Sanofi Company	Not recruiting	18 Years	50 Years	All	8	Phase 4
774	NCT01428726	June 2011	19 February 2015	A Phase IIa Study of NT-KO-003 for Multiple Sclerosis	A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: NT-KO-003	Neurotec Pharma	Advancell - Advanced In Vitro Cell Technologies, S.A.	Not recruiting	18 Years	55 Years	Both	99	Phase 2	Germany;Spain
775	EUCTR2011-001956-12-CZ	25/05/2011	12 December 2016	Biological Efficacy of Interferon ß Therapy in Patients with Multiple Sclerosis	Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis.	To correlate bioactivity of IFNß reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNß depending on NAbs status NAbs positive cohorts will be correlated NAbs titer with level of MxA expression, respectively if the MxA decrease is not preceding NAbs positivity. The MxA induction test will be tested.	Trade Name: Avonex® Product Name: Avonex® Product Code: EU/1/97/033/002 Pharmaceutical Form: Injection Trade Name: Betaferon® Product Name: Betaferon® Product Code: EU/1/95/003/005-010 Pharmaceutical Form: Injection Trade Name: Rebif 22® Product Name: Rebif 22® Product Code: EU/1/98/063/001-003 Pharmaceutical Form: Injection Trade Name: Rebif 44® Product Name: Rebif 44® Product Code: EU/1/98/063/004-006 Pharmaceutical Form: Injection Trade Name: Extavia® Product Name: Extavia® Product Code: EU/1/08/454/001-002, EU/1/08/454/005-007 Pharmaceutical Form: Injection	University Hospital Motol		Not Recruiting			Female: yes Male: yes		Phase 4	Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
776	EUCTR2010-024561-43-DK	24/05/2011	5 August 2014	Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis	Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis	progressive multiple sclerosis MedDRA version: 13.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Trade Name: Medrol Pharmaceutical Form: Tablet CAS Number: 83-43-2 Other descriptive name: METHYLPREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-	Scleroseklinikken, Rigshospitalet		Not Recruiting			Female: yes Male: yes	30		Denmark
777	NCT01416363	May 20, 2011	16 December 2017	Healthy Volunteer Study Using 3 Different Formulations of Firategrast	A Single/Repeat Dose Study With Three Oral Formulations of Firategrast (Immediate Release Tablet, Modified Release Tablet, and Naso-gastric Infusion) in Healthy Male Volunteers	Multiple Sclerosis, Relapsing-Remitting	Drug: Firategrast immediate release tablet;Drug: Firategrast modified release tablet;Drug: Firategrast gastro-retentive solution	GlaxoSmithKline		Not recruiting	18 Years	65 Years	Male	38	Phase 1	Australia
778	EUCTR2010-024477-39-LV	06/05/2011	16 November 2015	A Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis	A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis - ATTAIN	Relapsing Multiple Sclerosis MedDRA version: 17.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta 1a Current Sponsor code: BIIB017 Other descriptive name: PEGylated Intereron Beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 125-	Biogen Idec Limited		Not Recruiting			Female: yes Male: yes	1600		Serbia;United States;Estonia;Greece;Spain;Ukraine;Chile;Russian Federation;Colombia;India;France;Peru;Latvia;Netherlands;United Kingdom;Czech Republic;Mexico;Canada;Belgium;Poland;Croatia;Romania;Bulgaria;Germany;New Zealand
779	EUCTR2010-021978-11-SE	04/05/2011	7 December 2015	A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tysabri Product Code: AN100226, BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Other descriptive name: SUB22282 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	Biogen Idec Limited		Not Recruiting			Female: yes Male: yes	856		United States;Finland;Spain;Ireland;Israel;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Belgium;Denmark;Netherlands;Germany;Sweden
780	NCT01259388	May 2011	11 April 2016	A Pilot Study of Lithium in Progressive Multiple Sclerosis	A Pilot Trial of Lithium in Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Lithium Carbonate	VA Office of Research and Development		Not recruiting	30 Years	65 Years	Both	20	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
781	NCT01333358	May 2011	19 February 2015	Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients	Phase III A Prospective, Longitudinal, Rater-blinded Single-arm Study to Evaluate Alemtuzumab as an Effective Treatment in Stabilizing Overall Neurocognitive Function in RRMS Subjects at Specified Timepoints	Multiple Sclerosis	Drug: Alemtuzumab	Central Texas Neurology Consultants	Genzyme, a Sanofi Company	Not recruiting	N/A	N/A	Both	30	Phase 3
782	NCT01337986	May 2011	19 February 2015	Ampyra for Optic Neuritis in MS	Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis	Multiple Sclerosis;Optic Neuritis	Drug: Dalfampridine/Placebo;Drug: Placebo/Dalfampridine	Washington University School of Medicine	Acorda Therapeutics	Not recruiting	18 Years	55 Years	Both	53	Phase 2/Phase 3	United States
783	NCT01357980	May 2011	26 August 2019	Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis	A Phase IIa, Multicentre, Double Blind, Single Dose, Parallel Group, Placebo Controlled, Clinical Pilot Study to Assess the Efficacy and Safety of a Single Dose, Intra-Detrusor Injections of 750 Units of Dysport® in Subjects Suffering From Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis.	Detrusor Muscle Hyperactivity	Biological: Botulinum toxin type A;Drug: Placebo	Ipsen		Not recruiting	18 Years	70 Years	All	47	Phase 2	Czechia;France;Germany;Italy;Poland;Austria;Czech Republic
784	NCT01359566	May 2011	16 December 2017	Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis	A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis	Multiple Sclerosis	Drug: Arbaclofen placarbil 15 mg BID;Drug: Placebo;Drug: Arbaclofen placarbil 30 mg BID;Drug: Arbaclofen placarbil 45 mg BID	Indivior Inc.		Not recruiting	18 Years	70 Years	All	228	Phase 3	United States
785	EUCTR2010-023678-38-IT	20/04/2011	16 February 2015	High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND	High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND	patients with multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10028245	Trade Name: *MANTADAN20CPR 100MG Pharmaceutical Form: Tablet INN or Proposed INN: Amantadine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Trade Name: AMPYRA Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Ampyra** Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the placebo: Oral use	FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR		Not Recruiting			Female: yes Male: yes			Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
786	EUCTR2011-000150-31-IT	13/04/2011	19 March 2012	EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY.	EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY.	Multiple Sclerosis patients MedDRA version: 14.1 Level: HLGT Classification code 10012303 Term: Demyelinating disorders System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: COPAXONE Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate Concentration unit: mg milligram(s) Concentration number: 20-	FONDAZIONE DON CARLO GNOCCHI ONLUS		Authorised			Female: yes Male: yes			Italy
787	EUCTR2011-000770-60-IT	12/04/2011	17 June 2013	“An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists” - ND	“An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists” - ND	approximately 600 patients with relapsing-remitting MS for whom no suitable therapy exists i.e. where existing therapies have failed. MedDRA version: 14.0 Level: SOC Classification code 10029205 Term: Nervous system disorders System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: other nervous system drugs CAS Number: 162359-56-0 Current Sponsor code: FINGOLIMOD Concentration unit: mg milligram(s) Concentration number: .5-	NOVARTIS FARMA		Not Recruiting			Female: yes Male: yes	600		Italy
788	NCT01407211	April 2011	19 February 2015	Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient	The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients	Relapsing Remitting Multiple Sclerosis	Dietary Supplement: vitamin A	Tehran University of Medical Sciences		Recruiting	20 Years	45 Years	Both	30	Phase 4	Iran, Islamic Republic of
789	EUCTR2010-023560-40-SE	23/03/2011	21 October 2013	Blood stem cell transplantation for patients with relapsiong-remitting multiple sclerosis, in whom standard treatment has failed.	Haematopoetic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study - MIST	Relapsing-remitting multiple sclerosis MedDRA version: 13.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Trade Name: Tysabri Pharmaceutical Form: INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Trade Name: Sendoxan Pharmaceutical Form: Powder for solution for injection CAS Number: 6055192 Other descriptive name: CYCLOPHOSPHAMIDE MONOHYDRATE Trade Name: Thymoglobuline Pharmaceutical Form: Powder for infusion* CAS Number: 0 Other descriptive name: RABBIT HUMAN T LYMPHOCYTE IMMUNOGLOBULIN Trade Name: Neupogen Pharmaceutical Form: Solution for injection Trade Name: Solu-Medrol Pharmaceutical Form: Powder and solvent for dispersion for injection	Uppsala l?ns landsting		Authorised			Female: yes Male: yes	120		United States;Canada;Brazil;Sweden
790	EUCTR2010-023677-19-IT	23/03/2011	3 April 2012	Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010	Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010	PATIENT WITH RRMS AND SPMS MedDRA version: 13.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive System Organ Class: 10029205 - Nervous system disorders	Trade Name: *BETAFERON15CONFEZ 0,25MG/ML+ Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1b Concentration unit: µmole/ml micromole(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: EXTAVIASC 15FL 250MCG/ML+15SI* Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1b Concentration unit: µg/µl microgram(s)/microlitre Concentration type: equal Concentration number: 250- Trade Name: DIBASE Pharmaceutical Form: Oral drops, solution INN or Proposed INN: Colecalciferol Concentration unit: U/ml unit(s)/millilitre Concentration type: equal Concentration number: 2000-	AZIENDA OSPEDALIERA S. LUIGI GONZAGA		Authorised			Female: yes Male: yes			Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
791	EUCTR2010-024017-31-IT	15/03/2011	28 August 2014	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy - GOLDEN	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy - GOLDEN	Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399	Product Name: FINGOLIMOD Product Code: FTY720D Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .5- Trade Name: EXTAVIA Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1b Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 250- Trade Name: AVONEX Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30- Trade Name: COPAXONE Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Glatiramer acetate Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	NOVARTIS FARMA		Not Recruiting			Female: yes Male: yes			Italy
792	NCT01194570	March 2, 2011	9 September 2019	A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis	A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive	Drug: Ocrelizumab;Other: Placebo	Hoffmann-La Roche		Not recruiting	18 Years	55 Years	All	732	Phase 3	United States;Uruguay;Czech Republic;Germany;Greece;Hungary;Israel;France;Finland;Denmark;Czechia;Canada;Bulgaria;Brazil;Belgium;United Kingdom;Ukraine;Turkey;Switzerland;Spain;Russian Federation;Romania;Portugal;Poland;Peru;Norway;New Zealand;Netherlands;Mexico;Lithuania;Italy;Australia;Austria
793	NCT00813969	March 2011	11 April 2016	Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS	A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Progressive Relapsing Multiple Sclerosis	Biological: Autologous mesenchymal stem cell transplantation	The Cleveland Clinic	University Hospital Case Medical Center	Not recruiting	18 Years	55 Years	Both	24	Phase 1	United States
794	NCT01328379	March 2011	19 October 2017	Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis	Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Dalfampridine-ER 5mg;Drug: Dalfampridine-ER 10mg;Other: Placebo	Acorda Therapeutics		Not recruiting	18 Years	70 Years	All	430	Phase 3	United States
795	EUCTR2010-023021-38-SE	23/02/2011	23 November 2015	Switch To RItuXimab in MS A phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach - STRIX-MS	Switch To RItuXimab in MS A phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach - STRIX-MS	Relapsing-remitting multiple sclerosis in stable condition while treated with first line injectible disease-modifying drugs (DMDs), eg beta-interferons or glatiramere acetate MedDRA version: 12.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000-	Västerbottens läns landsting		Not Recruiting			Female: yes Male: yes		Phase 2	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
796	EUCTR2010-023172-12-NL	15/02/2011	14 January 2013	Efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis and treated with interferon-beta	A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - TERACLES	Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	sanofi-aventis recherche et development		Not Recruiting			Female: yes Male: yes	1455		United States;Portugal;Estonia;Slovakia;Greece;Spain;Chile;Russian Federation;Colombia;Italy;France;Denmark;Australia;Tunisia;Netherlands;Korea, Republic of;Finland;Guatemala;Turkey;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Canada;Argentina;Brazil;Belgium;Germany;Norway;Sweden
797	NCT01281657	February 2011	19 February 2015	Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program	A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program	Multiple Sclerosis	Drug: fingolimod	Novartis		Not recruiting	18 Years	N/A	Both	64	N/A	United States;Canada
798	NCT01310166	February 2011	28 November 2016	Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis	A 6-month Multicenter, Single-arm, Open-label Study to Investigate Changes in Biomarkers After Initiation of Treatment With 0.5 mg Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: Fingolimod	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	Both	447	Phase 4	Germany
799	NCT02073474	February 2011	16 December 2017	An Observational Post-Marketing Safety Registry of Sativex®	An Observational Post-Marketing Safety Registry Of Patients Who Have Been Prescribed Sativex®	Multiple Sclerosis;Diabetes;Cancer;Neuropathic Pain	Drug: Sativex®	GW Pharmaceuticals Ltd.		Not recruiting	N/A	N/A	All	978	N/A
800	EUCTR2010-022066-28-DE	18/01/2011	30 April 2018	A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis	A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis	relapsing remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Gilenya Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720 Other descriptive name: Fingolimod Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Pharma GmbH		Not Recruiting			Female: yes Male: yes	445	Phase 3	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
801	EUCTR2010-020338-25-PT	12/01/2011	28 February 2019	A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis	A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis - Oratorio	Primary Progressive Multiple Sclerosis (PPMS) MedDRA version: 20.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ocrelizumab 300mg/10ml Product Code: Ro 496-4913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: OCREVUS Product Name: ocrelizumab 300mg/10ml Product Code: Ro 496-4913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Other descriptive name: OCRELIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F.Hoffmann-La Roche		Authorised			Female: yes Male: yes	630	Phase 3	United States;Portugal;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;France;Peru;Australia;Denmark;Netherlands;Finland;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Poland;Brazil;Belgium;Bulgaria;Norway;Germany;New Zealand
802	EUCTR2010-022033-28-NL	10/01/2011	6 May 2013	A study investigating safety, tolerability and efficacy of ECP002A (?9-THC) in Multiple Sclerosis patients suffering from spasticity and pain.	A two-phased, randomized, double blind, placebo-controlled study of ECP002A (?9-THC) to determine safety, tolerability and efficacy in Multiple Sclerosis patients suffering from spasticity and pain. - ECP002A (?9-THC) in MS patients	Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Namisol Product Code: ECP002A Pharmaceutical Form: Tablet INN or Proposed INN: dronabinol CAS Number: 1972-08-03 Current Sponsor code: ECP002A Other descriptive name: Namisol Concentration unit: mg milligram(s) Concentration type: range Concentration number: 1.5-5.0 Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Echo Pharmaceuticals B.V.		Not Recruiting			Female: yes Male: yes			Netherlands
803	NCT01071694	January 2011	19 February 2015	QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea	QOLBET Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With BETaferon® in Korea	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	0	N/A	Korea, Republic of
804	NCT01454791	January 2011	19 October 2017	Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate	Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate: A Randomized Controlled Double- Blind Crossover Trial	Multiple Sclerosis	Drug: diclofenac sodium topical gel;Other: Placebo	Brown, Theodore R., M.D., MPH	Teva Neuroscience, Inc.	Not recruiting	18 Years	N/A	All	40	Phase 4	United States
805	NCT01455220	January 2011	16 December 2017	The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis	The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis	Multiple Sclerosis	Drug: Tysabri ® (Natalizumab)	University of South Florida		Not recruiting	18 Years	60 Years	All	45	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
806	EUCTR2011-001692-39-DE		9 December 2013	A study to evaluate the safety and tolerability of the combination of an antidepressive therapy with oral fingolimod in the treatment of relapsing remitting multiple sclerosis patients with mild to moderate depression	A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS patients with mild to moderate depression	Multiple Sclerosis Depression MedDRA version: 14.1 Level: PT Classification code 10012378 Term: Depression System Organ Class: 10037175 - Psychiatric disorders MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Gilenya Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Venlafaxin Hexal Product Name: Venlafaxin Hexal Pharmaceutical Form: Capsule, hard CAS Number: 99300-78-4 Other descriptive name: VENLAFAXINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Trade Name: Fluoxetin Hexal Product Name: Fluoxetin Hexal Pharmaceutical Form: Tablet INN or Proposed INN: FLUOXETINE HYDROCHLORIDE CAS Number: 59333-67-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Trade Name: Venlafaxin Hexal Product Name: Venlafaxin Hexal Pharmaceutical Form: Capsule, hard CAS Number: 99300-78-4 Other descriptive name: VENLAFAXINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- Trade Name: Fluoxetin Hexal Product Name: Fluoxetin Hexal Pharmaceutical Form: Tablet INN or Proposed INN: FLUOXETINE HYDROCHLORIDE CAS Number: 59333-67-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Trade Name: Gilenya Product Name: Gilenya Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Other descriptive name: FINGOLIMOD HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Pharma GmbH		Not Recruiting			Female: yes Male: yes			Germany
807	EUCTR2010-020337-99-LV	29/12/2010	10 September 2018	A Study of Ocrelizumab in Comparison With Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis	A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis - OPERA I	Relapsing Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: range Concentration number: 8.8-22 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for injection Route of administration of the placebo: Intravenous use	F.Hoffmann-La Roche		Authorised			Female: yes Male: yes	800	Phase 3	Hungary;Mexico;Argentina;Czech Republic;United Kingdom;Austria;Lithuania;Finland;Latvia;Tunisia;Netherlands;South Africa;Peru;Australia;Switzerland;Italy;Russian Federation;Chile;Israel;Ukraine;Spain;Slovakia;Morocco;Estonia;Serbia;United States;Portugal;Poland;Brazil;Belgium;Bulgaria;Germany;New Zealand
808	EUCTR2010-023023-19-IT	28/12/2010	11 April 2016	A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b in treating the cognitive symptoms associated to relapsing-remitting multiple sclerosis and to assess possible relationship of these effects to regional brain atrophy. - ND	A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b in treating the cognitive symptoms associated to relapsing-remitting multiple sclerosis and to assess possible relationship of these effects to regional brain atrophy. - ND	relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399	Product Name: FINGOLIMOD Product Code: FTY720D Pharmaceutical Form: Capsule, hard CAS Number: 162359-56-0 Current Sponsor code: FTY720D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .5- Trade Name: EXTAVIA Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1b Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 250-	NOVARTIS FARMA		Not Recruiting			Female: yes Male: yes			Germany;Italy
809	NCT01466322	December 22, 2010	16 December 2017	A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.	An Open-label, Randomised, Crossover Study to Assess the Relative Bioavailability of Different 2mg Formulations of GSK2018682(S1P1 Agonist) in Healthy Volunteers	Multiple Sclerosis, Relapsing-Remitting	Drug: GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state	GlaxoSmithKline		Not recruiting	18 Years	55 Years	All	16	Phase 1	Australia
810	EUCTR2010-023996-25-BE	21/12/2010	19 August 2013	The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.	The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.	Multiple sclerosis (both relapsing remitting and progressive forms)	Product Name: fluoxetine Pharmaceutical Form: Coated tablet CAS Number: 54910-89-3 Other descriptive name: FLUOXETINE Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 20-40 Product Name: Cisapride Pharmaceutical Form: Coated tablet INN or Proposed INN: CISAPRIDE CAS Number: 81098604 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 10-20 Product Name: Prucalopride Pharmaceutical Form: Coated tablet INN or Proposed INN: PRUCALOPRIDE CAS Number: 179474818 Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 1-2			Authorised			Female: yes Male: yes	32		Belgium
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
811	EUCTR2009-017978-21-DE	20/12/2010	28 February 2019	Long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials	Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE) - PREMIERE Registry	Multiple Sclerosis patients who have participated in cladribine tablets clinical trials MedDRA version: 20.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Cladribine tablets Product Code: Not applicable Pharmaceutical Form: Tablet INN or Proposed INN: Cladribine CAS Number: 4291-63-8 Current Sponsor code: EMD280922 Other descriptive name: 2-CdA, 2-chloro-2’-deoxy-ß-D-adenosine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	Merck Serono S.A. - Geneva		Not Recruiting			Female: yes Male: yes	2175	Phase 3	Serbia;Bosnia and Herzegovina;Finland;Lithuania;Turkey;Austria;United Kingdom;Czech Republic;Canada;Argentina;Poland;Belgium;Brazil;Singapore;Romania;Croatia;Korea, Republic of;Tunisia;Latvia;Netherlands;Denmark;Australia;Macedonia, the former Yugoslav Republic of;France;India;Switzerland;Italy;Russian Federation;Lebanon;Ukraine;Spain;Thailand;Greece;Morocco;Estonia;Taiwan;Saudi Arabia;United Arab Emirates;United States;Portugal;Georgia;Bulgaria;Norway;Germany;Sweden
812	EUCTR2009-017939-18-GB	15/12/2010	19 March 2012	A Phase 4 randomised, double-blind, placebo controlled, crossover trial Nitrofurantoin Macrocrystals 100 mg twice daily for six weeks in the treatment of overactive bladder symptoms associated with a negative mid stream urine culture and pyuria in patients with Multiple Sclerosis. - Recurrent urine infection in MS	A Phase 4 randomised, double-blind, placebo controlled, crossover trial Nitrofurantoin Macrocrystals 100 mg twice daily for six weeks in the treatment of overactive bladder symptoms associated with a negative mid stream urine culture and pyuria in patients with Multiple Sclerosis. - Recurrent urine infection in MS	Chronic urinary tract infection. MedDRA version: 14.0 Level: LLT Classification code 10059617 Term: Overactive bladder System Organ Class: 10038359 - Renal and urinary disorders	Trade Name: Nitrofurantoin Product Name: Nitrofurantoin Product Code: PL 12762/0049 Pharmaceutical Form: Capsule INN or Proposed INN: Nitrofurantoin CAS Number: 67-20-9 Other descriptive name: Nitrofurantoin Concentration unit: Bq/mg becquerel(s)/milligram Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use	UCLH/UCL Biomedical Research Unit		Authorised			Female: yes Male: yes		Phase 4	United Kingdom
813	EUCTR2010-020338-25-FI	15/12/2010	28 February 2019	A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis	A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis - Oratorio	Primary Progressive Multiple Sclerosis (PPMS) MedDRA version: 20.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ocrelizumab 300 mg Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Ocrevus Product Name: ocrelizumab 300 mg Product Code: RO4964913/F07 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab CAS Number: 637334-45-3 Current Sponsor code: RO4964913 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30-	F.Hoffmann-La Roche		Authorised			Female: yes Male: yes	630	Phase 3	Portugal;United States;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israel;Switzerland;Italy;France;Peru;Australia;Denmark;Netherlands;Finland;Lithuania;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Poland;Brazil;Belgium;Bulgaria;Germany;Norway
814	NCT01228266	December 2010	19 February 2015	Mesenchymal Stem Cell Transplantation in MS	Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study	Multiple Sclerosis	Biological: autologous mesenchymal stem cells	Albert Saiz	Instituto de Salud Carlos III	Not recruiting	18 Years	50 Years	Both	9	Phase 2	Spain
815	NCT01235221	December 2010	19 February 2015	Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.	Open-Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine SR in Canadian Subjects With Multiple Sclerosis Who Participated in Acorda Extension Trials	Multiple Sclerosis	Drug: BIIB041 (Fampridine-SR)	Biogen Idec	Acorda Therapeutics	Not recruiting	18 Years	70 Years	Both	38	Phase 3	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
816	NCT01318421	December 2010	21 December 2015	A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis	An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: ELND002	Elan Pharmaceuticals		Not recruiting	18 Years	65 Years	Both	12	Phase 1
817	NCT01712373	December 2010	19 February 2015	Ginseng in Treatment of Fatigue in Multiple Sclerosis	Study of Ginseng in Treatment of Fatigue in Multiple Sclerosis	Fatigue	Drug: Ginseng;Drug: Placebo	Isfahan University of Medical Sciences		Not recruiting	18 Years	50 Years	Both	60	Phase 2	Iran, Islamic Republic of
818	NCT00939549	November 2010	1 October 2018	High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis	Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: Cyclophosphamide/Glatiramer acetate	Johns Hopkins University		Not recruiting	18 Years	70 Years	All	0	Phase 2	United States
819	NCT01236534	November 2010	19 October 2017	Lubiprostone in Patients With Multiple Sclerosis Associated Constipation	Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-groups Study of Lubiprostone in Patients With Multiple Sclerosis-Associated Constipation	Multiple Sclerosis;Constipation	Drug: Lubiprostone;Drug: Placebo	University of Rochester	Takeda	Not recruiting	18 Years	N/A	All	21	Phase 4	United States
820	NCT01356940	November 2010	19 October 2017	A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis	A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis	Multiple Sclerosis	Drug: dalfampridine ER;Drug: placebo	Brown, Theodore R., M.D., MPH	Acorda Therapeutics	Not recruiting	18 Years	75 Years	All	43	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
821	NCT01440101	November 2010	19 October 2017	Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)	Multicenter Study of BG00002 in Japanese Subjects With RRMS, Consisting of a Multiple-Dose, Open-Label Evaluation of Its Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Part A) and a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Evaluation of Safety and Efficacy (Part B)	Multiple Sclerosis	Drug: Placebo;Drug: Natalizumab (BG00002)	Biogen		Not recruiting	18 Years	65 Years	All	106	Phase 2/Phase 3	Japan;China
822	NCT01667796	November 2010	18 March 2019	Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health	Pharmacodynamic and Immunologic Effects of Vitamin D Supplementation in Patients With Multiple Sclerosis and Healthy Controls	Multiple Sclerosis, Relapsing-remitting	Dietary Supplement: Vitamin D3	Johns Hopkins University	University of California, San Francisco;National Multiple Sclerosis Society	Not recruiting	18 Years	60 Years	Female	57	N/A	United States
823	EUCTR2010-020328-23-FI	21/10/2010	4 August 2015	Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment.	A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol® oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with 44 µg tiw of Rebif® SOLAR Supplementation of VigantOL® Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif® treatment. - SOLAR	Relapsing-Remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Vigantol Oel Product Name: Vigantol Oil Product Code: 200106 or EMD 28162 Pharmaceutical Form: Oral solution INN or Proposed INN: COLECALCIFEROL CAS Number: 67-97-0 Current Sponsor code: 200109, EMD 28162, 300910 Other descriptive name: Cholecalciferol, Vitamin D3 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	Merck Serono		Not Recruiting			Female: yes Male: yes	230	Phase 2	Portugal;Estonia;Finland;Lithuania;Austria;Switzerland;Italy;Belgium;Denmark;Norway;Germany;Latvia;Netherlands
824	NCT01431937	October 10, 2010	16 December 2017	Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers	A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers	Multiple Sclerosis, Relapsing-Remitting	Drug: GSK2018682;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	55 Years	All	40	Phase 1	Australia
825	NCT01005095	October 2010	19 February 2015	The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients	A One Year Prospective, Randomized, Double Blind Interventional Study to Assess Tolerability, Quality of Life and Immunomodulation With Interferon Beta Combined With Vitamin D in Patients With Relapsing Remitting Multiple Sclerosis	MULTIPLE SCLEROSIS	Dietary Supplement: Vitamin D3	Carmel Medical Center		Not recruiting	18 Years	65 Years	Both	45	Phase 4	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
826	NCT01188811	October 2010	19 October 2017	Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)	Lipoic Acid for Neuroprotection in Secondary Progressive MS	Multiple Sclerosis, Chronic Progressive	Drug: lipoic acid;Drug: Placebo	VA Office of Research and Development	Oregon Health and Science University	Not recruiting	40 Years	70 Years	All	54	Phase 2/Phase 3	United States
827	NCT01244139	October 2010	16 December 2017	Safety Study of BIIB033 in Subjects With Multiple Sclerosis	A Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis	Drug: BIIB033;Drug: Placebo	Biogen		Not recruiting	18 Years	60 Years	All	47	Phase 1	United States
828	NCT01279876	October 2010	24 August 2015	Melatonin in Relapsing-Remitting Multiple Sclerosis Patients	Effects of Melatonin on Clinical and Neuroimaging Indices of Relapsing-Remitting Multiple Sclerosis Patients	Multiple Sclerosis, Relapsing-Remitting	Drug: Melatonin	Tehran University of Medical Sciences		Not recruiting	20 Years	45 Years	Both	25	Phase 2	Iran, Islamic Republic of
829	NCT01381354	October 2010	2 July 2018	Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)	Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)	Multiple Sclerosis	Other: Progressive exercise;Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV;Other: Modified paleolithic diet;Dietary Supplement: Omega 3 fatty acids;Dietary Supplement: Full Spectrum vitamin;Dietary Supplement: Essential - hydroxytyrosol;Dietary Supplement: Maltodextrin fiber supplement;Dietary Supplement: Mineral boost (magnesium);Dietary Supplement: Niacinamide;Dietary Supplement: Methyl B12;Dietary Supplement: Taurine;Dietary Supplement: creatine;Dietary Supplement: thiamine;Dietary Supplement: riboflavin;Dietary Supplement: N acetylcysteine;Dietary Supplement: alpha lipoic acid;Dietary Supplement: L acetyl carnitine;Dietary Supplement: methyl folate;Dietary Supplement: coenzyme Q;Behavioral: meditation;Behavioral: self massage;Behavioral: learning;Dietary Supplement: Coconut oil	University of Iowa	Direct MS Canada;DJO Incorporated;Pinnaclife Inc.;TZ Press, LLC	Not recruiting	18 Years	65 Years	All	38	Phase 1	United States
830	NCT01416155	October 2010	19 October 2017	Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis	A Long-Term, Open-Label, Multicenter, Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	18 Years	65 Years	All	97	Phase 2	Japan;China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
831	EUCTR2010-018705-11-BE	13/09/2010	17 August 2015	A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS	A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS	Relapsing-remitting Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ONO-4641/MSC2430913A Product Code: ONO-4641/MSC2430913A Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641/MSC2430913A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.05- Product Name: ONO-4641/MSC2430913A Product Code: ONO-4641/MSC2430913A Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641/MSC2430913A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Product Name: ONO-4641/MSC2430913A Product Code: ONO-4641/MSC2430913A Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641/MSC2430913A Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.15-	Merck Serono S.A. - Geneva		Not Recruiting			Female: yes Male: yes	376		United States;Czech Republic;Greece;Canada;Spain;Belgium;Ukraine;Russian Federation;Germany;Japan
832	JPRN-JapicCTI-101335	01/9/2010	2 April 2019	An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain	An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)	Spinal Cord Diseases, Spinal Cord Injuries, Neuralgia, Pain	Intervention name : pregabalin INN of the intervention : pregabalin Dosage And administration of the intervention : pregabalin capsules 150mg/day, 300mg/day, 450mg/day or 600mg/day BID Control intervention name : null	Pfizer Japan Inc.			18		BOTH	100	Phase 3
833	NCT01116427	September 2010	19 October 2017	A Cooperative Clinical Study of Abatacept in Multiple Sclerosis	A Phase II, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Biological: abatacept;Drug: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN)	Not recruiting	18 Years	65 Years	All	65	Phase 2	United States;Canada
834	NCT01181089	September 2010	19 February 2015	Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)	A Multicenter, Randomized, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF) and Safety in Subjects With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Biological: Placebo;Biological: Baminercept	Biogen Idec		Not recruiting	18 Years	57 Years	Both	0	Phase 1/Phase 2	Canada;United Kingdom
835	NCT01202227	September 2010	19 October 2017	An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain	An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain (Post Spinal Cord Injury Pain, Post Stroke Pain, And Multiple Sclerosis Pain)	Spinal Cord Diseases;Spinal Cord Injuries;Neuralgia;Pain	Drug: pregabalin	Pfizer		Not recruiting	18 Years	N/A	All	104	Phase 3	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
836	NCT01212094	September 2010	19 October 2017	Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)	Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)	Multiple Sclerosis	Drug: Rituximab;Other: normal saline	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	18 Years	65 Years	All	44	Phase 1/Phase 2	United States
837	EUCTR2010-020515-37-FI	06/08/2010	19 November 2018	Long-term safety and tolerability study of 0.5 mg fingolimod once daily in patients with relapsing forms of multiple sclerosis	A single arm, open-label, multicenter study evaluating the long-term, safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis.	multiple sclerosis MedDRA version: 19.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720D Other descriptive name: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	5000	Phase 3	Portugal;United States;Estonia;Slovakia;Greece;Spain;Ireland;Russian Federation;Israel;Italy;Switzerland;France;Jordan;Malaysia;Peru;Australia;Denmark;South Africa;Netherlands;Korea, Republic of;Panama;Finland;Guatemala;Turkey;Austria;United Kingdom;Egypt;Czech Republic;Hungary;Canada;Argentina;Poland;Belgium;Brazil;Romania;Norway;Germany;Sweden
838	NCT00997438	August 2010	19 October 2017	Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis	Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Lipoic Acid	Portland VA Medical Center	Oregon Health and Science University	Not recruiting	18 Years	N/A	All	69	Phase 1	United States
839	NCT01191996	August 2010	19 February 2015	Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis	A Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Biological: MIS416	Innate Immunotherapeutics	Primorus Clinical Trials;National Multiple Sclerosis Society	Not recruiting	18 Years	N/A	Both	34	Phase 1/Phase 2	New Zealand
840	NCT01216072	August 2010	19 October 2017	A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis	A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)	Relapsing Forms of Multiple Sclerosis	Drug: Fingolimod;Drug: Standard MS DMTs	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	1053	Phase 4	United States;Canada;Puerto Rico
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
841	NCT01337427	August 2010	19 February 2015	Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis	Optical Coherence Tomography (OCT) in a Multicenter, Randomized,Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: BIIB017	Johns Hopkins University	Biogen Idec	Not recruiting	18 Years	55 Years	Both	0	Phase 3	United States
842	EUCTR2009-011888-37-DE	23/07/2010	10 December 2012	A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multiple sclerosis followed by a 1-year open-label treatment phase - EXALT	A 1-year, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of zoledronic acid 5 mg (Aclasta®) on bone mineral density in patients with multiple sclerosis followed by a 1-year open-label treatment phase - EXALT	osteoporosis in patients with multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10049088 Term: Osteopenia System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 14.1 Level: PT Classification code 10031282 Term: Osteoporosis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: Aclasta 5 mg Infusionslösung Product Name: Aclasta Product Code: ZOL446H Pharmaceutical Form: Solution for infusion CAS Number: 165800-06-6 Other descriptive name: ZOLEDRONIC ACID MONOHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	Novartis Pharma GmbH		Not Recruiting			Female: yes Male: yes			Germany
843	EUCTR2009-009503-19-BE	20/07/2010	21 August 2017	A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients. - TIMER	A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients. - TIMER	Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Natalizumab Current Sponsor code: BG00002 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-	Biogen Idec International GmbH		Not Recruiting			Female: yes Male: yes	200	Phase 4	Belgium
844	EUCTR2010-019028-30-FI	07/07/2010	23 May 2012	A 3-month blinded, randomized, multicenter, placebocontrolled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with relapsing forms of multiple sclerosis.	A 3-month blinded, randomized, multicenter, placebocontrolled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus toxoid booster injection in patients with relapsing forms of multiple sclerosis.	Relapsing forms of multiple sclerosis. MedDRA version: 12.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse	Product Name: FTY720 Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	120		Finland;United Kingdom;France;Spain
845	NCT01167426	July 2010	19 October 2017	Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients	An Open-Label, Multicenter Study Evaluating Patient Injection Satisfaction With Two Formulations of Glatiramer Acetate (GA) Using Autoject 2 as the Subcutaneous Injection Delivery Method.	Multiple Sclerosis	Drug: Glatiramer Acetate 20 mg/0.5 mL;Drug: Glatiramer acetate 20 mg/0.5 mL	Teva Neuroscience, Inc.		Not recruiting	18 Years	N/A	All	148	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
846	NCT01207648	July 2010	19 October 2017	Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)	Retrospective Cohort Study of Rebif® Use in Pediatric MS Patients	Multiple Sclerosis	Drug: Rebif®	EMD Serono		Not recruiting	N/A	18 Years	All	307	N/A	United States;Argentina;Canada;France;Italy;Russian Federation;Tunisia;Venezuela
847	NCT01085318	June 2010	19 October 2017	Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial	A Twenty-four Week, Two Arm, Pilot Trial to Evaluate Remyelination/ Demyelination, Gray Matter Volume and Iron Deposition in the Central Nervous System (CNS) and Immune Status of Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) Treated With Rebif® 44 Mcg Subcutaneously (sc) Three Times a Week (Tiw) Compared to a Healthy Control Group	Multiple Sclerosis	Drug: Rebif	EMD Serono		Not recruiting	18 Years	65 Years	All	38	Phase 4	United States
848	NCT01144052	June 2010	19 October 2017	Natalizumab De-escalation With Interferon Beta-1b	De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: interferon beta-1b;Drug: Natalizumab	Claudio Gobbi	Ospedale Civico, Lugano	Not recruiting	18 Years	60 Years	All	19	Phase 4	Switzerland
849	NCT01149525	June 2010	16 December 2017	Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis	A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis	Multiple Sclerosis	Drug: L-Carnitine;Drug: Placebo	University Hospital, Bordeaux		Not recruiting	18 Years	N/A	All	59	Phase 3	France
850	NCT01156311	June 2010	16 December 2017	BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis	An Open-Label, Multicenter Study in Subjects With Relapsing-Remitting Multiple Sclerosis to Evaluate the Safety of 240 mg BG00012 TID Administered as Add-On Therapy to Beta Interferons (IFNß) or Glatiramer Acetate (GA)	Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis	Drug: dimethyl fumarate	Biogen		Not recruiting	18 Years	55 Years	All	108	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
851	NCT01067521	May 31, 2010	16 December 2017	A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo	A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo in a Double-blind Design	Relapsing Remitting Multiple Sclerosis	Drug: Glatiramer acetate (GA);Other: Placebo	Teva Pharmaceutical Industries, Ltd.		Not recruiting	18 Years	55 Years	All	1404	Phase 3	United States;Bulgaria;Croatia;Czechia;Estonia;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Poland;Romania;Russian Federation;South Africa;Ukraine;United Kingdom;Czech Republic;Turkey
852	NCT01047319	May 27, 2010	21 January 2019	A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis	A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Drug: Laquinimod	Teva Pharmaceutical Industries, Ltd.		Not recruiting	N/A	N/A	All	1047	Phase 3	United States;Bulgaria;Croatia;Czechia;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, The Former Yugoslav Republic of;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Ukraine;Czech Republic;Puerto Rico
853	NCT01387217	May 21, 2010	16 December 2017	GSK2018682 FTIH in Healthy Volunteers	A Single-blind, Placebo-controlled, Two Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of GSK2018682 in Healthy Volunteers	Multiple Sclerosis	Drug: GSK2018682;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	55 Years	All	27	Phase 1	Australia
854	NCT01143441	May 13, 2010	11 November 2019	Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)	Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Biological: DAC-HYP	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	18 Years	60 Years	All	48	Phase 1	United States
855	NCT01093326	May 12, 2010	16 September 2019	Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis	Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Ponesimod 10 mg;Drug: Ponesimod 20 mg;Drug: Ponesimod 40 mg	Actelion		Not recruiting	18 Years	55 Years	All	353	Phase 2	United States;Austria;Bulgaria;Canada;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
856	EUCTR2010-019029-32-DE	06/05/2010	22 October 2012	A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis.	A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis.	Relapsing multiple sclerosis. MedDRA version: 12.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse	Product Name: FTY720 Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: fingolimod hydrochloride CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	2400		Portugal;Slovakia;Greece;Finland;Spain;Ireland;Austria;Italy;United Kingdom;Hungary;Czech Republic;Denmark;Germany;Netherlands;Sweden
857	EUCTR2009-017490-38-DE	03/05/2010	24 April 2012	Randomized Treatment Interruption of Natalizumab - RESTORE	Randomized Treatment Interruption of Natalizumab - RESTORE	Natalizumab is a highly efficacious therapy used in the treatment of patients with relapsing multiple sclerosis (MS). This is a prospective randomized study in subjects with relapsing forms of MS who have been receiving natalizumab treatment for at least 12 months with no MS relapses during these 12 months. MedDRA version: 12.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Other descriptive name: TYSABRI Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Trade Name: Copaxone Pharmaceutical Form: Solution for injection INN or Proposed INN: GLATIRAMER ACETATE CAS Number: 147245-92-9 Other descriptive name: COPAXONE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: AVONEX Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Other descriptive name: AVONEX Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 60- Trade Name: Urbason Forte Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: METHYLPREDNISOLONE CAS Number: 83-43-2 Other descriptive name: URBASON FORTE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000-	Biogen Idec		Not Recruiting			Female: yes Male: yes	200		Germany;Spain
858	NCT01006941	May 2010	19 February 2015	Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study	Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study	Relapsing Multiple Sclerosis	Biological: Trichuris suis ova	Rigshospitalet, Denmark	University of Copenhagen;Statens Serum Institut;Copenhagen University Hospital, Hvidovre;OvaMed GmbH	Not recruiting	19 Years	55 Years	Both	10	Phase 2	Denmark
859	NCT01076595	May 2010	3 August 2015	Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period	Prospective Multicenter, Non Interventional Study to Evaluate the Patient's Characteristics Associated With Adherence to Treatment Regimen by Betaferon in the BetaPlus Program	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	73	N/A	France
860	NCT01354665	May 2010	19 February 2015	Depression and Fatigue in MS Patients Treated With Betaferon.	The Short-term Effect of Immunomodulatory Treatment With Interferon Beta-1b (Betaferon) on Fatigue and Depression in First-time Treated Patients With Relapsing-remitting Multiple Sclerosis.	Multiple Sclerosis	Biological: Interferon beta-1b (Betaferon, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	567	N/A	Poland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
861	NCT01842191	May 2010	19 February 2015	Efficacy of Fish Oil in Multiple Sclerosis	Efficacy of Fish Oil on Serum TNFa, IL-1ß, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b	Relapsing- Remitting Multiple Sclerosis	Dietary Supplement: Fish Oil;Dietary Supplement: Placebo	Coordinación de Investigación en Salud, Mexico		Not recruiting	18 Years	55 Years	Both	50	Phase 4	Mexico
862	EUCTR2009-012500-11-IE	12/04/2010	23 February 2015	Comparison of Daclizumab HYP and Avonex® in Multiple Sclerosis	Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon ß 1a) in Patients with Relapsing-Remitting Multiple Sclerosis - DECIDE	Relapsing-remitting Multiple Sclerosis MedDRA version: 17.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: DACLIZUMAB HYP Product Code: BIIB019 Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab Current Sponsor code: BIIB019 Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: AVONEX Pharmaceutical Form: Solution for injection Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use	Biogen Idec Ltd		Not Recruiting			Female: yes Male: yes	1800		Serbia;United States;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;India;France;Australia;Denmark;Moldova, Republic of;Slovenia;Finland;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Romania;Georgia;Germany;Sweden
863	EUCTR2009-017003-28-IT	12/04/2010	23 December 2013	Relationship between IL-6 and TNF-α polymorphism and flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1a i.m. Open label multicentre study - Flu-like Symdrome	Relationship between IL-6 and TNF-α polymorphism and flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1a i.m. Open label multicentre study - Flu-like Symdrome	multiple sclerosis MedDRA version: 9.1 Level: SOC Classification code 10029205 MedDRA version: 9.1 Level: HLGT Classification code 10012303 MedDRA version: 9.1 Level: HLT Classification code 10052785 MedDRA version: 9.1 Level: LLT Classification code 10063399	Trade Name: AVONEX Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30-	BIOGEN-DOMPE` SRL		Not Recruiting			Female: yes Male: yes			Italy
864	EUCTR2009-016824-29-DK	06/04/2010	19 March 2012	REsPons på interferon-Alfa hos InterfeRon-ß-neutraliserende antistof-positive patienter med multipel sklerose - REPAIR	REsPons på interferon-Alfa hos InterfeRon-ß-neutraliserende antistof-positive patienter med multipel sklerose - REPAIR	Multiple Sclerosis MedDRA version: 12.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: Multiferon Pharmaceutical Form: Solution for injection INN or Proposed INN: HUMAN LEUCOCYTE INTERFERON-ALPHA CAS Number: 0 Current Sponsor code: SWEDISH ORPHAN INTERNATIONAL Other descriptive name: HUMAN LEUCOCYTE INTERFERON-ALPHA Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 6000000- Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 220581-49-7 Current Sponsor code: Merck Serono Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: range Concentration number: 22-44 Trade Name: Betaferon Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INTERFERON BETA-1B CAS Number: 145155-23-3 Current Sponsor code: Bayer Other descriptive name: INTERFERON BETA-1B Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 8000000-	Dansk Multipel Sclerose Center		Not Recruiting			Female: yes Male: yes	10		Denmark
865	NCT01071512	April 2010	16 December 2017	Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis	Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis	Multiple Sclerosis	Drug: Tysabri	University of Chicago	Biogen	Not recruiting	18 Years	60 Years	All	20	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
866	NCT01181115	April 2010	19 February 2015	Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)	An Open-Label Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Avonex (Interferon Beta-1a) in Chinese Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Avonex	Biogen Idec		Not recruiting	18 Years	55 Years	Both	60	Phase 3	China
867	EUCTR2009-011470-15-FI	30/03/2010	26 November 2018	An international study, which is an extension to protocol AC 058B201, with the aim to study how safe and efficacious is the long-term treatment with ponesimod in three different doses in patients with relapsing-remitting multiple sclerosis.	Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ponesimod, an oral S1P1 receptor agonist, in patients with relapsing-remitting multiple sclerosis	relapsing-remitting multiple sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Product Name: ponesimod Product Code: ACT-128800 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-	ACTELION Pharmaceuticals Ltd		Authorised			Female: yes Male: yes	353	Phase 2	Serbia;United States;Finland;Spain;Ukraine;Austria;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Romania;Australia;Bulgaria;Netherlands;Germany;Sweden
868	EUCTR2008-005167-33-DE	29/03/2010	13 June 2016	Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease - GABATAX	Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease - GABATAX	Patients with cerebellar ataxia with coordination deficits in walking, upper and lower limb movements and oculomtoor coordination deficits are included in the trial. The cause of their atayia is either a degenerative CNS disease (36 patients) such as autosomal dominant Spinocerebellar Ataxia or sporadic ataxia with late onset or inflammatory CNS disease (Multiple Sclerosis; 36 patients).	Trade Name: Neurontin 300 mg hard capsule Product Name: gabapentine 300mg Product Code: GBP Pharmaceutical Form: Capsule, hard INN or Proposed INN: Gabapentin CAS Number: 60142-96-3 Current Sponsor code: 1210 Other descriptive name: GABAPENTIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Charité University Medicine Berlin		Not Recruiting			Female: yes Male: yes		Phase 4	Germany
869	EUCTR2009-014339-19-CZ	26/03/2010	19 March 2012	A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS	A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS	Relapsing-remitting Multiple Sclerosis MedDRA version: 12.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Code: ONO-4641 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.05- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: ONO-4641 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: ONO-4641 Pharmaceutical Form: Film-coated tablet Current Sponsor code: ONO-4641 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.15- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	ONO Pharmaceutical Co., Ltd.		Not Recruiting			Female: yes Male: yes	376		Germany;Czech Republic;Spain;Greece
870	EUCTR2009-011088-35-DE	24/03/2010	19 March 2012	Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial - PACAMUS	Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial - PACAMUS	Patients with Multiple Sclerosis (MS) or Clinically isolated syndrome suggestive for MS (CIS) are investigated. The main objective is to conserve data about changes in the VIP/PACAP (vasoactive intestinal polypaptide/pituitary adenylate cyclase activating polypeptide) system in stresses patients who start a immunomodulatory treatment with glatiramer acetate (Copaxone).	Trade Name: Copaxone Product Name: copaxone Product Code: 52069.00.01 Pharmaceutical Form: Solution for injection INN or Proposed INN: glatiramer acetate CAS Number: 147245-92-9 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Philipps-Universität Marburg		Authorised			Female: yes Male: yes			Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
871	NCT01024777	March 2010	19 February 2015	Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis	A Pilot Study to Assess the Relative Safety and Immunology Effects of Low Dose Versus High Dose Cholecalciferol Supplementation in Patients With Multiple Sclerosis	Multiple Sclerosis;Vitamin D Deficiency	Drug: Cholecalciferol	Johns Hopkins University		Not recruiting	18 Years	55 Years	Both	40	Phase 1	United States
872	NCT01058005	March 2010	19 October 2017	Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis	A Multicenter, Randomized, Open-Label, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon Beta-1a) to Natalizumab in Subjects With Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: BG00002 (natalizumab);Drug: interferon beta-1a;Drug: glatiramer acetate	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	60 Years	All	84	Phase 3	United States;Australia;Canada;Czech Republic;Finland;France;Hungary;Italy;Latvia;Poland;Slovenia;Spain;Sweden
873	NCT01070823	March 2010	17 October 2016	JC-Virus (JCV) Antibody Program	JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri®: STRATIFY-1	Multiple Sclerosis	Drug: Tysabri® (natalizumab)	Biogen	United BioSource Corporation;Elan Pharmaceuticals;United BioSource Corporation;Elan Pharmaceuticals	Not recruiting	N/A	N/A	Both	1096	N/A	United States
874	NCT01070836	March 2010	10 October 2016	JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab	JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2	Relapsing Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	N/A	N/A	Both	35895	N/A	United States;Puerto Rico
875	NCT01071083	March 2010	19 October 2017	Treatment Interruption of Natalizumab	Randomized Treatment Interruption of Natalizumab	Relapsing Remitting Multiple Sclerosis	Drug: natalizumab;Drug: interferon beta 1-a;Drug: methylprednisolone;Other: IV placebo;Drug: glatiramer acetate	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	60 Years	All	175	Phase 2	United States;Germany;Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
876	NCT01077466	March 2010	19 February 2015	Natalizumab Treatment of Progressive Multiple Sclerosis	Natalizumab Treatment of Progressive Multiple Sclerosis	Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: Natalizumab	Rigshospitalet, Denmark	Copenhagen University Hospital, Hvidovre;Biogen Idec;University of Copenhagen;Signifikans ApS	Not recruiting	19 Years	55 Years	Both	24	Phase 2	Denmark
877	NCT01097668	March 2010	19 October 2017	ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis	SAFETY AND PROOF OF PRINCIPLE STUDY OF ATX-MS-1467 IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS: OPEN LABEL UPWARD TITRATION OVER FIVE DOSE LEVELS AND USING TWO ROUTES OF ADMINISTRATION (INTRADERMAL AND SUBCUTANEOUS).	Relapsing Remitting Multiple Sclerosis	Biological: ATX-MS-1467	Apitope Technology (Bristol) Ltd.	Aptiv Solutions;ClinStar, LLC	Not recruiting	18 Years	55 Years	All	43	Phase 1	Russian Federation;United Kingdom
878	NCT01144351	March 2010	21 December 2015	A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis	A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: ELND002;Drug: Placebo	Elan Pharmaceuticals		Not recruiting	18 Years	65 Years	Both	32	Phase 1	United States;Canada
879	NCT01424423	February 11, 2010	16 December 2017	NOGO-A in Multiple Sclerosis FTIH	A Randomized, Single-blind (Investigator and Subject), Placebo-controlled, Single Ascending Dose Study Exploring the Preliminary Safety, Tolerability, and Pharmacokinetics of GSK1223249 Administered by Intravenous (IV) Infusion to Subjects With Relapsing Forms of Multiple Sclerosis, Not on Disease Modifying Therapy	Multiple Sclerosis	Drug: Placebo;Drug: GSK1223249	GlaxoSmithKline		Not recruiting	18 Years	55 Years	All	3	Phase 1	Australia
880	EUCTR2009-015934-30-FR	02/02/2010	3 April 2017	étude randomisée en double insu et crossover comparant l’efficacité de la L-carnitine à un placebo dans le traitement de la fatigue dans la sclérose en plaques - FACTSEP	étude randomisée en double insu et crossover comparant l’efficacité de la L-carnitine à un placebo dans le traitement de la fatigue dans la sclérose en plaques - FACTSEP	sclérose en plaque fatigue MedDRA version: 12.0 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: levocarnil Product Name: Levocarnil Product Code: na Pharmaceutical Form: Oral solution INN or Proposed INN: L-carnitine Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	CHU de Bordeaux		Not Recruiting			Female: yes Male: yes		Phase 3	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
881	EUCTR2009-014857-34-DE	01/02/2010	20 May 2013	Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T - Gadovist in MS	Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T - Gadovist in MS	Patients with clinically definite MS or a clinically isolated episode of CNS involvement and disease dissemination in space, according to the McDonald’s criteria MedDRA version: 12.0 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: Gadovist 1.0 mmol/ml Injektionslösung Product Code: V08CA09 Pharmaceutical Form: Solution for injection INN or Proposed INN: GADOBUTROL CAS Number: 138071-82-6 Other descriptive name: GADOBUTROL Concentration unit: mmol/ml millimole(s)/millilitre Concentration type: equal Concentration number: 1.0- Trade Name: Dotarem 0,5mmol/ml, Pharmaceutical Form: Solution for injection INN or Proposed INN: gadoteric acid CAS Number: 92923-44-9 Concentration unit: mmol/ml millimole(s)/millilitre Concentration number: 0,5-	Universitätsklinikum Erlangen		Authorised			Female: yes Male: yes	50		Germany
882	NCT00988988	February 2010	19 February 2015	The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections	The Effects of Ethyl-alpha-Guanido-methyl Ethanoate on Skin Reactions Form Glatiramer Acetate	Multiple Sclerosis	Drug: AGEE cream;Drug: 1% Steroid Cream;Drug: topical placebo cream with no active ingredients	University of Nebraska	Teva Pharmaceutical Industries	Not recruiting	19 Years	65 Years	Both	0	Phase 4	United States
883	NCT01065727	February 2010	19 February 2015	Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis	Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis	Multiple Sclerosis	Other: mitoxantrone - immunomodulator;Other: natalizumab	Rennes University Hospital		Recruiting	18 Years	N/A	Both	250	N/A	France
884	NCT01073813	February 2010	19 February 2015	Neuroprotection and Repair in Optic Neuritis	Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON)	Multiple Sclerosis;Optic Neuritis	Drug: Minocycline	University of Calgary	Neuroscience Canada	Not recruiting	18 Years	60 Years	Both	6	Phase 2	Canada
885	NCT01414634	February 2010	19 October 2017	Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells	Establish Tolerance in Multiple Sclerosis With Peptide-coupled, Peripheral Blood Mononuclear Cells - A MRI-controlled, Single Center, Phase I Trial in Relapsing-remitting MS Patients	Multiple Sclerosis, Relapsing-Remitting	Biological: ETIMS	Universitätsklinikum Hamburg-Eppendorf		Not recruiting	18 Years	55 Years	All	9	Phase 1/Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
886	NCT01417273	February 2010	19 February 2015	Impact of Vitamin A on Multiple Sclerosis (MS)	Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients	Relapsing Remitting Multiple Sclerosis	Dietary Supplement: vitamin A;Drug: Drug: placebo	Tehran University of Medical Sciences		Recruiting	20 Years	45 Years	Both	100	Phase 4	Iran, Islamic Republic of
887	NCT01705457	February 2010	19 February 2015	Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis	Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients	Relapsing Remitting Multiple Sclerosis	Drug: Dietary Supplement: vitamin A;Drug: placebo	Tehran University of Medical Sciences		Recruiting	20 Years	45 Years	Both	20	Phase 4	Iran, Islamic Republic of
888	EUCTR2009-012431-15-CZ	21/01/2010	19 March 2012	Možnosti terapeutického ovlivnení neurogenního hyperaktivního detruzoru u pacientu po spinálním poranení a s roztroušenou sklerózou aplikací botulinumtoxinu A. Prospektivní, otevrená studie porovnávající efekt aplikace 300 U Botoxu® pri podání do detruzoru mocového mechýre a subsliznicního podání. Therapeutic Use of Botulinum-A toxin in Neurogenic Detrusor Overactivity in Patient after Spinal Cord Injury and Multiple Sclerosis. A Prospective, Open Study with Comparison of Suburothelial and Intradetrusor Application of 300 U of Botox®.	Možnosti terapeutického ovlivnení neurogenního hyperaktivního detruzoru u pacientu po spinálním poranení a s roztroušenou sklerózou aplikací botulinumtoxinu A. Prospektivní, otevrená studie porovnávající efekt aplikace 300 U Botoxu® pri podání do detruzoru mocového mechýre a subsliznicního podání. Therapeutic Use of Botulinum-A toxin in Neurogenic Detrusor Overactivity in Patient after Spinal Cord Injury and Multiple Sclerosis. A Prospective, Open Study with Comparison of Suburothelial and Intradetrusor Application of 300 U of Botox®.	Studie se zabývá lécbou hyperaktivního neurogeního detruzoru u pacientu, kterí trpí príznaky hyperaktivního mocového mechýre jako dusledek spinálního poranení nebo roztroušené sklerózy. K lécbe se pužívá botulinumotoxin. Ve studii se porovnávaní dve ruzné formy aplikace studjiního léku.	Trade Name: Botox Pharmaceutical Form: Powder and solvent for solution for injection CAS Number: 8000049323 Other descriptive name: BOTULINUM TOXIN TYPE A Concentration unit: U unit(s)	Krajská nemocnice Liberec, a.s.		Authorised			Female: yes Male: yes	40		Czech Republic
889	EUCTR2009-015318-23-CZ	21/01/2010	19 September 2016	A study designed to determine safety and efficacy of Daclizumab High Yield Process (DAC HYP) in patients with Multiple Sclerosis Who Have Completed Treatment in a previous study, 205MS202 (SELECTION)	A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION)	Relapsing-remitting Multiple Sclerosis MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Daclizumab High Yield Process Product Code: BIIB019 Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab Current Sponsor code: BIIB019 Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Biogen Idec Ltd.		Not Recruiting			Female: yes Male: yes	450	Phase 2	Hungary;Czech Republic;Ukraine;Russian Federation;Germany;United Kingdom;India
890	EUCTR2009-016140-39-ES	19/01/2010	19 March 2012	MRI in Clinically Isolated Syndromes and relapsing multiple sclerosis after single dose (0.1 mmol/kg) and cumulative dose (0.1 + 0.1 mmol/kg) of GADOVIST at 3.0T Estudio de resonancia magnética 3.0T posterior a la administración de GADOVIST® en dosis única (0.1 mmol/kg) y dosis acumulada (0.1+0.1 mmol/kg) en pacientes con Síndrome Clínico Aislado o recaída de Esclerosis Múltiple.	MRI in Clinically Isolated Syndromes and relapsing multiple sclerosis after single dose (0.1 mmol/kg) and cumulative dose (0.1 + 0.1 mmol/kg) of GADOVIST at 3.0T Estudio de resonancia magnética 3.0T posterior a la administración de GADOVIST® en dosis única (0.1 mmol/kg) y dosis acumulada (0.1+0.1 mmol/kg) en pacientes con Síndrome Clínico Aislado o recaída de Esclerosis Múltiple.	Realce de contraste en resonancia magnética en pacientes con Síndrome Clínico Aislado o recaída de Esclerosis Múltiple con resonancia magnética anormal anterior después de la administración de dosis única y acumulada de GADOVIST® High field strength MRI in patients with clinically isolated syndromes or relapsing MS with abnormal previous MRI after single and double dose of Gadovist®	Trade Name: GADOVIST 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado Pharmaceutical Form: Solution for injection INN or Proposed INN: GADOBUTROL Other descriptive name: GADOBUTROL Concentration unit: mmol/kg millimole(s)/kilogram Concentration type: equal Concentration number: 0.2-	Institut Diagnostic per la Imatge		Authorised			Female: yes Male: yes			Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
891	EUCTR2007-001496-11-GB	15/01/2010	28 February 2019	The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis - Multiple Sclerosis Tetanus Vaccine for Reduction of Inflammation-1	The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis - Multiple Sclerosis Tetanus Vaccine for Reduction of Inflammation-1	Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple Sclerosis	Trade Name: Revaxis Product Name: Revaxis Pharmaceutical Form: Injection*	University of Nottingham		Not Recruiting			Female: yes Male: yes	46	Phase 2	United Kingdom
892	EUCTR2009-016703-35-DK	08/01/2010	2 September 2013	Natalizumabbehandling af progressiv multipel sklerose - NAPMS	Natalizumabbehandling af progressiv multipel sklerose - NAPMS	Secondary progressive multiple sclerosis and primary progressive multiple sclerosis MedDRA version: 12.0 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 12.0 Level: LLT Classification code 10063401 Term: Primary progressive multiple sclerosis	Trade Name: Tysabri Product Name: Natalizumab Pharmaceutical Form: Intravenous infusion INN or Proposed INN: NATALIZUMAB CAS Number: 189261-10-7 Current Sponsor code: Natalizumab Other descriptive name: Tysabri Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Dansk Multipel Sclerose Center		Not Recruiting			Female: yes Male: yes	24		Denmark
893	NCT01031459	January 2010	19 February 2015	Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.	An Observational 20-year, Cross-sectional, Long-term Follow up of the Patient Cohort Enrolled in the Pivotal Study of Betaseron® (Interferon Beta-1b) in Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Betaseron (Interferon beta-1b, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	176	N/A	United States;Canada
894	NCT01101776	January 2010	19 February 2015	Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.	Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting	Multiple Sclerosis	Drug: Interferon beta-1a (Rebif)	Merck KGaA	Merck Serono Australia Pty Ltd	Not recruiting	18 Years	N/A	Both	49	N/A	Australia
895	NCT01364246	January 2010	19 February 2015	Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica	Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica	Progressive Multiple Sclerosis;Neuromyelitis Optica.	Biological: human umbilical cord mesenchymal stem cells	Shenzhen Beike Bio-Technology Co., Ltd.	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School;The Affiliated Nanjing Brain Hospital of Nanjing University Medical School;Nanjing University Medical College Affiliated Wuxi Second Hospital;Xuzhou Medical College;The Second Hospital of Nanjing Medical University	Recruiting	18 Years	60 Years	Both	20	Phase 1/Phase 2	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
896	EUCTR2009-012716-40-EE	31/12/2009	19 March 2012	The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four–arm, parallel, placebo-controlled and active descriptive-comparator, 40 week trial	The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four–arm, parallel, placebo-controlled and active descriptive-comparator, 40 week trial	Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: PI-2301 Product Code: PI-2301 Pharmaceutical Form: Solution for injection CAS Number: 1026791-66-1 Current Sponsor code: PI-2301 acetate salt Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: PI-2301 Product Code: PI-2301 Pharmaceutical Form: Solution for injection CAS Number: 1026791-66-1 Current Sponsor code: PI-2301 acetate salt Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Copaxone Product Name: Copaxone Pharmaceutical Form: Solution for injection CAS Number: 147245-92-9 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Peptimmune Inc.		Not Recruiting			Female: yes Male: yes	350	Phase 2	Germany;Czech Republic;Bulgaria;France;Estonia;Poland
897	EUCTR2008-008554-23-SE	29/12/2009	19 March 2012	Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation - NAb development with RNF	Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation - NAb development with RNF	IFNß-naïve patients fulfilling Poser or McDonald criteria for CDMS or MS and in whom a decision has been made to initiate treatment with RNF (Rebif New Formulation). MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: Rebif Product Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: 145258-61-3 Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22-44	The Multiple Sclerosis Research Group, Department of Clinical Neuroscience		Not Recruiting			Female: yes Male: yes	100		Sweden
898	EUCTR2009-016087-37-ES	18/12/2009	24 April 2012	Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease). A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial - REGARD-PGx	Estudio farmacogenético exploratorio, multinacional, multicéntrico y con una sola toma de muestras de sangre del ensayo REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease). A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial - REGARD-PGx	Esclerosis Múltiple MedDRA version: 12.0 Level: PT Classification code 10028245 Term: Multiple sclerosis	Product Name: Rebif Pharmaceutical Form: Solution for injection Product Name: Copaxone Pharmaceutical Form: Solution for injection	Merck Serono S.A. - Geneva		Not Recruiting			Female: yes Male: yes	325		United Kingdom;France;Ireland;Spain;Italy
899	NCT00963833	December 17, 2009	16 December 2017	Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis	Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	12 Years	16 Years	All	68	N/A	Austria;Belgium;Finland;Germany;Israel;United Kingdom;Italy;Portugal
900	EUCTR2009-013284-19-AT	10/12/2009	10 July 2015	Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta - HINABS	Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta - HINABS	multiple sclerosis patients with neutralizing antibodies against interferon-beta	Trade Name: Betaferon Pharmaceutical Form: Intravenous infusion CAS Number: 145155-23-3 Other descriptive name: INTERFERON BETA-1B Concentration unit: million IU million international units Concentration type: equal Concentration number: 48-	Medical University Innsbruck		Not Recruiting			Female: yes Male: yes			Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
901	NCT00913510	December 2009	19 October 2017	Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction	Efficacy of Clean Intermittent Self-catheterization in Combination With Anticholinergic Drugs for Treatment of Bladder Dysfunction in Multiple Sclerosis	Bladder Dysfunction;Multiple Sclerosis	Device: CIC using LoFric Primo;Drug: Anticholinergic medication	Wellspect HealthCare		Not recruiting	18 Years	N/A	All	24	N/A	Belgium;Germany;Netherlands;United Kingdom;France
902	NCT00986960	December 2009	15 July 2019	Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)	Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up Study	Multiple Sclerosis	Drug: repository corticotropin injection;Drug: Saline	University at Buffalo		Not recruiting	18 Years	65 Years	All	3	Phase 2	United States
903	NCT01037088	December 2009	19 October 2017	Effects of Vaporized Marijuana on Neuropathic Pain	CCRC: The Analgesic Effect of Vaporized Cannabis on Neuropathic Pain	Neuropathic Pain;Reflex Sympathetic Dystrophy;Peripheral Neuropathy;Post-herpetic Neuralgia;Spinal Cord Injury;Multiple Sclerosis	Drug: Cannabis	University of California, Davis	Center for Medicinal Cannabis Research;VA Northern California Health Care System	Not recruiting	18 Years	70 Years	All	44	Phase 1/Phase 2	United States
904	NCT02442557	December 2009	25 May 2015	Safety and Dose-finding Study of DC-TAB in Healthy Subjects	A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and T-cell Tolerizing Effect of DC-TAB in Healthy Volunteers	Multiple Sclerosis	Biological: recombinant human alpha B-crystallin;Other: placebo comparator	Delta Crystallon BV		Not recruiting	18 Years	55 Years	Both	76	Phase 1	Netherlands
905	NCT01013350	November 30, 2009	26 August 2019	Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials	Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials	Multiple Sclerosis	Drug: Cladribine	EMD Serono		Not recruiting	N/A	N/A	All	1191	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
906	EUCTR2008-004408-29-DE	27/11/2009	19 March 2012	ESTABLISH TOLERANCE IN MS WITH PEPTIDE-PULSED, PERIPHERAL BLOOD MONONUCLEAR CELLS - A MRI-CONTROLLED, SINGLE CENTER, BASELINE-TO-TREATMENT CROSS-OVER, PHASE I/IIA TRIAL IN RELAPSING-REMITTING MS PATIENTS - ETIMS - - ETIMS	ESTABLISH TOLERANCE IN MS WITH PEPTIDE-PULSED, PERIPHERAL BLOOD MONONUCLEAR CELLS - A MRI-CONTROLLED, SINGLE CENTER, BASELINE-TO-TREATMENT CROSS-OVER, PHASE I/IIA TRIAL IN RELAPSING-REMITTING MS PATIENTS - ETIMS - - ETIMS	relapsing-remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: ETIMS (EDC-fixed autologous PBMCs coupled with 7 immunodominant myelin peptides in MS patients) Product Code: ETIMS Pharmaceutical Form: Intravenous infusion	University Medical Center Hamburg-Eppendorf		Authorised			Female: yes Male: yes		Phase 1/2A	Germany
907	EUCTR2009-013884-21-DE	18/11/2009	24 November 2014	A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)	A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)	Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome MedDRA version: 14.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PEG-liposomal Prednisolone Sodium Phosphate Product Code: Nanocort Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Prednisolone Sodium Phosphate CAS Number: 125-02-0 Other descriptive name: PREDNISOLONE SODIUM PHOSPHATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 1.0-3.2 Trade Name: Solu-Medrol Pharmaceutical Form: Powder for infusion INN or Proposed INN: METHYLPREDNISOLONE SODIUM SUCCINATE CAS Number: 03/03/2375 Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000-	Enceladus Pharmaceuticals BV		Not Recruiting			Female: yes Male: yes	90		Poland;Belgium;Germany
908	EUCTR2009-012989-30-GB	17/11/2009	17 October 2016	A clinical study in subjects with multiple sclerosis who successfully completed the MS-LAQ-301 (ALLEGRO) study, to assess the safety of laquinimod (experimental drug) when taken for a long period of time and how it affects the course of the disease.	A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis - -	Laquinimod is developed for the treatment of relapsing remitting multiple sclerosis. MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Laquinimod Capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6-	Teva Pharmaceutical Industries Ltd		Authorised			Female: yes Male: yes	542	Phase 3	Serbia;United States;Estonia;Spain;Ukraine;Lithuania;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Romania;Bulgaria;Georgia;Netherlands;Germany;Sweden
909	NCT00988052	November 10, 2009	21 January 2019	A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course	A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 (ALLEGRO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing MS	Relapsing Multiple Sclerosis	Drug: Laquinimod	Teva Pharmaceutical Industries, Ltd.		Not recruiting	18 Years	55 Years	All	839	Phase 3	United States;Austria;Bulgaria;Canada;Czechia;Estonia;France;Georgia;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Turkey;Ukraine;United Kingdom;Czech Republic;Latvia
910	NCT01028209	November 2009	15 April 2019	Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions		Alzheimer Disease;Parkinson Disease;Multiple Sclerosis	Drug: [18F] PBR06	Institute for Neurodegenerative Disorders		Not recruiting	18 Years	N/A	All	12	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
911	NCT01037907	November 2009	19 February 2015	A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)	A Placebo-controlled Phase IIa Study of Orally Administered BGC20-0134/Pleneva TM (Structured Lipid) in Patients With RRMS	Relapsing Remitting Multiple Sclerosis	Drug: Pleneva TM BGC20-0134;Drug: Placebo	BTG International Inc.		Not recruiting	18 Years	65 Years	Both	173	Phase 2	Belgium;France;Germany;Poland;Russian Federation;Spain;Italy
912	NCT01049451	November 2009	16 December 2017	Pulse ACTH vs. MP for MS	Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)	Multiple Sclerosis	Drug: ACTH;Drug: Methylprednisolone	University of Southern California		Not recruiting	18 Years	65 Years	All	23	Phase 1	United States
913	NCT01615887	November 2009	19 February 2015	Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis	Effects of Lisdexamfetamine on Bradyphrenia in Multiple Sclerosis	Multiple Sclerosis	Drug: lisdexamfetamine sulfate;Drug: placebo	State University of New York at Buffalo		Not recruiting	18 Years	55 Years	Both	63	Phase 2	United States
914	NCT01719159	November 2009	28 November 2016	Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis	Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: Rituximab	Anders Svenningsson	Västerbotten County Council, Sweden	Not recruiting	18 Years	65 Years	Both	23	Phase 2	Sweden
915	EUCTR2009-011626-34-SE	28/10/2009	15 May 2012	A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with relapsing-remitting multiple sclerosis - B2201	A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 week period in patients with relapsing-remitting multiple sclerosis - B2201	Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: AIN457 Product Code: AIN457 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: not available CAS Number: not availabl Current Sponsor code: AIN457 Other descriptive name: rhumAb to Il-17A (IgG1-k-class) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Powder for solution for infusion Route of administration of the placebo: Intravenous use	Novartis Pharma Services AG		Authorised			Female: yes Male: yes	88		Czech Republic;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
916	EUCTR2009-013695-46-FR	22/10/2009	14 March 2016	ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQUES RECURRENTE (SEP-R) TRAITES PAR INTERFERON BETA 1A 44 µG 3 FOIS PAR SEMAINE PAR VOIE SOUS-CUTANEE - choline	ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQUES RECURRENTE (SEP-R) TRAITES PAR INTERFERON BETA 1A 44 µG 3 FOIS PAR SEMAINE PAR VOIE SOUS-CUTANEE - choline	Sclérose en plaques récurrente (SEP-R) MedDRA version: 12.0 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: UVEDOSE 100 000 UI, solution buvable en ampoule Product Name: UVEDOSE 100 000 UI Pharmaceutical Form: Oral solution INN or Proposed INN: COLECALCIFEROL CAS Number: 67-97-0 Concentration unit: IU/ml international unit(s)/millilitre Concentration type: equal Concentration number: 50000- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	MERCK SERONO s.a.s		Not Recruiting			Female: yes Male: yes			France
917	EUCTR2008-005021-11-BE	14/10/2009	12 June 2012	An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Extension) - Atacicept 28063 (RMS) extension study	An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS-Extension) - Atacicept 28063 (RMS) extension study	Relapsing multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: atacicept Pharmaceutical Form: Solution for injection INN or Proposed INN: atacicept Other descriptive name: TACI-Fc5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Product Name: atacicept Pharmaceutical Form: Solution for injection INN or Proposed INN: atacicept Other descriptive name: TACI-Fc5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 75- Product Name: atacicept Pharmaceutical Form: Solution for injection INN or Proposed INN: atacicept Other descriptive name: TACI-Fc5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150-	Merck Serono SA - Geneva, An affiliate of Merck KGaA, Darmstadt, Germany		Not Recruiting			Female: yes Male: yes	68	Phase 2	Czech Republic;Belgium;France;Sweden
918	NCT00787722	October 10, 2009	15 April 2019	Hematopoietic Stem Cell Transplant in Devic's Disease	Trial of High Dose Immunosuppressive Therapy With Hematopoietic Stem Cell Support in Devic's Disease	Devic's Disease	Procedure: Hematopoietic Stem Cell Transplantation;Drug: Cyclophosphamide;Drug: G-CSF;Drug: rATG;Drug: Mesna;Drug: Rituximab;Drug: Methylprednisolone	Northwestern University		Not recruiting	16 Years	65 Years	All	13	Phase 1/Phase 2	United States
919	EUCTR2008-007459-28-DE	08/10/2009	19 November 2012	Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis	Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: LY2127399 Product Code: LY2127399 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: N/a CAS Number: N/a Current Sponsor code: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4-120 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	245		France;Czech Republic;Hungary;Finland;Belgium;Denmark;Bulgaria;Germany
920	EUCTR2009-011585-28-DE	08/10/2009	4 March 2013	Early phase clinical trial to evaluate the effectiveness and safety of a new orally administered drug in patients with relapsing-remitting multiple sclerosis	A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS)	relapsing-remitting multiple sclerosis MedDRA version: 14.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BCG20-0134 Product Code: BCG20-0134 Pharmaceutical Form: Capsule, soft Current Sponsor code: BGC20-0134 Other descriptive name: Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate Concentration unit: g gram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use	BTG International Ltd		Not Recruiting			Female: yes Male: yes	184	Phase 2a	France;European Union;Spain;Belgium;Russian Federation;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
921	NCT01006265	October 1, 2009	16 December 2017	Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis	Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: ACT-128800 Dose 1;Drug: Placebo;Drug: ACT-128800 Dose 2;Drug: ACT-128800 Dose 3	Actelion		Not recruiting	18 Years	55 Years	All	464	Phase 2	United States;Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;Switzerland;Ukraine;United Kingdom
922	NCT00947895	October 2009	11 April 2016	Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone	Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study	Multiple Sclerosis	Drug: Methylprednisolone;Drug: ACTH;Other: IV placebo;Other: IM placebo	Neurologique Foundation, Inc.	Mallinckrodt	Not recruiting	18 Years	N/A	Both	30	Phase 2/Phase 3	United States
923	NCT01225289	October 2009	19 October 2017	Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients	The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Dietary Supplement: Vitamin A;Drug: Placebo	Tehran University of Medical Sciences		Not recruiting	20 Years	45 Years	All	36	Phase 4	Iran, Islamic Republic of
924	NCT02275741	October 2009	10 December 2018	Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis	Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Biological: prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)	Dr. med. Micha Loebermann		Not recruiting	18 Years	70 Years	All	226	Phase 2	Germany
925	EUCTR2006-001152-12-DE	14/09/2009	11 April 2016	An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis plus a long-term extension period.	An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis plus a long-term extension period.	Multiple Sclerosis MedDRA version: 16.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	sanofi-aventis recherche & développement		Not Recruiting			Female: yes Male: yes	780		France;Estonia;Hungary;Czech Republic;Slovakia;Finland;Lithuania;Denmark;Austria;Bulgaria;Germany;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
926	NCT00910598	September 2009	19 February 2015	Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)	A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS	Multiple Sclerosis	Drug: glatiramer acetate	Amphia Hospital	Sanofi;TEVA Pharmachemie	Recruiting	18 Years	55 Years	Both	60	Phase 4	Netherlands
927	NCT00981084	September 2009	19 October 2017	Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)	The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover Study	Multiple Sclerosis	Drug: armodafinil	University of Missouri, Kansas City	University of Kansas	Not recruiting	18 Years	60 Years	All	33	Phase 2/Phase 3	United States
928	EUCTR2009-013333-24-IT	03/08/2009	19 March 2012	Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inject Rebif New Formulation (RNF) In a multi-dose cartriDGE (BRIDGE) - BRIDGE	Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inject Rebif New Formulation (RNF) In a multi-dose cartriDGE (BRIDGE) - BRIDGE	RELAPSING MULTIPLE SCLEROSIS MedDRA version: 12.0 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: REBIF Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-	MERCK SERONO SPA		Not Recruiting			Female: yes Male: yes		Phase 4	Italy
929	NCT00871780	August 2009	16 December 2017	A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients	A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients TIMER Study	Relapsing Remitting Multiple Sclerosis (RRMS)	Drug: BG00002 (natalizumab)	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	60 Years	All	224	Phase 4	Belgium;Mexico;Poland;Romania;Saudi Arabia;Ukraine;Venezuela
930	NCT00930553	August 2009	16 December 2017	An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab	An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab	Multiple Sclerosis, Relapsing-Remitting	Biological: alemtuzumab	Genzyme, a Sanofi Company	Bayer	Not recruiting	N/A	N/A	All	1314	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czechia;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom;Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
931	NCT00940719	August 2009	19 February 2015	Vitamin D3 Supplementation and the T Cell Compartment in Multiple Sclerosis (MS)	The Effects of Vitamin D3 Supplementation on the T Cell Compartment in Multiple Sclerosis; a Pilot Study	Multiple Sclerosis	Dietary Supplement: vitamin D3	Maastricht University Medical Center	Orbis Medical Centre	Not recruiting	18 Years	N/A	Both	15	N/A	Netherlands
932	NCT00970333	August 2009	19 February 2015	Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions	Evaluation of [18F] FEPPA and PET as a Marker of Inflammation in Subjects With Neurological Conditions	Alzheimer Disease;Parkinson Disease;Multiple Sclerosis	Drug: [18F]-FEPPA	Institute for Neurodegenerative Disorders		Not recruiting	18 Years	N/A	Both	3	Phase 1	United States
933	EUCTR2009-010661-23-IT	30/07/2009	19 March 2012	MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS - aMICO STUDY	MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS - aMICO STUDY	subjects affected by secondary-progressive Multiple Sclerosis MedDRA version: 9.1 Level: SOC Classification code 10029205	Pharmaceutical Form: Solution for injection INN or Proposed INN: Mitoxantrone Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2- Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Glatiramer acetate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-	AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI		Not Recruiting			Female: yes Male: yes			Italy
934	NCT00950248	July 22, 2009	20 August 2018	Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS)	Double Blind Placebo-Controlled Phase I/II Clinical Trial of Idebenone in Patients With Primary Progressive Multiple Sclerosis	Primary Progressive Multiple Sclerosis	Drug: Idebenone	National Institute of Allergy and Infectious Diseases (NIAID)		Not recruiting	18 Years	65 Years	All	85	Phase 1/Phase 2	United States
935	EUCTR2009-013129-41-NL	20/07/2009	19 March 2012	A multicenter open label randomized pilot study, to compare retinal nerve fiber layer thickness measured by Optical Coherence Tomography after treatment with daily 20 mg glatiramer acetate subcutaneously or after no treatment, in patients with a clinical isolated syndrome, other than optic neuritis or early relapsing remitting multiple sclerosis patients - OCT	A multicenter open label randomized pilot study, to compare retinal nerve fiber layer thickness measured by Optical Coherence Tomography after treatment with daily 20 mg glatiramer acetate subcutaneously or after no treatment, in patients with a clinical isolated syndrome, other than optic neuritis or early relapsing remitting multiple sclerosis patients - OCT	clinical isolated syndrome MedDRA version: 9.1 Level: LLT Classification code 10028248 Term: Multiple sclerosis-like syndrome	Trade Name: Copaxone Product Name: Copaxone Pharmaceutical Form: Solution for injection CAS Number: 147245929 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Amphia Ziekenhuis		Authorised			Female: yes Male: yes			Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
936	EUCTR2008-002626-11-SE	02/07/2009	24 July 2017	Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis	Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis - PMSIT	Severe progressive multiple sclerosis in which there is no other documented treatment avalilable or allready tested. It is estimated that the prognosis for these patients are poor without any effective treatment MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Trade Name: Mabthera Pharmaceutical Form: Concentrate for solution for infusion Other descriptive name: RITUXIMAB	Dept of Neurology		Not Recruiting			Female: yes Male: yes		Phase 2	Sweden
937	NCT00947752	July 2009	16 December 2017	Safety of New Formulation of Glatiramer Acetate	An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection	Relapsing Remitting Multiple Sclerosis	Drug: Glatiramer Acetate;Drug: Experimental Glatiramer Acetate	Teva Pharmaceutical Industries		Not recruiting	18 Years	N/A	All	147	Phase 3	United States
938	NCT00965497	July 2009	19 October 2017	Escitalopram (Lexapro) for Depression MS or ALS	An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis	Major Depression;Multiple Sclerosis;Amyotrophic Lateral Sclerosis	Drug: escitalopram	University of South Carolina		Not recruiting	18 Years	70 Years	All	13	Phase 3	United States
939	EUCTR2009-011234-99-DE	23/06/2009	3 February 2014	A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the tolerability and safety of escalating doses of oral laquinimod administered daily in subjects with relapsing remitting multiple sclerosis (RRMS)	A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the tolerability and safety of escalating doses of oral laquinimod administered daily in subjects with relapsing remitting multiple sclerosis (RRMS) - MS-LAQ-101	Laquinimod is developed for the treatment of relapsing remitting multiple sclerosis (RRMS). This study is planned to assess the tolerability and safety of escalating doses of oral laquinimod administered daily in subjects with RRMS. MedDRA version: 15.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Laquinimod Capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Laquinimod Capsules 0.3 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.3- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Teva Pharmaceutical Industries Ltd		Not Recruiting			Female: yes Male: yes	160	Phase 1	Germany
940	EUCTR2009-011523-31-GB	23/06/2009	19 March 2012	A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC	A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC	The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab. MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10046859 Term: Vaccination	Trade Name: Menitorix Pharmaceutical Form: Powder and solvent for solution for injection Trade Name: Pneumovax II Pharmaceutical Form: Solution for injection Trade Name: REVAXIS Pharmaceutical Form: Suspension for injection	R & D, Cambridge University Hospitals		Not Recruiting			Female: yes Male: yes	60		United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
941	EUCTR2008-006333-27-LV	19/06/2009	27 January 2014	A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis - ADVANCE	A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Sclerosis - ADVANCE	Relapsing Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Product Name: PEGylated Interferon Beta-1a Product Code: BIIB017 Pharmaceutical Form: Solution for injection Current Sponsor code: BIIB017 Other descriptive name: PEGylated Interferon Beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 63-125 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Biogen Idec LTD		Not Recruiting			Female: yes Male: yes	1260		Czech Republic;Estonia;Greece;Spain;Belgium;Bulgaria;Netherlands;Germany;Latvia;United Kingdom
942	EUCTR2008-006786-92-CZ	18/06/2009	19 March 2012	Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis	Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis	relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: ACT-128800 Product Code: ACT-128800 Pharmaceutical Form: Capsule, hard Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: ACT-128800 Product Code: ACT-128800 Pharmaceutical Form: Capsule, hard Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: ACT-128800 Product Code: ACT-128800 Pharmaceutical Form: Capsule, hard Current Sponsor code: ACT-128800 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Actelion Pharmaceuticals Ltd		Authorised			Female: yes Male: yes	460		Hungary;Finland;United Kingdom;Czech Republic;Netherlands;Bulgaria;France;Spain;Italy;Austria;Poland;Sweden
943	EUCTR2008-007549-29-DK	09/06/2009	19 March 2012	Trichuris suis Ova Therapy for Relapsing Multiple Sclerosis - a safety study - TRIMS A	Trichuris suis Ova Therapy for Relapsing Multiple Sclerosis - a safety study - TRIMS A	Relapsing Multipel Sclerosis MedDRA version: 12.0 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 12.0 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 12.0 Level: LLT Classification code 10053395 Term: Progressive multiple sclerosis	Product Name: Trichuris suis Ova Product Code: TSO Pharmaceutical Form: Oral suspension INN or Proposed INN: Trichuris suis eggs Current Sponsor code: Trichuris suis eggs Other descriptive name: Trichuris suis eggs Concentration unit: thousand organisms/ml thousand organisms/millilitre Concentration type: range Concentration number: 0,15-0,183	Danish Multiple Sclerosis Research Center		Not Recruiting			Female: yes Male: yes	10		Denmark
944	NCT00917839	June 2009	19 February 2015	The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis	Randomized, Placebo-Controlled Phase II Monocentric Trial for the Neuroprotective Effect of Lamotrigine Plus Interferon Beta 1a 30mcg Once Weekly Intramuscular in Patients With Relapsing-Remitting Multiple Sclerosis.	Relapsing-Remitting Multiple Sclerosis	Drug: lamotrigine	Cantonal Hospital of St. Gallen		Recruiting	18 Years	50 Years	Both	88	Phase 2	Switzerland
945	NCT00942214	June 2009	19 February 2015	Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment	Biomarkers Associated With Response to Natalizumab in Multiple Sclerosis Patients. A Prospective Multicentric Open Label Phase IV Study	Multiple Sclerosis	Drug: Natalizumab	University Hospital, Toulouse		Not recruiting	18 Years	55 Years	Both	300	Phase 4	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
946	EUCTR2009-011516-37-DK	29/05/2009	8 August 2016	Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis - EPO-ProgMS	Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis - EPO-ProgMS	Multiple Sclerosis, with primary and secondary progressive courses. MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: NeoRecormon Pharmaceutical Form: Solution for infusion INN or Proposed INN: Solu-Medrol CAS Number: 2375033 Current Sponsor code: Pfizer Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Concentration unit: mg milligram(s) Concentration type: equal Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous drip use (Noncurrent)	Danish Multiple Sclerosis Research Centre		Not Recruiting			Female: yes Male: yes		Phase 2	Denmark
947	NCT00799890	May 2009	10 December 2018	Sunphenon in Progressive Forms of Multiple Sclerosis	Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Sunphenon EGCG;Drug: Placebo	Friedemann Paul	TAIYO EUROPE	Not recruiting	18 Years	65 Years	All	60	Phase 2/Phase 3	Germany
948	NCT00854750	May 2009	19 February 2015	Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis	Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis	Multiple Sclerosis	Drug: ACTHAR	Elliot Frohman	Questcor Pharmaceuticals, Inc.	Not recruiting	18 Years	65 Years	Both	1	Phase 4	United States
949	NCT00902135	May 2009	3 August 2015	Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)	Betaferon® Injection Management: Non-interventional Study on Personal Digital Assistant (PDA)Supported Effects on Adherence to a Long-term Injection Therapy (BETAPATH)	Relapsing-Remitting Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	702	N/A	Germany
950	NCT01075880	May 2009	19 February 2015	Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®	Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With Rebif	Multiple Sclerosis, Relapsing-Remitting	Drug: Rebif (Interferon beta-1a)	Merck KGaA	Merck spol.s.r.o., Czech Republic	Not recruiting	18 Years	65 Years	Both	300	N/A	Czech Republic
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
951	EUCTR2008-007447-14-IT	03/04/2009	7 January 2013	GH-IGF-I status and Multiple Sclerosis: clinical implications (a prevalence study).	GH-IGF-I status and Multiple Sclerosis: clinical implications (a prevalence study).	patients with Multiple Sclerosis MedDRA version: 14.1 Level: SOC Classification code 10022891 Term: Investigations System Organ Class: 10022891 - Investigations MedDRA version: 14.1 Level: SOC Classification code 10014698 Term: Endocrine disorders System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Somatorelin Concentration unit: µg microgram(s) Concentration number: 50-	UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II		Authorised			Female: yes Male: yes			Italy
952	NCT00764413	April 2009	19 February 2015	Chronotherapy in Acute Multiple Sclerosis (MS) Attack	Treatment With Methylprednisolone in Acute Exacerbations of Multiple Sclerosis: Enhanced Effect With Nighttime Treatment?	Multiple Sclerosis	Drug: methylprednisolone;Drug: Sodium chlorid	Sykehuset Innlandet HF		Not recruiting	18 Years	N/A	Both	57	N/A	Norway
953	NCT00881205	April 2009	19 October 2017	Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment	A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment Phase	Multiple Sclerosis;Cognitive Impairment	Drug: Rivastigmine transdermal patch;Drug: Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	65 Years	All	86	Phase 4	Germany
954	NCT00882999	April 2009	26 November 2018	A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)	Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: LY2127399;Drug: Placebo	Eli Lilly and Company		Not recruiting	18 Years	64 Years	All	245	Phase 2	United States;Bulgaria;Czechia;France;Germany;Hungary;Israel;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine;Belgium;Canada;Czech Republic;Denmark;Finland;Switzerland
955	NCT00904826	April 2009	19 October 2017	An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica	An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica	Neuromyelitis Optica;Devic's Disease	Drug: Eculizumab	Mayo Clinic	Alexion Pharmaceuticals	Not recruiting	18 Years	N/A	All	14	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
956	NCT00914290	April 2009	16 December 2017	A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis	A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis	Spasticity;Multiple Sclerosis	Drug: IPX056;Drug: Baclofen IR;Drug: Placebo IPX056;Drug: Placebo IR	IMPAX Laboratories, Inc.		Not recruiting	18 Years	N/A	All	23	Phase 2	United States
957	EUCTR2008-006226-34-ES	25/03/2009	10 July 2015	Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple recidivante ------------------------------------------------------------ A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosisA multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis. - TENERE	Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple recidivante ------------------------------------------------------------ A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosisA multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis. - TENERE	Esclerosis Múltiple ------------------------ Multiple sclerosis	Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Product Name: Teriflunomide Product Code: HMR1726 Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Trade Name: REBIF 44 microgramos solución inyectable Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA1A Other descriptive name: INTERFERON BETA1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-	sanofi-aventis recherche et development		Not Recruiting			Female: yes Male: yes	300		France;Czech Republic;Hungary;Belgium;Spain;Germany;United Kingdom;Italy
958	EUCTR2007-004452-36-GB	24/03/2009	25 September 2012		A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis using interferon-beta 1a (Rebif®) as an open-label rater-blind calibrator -	Multiple sclerosis MedDRA version: 15.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Teriflunomide Product Code: HMR 1726D Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Sanofi-aventis recherche & développement		Authorised			Female: yes Male: yes	1110		Germany;France;Austria;Australia;Sweden;Czech Republic;Tunisia;Canada;Belarus;Belgium;Greece;United States;Philippines;Poland;Turkey;Netherlands;Chile;United Kingdom;Slovakia;Ukraine;Mexico;Estonia;China;Romania;Spain;Thailand
959	NCT00884481	March 23, 2009	19 November 2018	Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS	A Multi-centre and Prospective Trial to Evaluate the Effects on Multiple Sclerosis Related Fatigue During Treatment With Tysabri in Patients With Relapsing Remitting Multiple Sclerosis Over the Course of 12 Months	Relapsing-Remitting Multiple Sclerosis;Fatigue	Other: Natalizumab	Biogen		Not recruiting	18 Years	65 Years	All	195	Phase 2	Austria;Denmark;Norway;Sweden;United States
960	EUCTR2008-008065-35-SE	13/03/2009	24 July 2012		A multi-centre and prospective trial to evaluate the effects on mul-tiple sclerosis related fatigue during treatment with Tysabri® in patients with relapsing remitting multiple sclerosis over the course of 12 months - TYNERGY	Mutiple sclerosis related fatigue in subjects with relapsing remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10016256 Term: Fatigue	Trade Name: Tysabri Pharmaceutical Form: Intravenous infusion	BiogenIdec A/S		Not Recruiting			Female: yes Male: yes	200		Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
961	EUCTR2008-004174-40-FR	06/03/2009	19 March 2012	Imagerie de la démyélinisation dans la sclérose en plaques : une étude en tomographie à émission de positons (TEP) avec le 11C-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (11C-PIB) - SHADOWTEP	Imagerie de la démyélinisation dans la sclérose en plaques : une étude en tomographie à émission de positons (TEP) avec le 11C-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (11C-PIB) - SHADOWTEP	Groupe I: volontaires sains Groupe II: patients avec une sclérose en plaques d'évolution rémittente . MedDRA version: 8.1 Level: PT Classification code 10012300 Term: Demyelinating disease (excl multiple sclerosis)	Product Name: 11C-PIB Pharmaceutical Form: Solution for injection INN or Proposed INN: 11C-PIB Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 740-	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)		Authorised			Female: yes Male: yes			France
962	NCT00818038	March 2009	19 February 2015	A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function	Phase IV, Proof of Concept Study to Evaluate Tysabri Effectiveness in RRMS Patient Bladder Function	Relapsing-Remitting Multiple Sclerosis	Drug: BG0002 (natalizumab)	Biogen Idec		Not recruiting	18 Years	85 Years	Both	30	N/A	United States
963	NCT00853762	March 2009	16 December 2017	Atacicept in Multiple Sclerosis Extension Study, Phase II	An Open-label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-term Follow-up Data in Subjects With Relapsing Multiple Sclerosis Treated With Atacicept for up to 5 Years (ATAMS-Extension)	Relapsing Multiple Sclerosis	Drug: Atacicept 25 mg;Drug: Atacicept 75 mg;Drug: Atacicept 150 mg	EMD Serono	Merck KGaA	Not recruiting	18 Years	60 Years	All	74	Phase 2	United States;Australia;Belgium;Canada;Czech Republic;France;Germany;Lebanon;Lithuania;Netherlands;New Caledonia;Russian Federation;Spain;Sweden;Switzerland;Ukraine;United Kingdom
964	NCT00879658	March 2009	12 March 2018	Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis	A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis.	Relapsing-remitting Multiple Sclerosis	Drug: BAF312;Drug: Placebo	Novartis Pharmaceuticals		Not recruiting	18 Years	55 Years	All	296	Phase 2	United States;Canada;Finland;Germany;Hungary;Italy;Norway;Poland;Russian Federation;Spain;Switzerland;Turkey
965	NCT02021825	March 2009	19 February 2015	Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders	Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders	Neuromyelitis Optica;Neuromyelitis Optica Spectrum Disorders	Drug: Mitoxantrone	Xuanwu Hospital, Beijing		Recruiting	18 Years	55 Years	Both	50	Phase 4	China
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
966	NCT00837785	February 28, 2009	26 February 2018	A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS	A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: BG00012	Biogen		Not recruiting	18 Years	55 Years	All	48	Phase 1	Germany;United Kingdom
967	EUCTR2008-000256-26-GB	16/02/2009	30 June 2014	An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonß-1a (IFNß-1a, Rebif®) therapy in the induction of tolerance to IFNß in MS patients with neutralising antibodies (NAbs) to subcutaneous IFNß-1a (Rebif® or Avonex®) - Tolerance induction with intravenous IFNß-1a	An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonß-1a (IFNß-1a, Rebif®) therapy in the induction of tolerance to IFNß in MS patients with neutralising antibodies (NAbs) to subcutaneous IFNß-1a (Rebif® or Avonex®) - Tolerance induction with intravenous IFNß-1a	Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: Mitoxantrone Product Name: Mitoxantrone Product Code: PL 04515/0127 Pharmaceutical Form: Concentrate for solution for infusion Trade Name: Rebif® Pharmaceutical Form: Solution for injection INN or Proposed INN: Mitoxantrone CAS Number: 70476-82-3 Concentration unit: 1X 100 milligrams/millilitre Concentration type: up to	Queen Mary, University of London		Not Recruiting			Female: yes Male: yes	15	Phase 2a	United Kingdom
968	EUCTR2008-005304-93-GB	13/02/2009	19 March 2012	A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis - Zoledronate in multiple sclerosis	A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis - Zoledronate in multiple sclerosis	Bone loss in patients with Multiple Sclerosis (MS) who require large short term doses of methylprednisolone for exacerbations of their disease. MedDRA version: 9.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse MedDRA version: 9.1 Level: LLT Classification code 10065687 Term: Bone loss	Trade Name: Aclasta 5mg solution for infusion Product Name: Aclasta Product Code: ZOL446H Pharmaceutical Form: Solution for infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	North Bristol Trust		Not Recruiting			Female: yes Male: yes			United Kingdom
969	EUCTR2008-005906-38-FR	09/02/2009	19 March 2012	Détermination de biomarqueurs associés à la réponse au Natalizumab dans la Sclérose en plaques	Détermination de biomarqueurs associés à la réponse au Natalizumab dans la Sclérose en plaques	sclérose en plaques MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: Tysabri Product Name: Tysabri Pharmaceutical Form: Solution for injection	CHU de Toulouse		Authorised			Female: yes Male: yes	300		France
970	EUCTR2007-002627-32-CZ	04/02/2009	6 January 2015	efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis	A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg fingolimod administered orally once daily versus placebo in patients with primary progressive multiple sclerosis.	Primary progressive multiple sclerosis. MedDRA version: 17.1 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359- 56-0 Current Sponsor code: FTY720D Other descriptive name: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	970		Finland;Spain;Ireland;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hungary;Czech Republic;Canada;Poland;Belgium;Australia;Denmark;South Africa;Netherlands;Germany;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
971	NCT03408093	February 3, 2009	2 July 2018	Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b	Cross-sectional Retrospective Study of Therapeutic Compliance in Patients With Multiple Sclerosis Treated With Interferon Beta-1b	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	100 Years	All	120	Phase 1/Phase 2
972	NCT00836719	February 2009	19 October 2017	Safety of Polyphenon E in Multiple Sclerosis Pilot Study	Safety and Neuroprotective Effects of Polyphenon E in Multiple Sclerosis	Multiple Sclerosis	Drug: Polyphenon E	Louisiana State University Health Sciences Center in New Orleans	National Center for Complementary and Integrative Health (NCCIH)	Not recruiting	18 Years	65 Years	All	10	Phase 1	United States
973	EUCTR2008-001999-67-ES	30/01/2009	26 June 2012	Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de 14 semanas de tratamiento para evaluar la eficacia, seguridad y tolerabilidad de Nerispirdina 50 mg, 100 mg y 200 mg en pacientes con Esclerosis Múltiple ___________________________________________________________________ A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis	Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos y de 14 semanas de tratamiento para evaluar la eficacia, seguridad y tolerabilidad de Nerispirdina 50 mg, 100 mg y 200 mg en pacientes con Esclerosis Múltiple ___________________________________________________________________ A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis	Esclerosis Múltiple ______________ Multiple Sclerosis MedDRA version: 11.0 Level: LLT Classification code 10028245 Term:	Product Name: Nerispirdine hydrochloride Product Code: HP184 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Nerispirdine hydrochloride CAS Number: 119229-64-0 Current Sponsor code: HP184 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	sanofi-aventis Recherche & Développement		Authorised			Female: yes Male: yes	368		Finland;Germany;France;Spain
974	EUCTR2008-005559-46-CZ	23/01/2009	26 August 2013	An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis who have completed Treatment in the study 205MS201 (SELECT)	A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT) - SELECTION	Relapsing-remitting Multiple Sclerosis MedDRA version: 14.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: DACLIZUMAB HYP Product Code: BIIB019 Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab with Greek suufix Current Sponsor code: BIIB019 Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: DACLIZUMAB HYP Product Code: BIIB019 Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab with Greek suufix Current Sponsor code: BIIB019 Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	Biogen Idec Ltd.		Not Recruiting			Female: yes Male: yes	600		Hungary;Czech Republic;Poland;Ukraine;Russian Federation;Germany;United Kingdom;India
975	EUCTR2008-004753-14-BE	22/01/2009	30 April 2018	Long-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple Sclerosis	A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis - ENDORSE	Relapsing-Remitting Multiple Sclerosis MedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BG00012 Product Code: BG00012 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Dimethyl Fumarate CAS Number: 624497 Current Sponsor code: BG00012 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120-	Biogen Idec Limited		Authorised			Female: yes Male: yes	1738	Phase 3	Serbia;Belarus;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Ireland;Israel;Switzerland;Italy;India;France;Macedonia, the former Yugoslav Republic of;Australia;South Africa;Netherlands;Latvia;Moldova, Republic of;Bosnia and Herzegovina;Guatemala;Austria;United Kingdom;Czech Republic;Mexico;Canada;Poland;Belgium;Romania;Croatia;Bulgaria;Germany;New Zealand
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
976	EUCTR2008-003098-42-CZ	06/01/2009	19 March 2012	A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis	A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis	To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: AVONEX Pharmaceutical Form: Solution for injection INN or Proposed INN: interferon beta 1a Concentration unit: µg/ml microgram(s)/millilitre Concentration type: not less then Concentration number: 30-	Biogen Idec Ltd		Authorised			Female: yes Male: yes	150		Czech Republic
977	EUCTR2007-004223-38-GB	05/01/2009	12 June 2012	A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients	A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients - Ofatumumab dose-finding in RRMS patients	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 13.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Product Name: Ofatumumab Product Code: HuMax-CD20 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ofatumumab CAS Number: 679818-59-8 Current Sponsor code: HuMax-CD20 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use	GlaxoSmithKline UK		Authorised			Female: yes Male: yes	57		Germany;Czech Republic;United Kingdom;Denmark;Sweden
978	NCT00666887	January 2009	16 December 2017	Minocycline in Clinically Isolated Syndromes (CIS)	A Phase III Double-blind, Randomized, Placebo-controlled Trial of Minocycline in Clinically Isolated Syndromes (CIS) and Early Single Relapse Multiple Sclerosis (MS)	Clinically Isolated Syndromes;Early Single Relapse of Multiple Sclerosis	Drug: Minocycline;Drug: Placebo	Dr. Luanne Metz	Multiple Sclerosis Society of Canada	Not recruiting	18 Years	60 Years	All	142	Phase 3	Canada
979	NCT00828204	January 2009	19 October 2017	Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects	An Open-Label, Multicenter Study to Evaluate the Safe and Effective Use of the Single-Use Autoinjector With an Avonex® Prefilled Syringe in Multiple Sclerosis Subjects	Multiple Sclerosis	Device: single-use autoinjector with a prefilled liquid Avonex syringe;Device: Avonex prefilled syringe via manual IM injection;Drug: BG9418 (interferon beta-1a)	Biogen		Not recruiting	18 Years	65 Years	All	95	Phase 3	United States
980	NCT00841321	January 2009	19 October 2017	Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis	Ginkgo Biloba for Cognitive Impairment in Multiple Sclerosis	Multiple Sclerosis;Cognitive Ability, General	Drug: Ginkgo biloba;Drug: Placebo	VA Office of Research and Development		Not recruiting	18 Years	65 Years	All	120	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
981	NCT01031199	January 2009	19 February 2015	Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers	Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 140 MBq (ca. 5 mSv) ZK 6032924 (BAY85-8101) for Its Diagnostic Potential in Either Drug-naïve or Specifically (IFN-beta) Pretreated Patients With Multiple Sclerosis (MS) With Acute Relapse or Patients With Clinically Isolated Syndrome (CIS), Compared to Healthy Volunteers	Positron-Emission Tomography;Multiple Sclerosis	Drug: F-18 FEDAA1106 (BAY85-8101)	Bayer		Not recruiting	20 Years	55 Years	Both	16	Phase 1	Australia;Sweden
982	EUCTR2009-014724-32-DE		3 April 2017	Boswellic Acids in Multiple Sclerosis	SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS): A MRI-CONTROLLED, MULTICENTER, BASELINE-TO-TREATMENT, 32-WEEKS, OPEN-LABEL, PHASE IIA TRIAL IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS OR CLINICALLY ISOLATED SYNDROME - SABA	Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: BOSWELAN Product Code: BOSWELAN Pharmaceutical Form: Capsule, soft INN or Proposed INN: BOSWELAN Current Sponsor code: BOSWELAN Other descriptive name: Boswellia serrata extract PS0201Bo capsules Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400-	University Medical Center Eppendorf		Not Recruiting			Female: yes Male: yes		Phase 2	Germany
983	EUCTR2009-016442-74-ES		29 April 2013	Trasplante autólogo de células madre mesenquimales en esclerosis múltiple: ensayo clínico fase II aleatorizado, enmascarado y cruzado con placebo.	Trasplante autólogo de células madre mesenquimales en esclerosis múltiple: ensayo clínico fase II aleatorizado, enmascarado y cruzado con placebo.	Esclerosis Múltiple MedDRA version: 9 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive	Product Name: Células madre mesenquimales Pharmaceutical Form: INN or Proposed INN: Células madre mesenquimales Current Sponsor code: CMM Concentration unit: EID50 50% Embryo Infective Dose Concentration type: up to Concentration number: 2000000- Route of administration of the placebo: Intravenous use	Fundació Clínic per a la Recerca Biomèdica		Authorised			Female: yes Male: yes			Spain
984	NCT00725985	December 31, 2008	16 December 2017	Oral Cladribine in Early Multiple Sclerosis (MS)	A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects With a First Clinical Event at High Risk of Converting to MS	Multiple Sclerosis	Drug: Cladribine;Drug: Placebo;Drug: Rebif® new formulation (RNF)	EMD Serono		Not recruiting	18 Years	55 Years	All	617	Phase 3	United States;Argentina;Austria;Belgium;Bosnia and Herzegovina;Bulgaria;Canada;Croatia;Czechia;Estonia;Finland;France;Georgia;Germany;India;Italy;Korea, Republic of;Lebanon;Macedonia, The Former Yugoslav Republic of;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;United Kingdom;Saudi Arabia
985	EUCTR2008-005125-11-GB	19/12/2008	19 March 2012	A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.	A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.	Primary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063401 Term: Primary progressive multiple sclerosis	Trade Name: Neorecormon Product Name: Recombinant Human Erythropoietin Product Code: rhEPO Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: epoetin beta CAS Number: 122312-54-3 Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 30000- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	Walton Centre for Neurology and Neurosurgery		Not Recruiting			Female: yes Male: yes			United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
986	EUCTR2007-004051-11-GB	18/12/2008	19 March 2012	Amiloride Treatment in Multiple Sclerosis - Amiloride in MS	Amiloride Treatment in Multiple Sclerosis - Amiloride in MS	Multiple Sclerosis	Trade Name: Amiloride Product Name: Amiloride Hydrochloride Pharmaceutical Form: Coated tablet	Oxford Racliffe NHS Trust		Not Recruiting			Female: yes Male: yes	23		United Kingdom
987	EUCTR2008-004954-34-CZ	12/12/2008	27 January 2014	Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)	Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of converting to MS, treated with Rebif® New Formulation (REFLEXION) - REFLEXION	Subjects of high risk of converting to Multiple Sclerosis or subjects already converted to Multiple Sclerosis. MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rebif INN or Proposed INN: Interferon-beta 1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Merck Serono S.A. - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany		Not Recruiting			Female: yes Male: yes	492		Serbia;Portugal;Estonia;Slovakia;Morocco;Greece;Spain;Lebanon;Russian Federation;Israel;Italy;France;Latvia;Finland;Turkey;Austria;Czech Republic;Canada;Argentina;Belgium;Poland;Romania;Croatia;Bulgaria;Germany
988	NCT00819000	December 2008	19 February 2015	Therapy Optimization in Multiple Sclerosis (MS)	TOP MS is a Study of Multiple Sclerosis Disease Management in Collaboration With Specialty Pharmacies	Multiple Sclerosis	Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b	Teva Neuroscience, Inc.		Not recruiting	18 Years	N/A	Both	2878	N/A	United States
989	NCT00819195	December 2008	19 February 2015	Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis	Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: Glatiramer acetate	University of California, San Francisco	National Multiple Sclerosis Society;Teva Neuroscience, Inc.	Not recruiting	18 Years	55 Years	Both	17	N/A	United States
990	EUCTR2007-007759-15-HU	10/11/2008	19 March 2012	The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmacokinetics in Subjects with the Secondary Progressive Form of Multiple Sclerosis A double-blind, placebo-controlled, randomized, multiple ascending dose (MAD) trial	The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmacokinetics in Subjects with the Secondary Progressive Form of Multiple Sclerosis A double-blind, placebo-controlled, randomized, multiple ascending dose (MAD) trial	Patients with current diagnosis of SP-MS MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis	Product Name: PI-2301 Product Code: CO-14 Pharmaceutical Form: Solution for injection CAS Number: 1026791-33-1 Current Sponsor code: PI-2301 Other descriptive name: CO-14 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	PEPTIMMUNE Inc		Not Recruiting			Female: yes Male: yes	53		Hungary
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
991	NCT00744679	November 2008	19 February 2015	A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State	An Assessment of the Steady-State Pharmacokinetic and Pharmacodynamic Profile of Tysabri 300 mg Following at Least 12 Monthly Infusions	Multiple Sclerosis	Drug: Natalizumab	Biogen Idec	Elan Pharmaceuticals	Not recruiting	18 Years	55 Years	Both	20	Phase 4	United States
992	NCT00771043	November 2008	19 February 2015	A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a	Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a	Relapsing-Remitting Multiple Sclerosis	Drug: TYSABRI and AVONEX	Biogen Idec		Not recruiting	18 Years	55 Years	Both	50	Phase 4	United States
993	EUCTR2008-004579-22-AT	14/10/2008	19 March 2012	A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam 5% in subjects with relapsing/remitting (RR) multiple sclerosis (MS)	A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam 5% in subjects with relapsing/remitting (RR) multiple sclerosis (MS)	Subjects with RR Multiple Sclerosis in whom intravenous immunoglobulin (IVIG) treatment is clinically indicated because first-line treatments are contraindicated or not tolerated.	Trade Name: Octagam 5% Product Name: Octagam 5% Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Immunoglobulin CAS Number: 9007-83-4 Concentration unit: % percent Concentration type: equal Concentration number: 5-	Octapharma AG		Not Recruiting			Female: yes Male: yes	30		Austria
994	NCT00755807	October 2008	19 October 2017	Duloxetine for Multiple Sclerosis Pain	Duloxetine in Patients With Central Neuropathic Pain Due to Multiple Sclerosis.	Multiple Sclerosis	Drug: Duloxetine Hydrochloride (HCI);Drug: Placebo	Eli Lilly and Company		Not recruiting	18 Years	N/A	All	239	Phase 3	United States;Belgium;Canada;Poland
995	NCT00784836	October 2008	19 October 2017	Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients	A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: BG9418 (interferon beta 1-a)	Biogen		Not recruiting	18 Years	60 Years	All	3	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
996	NCT01018485	October 2008	25 May 2015	The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor	Double-Blind, Randomized, Controlled, Cross-over Comparison of Efficacy and Safety of Botulinum Toxin Type A in the Targeted Treatment of Disabling Tremor in Multiple Sclerosis	Multiple Sclerosis;Tremor	Drug: Botulinum Toxin Type A	Melbourne Health	Eastern Health	Not recruiting	18 Years	80 Years	Both	30	Phase 3	Australia
997	NCT01080027	October 2008	19 February 2015	Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)	An International, Multi Centre, Prospective, Observational Study of Safety, Tolerability and Adherence of Patients With Relapsing Remitting Multiple Sclerosis Administered Interferon Beta-1a (Rebif® New Formulation) in Real Life Settings	Multiple Sclerosis, Relapsing Remitting	Drug: Rebif® New Formulation	Merck KGaA	Merck A.E., Greece;Merck OY, Finland;Merck B.V., Netherlands;Merck A.B., Sweden;Merck, S.A., Portugal	Not recruiting	18 Years	60 Years	Both	254	N/A	Greece
998	EUCTR2008-002096-27-PL	10/09/2008	19 March 2012	A 24-month double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. - N/A	A 24-month double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. - N/A	Relapsing-remitting multiple sclerosis. MedDRA version: 13.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Product Name: Fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720D Other descriptive name: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Product Name: Fingolimod Product Code: FTY720D Pharmaceutical Form: Capsule, hard INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720D Other descriptive name: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	1080		United Kingdom;Austria;Poland;Lithuania
999	EUCTR2008-002560-34-BE	02/09/2008	19 March 2012	A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis - HMFR	A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis - HMFR	Central neuropathic pain due to Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10054095 Term: Neuropathic pain	Trade Name: Cymbalta Product Name: Duloxetine Product Code: LY248686 Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: DULOXETINE CAS Number: 116539594 Current Sponsor code: LY248686 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Gastro-resistant capsule, hard Route of administration of the placebo: Oral use	Eli Lilly and Company		Not Recruiting			Female: yes Male: yes	238		Belgium
1000	NCT00772525	September 2008	19 February 2015	Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis	A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis	Multiple Sclerosis;Optic Nerve;Neuritis	Drug: Nerispirdine (HP184);Drug: Placebo	Sanofi		Not recruiting	18 Years	N/A	Both	31	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1001	NCT01184833	September 2008	19 February 2015	Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis	Evaluation of Risk Factors for Premature Discontinuation of Injection Treatment With Betaferon in Patients With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	852	N/A	Poland
1002	NCT01074346	August 2008	19 February 2015	Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis	A Prospective, Multi-center, Observational Study to Assess the Tolerability of Interferon-beta 1-A (Rebif®) Therapy for Korean Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon-ß-1a	Merck KGaA		Not recruiting	N/A	N/A	Both	60	N/A	Korea, Republic of
1003	NCT00676715	July 31, 2008	7 October 2019	A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis	Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS	Multiple Sclerosis, Relapsing-Remitting	Drug: Placebo;Drug: Ocrelizumab;Drug: Avonex	Genentech, Inc.	Roche Pharma AG	Not recruiting	18 Years	55 Years	All	220	Phase 2	United States;Belgium;Bulgaria;Canada;Czechia;Denmark;Finland;France;Germany;Italy;Mexico;Netherlands;Romania;Russian Federation;Serbia;Slovakia;Spain;Switzerland;Ukraine;United Kingdom;Czech Republic
1004	EUCTR2007-003997-24-GB	08/07/2008	18 April 2012	Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiramer acetate in patients with multiple sclerosis with relapses	Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiramer acetate in patients with multiple sclerosis with relapses	Multiple Sclerosis MedDRA version: 12.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Product Name: Teriflunomide Product Code: HMR 1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Sanofi-Aventis recherche & développement		Not Recruiting			Female: yes Male: yes	240		United Kingdom;Spain;Italy;Austria
1005	JPRN-UMIN000002725	2008/07/01	2 April 2019	Efficacy of ramatroban in multiple sclerosis patients		Multiple sclerosis	Addition of ramatroban to conventional MS therapy	Iou hospital		Not Recruiting	Not applicable	Not applicable	Male and Female	5	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1006	NCT00645749	July 2008	25 February 2019	Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis	Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Biological: Helminth ova	University of Wisconsin, Madison	National Multiple Sclerosis Society	Not recruiting	18 Years	50 Years	All	17	Phase 1	United States
1007	NCT00674141	July 2008	19 February 2015	Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment	Nasal Administration of Dexamethasone for MS Treatment	MS Patient With Relpasing Remitting Attacks	Drug: Dexamethasone soduim phosphate	Hadassah Medical Organization		Not recruiting	18 Years	N/A	Both	10	Phase 1	Israel
1008	NCT00726648	July 2008	19 February 2015	CDP323 Biomarker Study	Double-blind, Placebo-controlled, Randomized, Parallel-group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability.	Relapsing Multiple Sclerosis	Drug: CDP323;Drug: Placebo	UCB Pharma	Biogen Idec	Not recruiting	18 Years	65 Years	Both	71	Phase 1/Phase 2	United Kingdom
1009	NCT00735007	July 2008	19 October 2017	12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.	International, Multicenter, Single-arm, Open-label, 12-week Phase IIIb Study to Evaluate RebiSmart™ Suitability for Self Injection of Rebif® New Formulation (RNF) in Multidose Cartridges in Patients With Relapsing Form of Multiple Sclerosis (RMS)	Multiple Sclerosis	Drug: Rebif® New Formulation (RNF) using RebiSmartTM	EMD Serono		Not recruiting	18 Years	65 Years	All	106	Phase 3	United States;Canada;Germany;Italy;Spain;Sweden
1010	EUCTR2007-001377-28-FR	11/06/2008	19 March 2012	Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL	Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™) - CLEAREST™-TRAIL	Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA, -- AND who have been treated with Raptiva (efalizumab) previously, -- AND who developed adverse events (AEs) corresponding to pre-specified newly diagnosed autoimmune disorders OR who developed severe thrombocytopenia. MedDRA version: 9.1 Level: LLT Classification code 10061664 Term: Autoimmune disorder MedDRA version: 9.1 Level: LLT Classification code 10025139 Term: Lupus erythematosus systemic MedDRA version: 9.1 Level: LLT Classification code 10047888 Term: Wegener's granulomatosis MedDRA version: 9.1 Level: LLT Classification code 10002817 Term: Antiphospholipid syndrome MedDRA version: 9.1 Level: LLT Classification code 10040767 Term: Sjogren's syndrome MedDRA version: 9.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease MedDRA version: 9.1 Level: LLT Classification code 10009900 Term: Colitis ulcerative MedDRA version: 9.1 Level: LLT Classification code 10003827 Term: Autoimmune hepatitis MedDRA version: 9.1 Level: LLT Classification code 10049046 Term: Autoimmune thyroiditis MedDRA version: 9.1 Level: LLT Classification code 10003822 Term: Autoimmune haemolytic anaemia NOS MedDRA version: 9.1 Level: LLT Classification code 10034697 Term: Pernicious anemia MedDRA version: 9.1 Level: LLT Classification code 10028417 Term: Myasthenia gravis MedDRA version: 9.1 Level: LLT Classification code 10018620 Term: Goodpasture's syndrome MedDRA version: 9.1 Level: LLT Classification code 10	Trade Name: Raptiva 100 mg/ml powder and solvent for solution for injection Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Efalizumab Other descriptive name: EFALIZUMAB Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100-	Merck Serono International S.A.		Authorised			Female: yes Male: yes	92	Phase 4	Portugal;Germany;Netherlands;France;Austria
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1011	NCT03577977	June 1, 2008	23 July 2018	Betaferon Use in Children and Adolescents With Multiple Sclerosis	Retrospective Data Collection on Betaferon Use in Children and Adolescents With Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)	Bayer		Not recruiting	N/A	18 Years	All	70	Phase 1	Russian Federation
1012	NCT00716066	June 2008	9 September 2019	Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases	High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases	Autoimmune Disease;Neurologic Autoimmune Disease;Autologous Transplant Autoimmune;Multiple Sclerosis Transplant;MS Stem Cell Transplant;Multiple Sclerosis Stem Cell Transplant;Stiff Person Syndrome;HCT for Neurologic Autoimmune Disorders;CIDP Transplant;Myasthenia Gravis Transplant	Biological: Anti-Thymocyte Globulin;Procedure: Autologous Hematopoietic Stem Cell Transplantation;Drug: Carmustine;Drug: Cytarabine;Drug: Etoposide;Other: Laboratory Biomarker Analysis;Drug: Melphalan;Procedure: Peripheral Blood Stem Cell Transplantation;Drug: Prednisone;Procedure: Syngeneic Bone Marrow Transplantation	Fred Hutchinson Cancer Research Center	National Cancer Institute (NCI)	Recruiting	N/A	70 Years	All	40	Phase 2	United States
1013	NCT00787657	June 2008	26 October 2015	Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment	Betaferon Prospective Study on Adherence, Coping and Nursing Support	Relapsing Remitting Multiple Sclerosis (RRMS)	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	12 Years	N/A	Both	1723	N/A	Argentina;Bahrain;Belgium;Bosnia and Herzegovina;Canada;China;Colombia;Czech Republic;Egypt;Estonia;France;Germany;Iran, Islamic Republic of;Israel;Italy;Jordan;Korea, Republic of;Kuwait;Lebanon;Libyan Arab Jamahiriya;Mexico;Netherlands;New Zealand;Norway;Pakistan;Portugal;Saudi Arabia;Singapore;Slovakia;Slovenia;Sweden;Syrian Arab Republic;Taiwan;United Arab Emirates;United Kingdom;Venezuela
1014	EUCTR2007-007394-22-GB	22/05/2008	19 March 2012	The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning	The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning	Multiple Sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive	Trade Name: Tysabri Product Name: Tysabri Pharmaceutical Form: Concentrate for solution for infusion	Imperial College London		Authorised			Female: yes Male: yes			United Kingdom
1015	EUCTR2007-000888-15-ES	19/05/2008	19 March 2012	ENSAYO CLÍNICO, MULTICÉNTRICO, CON ASIGNACIÓN ALEATORIA Y DOBLE CIEGO, PARA COMPARAR LA EFICACIA CLÍNICA Y RADIOLÓGICA DE DOSIS EQUIVALENTES DE METILPREDNISOLONA ADMINISTRADAS POR VÍA ORAL O VÍA INTRAVENOSA EN PACIENTES EN BROTE DE ESCLEROSIS MÚLTIPLE - Corticoterapia Oral en Megadosis para el Tratamiento del Brote de Esclerosis Múltiple	ENSAYO CLÍNICO, MULTICÉNTRICO, CON ASIGNACIÓN ALEATORIA Y DOBLE CIEGO, PARA COMPARAR LA EFICACIA CLÍNICA Y RADIOLÓGICA DE DOSIS EQUIVALENTES DE METILPREDNISOLONA ADMINISTRADAS POR VÍA ORAL O VÍA INTRAVENOSA EN PACIENTES EN BROTE DE ESCLEROSIS MÚLTIPLE - Corticoterapia Oral en Megadosis para el Tratamiento del Brote de Esclerosis Múltiple	Pacientes afectos de esclerosis múltiple MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: SOLU-MODERIN 1 g Pharmaceutical Form: Intravenous infusion INN or Proposed INN: METHYLPREDNISOLONE CAS Number: 83432 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous use Trade Name: URBASON 40 mg comprimidos Pharmaceutical Form: Tablet INN or Proposed INN: METHYLPREDNISOLONE CAS Number: 83432 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Servicio de Neurología		Authorised			Female: yes Male: yes			Spain
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1016	EUCTR2007-005362-12-FR	13/05/2008	19 March 2012	Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de l'IRM multimodale 3 tesla dans l'analyse des lésions de la SEP et leur progression. Etude longitudinale sur 3 ans. - USPIO-Mitox	Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de l'IRM multimodale 3 tesla dans l'analyse des lésions de la SEP et leur progression. Etude longitudinale sur 3 ans. - USPIO-Mitox	1. Multiple Sclerosis 2. Clinically isolated syndromes (at high risk to develop Multiple Sclerosis) MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive MedDRA version: 9.1 Level: LLT Classification code 10028246 Term: Multiple sclerosis aggravated MedDRA version: 9.1 Level: LLT Classification code 10028247 Term: Multiple sclerosis like syndrome MedDRA version: 9.1 Level: LLT Classification code 10028248 Term: Multiple sclerosis-like syndrome MedDRA version: 9.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse MedDRA version: 9.1 Level: LLT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063401 Term: Primary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10064137 Term: Progression of multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse MedDRA version: 9.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis	Product Code: SH U 555 C Pharmaceutical Form: Intravenous infusion Current Sponsor code: ZK 132 281 Concentration unit: mmol/ml millimole(s)/millilitre Concentration type: equal Concentration number: 0.5-	C.H.U. de RENNES		Authorised			Female: yes Male: yes			France
1017	EUCTR2007-005363-10-FR	13/05/2008	19 March 2012	Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de la RMN multimodale dans l'analyse des lésions de sclérose en plaques : étude longitudinale sur 3 ans d'une cohorte de 50 patients après un premier évènement (CIS patients) à haut risque de développer une sclérose en plaques. - USPIO-CIS	Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de la RMN multimodale dans l'analyse des lésions de sclérose en plaques : étude longitudinale sur 3 ans d'une cohorte de 50 patients après un premier évènement (CIS patients) à haut risque de développer une sclérose en plaques. - USPIO-CIS	1. Multiple Sclerosis 2. Clinically isolated syndromes (at high risk to develop Multiple Sclerosis) MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive MedDRA version: 9.1 Level: LLT Classification code 10028246 Term: Multiple sclerosis aggravated MedDRA version: 9.1 Level: LLT Classification code 10028247 Term: Multiple sclerosis like syndrome MedDRA version: 9.1 Level: LLT Classification code 10028248 Term: Multiple sclerosis-like syndrome MedDRA version: 9.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse MedDRA version: 9.1 Level: LLT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063401 Term: Primary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10064137 Term: Progression of multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10028245 Term: Multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse MedDRA version: 9.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10053395 Term: Progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis	Product Code: SH U 555 C Pharmaceutical Form: Intravenous infusion Current Sponsor code: ZK 132 281 Concentration unit: mmol/ml millimole(s)/millilitre Concentration type: equal Concentration number: 0.5-	C.H.U. de RENNES		Authorised			Female: yes Male: yes			France
1018	EUCTR2007-006338-32-FR	06/05/2008	18 September 2012	Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis	Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis	Relapsing remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: Ocrelizumab Product Code: RO4964913/F03 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: ocrelizumab Current Sponsor code: RO4964913/F03 Other descriptive name: RhuMab 2H7 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 30- Pharmaceutical form of the placebo: Concentrate for solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Avonex Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30-	Hoffman La Roche Ltd		Authorised			Female: yes Male: yes	200	Phase 2	Finland;Czech Republic;Germany;United Kingdom;Netherlands;Belgium;Denmark;Bulgaria;France;Spain;Italy
1019	NCT00640328	May 2008	16 December 2017	Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients	A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients	Multiple Sclerosis	Drug: Ofatumumab 100;Drug: Ofatumumab 300;Drug: Ofatumumab 700;Drug: Placebo	GlaxoSmithKline		Not recruiting	18 Years	55 Years	All	38	Phase 2	Belgium;Czech Republic;Denmark;Former Serbia and Montenegro;Germany;Poland;Serbia;Sweden;United Kingdom
1020	EUCTR2006-006299-39-NL	23/04/2008	19 March 2012	A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment	A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment	Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy and have neurological respiratory impairment. MedDRA version: 8.1 Level: LLT Classification code 10046543 Term: Urinary incontinence	Trade Name: BOTOX® Product Name: BOTOX® Product Code: 9060X Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Botulinum toxin type A CAS Number: 93384-43-1 Current Sponsor code: AGN 191622 Other descriptive name: Botulinum toxin type A Concentration type: equal Concentration number: vials of 100-Allergan units Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Intramuscular use	Allergan		Not Recruiting			Female: yes Male: yes	135		Netherlands;France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1021	EUCTR2008-001940-38-IT	22/04/2008	19 March 2012	Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function. - ND	Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function. - ND	patients affected by multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: ARICEPT Pharmaceutical Form: Coated tablet INN or Proposed INN: Donepezil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: ARICEPT Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Donepezil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5-	OSPEDALE S. RAFFAELE		Authorised			Female: yes Male: yes			Italy
1022	EUCTR2007-003086-40-FR	08/04/2008	19 March 2012	A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)	A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS)	aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis	Product Name: Pixantrone Product Code: BBR 2778 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Pixantrone CAS Number: 144675-97-8 Current Sponsor code: BBR 2778 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-	Fondation Charcot Stichting		Authorised			Female: yes Male: yes	20	Phase 1/2	France
1023	NCT00605215	April 2008	19 February 2015	BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon ß-1a (Avonex®)	A Multinational, Multicenter, Randomized, Parallel-group Study Performed in Subjects With RRMS to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and a Reference Arm of Interferon ß-1a (Avonex®) in a Rater-blinded Design.	Multiple Sclerosis	Drug: laquinimod;Drug: placebo;Drug: Interferon ß-1a (Avonex®)	Teva Pharmaceutical Industries		Not recruiting	18 Years	55 Years	Both	1331	Phase 3	United States;Bulgaria;Croatia;Czech Republic;Estonia;Georgia;Germany;Israel;Italy;Lithuania;Macedonia, The Former Yugoslav Republic of;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Ukraine;Latvia;Montenegro;Turkey
1024	NCT00642902	April 2008	19 October 2017	A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)	A Four-Arm Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study to Evaluate the Safety, Tolerability and Efficacy as Assessed by Frequent MRI Measures of 3 Doses of Atacicept Monotherapy in Subjects With Relapsing Multiple Sclerosis (RMS) Over a 36 Week Treatment Course	Relapsing Multiple Sclerosis	Drug: Atacicept;Drug: Placebo matched to atacicept	EMD Serono		Not recruiting	18 Years	60 Years	All	255	Phase 2	United States;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Lebanon;Lithuania;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Ukraine;United Kingdom
1025	NCT00670449	April 2008	19 October 2017	An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis	An Extension of the 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Fingolimod	Novartis	Mitsubishi Tanabe Pharma Corporation	Not recruiting	18 Years	60 Years	All	143	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1026	NCT01414816	April 2008	19 February 2015	Betaferon® Regulatory Post-Marketing Surveillance	Betaferon® Regulatory Post-Marketing Surveillance	Multiple Sclerosis;Clinically Isolated System	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	12 Years	N/A	Both	355	N/A	Korea, Republic of
1027	EUCTR2007-003936-50-ES	10/03/2008	12 June 2012	Estudio en fase II, multicéntrico, aleatorizado, a doble ciego, con cuatro brazos y controlado frente a placebo, para evaluar, mediante RM frecuentes, la seguridad, tolerabilidad y eficacia de tres dosis de monoterapia con atacicept en sujetos con esclerosis múltiple recidivante (EMR) durante un periodo de tratamiento de 36 semanas. A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMS	Estudio en fase II, multicéntrico, aleatorizado, a doble ciego, con cuatro brazos y controlado frente a placebo, para evaluar, mediante RM frecuentes, la seguridad, tolerabilidad y eficacia de tres dosis de monoterapia con atacicept en sujetos con esclerosis múltiple recidivante (EMR) durante un periodo de tratamiento de 36 semanas. A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMS	Esclerosis múltiple recidivante Relapsing multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: atacicept Pharmaceutical Form: Solution for injection INN or Proposed INN: atacicept Other descriptive name: TACI-Fc5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: range Concentration number: 25-150 Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Merck Serono International S.A.		Authorised			Female: yes Male: yes	332	Phase 2	United Kingdom;Czech Republic;Netherlands;France;Spain;Austria;Lithuania;Sweden
1028	EUCTR2007-002179-15-FR	04/03/2008	19 March 2012	Etude des effets de la méthylprednisolone à fortes doses sur les caractéritiques électrophysiologiques de la fatigabilité à l'effort au cours des poussées de sclérose en plaques - CORTICOFLASH	Etude des effets de la méthylprednisolone à fortes doses sur les caractéritiques électrophysiologiques de la fatigabilité à l'effort au cours des poussées de sclérose en plaques - CORTICOFLASH	Méthylprednisolone administrée aux patients et contrôles à la dose de 1g/j pendant 3 jours, comme prescrit habituellement dans le cadre de leur pathologie. MedDRA version: 8.1 Level: PT Classification code 10028245 Term: Multiple sclerosis	Trade Name: Methylprednisolone Product Name: Methylprednisolone Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Methylprednisolone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)		Authorised			Female: yes Male: yes			France
1029	NCT00429442	March 2008	19 February 2015	Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis	A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in Patients Treated With Copaxone for at Least 3 Months	Relapsing Remitting Multiple Sclerosis	Drug: Simvastatin;Drug: placebo	Anna Tsakiri	Sanofi	Not recruiting	18 Years	60 Years	Both	0	Phase 3	Denmark
1030	NCT00616733	March 2008	19 February 2015	12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients	An Open-label, Escalating-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral CS-0777, Administered for 12 Weeks, in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: CS-0777 tablets	Daiichi Sankyo Inc.		Not recruiting	18 Years	65 Years	Both	25	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1031	NCT00638196	March 2008	17 August 2015	Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS	Phase II Study of Linoleic Acid in Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Linoleic Acid/Oleic Acid	University of Rochester		Not recruiting	18 Years	70 Years	Both	9	Phase 1	United States
1032	EUCTR2008-000490-37-IT	26/02/2008	10 December 2012	Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study. - ND	Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study. - ND	multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028053 Term: MS	Trade Name: EBIXA Pharmaceutical Form: Oral drops, solution INN or Proposed INN: Memantine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Oral drops, solution Route of administration of the placebo: Oral use	OSPEDALE S. RAFFAELE		Not Recruiting			Female: yes Male: yes			Italy
1033	EUCTR2005-002305-23-GB	05/02/2008	19 March 2012	A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3. - SM3	A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3. - SM3	Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: MabCampath ® Product Name: Alemtuzumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: Alemtuzumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-	R&D Addenbrookes Hospital		Authorised			Female: yes Male: yes			United Kingdom
1034	NCT00391352	February 2008	19 February 2015	fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls	A Phase 4, fMRI Study of Treatment Recommendations Comparing Patients Taking IFN-ß-1a 44 mcg Tiw SC (Rebif®) to Controls of Patients Recently Diagnosed With Relapsing Remitting Multiple Sclerosis Currently Naive to Disease-Modifying Therapy.	Relapsing-Remitting Multiple Sclerosis	Drug: IFN-ß-1a (Rebif®)	Waukesha Memorial Hospital	The Cleveland Clinic	Not recruiting	18 Years	65 Years	Both	21	Phase 4	United States
1035	NCT00630383	February 2008	19 February 2015	Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.	Immunoregulation by Controlled Parasite Exposure in Multiple Sclerosis.	Multiple Sclerosis	Biological: Live Hookworm Larvae;Other: Histamine	University of Nottingham		Not recruiting	18 Years	60 Years	Both	0	Phase 2	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1036	EUCTR2007-004122-24-SE	23/01/2008	16 October 2012	An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis.	An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis.	Relapsing-remitting multiple sclerosis. MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Pharmaceutical Form: Capsule* INN or Proposed INN: fingolimod hydrochloride CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-	Novartis Pharma AG		Not Recruiting			Female: yes Male: yes	1250		Estonia;Slovakia;Greece;Finland;Ireland;United Kingdom;France;Czech Republic;Hungary;Belgium;Netherlands;Germany;Sweden
1037	EUCTR2007-006268-32-IT	23/01/2008	19 March 2012	EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY IN INFLAMMATORY AND DEMIELINIZZATING DISEASE OF CENTRAL NERVOUS SYSTEM. - ND	EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY IN INFLAMMATORY AND DEMIELINIZZATING DISEASE OF CENTRAL NERVOUS SYSTEM. - ND	multiple sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive	Trade Name: xeomin Pharmaceutical Form: Solution for injection INN or Proposed INN: xeomin Concentration unit: U unit(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use	OSPEDALE S. RAFFAELE		Authorised			Female: yes Male: yes			Italy
1038	EUCTR2006-006872-39-GB	04/01/2008	19 March 2012	A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis - AIMSPRO in MS bladder function	A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis - AIMSPRO in MS bladder function	Overactive Bladder in Secondary Progressive Multiple Sclerosis and the other neurological symptoms associated with Secondary Progressive Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10059617 Term: Overactive bladder MedDRA version: 9.1 Level: LLT Classification code 10012547 Term: Detrusor hyperreflexia	Product Name: AIMSPRO Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Daval International Limited		Authorised			Female: yes Male: yes			United Kingdom
1039	NCT00464958	January 2008	19 February 2015	One Year Extension Study To Protocol C2/5/TZ:MS-05	Long Term Clinical Efficacy and Safety of Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in Patients With Multiple Sclerosis - Open Label Extension Study	Spasticity;Multiple Sclerosis	Drug: sublingual tizanidine 12 mg	Teva GTC		Not recruiting	20 Years	65 Years	Both	10	Phase 1/Phase 2	Israel
1040	NCT00536120	January 2008	19 October 2017	The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis	A Randomized, Open-Label Study to Assess the Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Biological: BG00002 (natalizumab);Biological: keyhole limpet hemocyanin (KLH);Biological: tetanus diphtheria toxoid vaccine (Td)	Biogen		Not recruiting	18 Years	60 Years	All	60	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1041	NCT00612872	January 2008	15 April 2019	Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects	Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy Subjects	Parkinson Disease;Alzheimer Disease;Healthy Controls;Multiple Sclerosis	Drug: [123I]CLINDE	Institute for Neurodegenerative Disorders		Not recruiting	30 Years	50 Years	All	46	Phase 1	United States
1042	NCT00681538	January 2008	19 October 2017	A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)	A Two-phase, Phase 3 Study of the Safety and Efficacy of Sativex, in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis: Phase A - Single-blind Response Assessment; Phase B - Double-blind, Randomised, Placebo Controlled, Parallel Group Study.	Spasticity;Multiple Sclerosis	Drug: Sativex®;Drug: Placebo	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	572	Phase 3	United Kingdom
1043	NCT00785473	January 2008	19 February 2015	Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple Sclerosis	Can Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre Study	Multiple Sclerosis, Osteoporosis	Dietary Supplement: cholecalciferol;Dietary Supplement: calcium carbonate	University Hospital of North Norway		Not recruiting	18 Years	50 Years	Both	80	Phase 4	Norway
1044	NCT00938366	January 2008	19 October 2017	Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects	An Open-label, Cross Over Study, to Assess the Interactions of Pantoprazole (Proton Pump Inhibitor) With Oral Cladribine Administered in Subjects With Multiple Sclerosis	Multiple Sclerosis	Drug: Cladribine;Drug: Pantoprazole	Merck KGaA	Merck Serono S.A., Geneva	Not recruiting	18 Years	65 Years	All	18	Phase 1
1045	EUCTR2008-000499-25-DE		26 June 2012	International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in multidose cartridges in patients with relapsing form of multiple sclerosis (RMS) - RebiSmartTM in RMS	International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in multidose cartridges in patients with relapsing form of multiple sclerosis (RMS) - RebiSmartTM in RMS	Relapsing forms of Multiple Sclerosis (RMS) MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: Rebif New Formulation 44mcg multidose cartridge Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A CAS Number: NA Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 88-	Merck Serono International S.A.		Not Recruiting			Female: yes Male: yes	100	Phase 3b	Germany;Spain;Italy;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1046	EUCTR2008-005213-22-DE		11 April 2016	SUPREMES - Sunphenon in progressive forms of multiple sclerosis	SUPREMES - Sunphenon in progressive forms of multiple sclerosis - SUPREMES	primary and secondary progressive forms of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Sunphenon Pharmaceutical Form: Capsule, hard Other descriptive name: Sunphenon EGCg Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Charite Universitätsmedizin Berlin		Not Recruiting			Female: yes Male: yes			Germany
1047	EUCTR2008-005773-35-IT		2 October 2017	AUTOLOUGUS STEM CELLS TRANSPLANTATION AFTER LINFOCYTE DEPLETION AS A NEW THERAPY FOR THE AGGRESSIVE AND DRUG RESISTANT FORMS OF MULTIPLE SLEROSIS IN THE ADULTS AND CHILDREN. - AUTOLOUGUS STEM CELLS TRANSPLANTATION IN SM	AUTOLOUGUS STEM CELLS TRANSPLANTATION AFTER LINFOCYTE DEPLETION AS A NEW THERAPY FOR THE AGGRESSIVE AND DRUG RESISTANT FORMS OF MULTIPLE SLEROSIS IN THE ADULTS AND CHILDREN. - AUTOLOUGUS STEM CELLS TRANSPLANTATION IN SM	MULTIPLE SCLEROSIS MedDRA version: 15.1 Level: LLT Classification code 10028053 Term: MS System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: ENDOXAN BAXTER Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Cyclophosphamide Concentration unit: mg/kg milligram(s)/kilogram Concentration number: 40- Trade Name: FLUDARA Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Fludarabine Concentration unit: mg/m2 milligram(s)/square meter Concentration number: 30- Trade Name: THYMOGLOBULINE Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Antithymocyte immunoglobulin (rabbit) Concentration unit: mg/kg milligram(s)/kilogram Concentration number: 2.5- Trade Name: MABTHERA Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab Concentration unit: mg/m2 milligram(s)/square meter Concentration number: 375.5-	AZIENDA OSPEDALIERA DI PADOVA		Not Available			Female: yes Male: yes		Phase 1	Italy
1048	EUCTR2008-007015-32-DE		11 March 2013	A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multiple sclerosis, followed by a 1-year open-label treatment phase	A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multiple sclerosis, followed by a 1-year open-label treatment phase	cognitive impairment in Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: Exelon transdermales Pflaster Product Name: Exelon Product Code: ENA713 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rivastigmin CAS Number: 123441-03-2 Current Sponsor code: ENA713 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Exelon transdermales Pflaster Product Name: Exelon Product Code: ENA713 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rivastigmin CAS Number: 123441-03-2 Current Sponsor code: ENA713 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: Exelon transdermales Pflaster Product Name: Exelon Product Code: ENA713 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rivastigmin CAS Number: 123441-03-2 Current Sponsor code: ENA713 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 9- Trade Name: Exelon transdermales Pflaster Product Name: Exelon Product Code: ENA713 Pharmaceutical Form: Transdermal patch INN or Proposed INN: Rivastigmin CAS Number: 123441-03-2 Current Sponsor code: ENA713 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18-	Novartis Pharma GmbH		Not Recruiting			Female: yes Male: yes			Germany
1049	EUCTR2008-008719-25-DE		1 May 2012	A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosis	A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determining the dose response curve of BAF312 given orally once daily in patients with relapsing-remitting multiple sclerosis	Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Code: BAF312 Pharmaceutical Form: Film-coated tablet Current Sponsor code: BAF312 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: BAF312 Pharmaceutical Form: Film-coated tablet Current Sponsor code: BAF312 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: BAF312 Pharmaceutical Form: Film-coated tablet Current Sponsor code: BAF312 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: BAF312 Pharmaceutical Form: Film-coated tablet Current Sponsor code: BAF312 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: BAF312 Product Code: BAF312 Pharmaceutical Form: Film-coated tablet Current Sponsor code: BAF312 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	275	Phase 2	Hungary;Finland;Germany;Spain;Italy
1050	EUCTR2007-001162-32-GB	24/12/2007	26 June 2012	A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy - CARE MS-II	A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy - CARE MS-II	Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: MabCampath ® Product Name: Alemtuzumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: Alemtuzumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-	Genzyme Corporation		Authorised			Female: yes Male: yes	573	Phase 3	Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Italy;Poland;Austria;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1051	EUCTR2007-000586-38-IT	21/12/2007	23 September 2013	HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS - ND	HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS - ND	PATIENTS AFFECTED BY MULTIPLE SCLEROSIS MedDRA version: 6.1 Level: HLT Classification code 10052785	Trade Name: THIOPLEX Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Thiotepa Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: ENDOXAN BAXTER Pharmaceutical Form: Tablet INN or Proposed INN: Cyclophosphamide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: NEUPOGEN Pharmaceutical Form: Solution for injection INN or Proposed INN: Filgrastim Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 5-	OSPEDALE S. RAFFAELE		Not Recruiting			Female: yes Male: yes			Italy
1052	EUCTR2007-005414-40-IT	21/12/2007	3 April 2012	Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study - ND	Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study - ND	Patients with an established and stable Multiple Sclerosis (according to Poser criteria). MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: KEPPRA Pharmaceutical Form: Coated tablet INN or Proposed INN: Levetiracetam Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500-	AZIENDA SANITARIA N. 3 GENOVESE		Authorised			Female: yes Male: yes			Italy
1053	EUCTR2007-001958-99-FI	18/12/2007	19 March 2012	Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS	Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS	Patients with relapsing remitting MS according to the revised Mc Donald's criteria who meet all criteria for inclusion and none criteria of exclusion. MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: Dekristol 20000 IE Product Name: Dekristol Pharmaceutical Form: Capsule* INN or Proposed INN: INN COLECALCIFEROL Product Name: Placebo Dekristol SGC 20000 Pharmaceutical Form: Capsule*	Merja Soilu Häninen		Not Recruiting			Female: yes Male: yes			Finland
1054	EUCTR2007-001962-34-DE	12/12/2007	1 February 2016	Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie - MIMIK	Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie - MIMIK	secondary progressive multiple sclerosis	Trade Name: Ralenova Pharmaceutical Form: Solution for injection INN or Proposed INN: mitoxantrone Current Sponsor code: Mitox Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Intravenous infusion Route of administration of the placebo: Intravenous drip use (Noncurrent)	University Medical Center Hamburg Eppendorf		Not Recruiting			Female: yes Male: yes	5		Germany
1055	NCT00573443	December 2007	16 December 2017	Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS	A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)	Pseudobulbar Affect (PBA)	Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Drug: Placebo	Avanir Pharmaceuticals	INC Research	Not recruiting	18 Years	80 Years	All	326	Phase 3	United States;Argentina;Brazil
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1056	NCT00623415	December 2007	11 June 2018	Flupirtine as Oral Treatment in Multiple Sclerosis	Multicentric, Prospective, Double Blind, Randomized/Stratified, Placebo-controlled Pilot-study for Evaluation of Safety and Efficacy of Flupirtine add-on to Interferon-ß1b on Neurodegeneration in Patients With Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: Flupirtine;Drug: Placebo	Charite University, Berlin, Germany	Bayer	Not recruiting	18 Years	60 Years	All	30	Phase 2	Germany
1057	EUCTR2007-000381-20-FI	16/11/2007	25 September 2012	CLARITY Extension Study	A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY). - CLARITY EXTENSION	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 13.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders	Product Name: cladribine Product Code: Not Applicable Pharmaceutical Form: Tablet INN or Proposed INN: CLADRIBINE CAS Number: 4291638 Current Sponsor code: EMD280922 Other descriptive name: 2-chloro-2’-deoxyadenosine (2-CdA) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Merck Serono S.A. - Geneva		Not Recruiting			Female: yes Male: yes	1100	Phase 3b	Germany;Bulgaria;France;Austria;Australia;Brazil;Czech Republic;Serbia;Canada;Belgium;United States;Croatia;Greece;Poland;Portugal;Turkey;Switzerland;Netherlands;Italy;Morocco;Latvia;Lithuania;Finland;United Kingdom;Russian Federation;Ukraine;Saudi Arabia;Denmark;Estonia;Lebanon
1058	NCT00595920	November 2007	19 October 2017	Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis	An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Subcutaneous Tovaxin in Subjects Previously Treated in the TERMS Study 2005-00	Multiple Sclerosis, Relapsing-Remitting;Clinically Isolated Syndrome	Biological: Tovaxin	Opexa Therapeutics, Inc.		Not recruiting	N/A	N/A	All	116	Phase 2	United States
1059	NCT00688948	November 2007	19 February 2015	Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)	A Pilot Study Looking At The Use Of Alfuzosin In The Treatment Of Bladder Dysfunction In Patients With Multiple Sclerosis	Multiple Sclerosis;Bladder Dysfunction	Drug: Alfuzosin	Capital District Health Authority, Canada	Sanofi	Not recruiting	18 Years	N/A	Both	20	Phase 2/Phase 3	Canada
1060	NCT00702468	November 2007	19 October 2017	Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis	A Placebo Controlled, Parallel Group, Randomised Withdrawal Study of Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Who Are Receiving Long-term Sativex®.	Spasticity;Multiple Sclerosis	Drug: Sativex;Drug: Placebo	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	36	Phase 3	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1061	NCT00937677	November 2007	19 February 2015	Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study	Effect of Natalizumab (Tysabri®) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study.	Multiple Sclerosis	Drug: Tysabri	University at Buffalo	Biogen Idec	Not recruiting	18 Years	65 Years	Both	85	N/A	United States
1062	EUCTR2008-007162-32-IT	30/10/2007	19 March 2012	ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS - RMaIDSM	ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS - RMaIDSM	Multiple Sclerosis MedDRA version: 9.1 Level: SOC Classification code 10029205 Term: Nervous system disorders	Trade Name: COPAXONE Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Trade Name: AVONEX Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: Munit million units Concentration type: equal Concentration number: 6-	ISTITUTO C. MONDINO		Authorised			Female: yes Male: yes			Italy
1063	EUCTR2006-001152-12-CZ	15/10/2007	20 February 2017	An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis plus a long-term extension period.	An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 mg once daily versus placebo in patients with a first clinical episode suggestive of multiple sclerosis plus a long-term extension period.	Multiple Sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	sanofi-aventis recherche & développement		Not Recruiting			Female: yes Male: yes	600	Phase 3	United States;Belarus;Estonia;Slovakia;Finland;Ukraine;Lithuania;Turkey;Austria;Chile;Russian Federation;United Kingdom;France;Hungary;Czech Republic;Mexico;Canada;Poland;Croatia;Romania;Denmark;Australia;Bulgaria;Germany
1064	NCT00104143	October 2007	5 September 2016	A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.	A Randomized, Double-blind, Placebo Controlled Dose-ranging Study to Determine the Effect on MRI Lesions and Safety of A4I Antagonist in Relapsing Multiple Sclerosis.	Multiple Sclerosis	Drug: A4I Antagonist	Hoffmann-La Roche		Not recruiting	18 Years	59 Years	Both	0	Phase 2	Bulgaria;Canada;Czech Republic;Germany;Poland;Russian Federation;Slovakia;Spain;United Kingdom;Finland;United States
1065	NCT00548405	October 2007	16 December 2017	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two	A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy	Multiple Sclerosis, Relapsing-Remitting	Biological: Alemtuzumab 12 mg;Biological: Alemtuzumab 24 mg;Biological: Interferon beta-1a	Genzyme, a Sanofi Company	Bayer	Not recruiting	18 Years	55 Years	All	840	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;France;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Ukraine;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1066	NCT00559702	October 2007	19 February 2015	Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)	A Randomized, Open-Label, Dose-Ranging Study to Evaluate the Pharmacokinetics and Initial Safety of Subcutaneous and Intramuscular Natalizumab in Subjects With Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis	Drug: natalizumab;Other: standard of care	Biogen Idec	Elan Pharmaceuticals	Not recruiting	18 Years	65 Years	Both	76	Phase 1	United States
1067	NCT00873340	October 2007	19 February 2015	Physical Disability in Patients Treated With Betaferon	Physical Disability Observational Study in Patients Treated With Betaferon in Daily Practice	Multiple Sclerosis	Drug: Interferon-1beta (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	83	N/A	Colombia
1068	EUCTR2006-001337-17-DE	25/09/2007	29 May 2012	Characterisation of multiple sclerosis pathology by “ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques [Charakterisierung der Multiple Sklerose Pathologie durch “ultra small particles of iron oxide (USPIO)” im Vergleich zu konventionellen und fortgeschrittenen MRT Techniken] - MS_USPIO_MPIP	Characterisation of multiple sclerosis pathology by “ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques [Charakterisierung der Multiple Sklerose Pathologie durch “ultra small particles of iron oxide (USPIO)” im Vergleich zu konventionellen und fortgeschrittenen MRT Techniken] - MS_USPIO_MPIP	Patients with Multiple Sclerosis (MS, N=90) and patients with a clinically isolated syndrome (ref. to as CIS in literature, i. e. not a clinically definite MS but a syndrome that may occur as first sign of MS early in the course, N=15) are planned to be investigated in the proposed clinical trial. MedDRA version: 8.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Product Name: ultra small particles of iron oxide (USPIO) Product Code: SH U 555 C Pharmaceutical Form: Solution for infusion INN or Proposed INN: SH U 555 C CAS Number: V08CB03 Current Sponsor code: USPIO Other descriptive name: Ultrasmall particles of iron oxide Concentration unit: mmol millimole(s) Concentration type: equal Concentration number: 0.5-	Max-Planck-Institute of Psychiatry		Authorised			Female: yes Male: yes			Germany
1069	EUCTR2007-001031-63-CZ	20/09/2007	12 December 2016	AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis.	AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis.	Spasticity associated with multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028335 Term: Muscle spasticity	Trade Name: Tolposan Product Code: AV605 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Tolperisone HC1 CAS Number: 728-88-1 Other descriptive name: Tolpersan Concentration unit: mg milligram(s) Concentration type: range Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Avigen Inc		Not Recruiting			Female: yes Male: yes	150	Phase 2	Czech Republic;Germany
1070	EUCTR2007-002138-13-GB	13/09/2007	19 March 2012	A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®).	A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®).	Symptoms of spasticity in multiple sclerosis.	Trade Name: Sativex Product Name: Sativex Product Code: GW-1000-02 Pharmaceutical Form: Oromucosal spray CAS Number: 1972-08-3 Other descriptive name: delta-9-tetrahydrocannabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 27- CAS Number: 13956-29-1 Other descriptive name: Cannabidiol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use	GW Pharma Ltd.		Not Recruiting			Female: yes Male: yes			United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1071	EUCTR2006-003037-32-LT	11/09/2007	19 March 2012	A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® New Formulation (IFN-beta-1a) in subjects with relapsing remitting multiple sclerosis. - IMPROVE (Investigating MRI Parameters with Rebif® imprOVEd formulation)	A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® New Formulation (IFN-beta-1a) in subjects with relapsing remitting multiple sclerosis. - IMPROVE (Investigating MRI Parameters with Rebif® imprOVEd formulation)	Relapsing remitting Multiple Sclerosis MedDRA version: 9.0 Level: PT Classification code 10063399	Trade Name: Rebif Product Name: Interferon beta-1a FBS-free/HSA-free, RNF Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon-beta 1a CAS Number: NA Current Sponsor code: Not applicable Other descriptive name: Not applicable Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Merck Serono International SA		Not Recruiting			Female: yes Male: yes	150	Phase 3b	Germany;Estonia;Spain;Italy;Lithuania
1072	EUCTR2006-006347-31-GB	06/09/2007	19 March 2012	A Phase II randomised placebo controlled clinical trial of Simvastatin in patients with secondary progressive multiple sclerosis	A Phase II randomised placebo controlled clinical trial of Simvastatin in patients with secondary progressive multiple sclerosis	Multiple Sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive	Product Name: Encapsulated Simvastatin tablets Product Code: MSTC-001 (MS-STAT) Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Imperial College London		Authorised			Female: yes Male: yes		Phase 2	United Kingdom
1073	EUCTR2007-003226-19-NL	05/09/2007	19 March 2012	Study Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS) - Allegro	Study Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS) - Allegro	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 9.1 Level: PT Classification code 10028245 Term: Multiple sclerosis	Product Name: Laquinimod Capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule* INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Teva Pharmaceutical Industries Ltd		Not Recruiting			Female: yes Male: yes	1419		Hungary;Portugal;Germany;Netherlands;Bulgaria;France;Italy;Latvia;Austria;Lithuania;Sweden;United Kingdom;Czech Republic;Estonia;Spain
1074	NCT00532532	September 2007	19 February 2015	Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis	AV650-018: A Two-Part (Double-Blind Followed by Open-Label), Placebo Controlled, Randomized Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AV650 (Tolperisone HCl) in Subjects With Spasticity Associated With Multiple Sclerosis	Muscle Spasticity	Drug: tolperisone HCl	Avigen		Not recruiting	18 Years	70 Years	Both	150	Phase 2	Czech Republic;Germany;Russian Federation;Serbia;Ukraine;Former Serbia and Montenegro
1075	NCT00537082	September 2007	19 October 2017	Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)	A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: FTY720;Drug: Placebo	Novartis	Mitsubishi Tanabe Pharma Corporation	Not recruiting	18 Years	60 Years	All	171	Phase 2	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1076	NCT00544037	September 2007	19 February 2015	BENEFIT Extension Study	Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	23 Years	50 Years	Both	283	N/A	Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Slovenia;Spain;Sweden;Switzerland;Portugal;United Kingdom
1077	NCT00638833	September 2007	19 February 2015	Memantine Therapy for Multiple Sclerosis	Pilot Clinical Trial With Memantine for Cognitive Deficits in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Memantine;Drug: Placebo	Clinica Universidad de Navarra, Universidad de Navarra	H. Lundbeck A/S	Not recruiting	18 Years	65 Years	Both	20	Phase 2	Spain
1078	NCT00937157	September 2007	19 October 2017	Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)	Comparison of Standard 1.5 Versus 3T Optimized Protocols in Patients Treated With Glatiramer Acetate. A Conventional and Non-conventional MRI Study	Multiple Sclerosis	Drug: Copaxone	University at Buffalo	Teva Neuroscience, Inc.	Not recruiting	18 Years	65 Years	All	12	N/A	United States
1079	NCT02523703	September 2007	24 August 2015	Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study		Multiple Sclerosis	Biological: glutamate and aspartate	University Hospital, Caen		Not recruiting	18 Years	60 Years	Both	36	N/A
1080	EUCTR2006-005910-11-CZ	29/08/2007	5 December 2016	A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study.	A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessment; Phase B - double blind, randomised, placebo controlled, parallel group study.	Spacticity in multiple sclerosis (MS)	Product Name: Sativex Product Code: GW-1000-02 Pharmaceutical Form: Oromucosal spray CAS Number: 1972-08-3 Other descriptive name: delta-9-tetrahydrocannabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 27- CAS Number: 13956-29-1 Other descriptive name: Cannabidiol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use	GW Pharma Ltd		Not Recruiting			Female: yes Male: yes	488	Phase 3	Czech Republic;Spain;Germany;Italy;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1081	EUCTR2007-001161-14-GB	24/08/2007	12 June 2012	A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris. - CARE MS-I	A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsing-Remitting Multiple Scleroris. - CARE MS-I	Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: MabCampath ® Product Name: Alemtuzumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: Alemtuzumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Rebif Pharmaceutical Form: Solution for injection INN or Proposed INN: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-	Genzyme Corporation		Not Recruiting			Female: yes Male: yes	525	Phase 3	Czech Republic;Germany;United Kingdom;France;Poland;Sweden
1082	EUCTR2007-001031-63-DE	15/08/2007	19 March 2012	AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis.	AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects with spasticity associated with multiple sclerosis.	Spasticity associated with multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028335 Term: Muscle spasticity	Trade Name: Tolposan Product Code: AV605 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Tolperisone HC1 CAS Number: 728-88-1 Other descriptive name: Tolpersan Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Avigen Inc		Not Recruiting			Female: yes Male: yes	150		Germany
1083	NCT00530348	August 2007	19 October 2017	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One	A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Biological: Alemtuzumab;Biological: Interferon beta-1a	Genzyme, a Sanofi Company	Bayer	Not recruiting	18 Years	50 Years	All	581	Phase 3	United States;Argentina;Australia;Brazil;Canada;Croatia;Czech Republic;France;Germany;Mexico;Poland;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;Former Serbia and Montenegro
1084	NCT00649792	August 2007	19 October 2017	Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial	Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial	Multiple Sclerosis	Drug: Fampridine-SR	Acorda Therapeutics		Not recruiting	18 Years	70 Years	All	214	Phase 3	United States;Canada
1085	NCT01235455	August 2007	19 February 2015	Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors	Portuguese BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis (MS) After Conversion to Betaferon by Using Elements of the BetaPlus Program	Relapsing Remitting Multiple Sclerosis (RRMS);Secondary Progressive Multiple Sclerosis (SPMS)	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	10	N/A	Portugal
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1086	EUCTR2006-004893-29-GB	25/07/2007	1 May 2012	A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis	A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis	Multiple sclerosis	Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Sanofi-aventis U.S. Inc.		Authorised			Female: yes Male: yes	120		Germany;United Kingdom;Italy;Austria
1087	EUCTR2007-000590-37-FR	17/07/2007	19 March 2012	Etude randomisée, en double aveugle, comparant l’efficacité et la tolérance de la méthylprednisolone administrée à forte dose par voie orale ou par voie intraveineuse dans le traitement des poussées de sclérose en plaques - COPOUSEP	Etude randomisée, en double aveugle, comparant l’efficacité et la tolérance de la méthylprednisolone administrée à forte dose par voie orale ou par voie intraveineuse dans le traitement des poussées de sclérose en plaques - COPOUSEP	Traitement des poussées de sclérose en plaques MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Product Name: METHYLPREDNISOLONE Pharmaceutical Form: Capsule* INN or Proposed INN: METHYLPREDNISOLONE CAS Number: 83432 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Trade Name: methylprednisolone Product Name: methylprednisolone Pharmaceutical Form: Powder for solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Trade Name: methylprednisolone Product Name: methylprednisolone Pharmaceutical Form: Powder for solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	CHU Rennes		Authorised			Female: yes Male: yes			France
1088	EUCTR2006-003697-10-BE	13/07/2007	21 August 2017	A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis - N/A	A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis - N/A	Relapsing-Remitting Multiple Sclerosis MedDRA version: 8.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: BG00012 Pharmaceutical Form: Capsule, hard CAS Number: 624497 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use Trade Name: Copaxone Product Name: Copaxone Pharmaceutical Form: Solution for injection CAS Number: 147245929 Other descriptive name: GLATIRAMER ACETATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Biogen Idec Ltd.		Not Recruiting			Female: yes Male: yes	1232	Phase 3	Estonia;Czech Republic;Greece;Spain;Belgium;Ireland;Bulgaria;Germany;Latvia
1089	EUCTR2004-000463-94-HU	03/07/2007	19 March 2012	A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).	A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).	Relapsing-remitting multiple sclerosis (R-R MS) MedDRA version: 5.1 Level: PT Classification code 10028245	Product Name: Glatiramer acetate 150mg enteric coated tablets Pharmaceutical Form: Coated tablet INN or Proposed INN: Glatiramer Acetate CAS Number: 147245-92-9 Current Sponsor code: COP-1 Other descriptive name: COP-1/Copolymer-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	TEVA Pharmaceutical Industries Ltd.		Not Recruiting			Female: yes Male: yes	25		Hungary;Italy
1090	NCT00467584	July 2007	19 October 2017	Aspirin for Treatment of Multiple Sclerosis-Related Fatigue	Aspirin for Treatment of Multiple Sclerosis-Related Fatigue	Multiple Sclerosis;Fatigue	Drug: High Dose Aspirin (1300 mg/day);Drug: Low Dose Aspirin (162 mg/day);Drug: Placebo	Mayo Clinic	National Multiple Sclerosis Society	Not recruiting	18 Years	65 Years	All	62	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1091	NCT00469378	July 2007	16 December 2017	Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis	An Open-label Study of Leukocyte Counts in the Cerebrospinal Fluid and Blood of Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment With Firategrast	Multiple Sclerosis	Drug: firategrast	GlaxoSmithKline		Not recruiting	18 Years	65 Years	All	46	Phase 2	Belgium;Czech Republic;Denmark;Norway;Sweden
1092	NCT00497952	July 2007	28 January 2019	Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis	Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis	Multiple Sclerosis	Biological: hematopoetic stem cell infusion	University of Louisville		Not recruiting	18 Years	55 Years	All	3	Phase 1/Phase 2	United States
1093	NCT00619307	July 2007	19 October 2017	Transition to Rebif New Formulation	A Randomized, Multicenter, Two-arm, Open-label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif® New Formulation From Rebif® (Interferon Beta-1a) With Ibuprofen When Necessary (PRN) or as Prophylaxis	Relapsing Multiple Sclerosis	Drug: Rebif New Formulation + prophylactic Ibuprofen;Drug: Rebif New Formulation + ibuprofen PRN	Merck KGaA		Not recruiting	18 Years	60 Years	All	117	Phase 3	France;Germany
1094	NCT01158183	July 2007	19 February 2015	Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis	Real-World Betaseron® Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon ß-1b (Betaseron®) Given Every Other Day for Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: BAY86-5046_Interferon-beta-1b	Bayer		Not recruiting	18 Years	65 Years	Both	226	N/A	United States
1095	EUCTR2004-002571-16-GB	29/06/2007	4 August 2015	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01	A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01	Secondary progressive multiple sclerosis MedDRA version: 8.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis	Product Name: MBP8298 Synthetic Peptide Product Code: MBP8298 Pharmaceutical Form: Powder for injection* INN or Proposed INN: Dirucotide acetate CAS Number: 781666-30-6 Current Sponsor code: MBP8298 Other descriptive name: MBP8298 Synthetic Peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	BioMS Technology Corp		Not Recruiting			Female: yes Male: yes	553		Estonia;Finland;Spain;Lithuania;Denmark;Latvia;Netherlands;United Kingdom;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1096	NCT00493298	June 29, 2007	30 September 2019	Tysabri Observational Program	TOP: Tysabri® Observational Program	Relapsing-Remitting Multiple Sclerosis	Drug: natalizumab	Biogen		Not recruiting	18 Years	65 Years	All	6620	Phase 4	Argentina;Australia;Belgium;Brazil;Canada;Czechia;Finland;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Portugal;Slovakia;Spain;United Kingdom;Czech Republic;Denmark;Switzerland
1097	EUCTR2006-006323-39-DE	19/06/2007	19 March 2012	Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS	Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MS	relapsing-remitting multiple sclerosis ICD classification: G35.1	Product Name: Sunphenon Pharmaceutical Form: Capsule, hard Other descriptive name: Sunphenon EGCg TM Concentration unit: mg milligram(s) Concentration number: 200- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Charité-Universitätsmedizin Berlin		Not Recruiting			Female: yes Male: yes	100		Germany
1098	EUCTR2006-005972-42-FR	12/06/2007	19 March 2012	A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF	A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interferon beta-1a) with ibuprofen pro re nata (PRN) or as prophylaxis. - Transition to RNF	Relapsing multiple sclerosis MedDRA version: 9.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Trade Name: NA Product Name: Interferon-beta 1a FBS-free/HSA-free, RNF Product Code: NA Pharmaceutical Form: Solution for injection	Merck Serono International SA		Authorised			Female: yes Male: yes	120	Phase 3b	Germany;France
1099	EUCTR2006-003134-14-DE	04/06/2007	19 March 2012	A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis	A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with interferon-beta in subjects with multiple sclerosis	Multiple sclerosis	Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Sanofi-aventis U.S. Inc.		Not Recruiting			Female: yes Male: yes	120		Germany;Spain;Italy
1100	NCT00468611	June 2007	19 February 2015	Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis	A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis	Multiple Sclerosis, Secondary Progressive	Drug: MBP8298	BioMS Technology Corp.		Not recruiting	18 Years	65 Years	Both	510	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1101	NCT00480181	June 2007	19 February 2015	Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis	A Comparative, Single Center, Randomized, Double-blinded, Parallel, Placebo-controlled Study to Evaluate the Efficacy of Nabilone (Cesamet) as Adjunctive Therapy to Gabapentin (Neurontin) in the Management of Neuropathic Pain (NPP) Symptoms in Subjects With Multiple Sclerosis (MS)	Neuropathic Pain;Multiple Sclerosis	Drug: nabilone;Other: placebo	University of Manitoba	Valeant Pharmaceuticals International, Inc.	Not recruiting	18 Years	65 Years	Both	50	Phase 4	Canada
1102	NCT00490906	June 2007	19 February 2015	Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis	Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis: A Pilot Study	Multiple Sclerosis;Low Bone Density	Drug: Copaxone;Drug: Interferon-beta 1a;Drug: Interferon-beta 1b	Nancy Hammond, MD	Kansas City Area Life Sciences Institute, Inc.	Not recruiting	18 Years	N/A	Female	60	N/A	United States
1103	NCT00574041	June 2007	19 February 2015	How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose	An Open-Label Study to Examine the Difference in Tolerability Associated With Titration Of Dose on Initiation of Avonex therapY (TODAY)	Relapsing Remitting Multiple Sclerosis	Drug: Interferon beta-1a	Biogen Idec		Not recruiting	18 Years	N/A	Both	19	Phase 4	Australia
1104	NCT00959218	June 2007	19 February 2015	Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis	Multi-centre, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Patients With Multiple Sclerosis Associated With Central Neuropathic Pain	Central Neuropathic Pain in Multiple Sclerosis	Drug: Dronabinol;Drug: Placebo	Bionorica Research GmbH		Not recruiting	18 Years	70 Years	Both	240	Phase 3	Germany
1105	EUCTR2006-005262-39-DE	30/05/2007	11 February 2013	Flupirtin as Oral Treatment in MS - FLORIMS	Flupirtin as Oral Treatment in MS - FLORIMS	Relapsing-remitting multiple sclerosis	Trade Name: Trancopal Dolo Product Name: Flupirtin Pharmaceutical Form: Capsule, hard INN or Proposed INN: Flupirtin CAS Number: 56995-20-1 Other descriptive name: Flupirtinmaleat Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Charité-Universitätsmedizin Berlin		Not Recruiting			Female: yes Male: yes			Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1106	EUCTR2006-007057-42-BE	29/05/2007	28 October 2013	An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast	An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast	relapsing forms of multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis	Product Name: firategrast (USAN approved name) Product Code: SB-683699 Pharmaceutical Form: Tablet CAS Number: 402567-16-2 Current Sponsor code: SB-683699 Other descriptive name: firategrast (USAN approved name) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	45		Czech Republic;Belgium;Denmark;Sweden
1107	EUCTR2007-000236-16-EE	28/05/2007	19 March 2012	A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the Pharmacokinetics and Pharmacodynamics of IPX056 in Subjects with Established Spasticity Resulting from Multiple Sclerosis	A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the Pharmacokinetics and Pharmacodynamics of IPX056 in Subjects with Established Spasticity Resulting from Multiple Sclerosis	Established Spasticity Resulting from Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10041416 Term: Spasticity	Product Code: IPX056-40 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Code: IPX056-35 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 35- Product Code: IPX056-30 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- Product Code: IPX056-20 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Code: IPX056-10 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: baclofen Product Name: baclofen Product Code: baclofen 20 mg Pharmaceutical Form: Capsule* INN or Proposed INN: BACLOFEN CAS Number: 1134470 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	IMPAX Laboratories, Inc.		Not Recruiting			Female: yes Male: yes	180		Estonia;Latvia
1108	EUCTR2006-005460-30-IT	22/05/2007	19 March 2012	POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiol in Multiple sclerosis - POPART`MUS	POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiol in Multiple sclerosis - POPART`MUS	Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: DEMESTRIL SEPTEM Pharmaceutical Form: Transdermal patch INN or Proposed INN: Estradiol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .075- Pharmaceutical form of the placebo: Transdermal patch Route of administration of the placebo: Transdermal use Trade Name: LUTENYL Pharmaceutical Form: Tablet INN or Proposed INN: Nomegestrol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	OSPEDALI CIVILI DI LIONE		Authorised			Female: yes Male: no	300		Italy
1109	NCT00461396	May 2007	19 February 2015	Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron	Open-Label, Multicenter, Observational, Phase IV Study to Evaluate the Adherence to Treatment With 250mcg (8MIU) IFNB-1b (Betaseron®) Given Subcutaneous Every Other Day Over a Period of up to 12 Months in Patients With a First Clinical Demyelinating Event Suggestive of Multiple Sclerosis and Patients With Onset of Relapsing-Remitting Multiple Sclerosis (RRMS) Within the Past 12 Months	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon-1beta (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	50 Years	Both	104	N/A	United States
1110	NCT00483652	May 2007	19 October 2017	Study of Fampridine-SR Tablets in Multiple Sclerosis Patients	Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Fampridine-SR;Drug: Placebo	Acorda Therapeutics		Not recruiting	18 Years	70 Years	All	240	Phase 3	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1111	NCT00928967	May 2007	19 October 2015	Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients	Prospective Multicenter, Non-interventional Study to Evaluate the Impact of the Introduction of Interferon Beta-1 b Treatment on Daily Life Activities in Patients at High Risk of Developing Multiple Sclerosis After a First Clinical Demyelinating Event or Having Received a Confirmed Diagnosis of RRMS	Multiple Sclerosis	Drug: Interferon beta-1b, (Betaseron BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	67	N/A	France
1112	EUCTR2008-000955-90-IT	24/04/2007	19 March 2012	Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac	Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients - renac	multiple sclerosis MedDRA version: 9.1 Level: HLT Classification code 10052785 Term: Multiple sclerosis acute and progressive	Product Name: n-acetylcysteine Pharmaceutical Form: Capsule, hard INN or Proposed INN: Acetylcysteine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 600- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	ISTITUTO C. MONDINO		Authorised			Female: yes Male: yes			Italy
1113	EUCTR2006-005270-47-FI	23/04/2007	1 May 2012	International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg or open-label Betaseron/Betaferon 250 µg and (Phase B) open-label Betaseron/Betaferon 500 µg version: final internal approved - Beyond Follow-up	International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg or open-label Betaseron/Betaferon 250 µg and (Phase B) open-label Betaseron/Betaferon 500 µg version: final internal approved - Beyond Follow-up	relapsing multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: Betaferon 250µg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1b CAS Number: L03 AB 08 Current Sponsor code: ZK 157046 Product Name: Betaferon 500µg Product Code: ZK 157046 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta-1b CAS Number: L03 AB 08 Current Sponsor code: ZK 157046	Schering AG		Authorised			Female: yes Male: yes	1880	Phase 3b	Hungary;Germany;Netherlands;France;Ireland;Italy;Latvia;Austria;Sweden;Finland;Slovenia;Spain;Greece
1114	NCT00548769	April 21, 2007	16 December 2017	Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients	An Open-label, Randomised, Four Period Crossover Study to Investigate the Relative Pharmacokinetic Profiles of Tablets From Three Batches of Firategrast With Different Surface Areas and Two Different Tablet Formulations Containing the Same Batch of Firategrast, Given as Single 900mg Doses to Male and Female Subjects With a Diagnosis of Multiple Sclerosis	Multiple Sclerosis	Drug: Formulation A;Drug: Formulation B;Drug: Formulation C;Drug: Formulation D	GlaxoSmithKline		Not recruiting	18 Years	65 Years	All	37	Phase 1	Czechia;Germany;Poland;Czech Republic
1115	NCT00468182	April 2007	25 May 2015	Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis	Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon-beta 1b (Betaseron)	Rutgers, The State University of New Jersey	Bayer	Not recruiting	18 Years	60 Years	Both	24	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1116	NCT00472797	April 2007	19 October 2017	Rebif New Formulation (RNF) Quality of Life (QOL) Study	A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From Rebif® (Interferon Beta-1a) to Rebif New Formulation (RNF)	Relapsing Multiple Sclerosis	Drug: Rebif New Formulation Non Titrated;Drug: Rebif New Formulation Titrated	EMD Serono		Not recruiting	18 Years	60 Years	All	232	Phase 3	United States
1117	EUCTR2006-002204-33-BE	02/03/2007	7 October 2014	Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks.	Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks.	Relapsing forms of multiple slerosis MedDRA version: 9.1 Level: LLT Classification code 10048393 Term: Multiple sclerosis relapse	Product Name: CDP323 Product Code: CDP323 Pharmaceutical Form: Capsule, hard CAS Number: 455264-30-9 Current Sponsor code: CDP323 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	UCB Pharma S.A.		Not Recruiting			Female: yes Male: yes	317	Phase 2	France;Hungary;Finland;Spain;Belgium;Netherlands;Germany;United Kingdom;Sweden
1118	EUCTR2006-003696-12-BE	02/03/2007	9 October 2012		A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis - N/A	Relapsing-Remitting Multiple Sclerosis MedDRA version: 8.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: BG00012 Pharmaceutical Form: Capsule, hard CAS Number: 624497 Other descriptive name: DIMETHYL FUMARATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Biogen Idec Ltd.		Not Recruiting			Female: yes Male: yes	1011		Czech Republic;Germany;United Kingdom;Netherlands;Belgium;Bulgaria;Italy;Greece;Austria;Sweden
1119	NCT00451204	March 2007	19 October 2017	A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)	A Combination Trial of Copaxone Plus Estriol in RRMS	Relapsing Remitting Multiple Sclerosis	Drug: Estriol;Drug: Placebo;Drug: Copaxone	University of California, Los Angeles	Washington University School of Medicine;University of Texas Southwestern Medical Center;Ohio State University;University of Medicine and Dentistry of New Jersey;University of Chicago;University of Utah;Johns Hopkins University;University of Kansas Medical Center;University of Minnesota, MN;Mayo Clinic;University of Colorado, Aurora;University of New Mexico;University of Pennsylvania;Dartmouth-Hitchcock Medical Center;National Multiple Sclerosis Society;National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)	Not recruiting	18 Years	50 Years	Female	158	Phase 2	United States;Canada
1120	NCT01111656	March 2007	19 February 2015	Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b	SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study (SWABIMS Follow Up-study)	Relapsing-remitting Multiple Sclerosis	Drug: Interferon beta-1b group;Drug: Interferon beta-1b/Atorvastatin group	University Hospital Inselspital, Berne	Viollier AG, Basel, Switzerland;PharmaPart GmbH, Thalwil, Switzerland	Not recruiting	18 Years	67 Years	Both	28	Phase 2	Switzerland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1121	EUCTR2006-003384-30-SK	26/02/2007	13 March 2017	A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis	A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis	Multiple Sclerosis	Product Name: NeuroVax 300ug/mL Dose for IM Injection Product Code: IR902 Pharmaceutical Form: Emulsion for injection Current Sponsor code: IR208 Other descriptive name: VB6S5 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: range Concentration number: 75-125 Current Sponsor code: IR401 Other descriptive name: VB13S1 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: range Concentration number: 75-125 Current Sponsor code: IR901 Other descriptive name: VB5S2 Concentration unit: µg/ml microgram(s)/millilitre Concentration type: range Concentration number: 75-125 Pharmaceutical form of the placebo: Emulsion for injection Route of administration of the placebo: Intramuscular use	The Immune Response Corporation		Not Recruiting			Female: yes Male: yes	200	Phase 2	Slovakia
1122	EUCTR2006-002856-14-DE	21/02/2007	16 September 2013	Randomised, placebo-controlled, three-arm parallel-group, double-blind, multicentre, national clinical phase II study to evaluate the efficacy, safety, and tolerability of intravenous 3 and 6 g/m² treosulfan given every 6 weeks in patients with secondary progressive and progressive relapsing multiple sclerosis.	Randomised, placebo-controlled, three-arm parallel-group, double-blind, multicentre, national clinical phase II study to evaluate the efficacy, safety, and tolerability of intravenous 3 and 6 g/m² treosulfan given every 6 weeks in patients with secondary progressive and progressive relapsing multiple sclerosis.	Secondary progressive or progressive relapsing multiple sclerosis with signs of disease activity in terms of inflammation MedDRA version: 8.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis	Trade Name: Ovastat 1000 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: TREOSULFAN CAS Number: 299752 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1000- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use Trade Name: Ovastat 5000 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: TREOSULFAN CAS Number: 299752 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5000- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use	medac Gesellschaft für klinische Spezialpräparate mbH		Not Recruiting			Female: yes Male: yes		Phase 2	Germany
1123	EUCTR2007-000503-15-IT	19/02/2007	19 March 2012	Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple Sclerosis	Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple Sclerosis	patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: EBIXA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Memantine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI		Authorised			Female: yes Male: yes			Italy
1124	NCT00501696	February 2007	19 February 2015	A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone	A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54)	Multiple Sclerosis	Drug: 4.5 mg Naltrexone;Drug: Naltrexone	University of California, San Francisco		Not recruiting	18 Years	86 Years	Both	80	Phase 3	United States
1125	NCT00870155	February 2007	19 February 2015	A Study for Patients With Multiple Sclerosis	An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Drug: dirucotide	Eli Lilly and Company	BioMS Technology Corp.	Not recruiting	18 Years	65 Years	Both	546	Phase 2/Phase 3	Canada;Denmark;Estonia;Finland;Germany;Latvia;Netherlands;Spain;Sweden;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1126	EUCTR2006-003361-14-GB	23/01/2007	24 July 2012		Long-term extension of the multinational, double-blind, placebo controlled study EFC6049 (HMR1726D/3001) to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple sclerosis with relapses -	Multiple sclerosis MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Product Name: teriflunomide Product Code: HMR1726D Pharmaceutical Form: Tablet INN or Proposed INN: teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726D Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14-	sanofi-aventis recherche & développement		Authorised			Female: yes Male: yes	1080		Portugal;Germany;Turkey;Switzerland;Netherlands;France;Norway;Italy;Austria;Sweden;Finland;Russian Federation;United Kingdom;Czech Republic;Ukraine;Canada;Denmark;Estonia;United States;Poland
1127	EUCTR2006-004736-79-SK	19/01/2007	13 March 2017	A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.	A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injections in patients with multiple sclerosis.	To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.	Product Name: ATL1102 Product Code: ATL1102 Pharmaceutical Form: Solution for injection Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Antisense Therapeutics Ltd.		Not Recruiting			Female: yes Male: yes	80	Phase 2	Czech Republic;Slovakia
1128	EUCTR2006-004255-38-AT	05/01/2007	20 May 2013	Multi-centre, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of the pain relieving effect of Dronabinol in patients with multiple sclerosis associated with central neuropathic pain	Multi-centre, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of the pain relieving effect of Dronabinol in patients with multiple sclerosis associated with central neuropathic pain	Patients with multiple sclerosis associated with central neuropathic pain MedDRA version: 16.0 Level: LLT Classification code 10054095 Term: Neuropathic pain System Organ Class: 100000004852	Product Name: dronabinol Product Code: cnp-MS-0601 Pharmaceutical Form: Oral solution INN or Proposed INN: dronabinol CAS Number: 1972-08-3 Current Sponsor code: cnp-MS-0601 Other descriptive name: (-)-trans-delta-9-Tetrahydrocannabinol Concentration unit: % percent Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use	Bionorica research GmbH		Not Recruiting			Female: yes Male: yes	240		Austria;Germany
1129	NCT00414453	January 2007	19 October 2017	Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis	Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis (TALENT-MS)	Neuropathic Pain;Chronic Pain;Multiple Sclerosis	Drug: Lidocaine patch 5%;Drug: Extended-release oxycodone;Drug: Placebo extended-release oxycodone pills;Drug: Placebo lidocaine patches	University of Rochester	Endo Pharmaceuticals	Not recruiting	18 Years	N/A	All	19	Phase 4	United States
1130	NCT00423527	January 2007	19 February 2015	Levetiracetam in Central Pain in Multiple Sclerosis(MS)	Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis	Multiple Sclerosis	Drug: levetiracetam	Odense University Hospital		Not recruiting	18 Years	N/A	Both	30	Phase 4	Denmark
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1131	NCT00424788	January 2007	19 February 2015	A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)	A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)	Relapsing Forms of Multiple Sclerosis	Procedure: Plasma exchange;Drug: natalizumab treatment	Biogen Idec		Not recruiting	18 Years	50 Years	Both	12	Phase 0	United States
1132	NCT00457730	January 2007	19 October 2017	A Study to Test the Use of Duloxetine for Pain in MS	A Randomized Placebo Controlled Trial of Duloxetine for Central Pain in Multiple Sclerosis	Multiple Sclerosis	Drug: Duloxetine;Drug: Placebo	Brown, Theodore R., M.D., MPH	Eli Lilly and Company	Not recruiting	18 Years	N/A	All	38	Phase 2/Phase 3	United States
1133	EUCTR2006-004318-42-NL	12/12/2006	19 March 2012	Influence on brain perfusion and metabolism through pharmacologic agents	Influence on brain perfusion and metabolism through pharmacologic agents	Multiple Sclerosis MedDRA version: 8.1 Level: PT Classification code 10028245 Term: Multiple sclerosis	Trade Name: Prepulsid Pharmaceutical Form: Tablet Trade Name: Spiropent Pharmaceutical Form: Tablet	Department of Neurology UMCG		Authorised			Female: yes Male: yes			Netherlands
1134	EUCTR2006-002361-39-DE	01/12/2006	19 March 2012	A 4-week, open-label, multicenter, urodynamic pilot study to explore the efficacy, tolerability and safety of darifenacin (7.5 mg with up-titration to 15 mg) in patients with multiple sclerosis and neurogenic detrusor overactivity	A 4-week, open-label, multicenter, urodynamic pilot study to explore the efficacy, tolerability and safety of darifenacin (7.5 mg with up-titration to 15 mg) in patients with multiple sclerosis and neurogenic detrusor overactivity	Neurogenic overactive bladder disaese in patients with multiple sclerosis MedDRA version: 8.1 Level: LLT Classification code 10059617 Term: Overactive bladder	Trade Name: EMSELEX 7,5 mg Retardtabletten Product Name: Darifenacin Product Code: BAY 79-4998 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Darifenacin Current Sponsor code: Bay 79-4998 Concentration unit: mg milligram(s) Concentration type: equal Trade Name: EMSELEX 15 mg Retardtabletten Product Name: Darifenacin Product Code: BAY 79-4998 Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Darifenacin Current Sponsor code: Bay 79-4998 Concentration unit: mg milligram(s) Concentration type: equal	Bayer Vital GmbH		Not Recruiting			Female: yes Male: yes			Germany
1135	NCT00358293	December 2006	19 February 2015	Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity	A Double-Blind, Randomized, Crossover Study to Evaluate the Clinical Efficacy and Safety of Oral Tizanidine HCl (12 mg) Versus Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in MS Patients	Muscle Spasticity	Drug: Tizanidine (sublingual or oral)	Teva GTC		Not recruiting	20 Years	65 Years	Both	20	Phase 1/Phase 2	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1136	NCT00395317	December 2006	19 February 2015	Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)	Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months Administration of SB-683699 in Subjects With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Other: Placebo;Drug: Firategrast 150 mg;Drug: Firategrast 300 mg	GlaxoSmithKline		Not recruiting	18 Years	65 Years	Both	343	Phase 2	Australia;Austria;Canada;Finland;France;Germany;Italy;Netherlands;New Zealand;Norway;Poland;Russian Federation;Spain;United Kingdom;Lithuania
1137	NCT00411723	December 2006	19 February 2015	Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis	Phase 1 Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis	Multiple Sclerosis, Chronic Progressive;Multiple Sclerosis, Relapsing-Remitting	Drug: RTL1000 (recombinant T cell receptor ligand);Drug: RTL1000 Placebo	Artielle ImmunoTherapeutics		Not recruiting	18 Years	65 Years	Both	34	Phase 1	United States
1138	NCT00428584	December 2006	19 October 2017	RNF and Betaseron® Tolerability Study	A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum, Rebif (New Formulation) Only Safety Extension	Relapsing Remitting Multiple Sclerosis (RRMS)	Drug: New Formulation of rebif - human interferon beta-1a;Drug: Interferon beta -1b	EMD Serono	Pfizer	Not recruiting	18 Years	60 Years	All	129	Phase 3	United States
1139	NCT00594087	December 2006	19 February 2015	Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)	Eszopiclone for Improving Sleep Continuity in MS Patients With Sleep Disturbances and Its Impact on Daytime Fatigue	Relapsing Remitting Multiple Sclerosis;Sleep Initiation and Maintenance Disorders;Fatigue	Drug: eszopiclone;Other: placebo	University of Vermont		Not recruiting	18 Years	64 Years	Both	30	N/A	United States
1140	EUCTR2006-002982-38-BE	29/11/2006	21 August 2017	A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX)	A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis - Rebif FLEXible dosing in early Multiple Sclerosis (REFLEX)	Subjects at high risk of converting to Multiple Sclerosis MedDRA version: 9.0 Level: PT Classification code 10028245	Trade Name: Rebif Product Name: Interferon-beta 1a FBS-free/HSA free, RNF Product Code: Not Applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon-beta 1a CAS Number: NA Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany		Not Recruiting			Female: yes Male: yes	480	Phase 3	Portugal;Estonia;Slovakia;Greece;Finland;Spain;Lithuania;Austria;Italy;France;Czech Republic;Belgium;Denmark;Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1141	EUCTR2006-000606-23-ES	23/11/2006	29 May 2012	?Post-authorization safety study to check the potential association between the safety profile of beta interferon 1a and the body mass index or pharmacodynamics during the titration phase	Post-authorization safety study to check the potential association between the safety profile of beta interferon 1a and the body mass index or pharmacodynamics during the titration phase - PASS-PD del escalado de dosis de Rebif	Not applicalbe MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rebif 22 y 44 mcg Product Name: Interferon-beta-1a Pharmaceutical Form: Solution for injection CAS Number: 220581-49-7 Other descriptive name: INTERFERON BETA-1A Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22-	Merck, S.L.		Authorised			Female: yes Male: yes			Spain
1142	EUCTR2006-002633-20-NL	17/11/2006	18 April 2012	Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple Sclerosis	Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice daily) in Subjects with Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis MedDRA version: 8.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: Firategrast Product Code: SB683699 Pharmaceutical Form: Tablet CAS Number: 402567-16-2 Current Sponsor code: SB683699 Other descriptive name: Firategrast (USAN approved name) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Name: Firategrast Product Code: SB683699 Pharmaceutical Form: Tablet CAS Number: 402567-16-2 Current Sponsor code: SB683699 Other descriptive name: Firategrast (USAN approved name) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	GlaxoSmithKline Research & Development Ltd		Not Recruiting			Female: yes Male: yes	350		Finland;United Kingdom;Germany;Netherlands;France;Spain;Italy;Austria;Lithuania
1143	NCT00370071	November 2006	19 October 2017	Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis	Open Label Study to Evaluate the Effect, Safety and Tolerability of 250µg (8 MIU) Interferon Beta 1b (Betaferon) Given Subcutaneously Every Other Day (for 24 Weeks) in Patients of Chinese Origin With Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	16 Years	55 Years	All	39	Phase 3	China
1144	NCT00436826	November 2006	19 October 2017	A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)	A Phase II, Multicenter, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy With Interferon-beta (IFN-ß) Treatment in Multiple Sclerosis Subjects With Active Disease	Multiple Sclerosis	Drug: Cladribine;Drug: Placebo;Drug: Interferon-beta (IFN-beta)	EMD Serono		Not recruiting	18 Years	65 Years	All	214	Phase 2	United States;Italy;Russian Federation;Spain
1145	NCT00529581	November 2006	19 February 2015	A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons With Multiple Sclerosis With Cognitive Impairment	Cognition Disorders;Multiple Sclerosis	Drug: C105	Cognition Pharmaceuticals, LLC		Not recruiting	18 Years	65 Years	Both	150	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1146	EUCTR2006-000704-17-GB	19/10/2006	1 May 2012	A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon ß-1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase - D2302 & E1	A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon ß-1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase - D2302 & E1	Relapsing-remitting multiple sclerosis (RRMS)	Product Code: FTY720 Pharmaceutical Form: Capsule* INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use Product Name: Interferon beta-1a Pharmaceutical Form: Solution for injection INN or Proposed INN: interferon beta-1a Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 30/0.5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use Product Code: FTY720 Pharmaceutical Form: Capsule* INN or Proposed INN: Fingolimod CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	1275		Portugal;Hungary;Germany;United Kingdom;Belgium;Spain;Italy;Greece;Austria
1147	NCT00516893	October 2006	19 October 2017	Natalizumab High Titer Immunogenicity and Safety	A Multicenter, Open-Label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in Subjects With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Biological: BG00002-E (natalizumab high titer)	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	55 Years	All	113	Phase 2	United States
1148	NCT00781872	October 2006	24 June 2019	Mesenchymal Stem Cells for the Treatment of MS	Explorative Trial to Investigate the Migration Ability of Mesenchymal Bone Marrow Stem Cells (MSC) in the Central Nervous System (CNS) Following Their Intrathecal Administration in Severe Cases of Multiple Sclerosis (MS)	Multiple Sclerosis	Biological: injection of autologous stem cells	Hadassah Medical Organization		Not recruiting	35 Years	65 Years	All	20	Phase 1/Phase 2
1149	NCT01091727	October 2006	19 February 2015	Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity	Prospective Randomized Double-blind Trial of Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity and Urinary Incontinence Related to Spinal Cord Injury or Multiple Sclerosis	Neurogenic Detrusor Overactivity	Drug: Botulinum toxin A	Sunnybrook Health Sciences Centre	ethica Clinical Research Inc.	Not recruiting	18 Years	75 Years	Both	57	Phase 3	Canada
1150	EUCTR2006-001947-70-SK	14/09/2006	13 March 2017	A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis	A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Product Name: MBP8298 Synthetic Peptide Product Code: MBP8298 Pharmaceutical Form: Powder for injection* CAS Number: 781666-30-6 Current Sponsor code: MBP8298 Other descriptive name: MBP8298 Synthetic Peptide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use	BioMS Technology Corp.		Not Recruiting			Female: yes Male: yes	215	Phase 2	Slovakia
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1151	EUCTR2004-001286-17-PT	08/09/2006	19 March 2012	Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresive multiple sclerosis with high activity. - Mitoxantrone in high activity multiple sclerosis	Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresive multiple sclerosis with high activity. - Mitoxantrone in high activity multiple sclerosis	Relapsing-remitting or relapsing secondary progressive multiple sclerosis with high activity MedDRA version: 7.0 Level: PT Classification code 10028245	Product Name: Mitoxantrone Product Code: N/A Pharmaceutical Form: Solution for infusion	Fundación Española de Esclerosis Múltiple (FEDEM)		Authorised			Female: yes Male: yes	50		Portugal
1152	EUCTR2005-005751-18-GB	07/09/2006	3 April 2012	A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy Study	A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy Study	Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the UK is approximately 125/100,000 of the population with an annual incidence of 6/100,000. Approximately 80,000 individuals are affected with MS in the UK.	Trade Name: Rebif 44 Product Name: Rebif 44 Product Code: Interferon beta 1a Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta 1a Current Sponsor code: IFNB-1a Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 44- Trade Name: Rebif 22 Product Name: Rebif 22 Product Code: Interferon beta 1a Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta 1a Current Sponsor code: IFNB-1a Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 22- Product Name: Betaferon 500mcg Product Code: Betaferon 500mcg Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Interferon beta 1b Current Sponsor code: IFNB-1b Concentration unit: µg/ml microgram(s)/millilitre Concentration type: equal Concentration number: 500-	UCL Biomedicine R&D Unit		Not Recruiting			Female: yes Male: yes	100		United Kingdom
1153	NCT00261326	September 2006	19 February 2015	Simvastatin Treatment of Patients With Acute Optic Neuritis	Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial	Optic Neuritis;Multiple Sclerosis	Drug: simvastatin;Drug: placebo	Glostrup University Hospital, Copenhagen	Alpharma ApS	Not recruiting	18 Years	59 Years	Both	64	Phase 3	Denmark
1154	NCT00381264	September 2006	19 February 2015	Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis	A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Cesamet™ (nabilone)	NEMA Research, Inc.		Not recruiting	18 Years	75 Years	Both	23	Phase 4	United States
1155	NCT00391079	September 2006	19 October 2017	Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS	A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex When Added to the Existing Treatment Regimen, in the Relief of Central Neuropathic Pain in Subjects With Multiple Sclerosis	Multiple Sclerosis	Drug: Sativex;Drug: Placebo	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	339	Phase 3	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1156	NCT00398528	September 2006	19 February 2015	An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis	An fMRI Study of Treatment Optimization Recommendations Comparing Patients Changing Treatment From Glatiramer Acetate 20 mg qd SC (Copaxone®) to IFN-ß-1a 30 Mcg qw IM (Avonex®) to Those Changing From to IFN-ß-1a 30 Mcg qw IM (Avonex®) to Glatiramer Acetate 20 mg qd SC (Copaxone®) in a Multicenter Study of Patients With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy.	Relapsing-Remitting Multiple Sclerosis	Drug: Glatiramer acetate, (Copaxone®);Drug: IFN-ß-1a, (Avonex®)	Neurognostics		Not recruiting	18 Years	65 Years	Both	48	Phase 4	United States
1157	NCT00588393	September 2006	19 February 2015	FolateScan in Autoimmune Disease	Study of the Efficacy and Safety of FolateScan (Technetium TC99m EC20) in Patients With Rheumatoid Arthritis and Other Inflammatory Diseases	Rheumatoid Arthritis;Osteoarthritis;Multiple Sclerosis;Crohn's Disease;Systemic Lupus Erythematosus	Drug: FolateScan (Technetium Tc 99mEC20)	Mayo Clinic	Endocyte	Not recruiting	18 Years	N/A	Both	75	Phase 2	United States
1158	EUCTR2005-005985-35-NL	29/08/2006	19 March 2012	A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with relapsing forms of Multiple Sclerosis.	A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 and 500 mg administered once daily in patients with relapsing forms of Multiple Sclerosis.	Relapsing forms of Multiple Sclerosis MedDRA version: 8.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Code: BIRT 2584 XX Pharmaceutical Form: Tablet CAS Number: 688756-00-5 Current Sponsor code: BIRT 2584 XX Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use Product Code: BIRT 2584 XX Pharmaceutical Form: Tablet CAS Number: 688756-00-5 Current Sponsor code: BIRT 2584 XX Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Boehringer Ingelheim		Authorised			Female: yes Male: yes	320		Czech Republic;Netherlands;Italy
1159	EUCTR2006-001161-42-GB	29/08/2006	3 July 2017	Multicentre, double-blind, placebo-controlled, dose-ranging study to determine the safety and efficacy of daclizumab HYP (DAC HYP) as a monotherapy treatment in subjects with relapsing-remitting multiple sclerosis. - SELECT	Multicentre, double-blind, placebo-controlled, dose-ranging study to determine the safety and efficacy of daclizumab HYP (DAC HYP) as a monotherapy treatment in subjects with relapsing-remitting multiple sclerosis. - SELECT	Multiple sclerosis (MS) MedDRA version: 8.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis	Product Name: DACLIZUMAB HYP Pharmaceutical Form: Solution for injection Other descriptive name: Daclizumab HYP (DAC HYP) Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Biogen Idec Ltd		Not Recruiting			Female: yes Male: yes	600	Phase 2	Czech Republic;Hungary;Germany;United Kingdom;Sweden
1160	EUCTR2006-003113-40-NL	18/08/2006	19 March 2012	Dexamethason for the treatment of exacerbations in multiple sclerosis	Dexamethason for the treatment of exacerbations in multiple sclerosis	Multiple Sclerosis MedDRA version: 8.1 Level: PT Classification code 10028245 Term: Multiple sclerosis	Product Name: Dexamethason Pharmaceutical Form: Capsule* INN or Proposed INN: Dexamethasone Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Department of Neurology UMCG		Authorised			Female: yes Male: yes	60		Netherlands
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1161	EUCTR2006-004937-13-IT	17/08/2006	19 March 2012	multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis - M.A.I.N. trial	multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis - M.A.I.N. trial	patients with relapsing remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: AZATIOPRINA HEX. 50CPR 50MG BL Pharmaceutical Form: Tablet INN or Proposed INN: Azathioprine CAS Number: 446-86-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: REBIF SC 12SIR 6000000UI 22MCG Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Trade Name: BETAFERON SC 15F 0,25MG 15SIR Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1b Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 8- Trade Name: REBIF SC 12SIR 12000000UI44MCG Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Trade Name: AVONEX IM 4SIR 30MCG/0,5ML 4AG Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 30-	Universita di Firenze		Authorised			Female: yes Male: yes			Italy
1162	NCT00337779	August 2006	19 October 2017	Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).	A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to That of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects With Relapsing Remitting (R-R) Multiple Sclerosis (MS)	Relapsing Remitting Multiple Sclerosis	Drug: Glatiramer Acetate (GA) 40 mg;Drug: glatiramer acetate 20 mg	Teva Pharmaceutical Industries		Not recruiting	18 Years	55 Years	All	1155	Phase 3	Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United Kingdom;United States
1163	NCT00618527	August 2006	19 February 2015	Combination Therapy Using Cellcept and Rebif in RRMS	Combination Therapy Using Mycophenolate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: mycophenolate mofetil (Cellcept);Drug: human interferon beta 1a (Rebif)	Aaron Boster	EMD Serono;Pfizer	Not recruiting	18 Years	65 Years	Both	31	Phase 0	United States
1164	NCT00882453	August 2006	19 February 2015	Physical Activity and Fatigue in Early Multiple Sclerosis (MS)	Betaferon Treatment and Exercise Data Gathering IN Early MS	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	1739	N/A	Australia;Austria;Bahrain;Belgium;Canada;Colombia;Czech Republic;Denmark;Egypt;France;Germany;Greece;Indonesia;Israel;Italy;Jordan;Kazakhstan;Korea, Republic of;Kuwait;Lebanon;Mexico;Netherlands;Norway;Oman;Portugal;Slovenia;Spain;Sweden;Switzerland;Taiwan;Thailand;United Arab Emirates;United Kingdom
1165	EUCTR2005-005592-14-DE	27/07/2006	29 May 2012	Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect	Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect	Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is mainly characterized by a subacute loss of vision.	Trade Name: Erypo/Erypo FS Product Name: Erypo/Erypo FS Pharmaceutical Form: Injection* INN or Proposed INN: Epoetin alfa Other descriptive name: Epo Concentration unit: IU/ml international unit(s)/millilitre Concentration type: up to Concentration number: 10000- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intravenous use Trade Name: Urbason solubile forte 1000mg Product Name: Methylprednisolone Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Methylprednisolon-21-hydrogensuccinat, Natriumsalz Concentration unit: mg milligram(s) Concentration type: not less then Concentration number: 1000 mg-	IFSgGmbH, Institute for clinical research		Not Recruiting			Female: yes Male: yes			Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1166	EUCTR2006-002037-20-HU	27/07/2006	19 March 2012	A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) - FORTE	A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) - FORTE	Relapsing-remitting Multiple Sclerosis (RR MS) MedDRA version: 8.1 Level: PT Classification code 10028245	Product Name: 40 mg glatiramer acetate Product Code: 40 mg GA Pharmaceutical Form: Solution for injection INN or Proposed INN: n.a. CAS Number: 147245-92-9 Current Sponsor code: 40 mg GA Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- Product Name: Copaxone 20 mg/ml Solution for Injection, pre-filled syringe Product Code: 20 mg GA Pharmaceutical Form: Solution for injection INN or Proposed INN: n.a. CAS Number: 147245-92-9 Current Sponsor code: 20 mg GA Other descriptive name: Copaxone Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Teva Pharmaceutical Industries, Ltd.		Not Recruiting			Female: yes Male: yes	980		Hungary;Germany;Czech Republic;United Kingdom;Belgium;Estonia;Spain;Italy;Latvia;Lithuania
1167	NCT00288626	July 2006	16 December 2017	High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study	A Phase II Study of High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, Melphalan, Thymoglobulin and Autologous CD34+ Hematopoietic Stem Cell Transplant for the Treatment of Poor Prognosis Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: Granulocyte-colony stimulating factor (G-CSF) and prednisone;Drug: Carmustine, etoposide, cytarabine, and melphalan (BEAM);Procedure: Autologous hematopoietic stem cell transplant	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN)	Not recruiting	18 Years	60 Years	All	25	Phase 2	United States
1168	NCT00501943	July 2006	19 October 2017	Neuroprotection With Riluzole Patients With Early Multiple Sclerosis	Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis	Multiple Sclerosis	Drug: Avonex (Interferon beta 1a);Drug: Riluzole;Drug: Placebo	University of California, San Francisco	National Multiple Sclerosis Society;Oregon Health and Science University	Not recruiting	18 Years	55 Years	All	43	Phase 2	United States
1169	NCT00638027	July 2006	19 October 2017	Memantine for Spasticity in MS Patients	Memantine for Spasticity in MS Patients	Multiple Sclerosis	Drug: placebo;Drug: memantine	University of Rochester	Forest Laboratories	Not recruiting	18 Years	70 Years	All	21	Phase 4	United States
1170	NCT00644904	July 2006	19 February 2015	Safety Trial of High Dose Oral Vitamin D3 With Calcium in Multiple Sclerosis	A Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Vitamin D3	University of Toronto	Direct MS-Proactive Charity;Multiple Sclerosis Society of Canada	Not recruiting	18 Years	55 Years	Both	49	Phase 1/Phase 2	Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1171	EUCTR2005-005679-13-IT	28/06/2006	19 March 2012	An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis. - ND	An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis. - ND	multiple sclerosis MedDRA version: 6.1 Level: PT Classification code 10053395	Pharmaceutical Form: Capsule, hard INN or Proposed INN: Naltrexone CAS Number: 16676-29-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-	OSPEDALE S. RAFFAELE		Authorised			Female: yes Male: yes	40		Italy
1172	EUCTR2005-001567-55-DE	23/06/2006	18 April 2012	A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis	A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis	This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought to be mediated by autoreactive T cells. Daclizumab is a genetically engineered humanized IgG1 monoclonal antibody that binds specifically to CD25 (alpha chain of the IL-2 receptor) and achieves immunosuppression at least in part by competitive antagonism of IL-2-induced T cell proliferation.	Product Name: Daclizumab Pharmaceutical Form: Solution for injection INN or Proposed INN: Daclizumab Other descriptive name: Anti-CD25 Humanized Monoclonal Antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use	Protein Design Labs, Inc.		Not Recruiting			Female: yes Male: yes	270	Phase 2	United Kingdom;Germany;Spain
1173	EUCTR2005-004061-41-GB	01/06/2006	28 February 2019	TYSABRI Long Term Re-Dosing Study	An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C-1802 and a Dosing Suspension Safety Evaluation - STRATA	Multiple sclerosis (MS) MedDRA version: 14.1 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: TYSABRI 300 mg concentrate for solution for infusion Product Name: NATALIZUMAB Product Code: BG00002 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Natalizumab Current Sponsor code: BG00002 Other descriptive name: Recombinant humanized anti-alpha 4 integrin antibody Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-	BIOGEN IDEC LTD		Not Recruiting			Female: yes Male: yes	458	Phase 3	Greece;Finland;Spain;Ireland;Turkey;Austria;Italy;United Kingdom;Switzerland;France;Hungary;Czech Republic;Canada;Poland;Belgium;Australia;Denmark;Germany;New Zealand;Sweden
1174	NCT00342381	June 2006	19 February 2015	Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation	Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation	Multiple Sclerosis;Fatigue	Drug: 3,4-diaminopyridine;Drug: Placebo	University of Aarhus	The Danish Multiple Sclerosis Society	Not recruiting	18 Years	55 Years	Both	120	Phase 2	Denmark
1175	NCT00355134	June 2006	19 October 2017	Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis	24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase	Multiple Sclerosis	Drug: Fingolimod;Drug: Placebo	Novartis		Not recruiting	18 Years	55 Years	All	1083	Phase 3	United States;Australia;Austria;Canada;Poland;Romania;Turkey;United Kingdom;Lithuania
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1176	NCT00648908	June 2006	19 October 2017	Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial	Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial	Multiple Sclerosis	Drug: Fampridine-SR	Acorda Therapeutics		Not recruiting	18 Years	70 Years	All	269	Phase 3	United States;Canada
1177	EUCTR2006-000397-71-DK	16/05/2006	19 March 2012	Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis - levetiracetam for central neuropathic pain in patients with multiple sclerosis	Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis - levetiracetam for central neuropathic pain in patients with multiple sclerosis		Trade Name: Keppra Product Name: Levetiracetam Product Code: ucb L059 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Søren H. Sindrup, Department of Neurology, Odense University Hospital		Not Recruiting			Female: yes Male: yes	30		Denmark
1178	NCT00245622	May 2006	19 February 2015	Autologous T Cell Vaccine (TCV) for Multiple Sclerosis	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Tovaxin in Subjects With CIS or RR-MS	Relapsing-Remitting Multiple Sclerosis	Biological: Tovaxin Autologous T cell vaccine;Biological: Placebo	Opexa Therapeutics, Inc.		Not recruiting	18 Years	55 Years	Both	150	Phase 2	United States
1179	NCT00324506	May 2006	19 February 2015	Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis	A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Mycophenolate Mofetil (CellCept)	University of Texas Southwestern Medical Center	Aspreva Pharmaceuticals	Not recruiting	18 Years	55 Years	Both	43	Phase 2	United States
1180	NCT00331747	May 2006	19 February 2015	Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate	Three Dimensional Gait Evaluation in Relapsing Remitting Multiple Sclerosis Patients Treated With Glatiramer Acetate	Multiple Sclerosis	Drug: Glatiramer acetate	Sheba Medical Center		Recruiting	18 Years	N/A	Both	20	N/A	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1181	NCT00340834	May 2006	16 December 2017	Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase	A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase	Multiple Sclerosis	Drug: Fingolimod 1.25 mg;Drug: Fingolimod 0.5 mg;Drug: Interferon ß-1a 30 µg	Novartis		Not recruiting	18 Years	55 Years	All	1292	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Egypt;France;Germany;Greece;Hungary;Italy;Korea, Republic of;Portugal;Spain;Switzerland;United Kingdom;Puerto Rico
1182	NCT02517788	May 2006	17 August 2015	Phase I BP Interferon (IFN) Beta-004	Comparative Pharmacokinetic Profile of Interferon Beta-1a (Bioferon®) Administered as Single i.v. Doses in HSA-free Formulation and HSA+ Solution and as Multiple s.c. Doses in Healthy Subjects	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta-1a HSA-free biosimilar;Drug: Interferon beta-1a HSA+ biosimilar;Drug: Interferon beta-1a original	Centre Hospitalier Universitaire Vaudois	BioPartners GmbH	Not recruiting	18 Years	45 Years	Both	24	Phase 1
1183	EUCTR2006-002562-19-IT	21/04/2006	19 March 2012	Immunoablation with Cyclophosphamide at high dosage and Rabbit antithymoglobulin followed by autologous hematopoietic stem cell transplantation in severe multiple sclerosis - LIGHT	Immunoablation with Cyclophosphamide at high dosage and Rabbit antithymoglobulin followed by autologous hematopoietic stem cell transplantation in severe multiple sclerosis - LIGHT	VERIFICARE Patients with multiple sclerosis, age between 18 and 50 MedDRA version: 6.1 Level: PT Classification code 10028245	Trade Name: L04AA04 - IMMUNOGLOBULINA ANTITIMOCITARIA (DI CONIGLIO) IMMUNOGLOBULINA DI CONIGLIO ANTITIMOCITI UMANI THYMOGLOBULINE Product Name: Thymoglobuline Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Antithymocyte Current Sponsor code: LIGHT Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Endoxan - ciclofosfamide Product Name: Endoxan Pharmaceutical Form: Powder and solvent for solution for infusion INN or Proposed INN: Cyclophosfamide Current Sponsor code: LIGHT Concentration unit: g gram(s) Concentration type: equal Concentration number: 1-	Dipartimento di Neuroscienze Oftalmologia e Genetica DINOG - Universita di Genova		Authorised			Female: yes Male: yes	12		Italy
1184	EUCTR2005-005265-11-GB	03/04/2006	19 March 2012	A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis. This will be followed by a 12 week open label treatment phase and then a 4 week randomised withdrawal phase (Part B) for a subset of subjects	A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of central neuropathic pain in subjects with multiple sclerosis. This will be followed by a 12 week open label treatment phase and then a 4 week randomised withdrawal phase (Part B) for a subset of subjects	Relief of central neuropathic pain in subjects with multiple sclerosis (MS)	Product Name: Sativex Product Code: GW-1000-02 Pharmaceutical Form: Oromucosal spray CAS Number: 1972-08-3 Other descriptive name: delta-9-tetrahydrocannabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 27- CAS Number: 13956-29-1 Other descriptive name: Cannabidiol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use	GW Pharma Ltd		Authorised			Female: yes Male: yes	312		Czech Republic;United Kingdom;France
1185	EUCTR2005-001540-23-SE	03/03/2006	19 March 2012	A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis. - BECAUSE - Betaferon in Early SPMS - SCAndinavian study on USE of double dose	A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis. - BECAUSE - Betaferon in Early SPMS - SCAndinavian study on USE of double dose	Early Secondary Progressive Multiple Sclerosis	Trade Name: Betaferon Product Name: Betaferon Pharmaceutical Form: Powder for solution for injection Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 2x250- Trade Name: Betaferon Product Name: Betaferon Pharmaceutical Form: Powder and solvent for solution for injection Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 250-	Schering Nordiska AB		Not Recruiting			Female: yes Male: yes	160		Denmark;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1186	NCT00291148	March 2006	19 February 2015	Neuropathic Pain Assessment Comparing Pregabalin and Paroxetine in Management of MS-induced Neuropathic Pain	A Comparative Single Center, Randomized Neuropathic Pain Assessment Study Involving Patients With Clinically Definite Multiple Sclerosis (MS) Receiving Treatment With Either Pregabalin or Paroxetine	Neuropathic Pain;Multiple Sclerosis	Drug: paroxetine;Drug: pregabalin;Drug: Paroxetine	University of Manitoba		Not recruiting	18 Years	65 Years	Both	75	Phase 3	Canada
1187	NCT00297232	March 2006	19 October 2017	Natalizumab (Tysabri) Re-Initiation of Dosing	An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation	Relapsing-Remitting Multiple Sclerosis	Drug: Natalizumab	Biogen		Not recruiting	18 Years	N/A	All	1094	Phase 3	Australia;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;Turkey;United Kingdom;Austria
1188	NCT00306592	March 2006	16 December 2017	Natalizumab Re-Initiation of Dosing	An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, or C-1803 and a Dosing Suspension Safety Evaluation	Multiple Sclerosis, Relapsing-Remitting	Biological: BG00002 (natalizumab)	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	N/A	All	404	Phase 3	United States;Canada
1189	NCT00317941	March 2006	19 October 2017	Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif	The AVANTAGE Study - A Randomized, Multicenter, Phase IV, Open-label Prospective Study Comparing Injection Site Reaction and Injection Site Pain in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) or After a First Demyelinating Event Suggestive of MS Newly Started on Interferon Beta-1b (Betaferon®) or Interferon Beta-1a (Rebif®).	Relapsing-remitting Multiple Sclerosis	Drug: Betaferon/Betaseron;Drug: Rebif	Bayer		Not recruiting	18 Years	55 Years	All	220	Phase 4	France
1190	EUCTR2004-004403-37-DE	27/02/2006	19 March 2012	Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur Standardtherapie A monocentric, randomised, controlled trial for the investigation of Interferon-beta in the treatment of multiple-slerosis (MS)-associated and primary uveitis intermedia compared to the standardized treatment - TEAM-Studie	Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur Standardtherapie A monocentric, randomised, controlled trial for the investigation of Interferon-beta in the treatment of multiple-slerosis (MS)-associated and primary uveitis intermedia compared to the standardized treatment - TEAM-Studie	Uveitis intermedia with inflammatory macula edema with or without associated Multiple Sclerosis	Product Name: Rebif Pharmaceutical Form: Cutaneous solution INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Product Name: Rebif Pharmaceutical Form: Cutaneous solution INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44- Product Name: Metex Pharmaceutical Form: Cutaneous liquid INN or Proposed INN: Methotrexat Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20-	Universitätsklinikum Heidelberg		Authorised			Female: yes Male: yes			Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1191	EUCTR2005-004334-41-GB	10/02/2006	17 October 2016	An extended clinical study in subjects with multiple sclerosis who successfully completed the LAQ/5062 and LAQ/5063 study, to assess the safety of laquinimod (experimental drug) when taken for a long period of time and how it affects the course of the disease.	An active extension of LAQ/5062 study. A multinational, multicenter, randomized, double-blind, parallel-group study, to evaluate the safety, tolerability and efficacy of two doses (0.3 mg and 0.6 mg) of laquinimod, orally administered in relapsing remitting (R-R) multiple sclerosis (MS) subjects (study LAQ/5063 active double-blind phase) followed by an open label phase of laquinimod 0.6 mg daily (LAQ/5063 OL).	Relapsing Remitting Multiple Sclerosis (RRMS) MedDRA version: 19.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Laquinimod Capsules 0.6 mg Product Code: TV-5600 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Laquinimod CAS Number: 248282-07-7 Current Sponsor code: TV-5600 Other descriptive name: ABR-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.6-	Teva Pharmaceutical Industries Ltd		Authorised			Female: yes Male: yes	105	Phase 2	Hungary;Czech Republic;Poland;Spain;Russian Federation;Israel;Germany;Italy;United Kingdom
1192	NCT00382629	February 2006	19 February 2015	BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis	BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: BHT-3009 0.5 mg;Drug: BHT-3009 1.5 mg;Drug: Placebo	Bayhill Therapeutics		Not recruiting	18 Years	55 Years	Both	252	Phase 2
1193	NCT00492765	February 2006	19 February 2015	Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment IM Administered Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon-beta-1a;Drug: Simvastatin;Drug: Placebo	Biogen Idec		Not recruiting	18 Years	55 Years	Both	380	Phase 4	Denmark
1194	EUCTR2005-005263-29-GB	31/01/2006	18 April 2012	Multiple Sclerosis and Extract of Cannabis (MUSEC): A randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in Multiple Sclerosis. - MUSEC study	Multiple Sclerosis and Extract of Cannabis (MUSEC): A randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in Multiple Sclerosis. - MUSEC study	Multiple Sclerosis	Product Name: Cannador Pharmaceutical Form: Capsule, soft Current Sponsor code: Standardised Cannabis Extract Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use	Gesellschaft fuer klinische Forschung e.V. (Society for Clinical Research)	WELEDA AG	Authorised			Female: yes Male: yes	300	Phase 3	United Kingdom
1195	EUCTR2005-004289-18-FI	26/01/2006	19 March 2012	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)	A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 44mcg tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis - Minocycline as add-on to Interferon-beta-1a (Rebif®) in RRMS (Recycline)	Relapse Remitting Multiple Sclerosis MedDRA version: 8.0 Level: PT Classification code 10063399	Product Name: Minocycline 100 mg Film-coated Tablets Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Minocycline Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Merck AB		Not Recruiting			Female: yes Male: yes	320		Finland;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1196	EUCTR2005-003903-35-GB	19/01/2006	3 April 2012	: The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis	: The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis	Multiple Sclerosis	Trade Name: Keppra 250mg Pharmaceutical Form: INN or Proposed INN: Levetiracetam Concentration unit: mg milligram(s) Concentration type: range Concentration number: 250mg bd-1500mg bd Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Keppra 500mg Product Name: Keppra ® Pharmaceutical Form: Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Newcastle-upon-Tyne Hospitals NHS Trust		Authorised			Female: yes Male: yes			United Kingdom
1197	EUCTR2005-003930-16-SE	19/01/2006	19 March 2012	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN	A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis - SIMCOMBIN	Patients with definite relapsing-remitting multiple sclerosis who have never received treatment with interferons or glatiramer acetate, who meet all the criteria for inclusion and none of the exclusion criteria. Patients will be recruited from the outpatient clinics of the participating neurological departments among patients who are eligible for treatment with interferon-beta-1a. MedDRA version: 7.0 Level: PT Classification code 10028425	Product Name: Simvastatin Alternova Pharmaceutical Form: Coated tablet INN or Proposed INN: Simvastatin Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 40- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	Biogen Idec A/S		Not Recruiting			Female: yes Male: yes	380		Finland;Sweden
1198	EUCTR2005-005211-21-FI	17/01/2006	19 March 2012	A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years	A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years	Remitting relapsing multiple sclerosis (RRMS) is one of the most common diseases of the central nervous system. The cause of MS is not yet known but it is a result of damage to myelin. Symptoms vary widely and include blurred vision, weak limbs, tingling sensations, unsteadiness and fatigue.	Trade Name: Betaferon Product Name: Betaferon Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Beta-1b interferoni Concentration unit: µg/ml microgram(s)/millilitre	Schering Oy		Not Recruiting			Female: yes Male: yes	80		Finland
1199	NCT00280592	January 2006	19 February 2015	Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients	Prospective, Randomized, Double-blind, Placebo-controlled Study on Parallel Groups Evaluating the Efficacy and Safety of Cranberry (Vaccinium Macrocarpon) in Prevention of Urinary Tract Infections in Multiple Sclerosis Patients.	Multiple Sclerosis;Urinary Tract Infections;Bladder Dysfunction	Drug: Cranberry;Drug: Placebo	Rennes University Hospital	Pierre Fabre Laboratories;Ministry of Health, France	Not recruiting	18 Years	70 Years	Both	171	Phase 3	France
1200	NCT00289978	January 2006	19 October 2017	Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis	A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: Fingolimod 1.25 mg;Drug: Fingolimod 0.5 mg;Drug: Placebo	Novartis		Not recruiting	18 Years	55 Years	All	1272	Phase 3	Australia;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Israel;Lithuania;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Sweden;Switzerland;Turkey;United Kingdom;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1201	NCT00818103	January 2006	19 February 2015	Characteristic Study on Chinese Patients With Multiple Sclerosis	Characteristic Study on Chinese Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: atorvastatin;Drug: ß-interferon;Drug: EPO	Sun Yat-sen University	Third Affiliated Hospital, Sun Yat-Sen University	Recruiting	N/A	65 Years	Both	600	N/A	China
1202	EUCTR2006-006465-16-DE		9 May 2016	Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis - rhGH in MS	Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis - rhGH in MS	Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1 Level: LLT Classification code 10063400 Term: Secondary progressive multiple sclerosis	Trade Name: Genotropin Product Name: Genotropin Pharmaceutical Form: Solution for injection INN or Proposed INN: human recombinant growth hormone CAS Number: 12629-01-5 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 5-12	University of Leipzig		Not Recruiting			Female: yes Male: yes		Phase 2	Germany
1203	EUCTR2005-000365-19-SE	19/12/2005	19 March 2012	A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis - D2301	A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis - D2301	Relapsing-remitting multiple sclerosis (RRMS)	Product Code: FTY720 Pharmaceutical Form: Capsule* CAS Number: 162359-56-0 Current Sponsor code: FTY720 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5, 1.25- Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use	Novartis Pharma Services AG		Not Recruiting			Female: yes Male: yes	1250		Hungary;Finland;Germany;Czech Republic;United Kingdom;Estonia;Ireland;Greece;Lithuania;Sweden
1204	NCT00241254	December 2005	19 February 2015	Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis	A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study	Multiple Sclerosis, Chronic Progressive	Drug: Cyclophosphamide (drug);Drug: Methylprednisolone (drug)	University Hospital, Bordeaux	Ministry of Health, France	Not recruiting	18 Years	65 Years	Both	138	Phase 3	France
1205	NCT00676156	December 2005	19 February 2015	A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis	A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis	Multiple Sclerosis	Drug: oral lipoic acid (LA);Drug: lipoic acid (LA) with fish oil and LA without fish oil;Drug: R lipoic acid	Oregon Health and Science University	National Center for Complementary and Integrative Health (NCCIH)	Not recruiting	18 Years	80 Years	Both	40	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1206	NCT01142466	December 2005	19 October 2017	A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone	Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta-1a (Rebif)	Merck KGaA	Gesellschaft für Therapieforschung mbH	Not recruiting	18 Years	60 Years	All	30	Phase 4
1207	EUCTR2005-003410-15-SE	21/11/2005	19 March 2012	A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis. - Aricept in MS	A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis. - Aricept in MS	Multiple sclerosis is a devastating inflammation in the central nervous system and it can often give cognitive dysfunction, affecting memory, mental concentration. Lately it has been shown that the cognitive dysfunction has a big impact on life quality. Immunomodulatory medication can only partially limit the bouts but there is no effective cure at the moment. There is little options to treat the effects on higher functions for the moment.	Trade Name: Aricept 5 mg filmdragerade tabletter Product Name: Aricept 5 mg Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Donepezil Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: Aricept 10 mg filmdragerade tabletter Product Name: Aricept 10 mg Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Donepezil Concentration unit: mg/l milligram(s)/litre Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Neurology Unit		Not Recruiting			Female: yes Male: yes	20		Sweden
1208	NCT00273364	November 16, 2005	15 April 2019	Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study	Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study	Multiple Sclerosis	Procedure: Hematopoietic Stem Cell Therapy;Drug: Standard treatment with a conventional drug	Northwestern University	Uppsala University;Sheffield Teaching Hospitals NHS Foundation Trust;University of Sao Paulo	Not recruiting	18 Years	55 Years	All	110	Phase 2	United States
1209	EUCTR2005-001008-37-SE	01/11/2005	19 March 2012	Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - Interferon beta dose and antibody	Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy - Interferon beta dose and antibody	Multiple sclerosis	Trade Name: Rebif® Product Name: Rebif® Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Current Sponsor code: Not applicable Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22, 44-	Sahlgrenska University Hospital		Authorised			Female: yes Male: yes	100		Sweden
1210	NCT00270816	November 2005	18 January 2018	Interferon ß-1b Treatment by Cyclical Administration	Effect of Cyclical Administration of Interferon ß-1b in Multiple Sclerosis - Comparison With Normal Dose.	Multiple Sclerosis	Drug: Interferon-ß-1b;Drug: Interferon ß-1b	S. Andrea Hospital	Italian Multiple Sclerosis Foundation	Not recruiting	18 Years	55 Years	All	60	Phase 2/Phase 3	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1211	NCT00242268	October 2005	19 February 2015	A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis		Relapsing Remitting Multiple Sclerosis	Drug: Simvastatin	Alabama Neurology Associates, PC	Biogen Idec	Recruiting	18 Years	55 Years	Both	30	Phase 3	United States
1212	EUCTR2005-001949-42-GB	08/09/2005	24 April 2012	A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis - Neuroprotection with lamotrigine in multiple sclerosis	A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis - Neuroprotection with lamotrigine in multiple sclerosis	Multiple sclerosis	Product Name: Lamotrigine extended release tablets Product Code: N/A Pharmaceutical Form: Modified-release tablet INN or Proposed INN: Lamotrigine CAS Number: N/A Current Sponsor code: N/A Other descriptive name: N/A Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 400- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	University College London		Authorised			Female: yes Male: yes			United Kingdom
1213	NCT00220506	September 2005	19 February 2015	Fatigue Treatment Using Provigil	Fatigue Treatment Using Provigil in Patients With Relapsing Remitting Multiple Sclerosis	All Multiple Sclerosis Patients	Drug: Provigil	Sheba Medical Center		Recruiting	18 Years	55 Years	Both	50	N/A	Israel
1214	NCT00754832	September 2005	19 October 2017	American Ginseng Treatment for Multiple Sclerosis Related Fatigue	A Double-blinded, Placebo-controlled Crossover Pilot Study of American Ginseng Treatment for Multiple Sclerosis Related Fatigue	Multiple Sclerosis	Drug: American ginseng extract HT-1001;Drug: placebo	Oregon Health and Science University	National Multiple Sclerosis Society	Not recruiting	18 Years	70 Years	All	56	Phase 2	United States
1215	NCT01074619	September 2005	19 February 2015	Study on Cognitive Disorders of Multiple Sclerosis	Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Memantine;Drug: Placebo	University Hospital, Caen	Ministry of Health, France;H. Lundbeck A/S	Not recruiting	18 Years	60 Years	Both	90	Phase 3	France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1216	EUCTR2005-006071-12-IT	31/08/2005	19 March 2012	Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCE	Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCE	MULTIPLE SCLEROSIS MedDRA version: 6.1 Level: PT Classification code 10028245	Trade Name: EPARMEFOLIN 30 CPR 0,1/0,5MG Pharmaceutical Form: Coated tablet INN or Proposed INN: CALCIO FOLINATO DC.IT CAS Number: 1492-18-8 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .5- INN or Proposed INN: CIANOCOBALAMINA FU DC.IT CAS Number: 68-19-9 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .5- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use Trade Name: LEVOFOLENE 4 MG 30 CPR Pharmaceutical Form: Tablet INN or Proposed INN: Calcium levofolinate CAS Number: 80433-71-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 4- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	AZIENDA OSPEDALIERA SAN CAMILLO FORLANINI		Not Recruiting			Female: yes Male: yes	276		Italy
1217	EUCTR2005-001340-22-GB	12/08/2005	24 April 2012	BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS	BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS	Multiple sclerosis results from an auto-immune reaction characterized by inflammation within the nervous system. Myelin basic protein is a target of the autoimmune response and is generally regarded as the predominant autoantigen. BHT-3009 is a 3.5 kb bacterial plasmid expression vector containing the coding sequences for full length human myelin basic protein (hMBP).	Product Name: BHT-3009 Product Code: BHT-3009 Pharmaceutical Form: Solution for injection Current Sponsor code: BHT-3009 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Intramuscular use	Bayhill Therapeutics		Authorised			Female: yes Male: yes	252		Finland;Czech Republic;United Kingdom
1218	EUCTR2005-001776-13-DE	05/08/2005	19 March 2012	Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study	Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study	Multiple Sclerosis	Product Name: Levetiracetam Pharmaceutical Form: Capsule, hard Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Organisation name was not entered		Authorised			Female: yes Male: yes	24		Germany
1219	NCT00239993	August 2005	16 December 2017	A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®	An Open-Label, Randomized, Single Cross-over Study of Warm Compress Versus Usual Injection Site Preparation on Local Injection Site Reactions Among Persons With MS Who Perform Daily Injections of Copaxone®.	Multiple Sclerosis	Drug: glatiramer acetate;Procedure: Warm compress prior to injection of glatiramer acetate	Teva Neuroscience, Inc.		Not recruiting	18 Years	55 Years	All	50	Phase 4	United States
1220	NCT00915577	August 2005	19 February 2015	Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe	An Open-Label, Multicenter Study to Determine Subject Satisfaction in Using the Single-Use Autoinjector With a Pre-Filled Liquid AVONEX® Syringe in Multiple Sclerosis Subjects	Multiple Sclerosis	Drug: Interferon beta-1a;Device: Single-use autoinjector	Biogen Idec		Not recruiting	18 Years	65 Years	Both	74	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1221	EUCTR2004-004903-39-GB	26/07/2005	1 May 2012	A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis. - UNKEMPT	A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis. - UNKEMPT	Early, active relapsing remitting Multiple Sclerosis (RRMS)	Trade Name: Mitoxantrone Product Name: Mitoxantrone Pharmaceutical Form: Trade Name: Copaxone Product Name: Glatiramer Acetate Pharmaceutical Form: Injection* Trade Name: Rebif 44 Product Name: Interferon Beta 1a Pharmaceutical Form: Injection*	The Walton Centre for Neurology and Neurosurgery		Authorised			Female: yes Male: yes	60		United Kingdom
1222	EUCTR2005-001009-25-IT	16/07/2005	7 January 2013	Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNA	Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. - ARIANNA	Multiple sclerosis treatment MedDRA version: 14.1 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: *TORVAST10CPR 10MG Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Atorvastatin CAS Number: 134523-03-8 Concentration unit: mg milligram(s) Concentration number: 40- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Trade Name: TORVAST10CPR 10MG* Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Atorvastatin Concentration unit: mg milligram(s) Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	DR DIMENSIONE RICERCA		Not Recruiting			Female: yes Male: yes			Italy
1223	EUCTR2005-001026-89-DE	14/07/2005	7 January 2013	Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)	Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)	Relapsing-remitting multiple sclerosis (RRMS) or secondary progressive multiple sclerosis (SPMS) with relapses MedDRA version: 7.1 Level: LLT Classification code 10028245	Trade Name: Rebif Product Name: Rebif 8,8 µg, Rebif 22µg Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1 a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 8,8 or 22- Trade Name: Rebif Product Name: Rebif 44 µg Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1 a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-	Serono GmbH		Not Recruiting			Female: yes Male: yes	100	Phase 4	Germany
1224	NCT00122954	July 2005	16 December 2017	Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis	Fish Oil as an Adjunct Therapy for Depression in Multiple Sclerosis	Multiple Sclerosis;Depression	Drug: Fish oil concentrate;Drug: Placebo	Oregon Health and Science University	National Center for Complementary and Integrative Health (NCCIH)	Not recruiting	18 Years	85 Years	All	39	Phase 1/Phase 2	United States
1225	NCT00202423	July 2005	19 February 2015	Use of Cannabinoids in Patients With Multiple Sclerosis	fMRI and Neurophysiological Study Protocol on Cannabinoids in Multiple Sclerosis	Multiple Sclerosis	Drug: Sativex	S. Andrea Hospital	University of Roma La Sapienza	Recruiting	18 Years	60 Years	Both	20	Phase 2	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1226	NCT01142518	July 2005	19 February 2015	An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone	A Prospective Analysis of MS Patients After Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment	Relapsing-Remitting Multiple Sclerosis	Drug: Interferon beta 1a	Merck KGaA		Not recruiting	N/A	N/A	Both	86	N/A
1227	NCT00127075	June 2005	19 February 2015	POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis	POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis	Multiple Sclerosis	Drug: nomegestrol acetate;Drug: estradiol;Drug: placebo	Hospices Civils de Lyon		Not recruiting	18 Years	50 Years	Female	300	Phase 3	France
1228	NCT00202397	June 2005	19 February 2015	Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia	Phase 2 Study of Riluzole Effects on Patients With Chronic Cerebellar Ataxia	Hereditary Ataxia;Multiple Sclerosis;Cerebellar Ataxia	Drug: Riluzole;Other: placebo	S. Andrea Hospital		Not recruiting	18 Years	80 Years	Both	40	Phase 2	Italy
1229	NCT00463710	June 2005	19 February 2015	Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS	Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Avonex® monotherapy (6.0 MIU administered i.m. each week)	State University of New York at Buffalo	Biogen Idec	Not recruiting	18 Years	65 Years	Both	150	Phase 4	United States
1230	NCT01450488	June 2005	18 December 2018	Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis	A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Activity of Oral AB1010 Administered at 2 Dose Levels to Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: masitinib	AB Science		Not recruiting	18 Years	60 Years	All	35	Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1231	EUCTR2004-005148-28-FI	26/05/2005	1 May 2012	A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis - Oral Cladribine versus Placebo in RRMS	A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis - Oral Cladribine versus Placebo in RRMS	Relapsing-remitting multiple sclerosis (RRMS) MedDRA version: 7.0 Level: PT Classification code 10028245	Product Name: Cladribine Product Code: Not Applicable Pharmaceutical Form: Tablet INN or Proposed INN: Cladribine Other descriptive name: 2-chloro-2'-deoxyadenosine, 2CdA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Merck Serono International S.A.		Not Recruiting			Female: yes Male: yes	1290	Phase 3	Finland;Germany;Czech Republic;United Kingdom;Denmark;Estonia;Italy;Latvia;Lithuania
1232	EUCTR2005-000171-18-FI	12/05/2005	19 March 2012	A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A	A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW - N/A	Multiple Sclerosis (Relapsing-remitting MS and Secondary progressive MS with relapses)	Product Name: Temsirolimus Tablets Product Code: CCI-779 Pharmaceutical Form: Coated tablet INN or Proposed INN: Temsirolimus Current Sponsor code: CCI-779 Other descriptive name: WAY-130799 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2-	Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development		Not Recruiting			Female: yes Male: yes	180		Finland
1233	NCT00094172	May 2005	16 December 2017	Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients With Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (ITN020AI)	Multiple Sclerosis	Drug: Atorvastatin;Drug: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN)	Not recruiting	18 Years	55 Years	All	82	Phase 2	United States;Canada
1234	NCT00127530	May 2005	19 October 2017	Study of Oral Fampridine-SR in Multiple Sclerosis	Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Multiple Sclerosis	Multiple Sclerosis	Drug: Fampridine-SR;Drug: Placebo	Acorda Therapeutics		Not recruiting	18 Years	70 Years	All	301	Phase 3	United States;Canada
1235	NCT00942591	May 2005	19 February 2015	Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b	Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.	Multiple Sclerosis	Drug: Interferon beta 1b;Drug: Atorvastatin	University Hospital Inselspital, Berne	CRO: PharmaPart AG, Bahnhofstrasse 20, P.O. Box 173, CH-8800 Thalwil;Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 Basel	Not recruiting	18 Years	55 Years	Both	77	Phase 2	Switzerland
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1236	NCT01142453	May 2005	19 February 2015	An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients	Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in MS Patients. Case Series for Adjustment of Treatment Strategy and Its Monitoring	Relapsing-Remitting Multiple Sclerosis	Drug: Interferon beta 1a	Merck KGaA	Gesellschaft für Therapieforschung mbH	Not recruiting	N/A	N/A	Both	231	N/A
1237	NCT01199640	May 2005	19 February 2015	Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis	A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis	Multiple Sclerosis	Drug: MLN1202	Millennium Pharmaceuticals, Inc.		Not recruiting	18 Years	N/A	Both	50	Phase 2
1238	NCT02515695	May 2005	17 August 2015	Phase I BP Interferon (IFN) Beta-001	Bioavailability, Pharmacokinetic and Pharmacodynamic Profile of Interferon Beta-1a (Bioferon®) Administered i.v. and s.c. as Single Doses to Healthy Subjects	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta-1a	Centre Hospitalier Universitaire Vaudois	BioPartners GmbH	Not recruiting	18 Years	45 Years	Both	12	Phase 1
1239	EUCTR2004-002567-24-CZ	04/04/2005	19 March 2012	A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not appilcable	A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis - Not appilcable	The purpose of this study is to investigate the safety, PK parameters, PD responses, and clinical responses of multiple dose administration of MLN1202 in patients with relapsing remitting multiple sclerosis (RRMS).	Product Name: MLN1202 Product Code: MLN1202 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Not yet available Current Sponsor code: Not yet available Other descriptive name: Not yet available Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150-	Millennium Pharmaceuticals, Inc.		Not Recruiting			Female: yes Male: yes	160	Phase 2a	Hungary;United Kingdom;Czech Republic
1240	NCT00109161	April 2005	19 February 2015	Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis	A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)	PDL BioPharma, Inc.		Not recruiting	18 Years	55 Years	Both	270	Phase 2	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1241	NCT00213135	April 2005	19 October 2017	A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)	A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis, Relapsing-Remitting	Drug: Cladribine 5.25 mg/kg;Drug: Cladribine 3.5 mg/kg;Other: Placebo	EMD Serono		Not recruiting	18 Years	65 Years	All	1326	Phase 3	Canada;Switzerland
1242	NCT00668343	April 2005	19 February 2015	Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo		Relapsing Remitting Multiple Sclerosis	Drug: simvastatin;Drug: placebo	Tehran University of Medical Sciences		Not recruiting	15 Years	60 Years	Both	80	Phase 3	Iran, Islamic Republic of
1243	EUCTR2004-002509-63-CZ	11/03/2005	19 March 2012	A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis - N/A	A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis - N/A	Spasticity due to Multiple Sclerosis (MS)	Product Name: Sativex Product Code: GW-1000-02 Pharmaceutical Form: Oromucosal spray Other descriptive name: delta-9-tetrahydrocannabinol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 27- Other descriptive name: cannabidiol Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Oromucosal spray Route of administration of the placebo: Oromucosal use	GW Pharma Ltd		Not Recruiting			Female: yes Male: yes	284		United Kingdom;Czech Republic
1244	EUCTR2004-003799-13-LT	08/03/2005	1 May 2012	A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - Rebif® New Formulation in RMS	A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - Rebif® New Formulation in RMS	Relapsing form of MS ; diagnosis of MS is in accordance with the McDonald criteria MedDRA version: 7.0 Level: PT Classification code 10028245	Product Name: Interferon-beta-1a FBS-free/HSA free, RNF Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon-beta-1a CAS Number: 9008-11-1 Other descriptive name: G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-	Serono International SA		Not Recruiting			Female: yes Male: yes	230	Phase 3b	United Kingdom;Spain;Ireland;Sweden;Lithuania
1245	NCT00146159	March 2005	19 February 2015	Study Evaluating Mitoxantrone in Multiple Sclerosis	A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Drug: Mitoxantrone	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	18 Years	55 Years	Both	336	Phase 3	Germany
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1246	NCT01599234	March 2005	19 October 2017	A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis	A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Sativex, in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis.	Multiple Sclerosis	Drug: Sativex;Drug: Placebo	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	337	Phase 3	United Kingdom
1247	EUCTR2004-003761-33-ES	17/02/2005	19 March 2012	Unicenter double-blind, cross-over, randomised, placebo controlled clinical trial to evaluate efficacy of vardenafil in subjects with E.D. and multiple sclerosis (M.S.) - EMDE	Unicenter double-blind, cross-over, randomised, placebo controlled clinical trial to evaluate efficacy of vardenafil in subjects with E.D. and multiple sclerosis (M.S.) - EMDE	Erectile Dysfunction	Trade Name: Levitra Product Name: Vardenafil (hidrocloride) Pharmaceutical Form: Buccal tablet INN or Proposed INN: VARDENAFILO HIDROCLORURO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Buccal tablet Route of administration of the placebo: Oral use Trade Name: Levitra Product Name: Vardenafil (hidrocloride) Pharmaceutical Form: Buccal tablet INN or Proposed INN: VARDENAFILO HIDROCLORURO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Buccal tablet Route of administration of the placebo: Oral use Trade Name: Levitra Product Name: Vardenafil (hidrocloride) Pharmaceutical Form: Buccal tablet INN or Proposed INN: VARDENAFILO HIDROCLORURO Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Buccal tablet Route of administration of the placebo: Oral use	Unidad de Neuroinmunología		Authorised			Female: Male: yes	28		Spain
1248	EUCTR2004-004130-14-AT	17/02/2005	22 April 2013	A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with relapsing multiple sclerosis previously treated with Interferon beta-1a (22 or 44 mcg SC three times a week).	A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with relapsing multiple sclerosis previously treated with Interferon beta-1a (22 or 44 mcg SC three times a week).	Male and female subjects with relapsing multiple sclerosis previously treated with interferon beta-1a (22 mcg or 44 mcg, SC three times a week).	Product Name: Natalizumab Product Code: Not Applicable Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: natalizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Trade Name: Rebif 44 micrograms Product Name: Rebif 44 micrograms Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-	Biogen Idec GmbH		Not Recruiting			Female: yes Male: yes	1050		Austria
1249	EUCTR2004-003943-28-HU	14/02/2005	8 May 2012	A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in relapsing remitting (R-R) multiple sclerosis (MS) subjects	A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in relapsing remitting (R-R) multiple sclerosis (MS) subjects	Relapsing Remitting Multiple Sclerosis MedDRA version: 5.1 Level: PT Classification code 10028245	Product Name: Laquinimod Tablets 0.3 mg Product Code: ABR-215062 sodium salt Pharmaceutical Form: Tablet INN or Proposed INN: laquinimod CAS Number: 248282-07-7 Current Sponsor code: ABR-215062 sodium salt Other descriptive name: PNU-215062 sodium salt Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.3- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Teva Pharmaceutical Industries Ltd		Not Recruiting			Female: yes Male: yes	265		Hungary;Germany;United Kingdom;Czech Republic;Spain;Italy
1250	EUCTR2004-003799-13-SE	03/02/2005	1 May 2012	A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - Rebif® New Formulation in RMS	A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis. - Rebif® New Formulation in RMS	Relapsing form of MS ; diagnosis of MS is in accordance with the McDonald criteria MedDRA version: 7.0 Level: PT Classification code 10028245	Product Name: Interferon-beta-1a FBS-free/HSA free, RNF Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon-beta-1a CAS Number: 9008-11-1 Other descriptive name: G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-	Serono International SA		Not Recruiting			Female: yes Male: yes	230	Phase 3b	United Kingdom;Spain;Ireland;Lithuania;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1251	NCT00190268	February 2005	19 February 2015	Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis	Multicentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple Sclerosis	Multiple Sclerosis	Drug: 3,4-diaminopyridine	Assistance Publique - Hôpitaux de Paris		Not recruiting	18 Years	60 Years	Both	126	Phase 3	France
1252	EUCTR2004-004519-43-CZ	12/01/2005	1 May 2012	Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis	Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Product Code: RO0506997 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO0506997 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: RO0506997 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO0506997 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: RO0506997 Pharmaceutical Form: Film-coated tablet Current Sponsor code: RO0506997 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	F. Hoffmann-La Roche Ltd		Authorised			Female: yes Male: yes	200	Phase 2	Germany;United Kingdom;Czech Republic;Spain
1253	NCT00110396	January 2005	19 October 2017	Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis	A Multicentre, Single Arm, Open-Label, Phase IIIB Study to Evaluate the Safety and Antigenicity of Rebif® (Interferon-beta-1a) in Subjects With Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Biological: Interferon-beta-1a FBS-free/HSA-free	EMD Serono	Pfizer	Not recruiting	18 Years	60 Years	All	260	Phase 3	United States
1254	NCT00139789	January 2005	19 February 2015	A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis	A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis	Multiple Sclerosis	Drug: Kemstro	UCB Pharma		Not recruiting	18 Years	65 Years	Both	60	Phase 3	United States
1255	NCT00203047	January 2005	19 October 2017	Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate	A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-on Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated With Glatiramer Acetate (GA)	Relapsing Remitting Multiple Sclerosis	Drug: Glatiramer Acetate;Drug: Placebo;Drug: Prednisone	Teva Pharmaceutical Industries		Not recruiting	18 Years	55 Years	All	414	Phase 4	Canada;United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1256	NCT00206635	January 2005	19 February 2015	Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis	A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron® (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	33 Years	N/A	Both	432	N/A	United States;Canada;United Kingdom
1257	NCT00211887	January 2005	19 October 2017	Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx	A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients With Relapsing-Remitting Multiple Sclerosis (CombiRx)	Relapsing Remitting Multiple Sclerosis	Drug: Interferon beta 1-a;Drug: glatiramer acetate;Other: placebo	Fred Lublin	National Institute of Neurological Disorders and Stroke (NINDS)	Not recruiting	18 Years	60 Years	All	1008	Phase 3	United States;Canada
1258	NCT01142492	January 2005	19 February 2015	A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)	Postmarketing Surveillance Study on the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis With Interferon Beta 1a (Rebif®)	Relapsing-Remitting Multiple Sclerosis	Drug: Interferon beta-1a	Merck KGaA		Not recruiting	N/A	N/A	Both	403	N/A
1259	NCT01201343	January 2005	19 October 2017	Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients	Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients	Multiple Sclerosis, Relapsing, Remitting	Drug: Interferon beta-1a	Merck KGaA	Merck Serono S.A.S, France	Not recruiting	18 Years	N/A	All	79	Phase 4
1260	NCT00097188	December 2004	19 February 2015	A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis	A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: rituximab	Genentech, Inc.		Not recruiting	18 Years	55 Years	Both	104	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1261	NCT00200655	December 2004	9 May 2016	Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis	Safety and Efficacy of Pravastatin in Relapsing-remitting MS: a Double Blind Placebo Controlled Study	Relapsing-remitting Multiple Sclerosis	Drug: Pravastatin;Drug: Placebo	Nantes University Hospital		Not recruiting	18 Years	45 Years	Both	40	Phase 3	France
1262	NCT00203099	December 2004	19 February 2015	Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine	A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)	Relapse Remitting Multiple Sclerosis	Drug: Glatiramer Acetate, N-Acetylcysteine	Teva Pharmaceutical Industries		Not recruiting	18 Years	50 Years	Both	18	Phase 2	Canada
1263	NCT00360906	December 2004	19 February 2015	Omega-3 Fatty Acid Treatment in Multiple Sclerosis	Omega-3 Fatty Acid Treatment in Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: Triomar™ (omega-3 fatty acids)	Haukeland University Hospital	The Multiple Sclerosis National Competence Centre;The Norwegian Multiple sclerosis Society;Pronova BioPharma;Serono Nordic;Amersham Health	Not recruiting	18 Years	55 Years	Both	100	Phase 2/Phase 3	Norway
1264	NCT00869726	December 2004	19 February 2015	A Study for Patients With Secondary Progressive Multiple Sclerosis	A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis	Secondary Progressive Multiple Sclerosis	Drug: dirucotide;Drug: Placebo	Eli Lilly and Company	BioMS Technology Corp.	Not recruiting	18 Years	65 Years	Both	596	Phase 2/Phase 3	Canada;Denmark;Estonia;Finland;Germany;Latvia;Netherlands;Spain;Sweden;United Kingdom
1265	EUCTR2004-000555-42-NO	22/11/2004	14 August 2012	A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses - TEMSO	A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses - TEMSO	Multiple sclerosis	Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 7- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use Product Code: HMR1726 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Teriflunomide CAS Number: 108605-62-5 Current Sponsor code: HMR1726 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 14- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use	Sanofi-aventis US, Inc		Not Recruiting			Female: yes Male: yes	1080		Portugal;Czech Republic;United Kingdom;Denmark;Estonia;Norway;Italy;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1266	EUCTR2004-001601-10-IT	19/11/2004	19 March 2012	MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON REBIF 44 mcg X 3 TIMES WEEKLY IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS, IN THE FIRST STEP OF THE DISEASE	MULTICENTTRIC, NATIONAL, SINGLE BLIND,CONTROLLED IN PARALLEL GROUP TO EVALUATE THE SAFETY AND EFFICACY OF THE SEQUENTIAL COMBINATION OF MITOXANTRONE AND BETA INTERFERON REBIF 44 mcg X 3 TIMES WEEKLY IN PATIENTS AFFECTED BY MULTIPLE SCLEROSIS, IN THE FIRST STEP OF THE DISEASE	MULTIPLE SCLEROSIS TREATMENT MedDRA version: 6.1 Level: SOC Classification code 10029205	Trade Name: *NOVANTRONEINF 2MG/ML 5ML Pharmaceutical Form: Solution for injection INN or Proposed INN: Mitoxantrone CAS Number: 70476-82-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: REBIFSC 12SIR 12000000UI44MCG* Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-	OSPEDALE S. RAFFAELE		Authorised			Female: yes Male: yes	266		France;Italy
1267	EUCTR2004-000145-38-CZ	16/11/2004	19 March 2012	A Phase 2, Double-blind, Placebo-controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-remitting Multiple Sclerosis.	A Phase 2, Double-blind, Placebo-controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-remitting Multiple Sclerosis.	Relapse-remitting Multiple Sclerosis (RRMS) Classification code 10048393	Product Name: Human monoclonal antibody (CNTO 1275) to interleukin-12p40 Product Code: CNTO 1275 Pharmaceutical Form: Powder for solution for injection Current Sponsor code: CNTO 1275 Other descriptive name: Anti-IL-12; Human anti-IL-12 Mab; Human anti-IL-12 IgG1 Mab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Powder for solution for injection Route of administration of the placebo: Subcutaneous use	Centocor B.V.		Authorised			Female: yes Male: yes	250	Phase 2	Hungary;United Kingdom;Czech Republic
1268	NCT00101959	November 2004	19 February 2015	Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects	An Implementation Study of Treatment Optimization Recommendations Comparing Subjects Continuing Treatment With IFN-ß-1a 30 Mcg qw IM (Avonex®) or Glatiramer Acetate 20 mg qd SC (Copaxone®) to Those Randomized to IFN-ß-1a 44 Mcg Tiw SC (Rebif®), in a Multicenter Study of Subjects With Relapsing Remitting Multiple Sclerosis Currently on Disease-Modifying Therapy	Relapsing-Remitting Multiple Sclerosis	Drug: Rebif	EMD Serono		Not recruiting	18 Years	60 Years	Both	0	Phase 4	United States
1269	NCT00151294	November 2004	19 February 2015	The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis	A Double-Blind, Placebo-Controlled Investigation Into the Safety and Efficacy of Escitalopram for Depression in Multiple Sclerosis	Depression;Multiple Sclerosis	Drug: escitalopram oxalate antidepressant	Weill Medical College of Cornell University	Forest Laboratories	Not recruiting	18 Years	N/A	Both	20	Phase 4	United States
1270	EUCTR2004-000759-40-IT	22/10/2004	19 March 2012	A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.	A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.	Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit. MedDRA version: 6.1 Level: PT Classification code 10028245	Product Name: glatiramer acetate Product Code: TV-5010 Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate Current Sponsor code: TV - 5010 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 15-	TEVA		Not Recruiting			Female: yes Male: yes	25		Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1271	NCT00137176	October 2004	19 February 2015	EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis	EARLY IFNb-1a (Rebif) and Atorvastatin (Lipitor) Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis	Multiple Sclerosis	Drug: Rebif	University of North Carolina, Chapel Hill		Not recruiting	18 Years	60 Years	Both	30	N/A	United States
1272	NCT00168701	October 2004	19 February 2015	Efficacy and Safety of BG00012 in MS	Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: BG00012	Biogen Idec		Not recruiting	18 Years	55 Years	Both	260	Phase 2	Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Sweden;Switzerland;Turkey;United Kingdom
1273	NCT00240032	October 2004	19 February 2015	A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.	A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Autoject® 2 for Glass Syringe.	Multiple Sclerosis	Drug: glatiramer acetate injection with oral cetirizine hydrochloride;Drug: glatiramer acetate with placebo	Teva Pharmaceutical Industries		Not recruiting	18 Years	N/A	Both	80	Phase 4	United States
1274	EUCTR2005-000393-47-IT	22/09/2004	19 March 2012	Effect of Cannabis Based Medicine Extract Sativex on brain function as assessed by fMRI and neurophysiologic evaluation in patients with Multiple Sclerosis a double blind, randomised, placebo-controlled, crossover study.	Effect of Cannabis Based Medicine Extract Sativex on brain function as assessed by fMRI and neurophysiologic evaluation in patients with Multiple Sclerosis a double blind, randomised, placebo-controlled, crossover study.	Treatment of spasticity in patients with Multiple Sclerosis MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis	Trade Name: Cannabis Based Medicine Extract (Sativex) Pharmaceutical Form: Oromucosal spray Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2.7-	AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA		Not Recruiting			Female: yes Male: yes			Italy
1275	EUCTR2004-000663-99-SE	10/09/2004	19 March 2012	Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis.	Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis.	MS is a chronic disease of the CNS. It's a disease of young adults, primarily women, with disease onset typically occuring between the ages of 20 and 40. Although etiology is uncertain, evidence points to MS being an autoimmune disease directed against protein components of myelin. The majority of patients with MS start out with a clinical course characterised by episodes or attacks (relapses) of neurologic dysfunction, which occurs over many years.	Product Name: second-generation fumaric acid Product Code: BG00012 Pharmaceutical Form: Capsule, hard INN or Proposed INN: dimethyl fumarate CAS Number: 62008-21 Current Sponsor code: dimethyl fumarate Other descriptive name: dimethyl fumarate Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 120- Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use	Biogen Idec Inc.	Biogen Idec Ltd	Not Recruiting			Female: yes Male: yes	260		Hungary;Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1276	EUCTR2004-000073-64-FI	03/09/2004	19 March 2012	A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Effects of L-000124467 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis as Measured by MRI. Satunnaistettu, kaksoissokkoutettu ja lumekontrolloitu rinnakkaisryhmin etenevä tutkimus, jossa tutkitaan L-000124467 -lääkkeen kliinistä tehoa, turvallissuutta ja siedettävyyttä aaltomaista MS-tautia sairastavilla potilailla MRI menetelmällä. - -	A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Effects of L-000124467 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis as Measured by MRI. Satunnaistettu, kaksoissokkoutettu ja lumekontrolloitu rinnakkaisryhmin etenevä tutkimus, jossa tutkitaan L-000124467 -lääkkeen kliinistä tehoa, turvallissuutta ja siedettävyyttä aaltomaista MS-tautia sairastavilla potilailla MRI menetelmällä. - -	Aaltomainen MS-tauti	Product Code: L-000124467 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use	Merck & Co., Inc./Suomen MSD Oy		Not Recruiting			Female: yes Male: yes	120		Finland
1277	NCT00097331	September 2004	20 April 2015	Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis	A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: SB683699	GlaxoSmithKline		Not recruiting	18 Years	65 Years	Both	261	Phase 2	Belgium;Germany;Poland;Russian Federation;Spain;United States;Canada;France;Italy;Romania
1278	NCT00146068	September 2004	19 February 2015	EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis	Phase IV Double-Blind Randomized Study to Evaluate Safety and Efficacy of Interferon Beta-1a (Avonex) Plus Simvastatin (Zocor) Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Over a One Year Period	Multiple Sclerosis	Drug: Avonex/Zocor	University of North Carolina		Not recruiting	18 Years	60 Years	Both	30	Phase 4	United States
1279	NCT00315367	September 2004	19 February 2015	A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties	A Double-Blind, Crossover Trial of Aricept® in Memory-Impaired Patients With Multiple Sclerosis: A Phase IV Demonstration of Functional MRI (fMRI) as a Surrogate Marker of Brain Activity Associated With Improvement in Memory Function	Relapsing-Remitting Multiple Sclerosis	Drug: Donepezil HCI (drug)	Neurognostics		Not recruiting	18 Years	65 Years	Both	26	Phase 4	United States
1280	EUCTR2004-000762-13-IT	31/08/2004	3 September 2012	A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.	A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.	Subject with relapsing remitting Multiple Sclerosis. Subject must have at least one documented relapse within one year prior to screening visit. MedDRA version: 15.0 Level: PT Classification code 10028245 Term: Multiple sclerosis System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Glatiramer acetate Product Code: TV-5010 Pharmaceutical Form: Solution for injection INN or Proposed INN: Glatiramer acetate Current Sponsor code: TV-5010 Concentration unit: mg milligram(s) Concentration number: 30-	TEVA ITALIA srl		Authorised			Female: yes Male: yes	7		Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1281	NCT00220922	August 2004	19 February 2015	A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.	An Open-Label, Randomized, Single Cross-Over Study of Isopropyl Alcohol Wipes Versus No Injection Site Preparation on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone®	Multiple Sclerosis	Procedure: Alcohol Wipes vs. No Alcohol Wipes	Teva Neuroscience, Inc.		Not recruiting	18 Years	N/A	Both	50	Phase 4	United States
1282	NCT00239655	August 2004	8 August 2016	A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)	A Randomized, Double-Blind Placebo Controlled, Parallel Groups Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by MRI	Relapsing-Remitting Multiple Sclerosis	Drug: MK0812	Merck Sharp & Dohme Corp.		Not recruiting	18 Years	55 Years	Both	120	Phase 2	Canada;Finland;Germany;United Kingdom;United States
1283	EUCTR2004-000047-18-SE	27/07/2004	19 March 2012	An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803.	An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803.	Male and female subjects with multiple sclerosis who have completed natalizumab studies C-1801, C-1802, or C-1803	Product Name: natalizumab Product Code: AN100226 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: natalizumab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20-	Biogen Idec Ltd.		Not Recruiting			Female: yes Male: yes	1900		Sweden
1284	EUCTR2004-000337-12-HU	23/07/2004	19 March 2012	A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects with Relapsing Remitting Multiple Sclerosis - EMEA Post Approval Commitment New Clone Study	A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects with Relapsing Remitting Multiple Sclerosis - EMEA Post Approval Commitment New Clone Study	MS with 2 or more relapses within the last 2 years MedDRA version: 7.0 Level: PT Classification code 10028245	Trade Name: Rebif Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a CAS Number: 9008-11-1 Current Sponsor code: IFN-beta Other descriptive name: Recombinant human interferon beta Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 22- Trade Name: Rebif Product Name: Rebif Product Code: Not applicable Pharmaceutical Form: Solution for injection INN or Proposed INN: Interferon beta-1a CAS Number: 9008-11-1 Current Sponsor code: IFN-beta Other descriptive name: Recombinant human interferon beta Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 44-	Serono International SA		Authorised			Female: yes Male: yes	400	Phase 4	Hungary
1285	EUCTR2004-000462-13-HU	12/07/2004	19 March 2012	A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).	A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS).	Relapsing-remitting multiple sclerosis (R-R MS) MedDRA version: 5.1 Level: PT Classification code 10028245	Product Name: Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets Pharmaceutical Form: Coated tablet INN or Proposed INN: Glatiramer Acetate CAS Number: 147245-92-9 Current Sponsor code: GA Other descriptive name: COP-1/Copolymer-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	TEVA Pharmaceutical Industries Ltd.		Not Recruiting			Female: yes Male: yes	25		Hungary;Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1286	NCT00103974	July 2004	19 February 2015	Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis	A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis	Multiple Sclerosis	Biological: BHT-3009-01	Bayhill Therapeutics		Not recruiting	18 Years	65 Years	Both	30	Phase 1	United States;Canada
1287	NCT00202995	July 2004	19 February 2015	Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS	A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety, of Copaxone® to That of High Dose Interferon (Betaseron® or Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients	Relapsing Remitting Multiple Sclerosis	Drug: Glatiramer Acetate;Drug: Betaseron;Drug: Rebif	Teva Pharmaceutical Industries		Not recruiting	18 Years	50 Years	Both	91	Phase 4	United States;Canada
1288	NCT00207727	July 2004	19 October 2017	A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis	A Phase II, Double-blind, Placebo-Controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40(CNTO1275) in Subjects With Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: CNTO 1275	Centocor, Inc.	Centocor BV	Not recruiting	18 Years	65 Years	All	249	Phase 2	Australia;Canada;Czech Republic;Hungary;Poland;United Kingdom;United States
1289	NCT00223301	July 2004	19 February 2015	Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis	A One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple Sclerosis	Multiple Sclerosis	Drug: Mycophenolate Mofetil (cellcept)	University of Texas Southwestern Medical Center	Roche Pharma AG;Biogen Idec	Not recruiting	21 Years	45 Years	Both	24	Phase 2/Phase 3	United States
1290	EUCTR2004-000374-31-IT	09/06/2004	19 March 2012	A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-Ranging Study to Investigate the Efficacy and Safety of Three Months administration of SB 683699 (150 - 1200mg twice daily) in Subjects with Relapsing Multiple Sclerosis	A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-Ranging Study to Investigate the Efficacy and Safety of Three Months administration of SB 683699 (150 - 1200mg twice daily) in Subjects with Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis	Trade Name: ALTRI FARMACI DEL SISTEMA NERVOSO Product Name: NA Product Code: aSB-683699 Pharmaceutical Form: Tablet Current Sponsor code: SB683699 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-	GLAXO SMITHKLINE		Not Recruiting			Female: yes Male: yes			Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1291	NCT00087529	June 2004	19 October 2017	A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis	A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: placebo;Drug: rituximab	Genentech, Inc.		Not recruiting	18 Years	65 Years	All	439	Phase 2/Phase 3	Canada;United States
1292	NCT00203112	June 2004	19 February 2015	Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline	A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated With Glatiramer Acetate (GA).	Relapse Remitting Multiple Sclerosis	Drug: glatiramer acetate with minocycline;Drug: Glatiramer acetate with placebo	Teva Pharmaceutical Industries		Not recruiting	18 Years	50 Years	Both	44	Phase 2	Canada
1293	NCT01142557	June 2004	19 February 2015	An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis	Therapy of the Chronic Multiple Sclerosis With Interferon-beta 1a (Rebif®)	Multiple Sclerosis	Drug: Interferon beta-1a (Rebif)	Merck KGaA	Gesellschaft für Therapieforschung mbH	Not recruiting	N/A	N/A	Both	522	N/A	Germany
1294	NCT00367484	May 2004	19 October 2017	Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis	Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Biological: Rebif® (clone 484-39)	Merck KGaA		Not recruiting	18 Years	60 Years	All	460	Phase 4
1295	NCT00493077	May 2004	19 February 2015	Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy	A Swedish Multi-Centre, Prospective, Open Label Study: Safety of Avonex Treatment in Multiple Sclerosis Patients Who Are NAB Positive on Previous s.c Interferon Beta Therapy	Multiple Sclerosis	Drug: low immunogenic interferon-beta-1a	Biogen Idec		Not recruiting	18 Years	55 Years	Both	3	Phase 4	Sweden
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1296	NCT00682929	April 14, 2004	11 June 2018	Cannabis for Spasticity in Multiple Sclerosis	Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study	Multiple Sclerosis	Drug: Inhaled Cannabis;Drug: Oral THC;Drug: Oral Placebo;Drug: Inhaled placebo	University of California, Davis	National Multiple Sclerosis Society	Not recruiting	21 Years	N/A	All	41	Phase 1/Phase 2	United States
1297	NCT00086671	April 2004	19 February 2015	Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)	A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase	Multiple Sclerosis	Drug: ABT-874/Human monoclonal antibody against IL-12;Drug: Placebo	AbbVie (prior sponsor, Abbott)		Not recruiting	18 Years	60 Years	Both	215	Phase 2	United States;Canada;Germany;Netherlands;United Kingdom
1298	NCT00217295	April 2004	19 February 2015	A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis	A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis.	Multiple Sclerosis	Drug: Avonex and Topamax	Multiple Sclerosis Institute		Recruiting	18 Years	55 Years	Both	30	Phase 2	United States
1299	NCT00300716	April 2004	22 October 2019	Trial of Memantine for Cognitive Impairment in Multiple Sclerosis	Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis	Multiple Sclerosis;Cognition Disorders	Drug: Memantine	Oregon Health and Science University	Forest Laboratories;University of Southern California;University of Texas Southwestern Medical Center;MS-Hub Seattle	Not recruiting	18 Years	65 Years	All	82	Phase 2/Phase 3	United States
1300	NCT01233245	April 2004	19 February 2015	BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program	BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program	Relapsing Remitting MS (RRMS);Secondary Progressive MS (SPMS)	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	N/A	Both	1077	N/A	Czech Republic;France;Germany;Iran, Islamic Republic of;Israel;Italy;Jordan;Korea, Republic of;Lebanon;Netherlands;Portugal;Saudi Arabia;Spain;Taiwan;Turkey
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1301	NCT00078338	March 2004	19 February 2015	Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis	Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: Human interferon beta-1a and glatiramer acetate	EMD Serono	Pfizer	Not recruiting	18 Years	60 Years	Both	764	Phase 4	United States;Argentina;Austria;Brazil;France;Germany;Italy;Netherlands;Russian Federation;Spain;Switzerland;United Kingdom
1302	NCT00168714	February 2004	19 February 2015	Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)	Avonex Pregnancy Exposure Registry	Prenatal Exposure Delayed Effects;Multiple Sclerosis;Pregnancy	Drug: BG9418 (interferon beta-1a)	Biogen Idec		Not recruiting	N/A	N/A	Female	329	N/A	United States
1303	NCT00501748	January 2004	19 February 2015	Safety and Tolerability of Rituximab in Neuromyelitis Optica	Open Label Study of Safety and Tolerability of Rituximab in Neuromyelitis Optica, Recurrent Transverse Myelitis and Recurrent Bilateral Simultaneous Optic Neuritis	Neuromyelitis Optica	Drug: Rituximab	University of California, San Francisco	Genentech, Inc.	Not recruiting	12 Years	86 Years	Both	20	Phase 1	United States
1304	NCT00666224	January 2004	19 October 2017	Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome	A Multinational, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Early Glatiramer Acetate Treatment in Delaying the Conversion to Clinically Definite Multiple Sclerosis (CDMS) of Subjects Presenting With Clinically Isolated Syndrome (CIS)	Multiple Sclerosis	Drug: Glatiramer Acetate (DB);Drug: Placebo;Drug: Glatiramer Acetate (OL)	Teva Pharmaceutical Industries		Not recruiting	18 Years	45 Years	All	481	Phase 3	Argentina;Australia;Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Romania;Spain;Sweden;United Kingdom;United States
1305	NCT00246324	December 2003	11 June 2018	Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis	An Open Label Trial of Safety and Efficacy of Combination Therapy With Interferon-B-1a and Oral Doxycycline in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis	Drug: Interferon beta 1a, oral doxycycline	Louisiana State University Health Sciences Center Shreveport	Biogen	Not recruiting	18 Years	55 Years	All	16	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1306	NCT00276172	December 2003	19 February 2015	Open-Label Natalizumab Safety Extension Study	An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803	Multiple Sclerosis	Drug: Natalizumab	Biogen Idec		Not recruiting	18 Years	N/A	Both	1615	Phase 3	United States
1307	NCT00099502	November 2003	19 February 2015	BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients	International, Randomized, Multicenter, Phase IIIb Study in Patients With Relapsing-Remitting Multiple Sclerosis Comparing Over a Treatment Period of at Least 104 Weeks: 1. Double-Blinded Safety, Tolerability, and Efficacy of Betaseron/ Betaferon 250 µg (8 MIU) and Betaseron/-Betaferon 500 µg (16 MIU), Both Given Subcutaneously Every Other Day, and 2. Rater-Blinded Safety, Tolerability, and Efficacy of Betaseron/-Betaferon s.c. Every Other Day With Copaxone 20 mg s.c. Once Daily.	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);Drug: Copaxone	Bayer		Not recruiting	18 Years	55 Years	Both	2244	Phase 3	United States;Argentina;Australia;Austria;Belgium;Brazil;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Latvia;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;Switzerland;Ukraine
1308	NCT00228397	November 2003	19 February 2015	Study Evaluating CCI-779 in Relapsing Multiple Sclerosis	A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis.	Multiple Sclerosis, Relapsing-Remitting	Drug: CCI-779	Wyeth is now a wholly owned subsidiary of Pfizer		Not recruiting	N/A	N/A	Both	221	Phase 2
1309	NCT00654927	November 2003	19 October 2017	Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis	Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Fampridine-SR b.i.d. (Twice Daily)	Acorda Therapeutics		Not recruiting	18 Years	70 Years	All	177	Phase 3	United States;Canada
1310	NCT00071838	October 30, 2003	16 December 2017	Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis	Zenapax (Daclizumab) Admin to Pts With Multiple Sclerosis (ZAP MS): Effect of Intravenously Admin Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (Daclizumab) on Inflammatory Activity in the Central Nervous System	Multiple Sclerosis, Relapsing-Remitting	Drug: Daclizumab	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	18 Years	65 Years	All	16	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1311	NCT00242177	October 2003	29 July 2019	Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability	Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability	Multiple Sclerosis, Relapsing-Remitting	Drug: ACTOS (Pioglitazone)	University of Illinois at Chicago	Takeda Pharmaceuticals North America, Inc.	Not recruiting	18 Years	65 Years	All	30	Phase 1	United States
1312	NCT00296205	October 2003	19 February 2015	Phase II High-Dose Cyclophosphamide for Multiple Sclerosis	Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis	Multiple Sclerosis	Drug: Cyclophosphamide	Stony Brook University		Not recruiting	18 Years	75 Years	Both	25	Phase 2	United States
1313	NCT00493116	October 2003	19 February 2015	Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta	A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability	Relapsing-Remitting Multiple Sclerosis	Drug: Interferon-beta-1a;Drug: methylprednisolone	Biogen Idec		Not recruiting	18 Years	55 Years	Both	20	Phase 4	Australia;New Zealand
1314	NCT00616187	October 2003	11 June 2018	Atorvastatin in Relapsing-Remitting Multiple Sclerosis	Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: interferon beta treatment to add-on atorvastatin treatment;Drug: untreated to atorvastatin treatment	Charite University, Berlin, Germany	German Research Foundation;German Federal Ministry of Education and Research;Pfizer	Not recruiting	18 Years	55 Years	All	41	Phase 2
1315	NCT00418145	September 2003	16 December 2017	Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks	Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA)	Multiple Sclerosis	Drug: megadose oral methylprednisolone;Drug: IV methylprednisolone	Fred Lublin	National Multiple Sclerosis Society;Pfizer	Not recruiting	18 Years	50 Years	All	16	Phase 3	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1316	NCT00202982	August 2003	19 February 2015	A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose	A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability and Safety of 40 mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients	Relapse-Remitting Multiple Sclerosis	Drug: glatiramer acetate 20 mg;Drug: glatiramer acetate 40 mg	Teva Pharmaceutical Industries		Not recruiting	18 Years	50 Years	Both	90	Phase 2	United States
1317	NCT00276341	August 2003	18 December 2018	Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis	Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.	Multiple Sclerosis, Relapsing-Remitting	Drug: EGb 761® (Tanakan®)	Ipsen		Not recruiting	18 Years	N/A	All	240	Phase 3	France
1318	NCT00913250	August 2003	19 February 2015	A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers	A Randomized, Single-Blind, Crossover Study in Healthy Volunteers to Demonstrate the Bioequivalence of AVONEX® (Interferon Beta-1a) Solutions for Injection Produced by a Serum-Containing Manufacturing Process and by a Serum-Free Manufacturing Process	Multiple Sclerosis	Drug: Serum containing Avonex;Drug: Serum Free Avonex	Biogen Idec		Not recruiting	18 Years	45 Years	Both	96	Phase 1
1319	NCT00079495	July 2003	19 February 2015	Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: NBI-5788	Neurocrine Biosciences	Immune Tolerance Network (ITN)	Not recruiting	18 Years	55 Years	Both	150	Phase 2
1320	NCT00097760	June 2003	19 February 2015	Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis	Safety Study of Natalizumab in Combination With Glatiramer Acetate (GA)	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab;Drug: Placebo	Biogen Idec	Elan Pharmaceuticals	Not recruiting	18 Years	55 Years	Both	110	Phase 2
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1321	NCT00112034	June 2003	19 February 2015	AVONEX® Combination Trial - ACT	A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy.	Multiple Sclerosis, Relapsing-Remitting	Drug: Methotrexate;Drug: IV methylprednisolone	Biogen Idec		Not recruiting	18 Years	55 Years	Both	350	Phase 4	United States
1322	NCT00142402	June 2003	19 February 2015	Modafinil in Multiple Sclerosis	Modafinil for Improving New Learning and Memory in Multiple Sclerosis	Multiple Sclerosis	Drug: Modafinil	Kessler Foundation	National Multiple Sclerosis Society	Not recruiting	18 Years	60 Years	Both	20	N/A	United States
1323	NCT00203073	June 2003	19 February 2015	A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.	A Multi-Center, Randomized, Open Label Study To Evaluate Safety, Tolerability And Efficacy Of Treatment With Mitoxantrone; Pre-Treatment With Glatiramer Acetate (GA) Versus Treatment With GA Alone In Relapsing Forms Of Multiple Sclerosis.	Relapsing Remitting Multiple Sclerosis	Drug: glatiramer acetate 20 mg;Drug: glatiramer acetate 20 mg, with mitoxantrone	Teva Pharmaceutical Industries		Not recruiting	18 Years	55 Years	Both	40	Phase 2	United States;Canada
1324	NCT00220493	June 2003	19 February 2015	Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients	Clinical Study Protocol: Evaluation of the Efficiency of Ritalin in Multiple Sclerosis Patients	Relapsing Remitting Multiple Sclerosis;Multiple Sclerosis, Chronic Progressive	Drug: Ritalin	Sheba Medical Center		Recruiting	25 Years	65 Years	Both	80	Phase 1	Israel
1325	NCT00235989	June 2003	19 October 2017	Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis	An Open-label Extension Study of the Double-blind, Randomized, Parallel Group, Multicenter Phase 2 Study 307000A to Further Evaluate the Safety and Tolerability of Betaseron® 500 mcg Subcutaneously Every Other Day and Betaseron® 250 mcg Subcutaneously Every Other Day in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)	Multiple Sclerosis, Relapsing-Remitting	Drug: Interferon beta 1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	55 Years	All	63	Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1326	NCT00267319	June 2003	19 February 2015	FOCUS Fatigue Outcome in Copaxone USers	Fatigue Outcomes of Copaxone Users in Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Glatiramer acetate	Sanofi		Not recruiting	18 Years	N/A	Both	111	Phase 4	Czech Republic
1327	NCT00278655	June 2003	19 October 2017	Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis	Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Interferon Therapy: A Phase II Multi-Center Trial	Multiple Sclerosis	Biological: Hematopoietic stem cell transplantation	Northwestern University		Not recruiting	18 Years	50 Years	All	21	Phase 1/Phase 2	United States
1328	NCT00095329	May 2003	3 October 2016	Treating Multiple Sclerosis With Sirolimus, an Immune System Suppressor	A Phase I/II, Open-Label Pilot Trial to Evaluate the Safety of Rapamune (Sirolimus) in Patients With Multiple Sclerosis	Multiple Sclerosis (MS) - Relapsing-remitting	Biological: sirolimus	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Not recruiting	18 Years	58 Years	Both	14	Phase 1/Phase 2	United States
1329	NCT00333138	May 2003	16 December 2017	Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis	Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Evaluating the Safety, Tolerability and Effect on MRI Lesion Parameters of FTY720 vs Placebo in Patients With Relapsing Multiple Sclerosis Including 18 Month Extension Phase	Multiple Sclerosis	Drug: FTY720;Drug: Placebo	Novartis		Not recruiting	18 Years	60 Years	All	281	Phase 2	Canada;Denmark;Finland;France;Germany;Italy;Poland;Portugal;Spain;Switzerland;United Kingdom
1330	NCT00206648	March 2003	19 February 2015	An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS	A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron 250 µg Subcutaneously Every Other Day With Avonex 30 µg Intramuscularly Once Per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated With Avonex	Multiple Sclerosis, Relapsing-Remitting	Drug: Betaferon/Betaseron	Bayer		Not recruiting	18 Years	60 Years	Both	271	Phase 4	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1331	NCT00260741	March 2003	19 February 2015	Cannabis for Spasticity in Multiple Sclerosis	Cannabis for Spasticity in Multiple Sclerosis: A Placebo-Controlled Study	Multiple Sclerosis	Drug: Smoked Cannabis	Center for Medicinal Cannabis Research		Not recruiting	21 Years	N/A	Both	60	Phase 1/Phase 2	United States
1332	NCT00492466	March 2003	19 February 2015	Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies	A Multicentre, Open Label, Non-Comparative Trial Investigating the Recovering of INF-Beta Efficacy in Breakthrough Relapsing-Remitting Multiple Sclerosis Patients With Neutralizing Interferon-Beta Antibodies	Relapsing-Remitting Multiple Sclerosis	Drug: Interferon-beta-1a;Drug: methylprednisolone	Biogen Idec		Not recruiting	18 Years	55 Years	Both	14	Phase 4	Finland
1333	NCT00053417	February 2003	19 October 2017	Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis	Double-Blind, Placebo-Controlled, 20-Week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis	Multiple Sclerosis	Drug: Placebo;Drug: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP);Drug: 15 mg fampridine-SR (4-aminopyridine, 4-AP);Drug: 20 mg fampridine-SR (4-aminopyridine, 4-AP)	Acorda Therapeutics		Not recruiting	18 Years	70 Years	All	206	Phase 2	United States;Canada
1334	NCT00298662	February 2003	19 February 2015	Combination Therapy of Betaseron-Prograf in Multiple Sclerosis	A Pilot Safety and Tolerability Open-Label Study of Interferon Beta-1b in Combination With Tacrolimus in Patients Suffering From Multiple Sclerosis Who Have Failed Treatment With Approved Disease Modifying Agents	Multiple Sclerosis	Drug: Interferon beta-1b and Tacrolimus	Clinique de sclérose en plaques et neuromusculaire de l'Outaouais		Not recruiting	18 Years	55 Years	Both	30	Phase 2	Canada
1335	NCT00076934	January 2003	16 December 2017	Safety of RG2077 in Patients With Multiple Sclerosis	A Phase I Study: Safety of RG2077 (CTLA4-IgG4m) in Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: RG2077 (CTLA4-IgG4m)	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN);Repligen Corporation	Not recruiting	18 Years	55 Years	All	20	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1336	NCT00176592	January 2003	19 February 2015	Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI	Phase IV, Rater-blinded, Randomized Study, Comparing 250 mg of Betaseron With 20 mg of Copaxone in Patients With the Relapsing-remitting(RR) or CIS Forms of ms Using 3 Tesla(3T) Magnetic Resonance Imaging (MRI) With Triple-dose Gadolinium	Multiple Sclerosis	Drug: Betaseron;Drug: Copaxone	Stuart D Cook MD		Not recruiting	18 Years	55 Years	Both	93	Phase 4	United States
1337	NCT00210301	January 2003	19 February 2015	Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS	Combination Therapy (Provigil + Avonex) in the Treatment of Attention Problems in Patients With Relapsing-Remitting MS	Relapsing-Remitting Multiple Sclerosis	Drug: Provigil (modafinil)	Institute for Clinical Research		Recruiting	20 Years	65 Years	Both	60	N/A	United States
1338	NCT00912860	January 2003	19 February 2015	Immunogenicity and Safety Study of Serum-Free Avonex	A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon Beta-1a) Administered Intramuscularly to Patients With Relapsing/Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon beta-1a	Biogen Idec		Not recruiting	18 Years	60 Years	Both	155	Phase 2
1339	NCT00050232	December 2002	8 August 2016	Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients		Multiple Sclerosis	Drug: AVP-923	Avanir Pharmaceuticals		Not recruiting	18 Years	68 Years	Both	96	Phase 3	United States
1340	NCT00050778	December 2002	19 October 2017	A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis	A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif®) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Biological: Interferon beta-1a;Biological: Alemtuzumab 12 mg;Biological: Alemtuzumab 24 mg	Genzyme, a Sanofi Company	Bayer	Not recruiting	18 Years	50 Years	All	334	Phase 2	United States;Croatia;Poland;Russian Federation;United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1341	NCT00220779	December 2002	19 October 2017	Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis	Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified;Drug: Albumin (Human) 25%, United States Pharmacopeia (USP)	Grifols Therapeutics Inc.		Not recruiting	18 Years	55 Years	All	128	Phase 2	United States;Austria;Canada;Czech Republic;Germany;Greece;Hungary;Israel;Poland;Slovakia;Sweden;United Kingdom
1342	NCT00893217	November 2002	19 February 2015	BEYOND Pilot Study	Double-blind, Randomized, Parallel Group, Multicenter Study of the Safety and Tolerability of Betaseron 500 Mcg Subcutaneously Every Other Day and Betaseron 250 Mcg Subcutaneously Every Other Day for at Least 12 Weeks in Patients With RRMS	Multiple Sclerosis;Relapsing-Remitting	Drug: Betaseron (Interferon beta-1b, BAY86-5046)	Bayer		Not recruiting	18 Years	55 Years	Both	71	Phase 2	United States
1343	NCT00913666	November 2002	19 February 2015	Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers	A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX®, MS Subjects Naïve to Treatment, and Healthy Control Subjects	Multiple Sclerosis	Drug: Interferon beta-1a (Avonex)	Biogen Idec		Not recruiting	18 Years	65 Years	Both	121	Phase 4
1344	NCT00185211	August 2002	19 October 2017	BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study	Open-label, Multi-center Phase III Extension of the Double-blind, Placebo-controlled BENEFIT Study (no. 92012/304747) to Obtain Long-term Follow-up Data of Patients With Clinically Definite Multiple Sclerosis (MS) and Patients With a First Demyelinating Event Suggestive of MS Treated With 8 MIU (250 µg) Interferon Beta-1b (Betaferon® / Betaseron®) Given Subcutaneously Every Other Day for at Least 36 Months.	Multiple Sclerosis	Drug: Interferon beta-1b (Betaseron, BAY86-5046)	Bayer		Not recruiting	18 Years	48 Years	All	468	Phase 3	Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Portugal;Slovenia;Spain;Sweden;Switzerland;United Kingdom
1345	NCT00599274	August 2002	19 February 2015	Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis	A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects With Relapsing Multiple Sclerosis (MS)	Multiple Sclerosis	Drug: Interferon beta-1a	Biogen Idec		Not recruiting	18 Years	50 Years	Both	136	N/A	United States;Australia;Austria;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1346	NCT00678795	August 2002	19 October 2017	A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis	A Double Blind, Randomised, Placebo Controlled, Parallel Group Study of Cannabis Based Medicine (CBM) Extract, in Patients Suffering Detrusor Overactivity Associated With Multiple Sclerosis.	Detrusor Overactivity;Multiple Sclerosis	Drug: Sativex®;Drug: Placebo	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	135	Phase 3	United Kingdom
1347	NCT00587691	July 2002	16 December 2017	Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis	An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Secondary Progressive	Biological: Tovaxin Autologous T Cell Vaccine	Opexa Therapeutics, Inc.		Not recruiting	18 Years	65 Years	All	16	Phase 1/Phase 2	United States
1348	NCT00047580	June 2002	21 December 2015	Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.	A Multicenter, Open-Label, Randomized, 4-Way Crossover Trial of the Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex (Tizanidine Hydrochloride) Tablets Taken Under Fed and Fasted Conditions in Patients With Moderate to Severe Spasticity	Multiple Sclerosis;Muscle Spasticity;Spinal Cord Injury;Stroke	Drug: tizanidine hydrochloride capsule	Elan Pharmaceuticals		Not recruiting	18 Years	N/A	Both	120	Phase 3	United States
1349	NCT00711646	June 2002	19 October 2017	A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.	A Double Blind, Randomised, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Cannabis Based Medicine 1:1 THC:CBD Compared With Placebo for the Treatment of Spasticity in Patients With Multiple Sclerosis.	Spasticity;Multiple Sclerosis	Drug: Sativex®;Drug: Placebo	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	189	Phase 3	United Kingdom
1350	NCT00037115	May 2002	11 June 2018	Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.	An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results.	Demyelinating Disorders;Multiple Sclerosis;Optic Neuritis;Myelitis;Neuritis	Drug: interferon beta 1a;Drug: methotrexate;Drug: methylprednisolone	MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute	Consultants in Neurology	Not recruiting	18 Years	50 Years	All	0	Phase 4	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1351	NCT00151801	May 2002	19 February 2015	Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients	Safety and Tolerability of Oral Two-Doses Estroprogestins Associated With Interferon-Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: estroprogestins;Drug: interferon-beta 1a	S. Andrea Hospital		Recruiting	18 Years	40 Years	Female	200	Phase 2	Italy
1352	NCT00228228	May 2002	19 February 2015	TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis	T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis	Multiple Sclerosis	Biological: T cell vaccination	Sheba Medical Center		Recruiting	15 Years	50 Years	Both	80	Phase 3	Israel
1353	NCT01448252	May 2002	19 February 2015	T Cell Vaccination in Patients With Progressive Multiple Sclerosis	Autologous T Cell Vaccination With Line Specific for 9 Myelin Peptides in Patients With Progressive / Relapsing Multiple Sclerosis	Multiple Sclerosis	Biological: multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides);Biological: T cell vaccination	Hadassah Medical Organization		Not recruiting	18 Years	60 Years	Both	30	Phase 1/Phase 2	Israel
1354	NCT00405353	April 2002	19 February 2015	Testosterone Treatment for Multiple Sclerosis	Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial	Multiple Sclerosis	Drug: Androgel 100mg gel	University of California, Los Angeles	National Multiple Sclerosis Society	Not recruiting	18 Years	65 Years	Male	10	Phase 1/Phase 2	United States
1355	NCT01604265	March 2002	19 October 2017	A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis	A Double Blind, Randomised, Parallel Group, Placebo Controlled Study of Sativex in the Treatment of Central Neuropathic Pain in Multiple Sclerosis.	Multiple Sclerosis;Neuropathic Pain	Drug: Placebo;Drug: Sativex	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	66	Phase 3	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1356	NCT01606176	March 2002	19 October 2017	A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin	A Multi Centre Randomised, Double Blind, Placebo Controlled, Parallel Group Comparison of the Effects of Cannabis Based Medicine Standardised Extracts Over 4 Weeks, in Patients With Chronic Refractory Pain Due to Multiple Sclerosis or Other Defects of Neurological Function.	Pain;Multiple Sclerosis	Drug: GW-1000-02;Drug: Placebo	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	70	Phase 3	United Kingdom
1357	NCT00067327	February 2002	19 February 2015	Treatment of Multiple Sclerosis Using Over the Counter Inosine	Treatment of Multiple Sclerosis Using Over the Counter Inosine	Multiple Sclerosis, Relapsing-Remitting	Drug: Inosine	National Center for Complementary and Integrative Health (NCCIH)		Not recruiting	18 Years	60 Years	Both	30	Phase 2	United States
1358	NCT01606137	February 2002	19 October 2017	A Study of the Long-term Safety of Sativex Use	A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine.	Multiple Sclerosis;Spasticity;Pain	Drug: GW-1000-02	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	507	Phase 3	United Kingdom
1359	NCT00030966	January 2002	19 February 2015	Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab;Drug: Placebo	Biogen Idec	Elan Pharmaceuticals	Not recruiting	18 Years	55 Years	Both	1200	Phase 3	United States;Austria;Belgium;France;Germany;Israel;Italy
1360	NCT00228163	January 2002	7 April 2015	Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses	Extension of Protocol HMR1726D/2001, A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses	Multiple Sclerosis	Drug: teriflunomide (HMR1726)	Sanofi		Not recruiting	18 Years	65 Years	Both	147	Phase 2	Canada;France
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1361	NCT00027300	November 2001	16 December 2017	Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab;Drug: Placebo	Biogen	Elan Pharmaceuticals	Not recruiting	18 Years	50 Years	All	900	Phase 3	United States;Belgium;Canada;Czech Republic;France;Germany;Netherlands;United Kingdom
1362	NCT00035529	November 2001	19 February 2015	A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis	A Phase II,Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Placebo;Drug: BMS 188667 (Abatacept)	Bristol-Myers Squibb		Not recruiting	18 Years	55 Years	Both		Phase 2	United States
1363	NCT00039988	November 2001	3 October 2016	Treatment of Multiple Sclerosis With Copaxone and Albuterol	Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol	Autoimmune Diseases;Multiple Sclerosis	Drug: Glatiramer acetate;Drug: Albuterol;Drug: Albuterol placebo	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence	Not recruiting	18 Years	55 Years	Both	40	N/A	United States
1364	NCT00202410	November 2001	19 February 2015	Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis	Phase 2-3 Use of Bacille Calmette-Guèrin (BCG) Vaccine in Patients With a First Clinical Demyelinating Episode: a Multicenter, Randomized, Single Blind Study.	Multiple Sclerosis	Biological: Bacille of Calmette-Guerin;Other: placebo	S. Andrea Hospital	Multiple Sclerosis Italian Foundation (FISM);Istituto Superiore di Sanità	Not recruiting	18 Years	N/A	Both	80	Phase 2/Phase 3	Italy
1365	NCT00248378	September 2001	19 February 2015	Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis	Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis	Multiple Sclerosis	Drug: Smoked Cannabis	Center for Medicinal Cannabis Research		Not recruiting	18 Years	N/A	Both	30	Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1366	NCT00304291	August 2001	19 February 2015	A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)	A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)	Neuromyelitis Optica;Myelitis, Transverse;Demyelinating Autoimmune Diseases, CNS;Autoimmune Diseases of the Nervous System	Drug: Mitoxantrone	State University of New York at Buffalo	EMD Serono	Not recruiting	18 Years	55 Years	Both	5	Phase 4	United States
1367	NCT00037102	July 2001	11 June 2018	Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis	An Open Label Study of the Safety and Efficacy of Combination Therapy With AVONEX and Bi-Monthly High Dose Intravenous Methotrexate With Leucovorin Rescue in the Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: interferon beta 1a;Drug: methotrexate	MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute	Consultants in Neurology;Biogen	Not recruiting	18 Years	60 Years	All	16	Phase 4	United States
1368	NCT01610687	July 2001	19 October 2017	A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis	A Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension	Multiple Sclerosis;Spasticity	Drug: GW-1000-02	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	137	Phase 3	United Kingdom
1369	NCT00043264	June 2001	19 February 2015	Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis	Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis	Multiple Sclerosis	Drug: Rifampin;Drug: Azithromycin	National Center for Research Resources (NCRR)	National Multiple Sclerosis Society	Not recruiting	18 Years	65 Years	Both	40	Phase 2	United States
1370	NCT01610700	May 2001	19 October 2017	An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients	Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension	Multiple Sclerosis	Drug: GW-1000-02;Drug: Placebo	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	160	Phase 3	United Kingdom
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1371	NCT01610713	May 2001	19 October 2017	An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis	Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension	Multiple Sclerosis	Drug: GW-1000-02	GW Pharmaceuticals Ltd.		Not recruiting	18 Years	N/A	All	154	Phase 3	United Kingdom
1372	NCT00017628	April 2001	19 February 2015	Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis		Multiple Sclerosis	Drug: cyclophosphamide;Drug: filgrastim;Drug: methylprednisolone;Procedure: Autologous Stem Cell Transplantation	Northwestern Memorial Hospital		Not recruiting	N/A	59 Years	Both	20	Phase 1	United States
1373	NCT01487096	April 2001	19 February 2015	Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses	A Phase II Study of the Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses	Multiple Sclerosis	Drug: Teriflunomide;Drug: Placebo (placebo for teriflunomide)	Sanofi		Not recruiting	18 Years	65 Years	Both	179	Phase 2	Canada;France
1374	NCT00011375	February 2001	19 February 2015	Rolipram to Treat Multiple Sclerosis	Safety, Tolerability & Effects of Rolipram on Inflammatory Activity in the Central Nervous System in Multiple Sclerosis. A Phase II, Open Label Crossover Trial Using MRI as an Outcome Measure	Multiple Sclerosis	Drug: Rolipram	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	N/A	N/A	Both	52	Phase 2	United States
1375	NCT00179478	February 2001	16 December 2017	Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis	Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10)	Multiple Sclerosis;Optic Neuritis;Transverse Myelitis;Acute Brainstem/Cerebellar Syndrome	Drug: interferon beta 1a 30 ug IM once weekly	Beth Israel Deaconess Medical Center	Biogen	Not recruiting	18 Years	N/A	All	155	Phase 4	United States;Canada
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1376	NCT01863069	January 2001	19 February 2015	Avonex®: Safety, Blood Levels and Effects	A Single-centre Study to Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Inhaled Formulation of AVONEX® (Interferon Beta-1a) in Healthy Volunteers	Multiple Sclerosis (MS)	Drug: Interferon beta 1a;Drug: (IM) AVONEX®	Trio Medicines Ltd.	Biogen Idec	Not recruiting	18 Years	45 Years	Both	77	Phase 1	United Kingdom
1377	NCT00292266	November 1999	19 February 2015	A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)	An Open Label, Randomized, Multicenter, Comparative, Parallel Group Study of Rebif® 44 Mcg Administered Three Times Per Week by Subcutaneous Injection, Compared With Avonex® 30 Mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Rebif®;Drug: Avonex®	EMD Serono	Merck Serono International SA	Not recruiting	18 Years	55 Years	Both	677	Phase 3
1378	NCT00534261	November 1999	19 February 2015	Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?	Evaluation of the Correlation Between the MS Functional Composite Index and Two Quality of Life Scales (MS54 and AMS Quality of Life) in Relapsing MS Patients Treated With Interferon Beta-1a (AVONEX®)	Relapsing Remitting Multiple Sclerosis	Drug: Interferon beta-1a	Biogen Idec		Not recruiting	18 Years	70 Years	Both	284	Phase 4	Belgium;Luxembourg;United Kingdom
1379	NCT00001934	September 1999	19 February 2015	Zenapax to Treat Multiple Sclerosis	Effect of the Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (IL-2R-Alpha; Zenapax(Registered Trademark)) on Inflammatory Activity in the CNS in MS in a Baseline-to-Treatment, Cross-Over, MRI-Controlled Single Center Phase I/II Trial	Multiple Sclerosis	Drug: Zenapax	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	18 Years	65 Years	Both	22	Phase 2	United States
1380	NCT00010842	September 1999	19 February 2015	Natural Antioxidants in the Treatment of Multiple Sclerosis	Natural Antioxidants in the Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: Ginkgo biloba;Drug: Alpha-lipoic acid;Drug: Vitamin E/Selenium;Drug: Essential fatty acids	National Center for Complementary and Integrative Health (NCCIH)		Not recruiting	N/A	N/A	Both		Phase 1/Phase 2	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1381	NCT00062972	September 1999	16 December 2017	Improving Memory in Patients With Multiple Sclerosis	Interventions to Improve Memory in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: donepezil;Drug: glucose	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	U.S. Department of Education	Not recruiting	18 Years	56 Years	All	0	Phase 3	United States
1382	NCT00473213	September 1999	19 February 2015	Optimizing IFN Beta - 1B Dose	Optimizing IFN Beta - 1B Dose	Multiple Sclerosis	Drug: Interferon Beta 1	University of Turin, Italy	Dimensione Ricerca s.r.l.	Not recruiting	18 Years	50 Years	Both	217	Phase 3
1383	NCT00915460	September 1999	19 February 2015	Open-Label Safety Extension Study of Avonex	An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830	Multiple Sclerosis	Drug: Interferon beta-1a (Avonex)	Biogen Idec		Not recruiting	N/A	N/A	Both	408	Phase 4
1384	NCT00219908	July 1999	19 February 2015	Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis	Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b	Relapsing-Remitting Multiple Sclerosis	Drug: Mitoxantrone	Rennes University Hospital	Bayer;Wyeth is now a wholly owned subsidiary of Pfizer;Farmades, Italy	Not recruiting	18 Years	45 Years	Both	124	Phase 2	France;Italy
1385	NCT00006060	April 1999	19 February 2015	Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis		Multiple Sclerosis	Drug: standard gadolinium contrast	National Center for Research Resources (NCRR)	University of Pennsylvania	Recruiting	20 Years	70 Years	Both	100	N/A	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1386	NCT00040482	April 1999	19 February 2015	High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple Sclerosis	Intensive Immunosuppression Followed by Rescue With CD34 Selected, T Cell Depleted, Leukopheresis Products in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Cyclophosphamide;Drug: ATG;Drug: MESNA;Procedure: Radiation therapy	Baylor College of Medicine	The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine	Not recruiting	18 Years	60 Years	Both	10	Phase 2	United States
1387	NCT00220428	July 1998	19 February 2015	T-Cell Vaccination in Multiple Sclerosis (MS)	The Effect of T-Cell Vaccination in Multiple Sclerosis - Phase I/II Safety and Efficacy Trial	Multiple Sclerosis	Biological: T-Cell Vaccination	Sheba Medical Center		Recruiting	16 Years	60 Years	Both	20	Phase 1/Phase 2	Israel
1388	NCT00001781	February 1998	19 February 2015	Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)	Open-Label Baseline vs. Treatment Trial Evaluating the Safety, Tolerability and Effect on MRI Lesion and Immunology Parameters of CGP 77116 in Patients With Multiple Sclerosis Mark	Multiple Sclerosis	Drug: CGP 77116	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	N/A	N/A	Both	25	Phase 2	United States
1389	NCT01257958	February 1998	12 October 2015	Vitamin D Pilot Study in Patients With Multiple Sclerosis	Vitamin D Pilot Study in Patients With Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: 19 nor vitamin d	University of Wisconsin, Madison		Not recruiting	18 Years	45 Years	Both		Phase 1	United States
1390	NCT00014755	December 1997	19 February 2015	Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis		Multiple Sclerosis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: filgrastim;Drug: prednisone;Procedure: peripheral blood stem cell transplantation;Procedure: irradiation	Fred Hutchinson Cancer Research Center		Not recruiting	18 Years	60 Years	Both	35	Phase 1	United States
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1391	NCT00001669	July 1997	19 February 2015	A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients	A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients	Multiple Sclerosis	Drug: rhIGF-1 (CEP-151)	National Institute of Neurological Disorders and Stroke (NINDS)		Not recruiting	N/A	N/A	Both	15	Phase 2	United States
1392	NCT00004816	July 1995	19 February 2015	A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis		Multiple Sclerosis	Drug: monoclonal antibody M-T412	National Center for Research Resources (NCRR)	Stanford University	Not recruiting	21 Years	75 Years	Both	25	Phase 1
1393	NCT00203021	March 26, 1994	18 December 2018	Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness.	Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone®	Multiple Sclerosis	Drug: Glatiramer acetate	Teva Branded Pharmaceutical Products, R&D Inc.		Not recruiting	18 Years	N/A	All	208	Phase 4	United States
1394	NCT00004744	February 1993	19 February 2015	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis		Multiple Sclerosis	Drug: immune globulin	National Institute of Neurological Disorders and Stroke (NINDS)	Mayo Clinic	Not recruiting	18 Years	60 Years	Both	76	Phase 3
1395	NCT00004814	October 1991	19 February 2015	Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis		Multiple Sclerosis	Drug: copolymer 1	National Center for Research Resources (NCRR)	University of Maryland	Not recruiting	18 Years	45 Years	Both	250	Phase 3
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1396	NCT00000146	July 1988	19 February 2015	Optic Neuritis Treatment Trial (ONTT)		Multiple Sclerosis;Optic Neuritis	Drug: Methylprednisolone;Drug: Prednisone	National Eye Institute (NEI)		Not recruiting	18 Years	46 Years	Both		Phase 3	United States
1397	NCT00000147	July 1988	19 February 2015	Longitudinal Optic Neuritis Study (LONS)		Multiple Sclerosis;Optic Neuritis	Drug: Methylprednisolone;Drug: Prednisone	National Eye Institute (NEI)		Not recruiting	18 Years	46 Years	Both		N/A	United States
1398	JPRN-JapicCTI-050031		23 April 2019	Intrathecal Baclofen therapy with the implanted pump system for Spastic Palsy (Post-marketing clinical trial extended phase 3 after NDA approval)	Intrathecal Baclofen therapy with the implanted pump system for Spastic Palsy (Post-marketing clinical trial extended phase 3 after NDA approval)	[Spinal cord Origin] Spinal cord Injury, Multiple sclerosis, Spinocerebellar degeneration, Circulatory disorder of the spinal, Ossification of the posterior longitudinal ligament [Cerebral Origin] Cerebral palsy, Traumatic head injury	Intervention name : Baclofen Dosage And administration of the intervention : Intertheacal injection	DAIICHI SANKYO COMPANY, LIMITED					BOTH		Phase 4

先頭へ